<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:VWAV="http://visionwave.tech/20260331"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vwav-20260331.xsd" xlink:type="simple"/>
    <context id="From2025-10-01to2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-03-202024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-19_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-19</instant>
        </period>
    </context>
    <context id="AsOf2024-03-19_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-19</instant>
        </period>
    </context>
    <context id="AsOf2024-03-19_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-19</instant>
        </period>
    </context>
    <context id="AsOf2024-03-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2024-03-19</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-03-202024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-03-202024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-03-202024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-02-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2025-02-15</instant>
        </period>
    </context>
    <context id="AsOf2025-02-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2025-02-25</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-07-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2025-07-15</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_ReverseAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:ReverseAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-07-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2025-07-14</instant>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_ReverseAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:ReverseAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_BannixClassACommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:BannixClassACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_RedemptionClassACommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:RedemptionClassACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_TotalBannixClassACommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:TotalBannixClassACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_BannixClassBCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:BannixClassBCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_BusinessCombinationSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:BusinessCombinationSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_BannixPublicRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:BannixPublicRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_BannixPrivateRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:BannixPrivateRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_VisionWaveTechnologiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:VisionWaveTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_CommonStockReverseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:CommonStockReverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_BannixClassACommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:BannixClassACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_RedemptionClassACommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:RedemptionClassACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_TotalBannixClassACommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:TotalBannixClassACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_BannixClassBCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:BannixClassBCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_BusinessCombinationSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:BusinessCombinationSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_BannixPublicRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:BannixPublicRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_BannixPrivateRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:BannixPrivateRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_VisionWaveTechnologiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:VisionWaveTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_CommonStockReverseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:CommonStockReverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_VisionWaveMember_custom_ClassACommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:VisionWaveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">VWAV:ClassACommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_ClassACommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">VWAV:ClassACommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_VisionWaveMember_custom_ClassBCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:VisionWaveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">VWAV:ClassBCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_VisionWaveTechnologiesMember_custom_ClassBCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:VisionWaveTechnologiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">VWAV:ClassBCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_VisionWaveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:VisionWaveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_VisionWaveTechnologiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:VisionWaveTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_VisionWaveMember_custom_ClassACommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:VisionWaveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">VWAV:ClassACommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_ClassACommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">VWAV:ClassACommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_VisionWaveMember_custom_ClassBCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:VisionWaveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">VWAV:ClassBCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_VisionWaveTechnologiesMember_custom_ClassBCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:VisionWaveTechnologiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">VWAV:ClassBCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_VisionWaveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:VisionWaveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_VisionWaveTechnologiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:VisionWaveTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_BannixCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:BannixCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_BannixCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:BannixCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_BannixCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:BannixCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_BannixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:BannixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_custom_BannixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:BannixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_BannixClassACommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:BannixClassACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_BannixClassACommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:BannixClassACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2022-12-122022-12-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2022-12-12</startDate>
            <endDate>2022-12-13</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_StanleyHillsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:StanleyHillsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_StanleyHillsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:StanleyHillsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_SureshYezhuvathMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:SureshYezhuvathMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-07-14_custom_SureshYezhuvathMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:SureshYezhuvathMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-14</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_SubashMenonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:SubashMenonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-07-14_custom_SubashMenonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:SubashMenonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-14</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_BannixManagementLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:BannixManagementLLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-07-14_custom_BannixManagementLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:BannixManagementLLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-14</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-07-14_custom_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-14</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_StanleyHillsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:StanleyHillsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-07-14_custom_StanleyHillsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:StanleyHillsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-14</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_AccruedExecutiveCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:AccruedExecutiveCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_AccruedExecutiveCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:AccruedExecutiveCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_AnatAttiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:AnatAttiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-07-14_custom_AnatAttiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:AnatAttiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-14</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SureshYezhuvathMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:SureshYezhuvathMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_StanleyHillsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:StanleyHillsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_AccruedExecutiveCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:AccruedExecutiveCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_AnatAttiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:AnatAttiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-07-132025-07-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2025-07-13</startDate>
            <endDate>2025-07-15</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-07-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2025-07-25</instant>
        </period>
    </context>
    <context id="AsOf2025-09-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2025-09-11</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ConversionPriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">VWAV:ConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-03-242024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2024-03-24</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-10-042025-10-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2025-10-04</startDate>
            <endDate>2025-10-06</endDate>
        </period>
    </context>
    <context id="AsOf2025-10-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2025-10-06</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_DebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_DebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_us-gaap_DebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_us-gaap_DebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ConvertibleNotesMember_us-gaap_DebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ConvertibleNotesMember_us-gaap_DebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-11-102025-11-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2025-11-10</startDate>
            <endDate>2025-11-12</endDate>
        </period>
    </context>
    <context id="AsOf2025-11-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2025-11-12</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_Debt1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">VWAV:Debt1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_Debt1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">VWAV:Debt1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_Debt1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">VWAV:Debt1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_custom_Debt1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">VWAV:Debt1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ConvertibleNotesMember_custom_Debt1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">VWAV:Debt1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ConvertibleNotesMember_custom_Debt1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">VWAV:Debt1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ConversionPriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">VWAV:ConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2026-01-09</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_January2026NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">VWAV:January2026NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_January2026NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">VWAV:January2026NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_January2026NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">VWAV:January2026NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_custom_January2026NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">VWAV:January2026NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ConvertibleNotesMember_custom_January2026NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">VWAV:January2026NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ConvertibleNotesMember_custom_January2026NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">VWAV:January2026NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_ConvertibleDebenturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:ConvertibleDebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ConvertibleDebenturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:ConvertibleDebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-10-012025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_UnderwriterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">VWAV:UnderwriterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_UnderwriterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">VWAV:UnderwriterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_BannixClassACommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:BannixClassACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_UnderwriterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">VWAV:UnderwriterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">VWAV:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">VWAV:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2025-05-22</instant>
        </period>
    </context>
    <context id="AsOf2025-09-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2025-09-24</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_CryptoAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">VWAV:CryptoAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">VWAV:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">VWAV:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_CryptoAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">VWAV:CryptoAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-04-162026-04-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2026-04-16</startDate>
            <endDate>2026-04-17</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2026-03-11</instant>
        </period>
    </context>
    <context id="AsOf2026-02-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2026-02-17</instant>
        </period>
    </context>
    <context id="AsOf2026-02-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2026-02-20</instant>
        </period>
    </context>
    <context id="AsOf2026-03-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2026-03-18</instant>
        </period>
    </context>
    <context id="From2026-05-112026-05-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2026-05-11</startDate>
            <endDate>2026-05-12</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-14_custom_PublicRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:PublicRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-14</instant>
        </period>
    </context>
    <context id="AsOf2025-07-14_custom_PrivateRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:PrivateRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-14</instant>
        </period>
    </context>
    <context id="AsOf2025-08-05_custom_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">VWAV:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-05</instant>
        </period>
    </context>
    <context id="AsOf2025-08-06_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-06</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-03-202024-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-022025-07-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2025-07-02</startDate>
            <endDate>2025-07-16</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-16_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-16</instant>
        </period>
    </context>
    <context id="From2025-07-302025-08-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2025-07-30</startDate>
            <endDate>2025-08-01</endDate>
        </period>
    </context>
    <context id="From2025-08-082025-08-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2025-08-08</startDate>
            <endDate>2025-08-09</endDate>
        </period>
    </context>
    <context id="From2025-07-022025-07-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2025-07-02</startDate>
            <endDate>2025-07-25</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_BlackScholesModelMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_BlackScholesModelMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2025-10-012025-12-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-02-012026-02-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-26</endDate>
        </period>
    </context>
    <context id="From2026-02-012026-02-26_custom_BlackScholesModelMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-26</endDate>
        </period>
    </context>
    <context id="From2026-01-022026-03-12_custom_BlackScholesModelMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-02</startDate>
            <endDate>2026-03-12</endDate>
        </period>
    </context>
    <context id="From2026-01-022026-03-12_custom_BlackScholesModelMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-02</startDate>
            <endDate>2026-03-12</endDate>
        </period>
    </context>
    <context id="From2025-08-052025-09-02_custom_BlackScholesModelMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-05</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="From2025-08-052025-09-02_custom_BlackScholesModelMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-05</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="From2026-01-022026-03-12_custom_BlackScholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-02</startDate>
            <endDate>2026-03-12</endDate>
        </period>
    </context>
    <context id="From2025-08-052025-09-02_custom_BlackScholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-05</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="From2025-03-042025-03-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2025-03-04</startDate>
            <endDate>2025-03-05</endDate>
        </period>
    </context>
    <context id="From2024-06-032024-06-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-04</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-04-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-28</endDate>
        </period>
    </context>
    <context id="AsOf2025-04-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2025-04-28</instant>
        </period>
    </context>
    <context id="From2025-04-272025-04-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2025-04-27</startDate>
            <endDate>2025-04-28</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CommonStockMember541144343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_SharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">VWAV:SharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">VWAV:SharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_SharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">VWAV:SharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">VWAV:SharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-10-012025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012025-12-31_custom_SharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">VWAV:SharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_SharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">VWAV:SharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012024-12-31_custom_SharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">VWAV:SharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_SharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">VWAV:SharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">VWAV:SharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_SharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">VWAV:SharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ComputerAndAccessoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">VWAV:ComputerAndAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_DronesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">VWAV:DronesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_IntellectualPropertyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-01-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2025-01-26</instant>
        </period>
    </context>
    <context id="AsOf2026-01-26_custom_VisionWaveStage1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:VisionWaveStage1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-26</instant>
        </period>
    </context>
    <context id="AsOf2026-01-26_custom_VisionWaveStage2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:VisionWaveStage2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-26</instant>
        </period>
    </context>
    <context id="AsOf2026-01-26_custom_VisionWaveStage3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:VisionWaveStage3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-26</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_Stage1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:Stage1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-252026-01-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2026-01-25</startDate>
            <endDate>2026-01-26</endDate>
        </period>
    </context>
    <context id="From2025-12-252025-12-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2025-12-25</startDate>
            <endDate>2025-12-26</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2025-12-26</instant>
        </period>
    </context>
    <context id="From2026-01-212026-01-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2026-01-21</startDate>
            <endDate>2026-01-22</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2026-01-22</instant>
        </period>
    </context>
    <context id="From2026-02-032026-02-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2026-02-03</startDate>
            <endDate>2026-02-04</endDate>
        </period>
    </context>
    <context id="AsOf2026-02-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2026-02-04</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_CompositeMaterialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:CompositeMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_DronesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">VWAV:DronesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2026-01-05</instant>
        </period>
    </context>
    <context id="AsOf2026-01-05_custom_AdrianNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:AdrianNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-05</instant>
        </period>
    </context>
    <context id="AsOf2026-01-05_custom_QuantumSpeedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VWAV:QuantumSpeedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-05</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_AcquisitionFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:AcquisitionFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_QuantumSpeedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:QuantumSpeedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SolarDroneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:SolarDroneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-02-252026-02-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2026-02-25</startDate>
            <endDate>2026-02-26</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_AdrianNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">VWAV:AdrianNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-02-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <instant>2026-02-26</instant>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ConvertibleDebentureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:ConvertibleDebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ConvertibleDebentureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VWAV:ConvertibleDebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-08-04_custom_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">VWAV:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-04</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-08-062025-09-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2025-08-06</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="From2026-01-022026-03-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2026-01-02</startDate>
            <endDate>2026-03-12</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-04_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-04</instant>
        </period>
    </context>
    <context id="AsOf2026-03-12_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-12</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_Septmber302025Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">VWAV:Septmber302025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_September302025Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">VWAV:September302025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_December312025Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">VWAV:December312025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_March312026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">VWAV:March312026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-02-082025-08-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2025-02-08</startDate>
            <endDate>2025-08-09</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-272026-01-28_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-27</startDate>
            <endDate>2026-01-28</endDate>
        </period>
    </context>
    <context id="From2025-11-282025-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2025-11-28</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="From2025-10-072025-10-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002038439</identifier>
        </entity>
        <period>
            <startDate>2025-10-07</startDate>
            <endDate>2025-10-09</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Ratio">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-10-01to2026-03-31" id="Fact000003">true</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2025-10-01to2026-03-31" id="Fact000004">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-10-01to2026-03-31" id="Fact000005">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="From2025-10-01to2026-03-31" id="Fact000006">S-1/A</dei:DocumentType>
    <dei:EntityCentralIndexKey contextRef="From2025-10-01to2026-03-31" id="Fact000007">0002038439</dei:EntityCentralIndexKey>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0047"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Supplies
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0050"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesReceivableGross
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0053"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CustomerDepositsCurrent
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0074"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TaxesPayableCurrent
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0077"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0080"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:PromissoryNotesEvie
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0083"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0089"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:DeferredUnderwritersDiscounts
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0092"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl0106"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0107"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0166"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeOperating
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0178"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0181"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ChangeInFairValueOfConvertibleNotesPayables
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0184"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0187"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0190"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-10-012025-09-30"
      id="xdx2ixbrl0195"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0196"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-19_us-gaap_CommonStockMember"
      id="xdx2ixbrl0217"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-19_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-19_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0219"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-19"
      id="xdx2ixbrl0220"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-19_us-gaap_CommonStockMember"
      id="xdx2ixbrl0222"
      unitRef="Shares"
      xsi:nil="true"/>
    <VWAV:IssuanceOfCommonStockInception
      contextRef="From2024-03-202024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0226"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfCommonStockPurchasingIntellectualProperties
      contextRef="From2024-03-202024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfCommonStockPurchasingIntellectualProperties
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0234"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfCommonStockInvestmentByAffiliate
      contextRef="From2024-03-202024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0240"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-03-202024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0247"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-03-202024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-03-202024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ConversionOfPublicAndPrivateRights
      contextRef="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ConversionOfPublicAndPrivateRights
      contextRef="From2024-10-012025-09-30"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfSharesPursuantToStandbyEquityPurchaseAgreement
      contextRef="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ExerciseOfWarrants
      contextRef="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseDebt
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ChangeInFairValueOfConvertibleNotesPayables
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidSupplies
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposit
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IncreaseDecreaseInDeferredOfferingCosts
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IncreaseDecreaseInExciseTaxPayable
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-10-012025-09-30"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-03-19"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:CashPaidForInterest
      contextRef="From2024-10-012025-09-30"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:CashPaidForInterest
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:CashPaidForTaxes
      contextRef="From2024-10-012025-09-30"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:CashPaidForTaxes
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:AccountsPayableAccruedLiabilitiesAndOtherCurrentLiabilitiesCombined
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ConversionOfPublicAndPrivateRight
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:NonCashIssuanceOfShares
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:NonCashIssuanceOfSharesForAdvisoryServices
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-09-30_custom_BannixClassBCommonStockMember"
      id="xdx2ixbrl0551"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2024-10-012025-09-30_custom_VisionWaveMember_custom_ClassBCommonMember"
      id="xdx2ixbrl0569"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2024-10-012025-09-30_custom_VisionWaveTechnologiesMember_custom_ClassBCommonMember"
      id="xdx2ixbrl0571"
      unitRef="Shares"
      xsi:nil="true"/>
    <VWAV:UnderwritersMarketingFee
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0588"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0591"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0594"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:FranchiseTaxPayable
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0597"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:InsurancePremiumFinancing
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0600"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0603"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-07-14_custom_SureshYezhuvathMember"
      id="xdx2ixbrl0641"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-09-30_custom_SubashMenonMember"
      id="xdx2ixbrl0643"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-07-14_custom_SubashMenonMember"
      id="xdx2ixbrl0645"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-09-30_custom_BannixManagementLLPMember"
      id="xdx2ixbrl0647"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-07-14_custom_BannixManagementLLPMember"
      id="xdx2ixbrl0649"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-07-14_custom_PromissoryNotesMember"
      id="xdx2ixbrl0653"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-07-14_custom_StanleyHillsMember"
      id="xdx2ixbrl0657"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2024-09-30_custom_AccruedExecutiveCompensationMember"
      id="xdx2ixbrl0661"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2024-10-012025-09-30_custom_ConvertibleDebenturesMember"
      id="xdx2ixbrl0726"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0829"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0831"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <VWAV:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
      contextRef="From2024-10-012025-09-30"
      id="xdx2ixbrl0839"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-10-012025-09-30"
      id="xdx2ixbrl0841"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2024-10-012025-09-30"
      id="xdx2ixbrl0904"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-10-012024-09-30"
      id="xdx2ixbrl0905"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2024-10-012025-09-30"
      id="xdx2ixbrl0907"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2023-10-012024-09-30"
      id="xdx2ixbrl0908"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IncomeTaxProvisionStateDeferred
      contextRef="From2024-10-012025-09-30"
      id="xdx2ixbrl0913"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IncomeTaxProvisionStateDeferred
      contextRef="From2023-10-012024-09-30"
      id="xdx2ixbrl0914"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
      contextRef="From2024-10-012025-09-30"
      id="xdx2ixbrl0919"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
      contextRef="From2023-10-012024-09-30"
      id="xdx2ixbrl0920"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ResearchAndDevelopmentExpenses
      contextRef="From2023-10-012024-09-30"
      id="xdx2ixbrl0926"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:EmployeeBenefitsAndSharesBasedCompensation
      contextRef="From2023-10-012024-09-30"
      id="xdx2ixbrl0930"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AcquisitionCosts
      contextRef="From2023-10-012024-09-30"
      id="xdx2ixbrl0938"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2024-10-012025-09-30"
      id="xdx2ixbrl0948"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2023-10-012024-09-30"
      id="xdx2ixbrl0950"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-10-012025-09-30"
      id="xdx2ixbrl0962"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-10-012024-09-30"
      id="xdx2ixbrl0963"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:BusinessDevelopment
      contextRef="From2024-03-202024-09-30"
      id="xdx2ixbrl0984"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl1028"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsAndNotesReceivableNet
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl1031"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl1034"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl1037"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl1040"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl1058"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl1076"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl1093"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl1094"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:SharesToBeIssuedRelatedToAcquisition
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl1132"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-03-31"
      id="xdx2ixbrl1157"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1159"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-01-012025-03-31"
      id="xdx2ixbrl1167"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1169"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeOperating
      contextRef="From2025-01-012025-03-31"
      id="xdx2ixbrl1187"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeOperating
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1189"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2025-01-012025-03-31"
      id="xdx2ixbrl1192"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1194"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="From2026-01-012026-03-31"
      id="xdx2ixbrl1196"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="From2025-10-01to2026-03-31"
      id="xdx2ixbrl1198"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ChangeInFairValueOfConvertibleNotesPayable
      contextRef="From2025-01-012025-03-31"
      id="xdx2ixbrl1202"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ChangeInFairValueOfConvertibleNotesPayable
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1204"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ChangeInFairValueOfOtherLiabilities
      contextRef="From2025-01-012025-03-31"
      id="xdx2ixbrl1207"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="From2025-01-012025-03-31"
      id="xdx2ixbrl1212"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1214"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ProvisionForIncomeTaxes
      contextRef="From2026-01-012026-03-31"
      id="xdx2ixbrl1226"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ProvisionForIncomeTaxes
      contextRef="From2025-01-012025-03-31"
      id="xdx2ixbrl1227"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ProvisionForIncomeTaxes
      contextRef="From2025-10-01to2026-03-31"
      id="xdx2ixbrl1228"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ProvisionForIncomeTaxes
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1229"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_custom_SharesToBeIssuedMember"
      id="xdx2ixbrl1270"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfSharesInAssetAcquisitions
      contextRef="From2025-10-012025-12-31_custom_SharesToBeIssuedMember"
      id="xdx2ixbrl1278"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfSharesInAssetAcquisitions
      contextRef="From2025-10-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1279"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfWarrantsInAssetAcquisitions
      contextRef="From2025-10-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1284"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfWarrantsInAssetAcquisitions
      contextRef="From2025-10-012025-12-31_custom_SharesToBeIssuedMember"
      id="xdx2ixbrl1286"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfWarrantsInAssetAcquisitions
      contextRef="From2025-10-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1287"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ExerciseOfWarrants
      contextRef="From2025-10-012025-12-31_custom_SharesToBeIssuedMember"
      id="xdx2ixbrl1292"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ExerciseOfWarrants
      contextRef="From2025-10-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-10-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-10-012025-12-31_custom_SharesToBeIssuedMember"
      id="xdx2ixbrl1300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-10-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-10-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-10-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-10-012025-12-31_custom_SharesToBeIssuedMember"
      id="xdx2ixbrl1306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_SharesToBeIssuedMember"
      id="xdx2ixbrl1312"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ExerciseOfWarrants
      contextRef="From2026-01-012026-03-31_custom_SharesToBeIssuedMember"
      id="xdx2ixbrl1320"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ExerciseOfWarrants
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1321"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfSharesInAssetAcquisition
      contextRef="From2026-01-012026-03-31_custom_SharesToBeIssuedMember"
      id="xdx2ixbrl1328"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfSharesInAssetAcquisition
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1329"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfSharesPursuantToSepa
      contextRef="From2026-01-012026-03-31_custom_SharesToBeIssuedMember"
      id="xdx2ixbrl1336"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfSharesPursuantToSepa
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1337"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfSharesPursuantToSaveroneExchangeAgreement
      contextRef="From2026-01-012026-03-31_custom_SharesToBeIssuedMember"
      id="xdx2ixbrl1344"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfSharesPursuantToSaveroneExchangeAgreement
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1345"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:SharesToBeIssuedRelatedToAssetAcquisition
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1350"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:SharesToBeIssuedRelatedToAssetAcquisition
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1351"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:SharesToBeIssuedRelatedToAssetAcquisition
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1353"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfWarrantsPursuantToLetterAgreement
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1356"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfWarrantsPursuantToLetterAgreement
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2026-01-012026-03-31_custom_SharesToBeIssuedMember"
      id="xdx2ixbrl1364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_custom_SharesToBeIssuedMember"
      id="xdx2ixbrl1372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_custom_SharesToBeIssuedMember"
      id="xdx2ixbrl1386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-10-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-10-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-10-012024-12-31_custom_SharesToBeIssuedMember"
      id="xdx2ixbrl1394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_custom_SharesToBeIssuedMember"
      id="xdx2ixbrl1400"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-03-31_custom_SharesToBeIssuedMember"
      id="xdx2ixbrl1408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_custom_SharesToBeIssuedMember"
      id="xdx2ixbrl1414"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:FairValueOfOtherLiabilities
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1430"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ChangeInFairValueOfConvertibleNotesPayable
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1433"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:GainOnInvestmentOfMarketableSecurities
      contextRef="From2025-10-01to2026-03-31"
      id="xdx2ixbrl1435"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1439"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1442"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:DepreciationAndAmortizations
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1445"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseDueFromOtherRelatedParties
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1454"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IncreaseDecreaseAdvancesToSupplier
      contextRef="From2025-10-01to2026-03-31"
      id="xdx2ixbrl1456"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IncreaseDecreaseInCustomerDeposit
      contextRef="From2025-10-01to2026-03-31"
      id="xdx2ixbrl1462"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1466"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IncreaseDecreaseInStockBasedCompensationLiability
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1472"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:LatePaymentPenaltyOnExciseTaxesPayable
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1475"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:LatePaymentPenaltyOnIncomeTaxesPayable
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1478"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ProceedsFromSaleOfMarketableSecuritiesNet
      contextRef="From2025-10-01to2026-03-31"
      id="xdx2ixbrl1486"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:AdvanceToC.m.CompositeMaterialsLtd
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1490"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireOilAndGasPropertyAndEquipment
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1493"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:DepositOnPropertyPlantAndEquipment
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1496"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:CashPaidForEquityMethodInvestment
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1502"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1511"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1514"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ProceedsFromIssuanceOfPromissoryNote
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1517"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:RepaymentOfPromissoryNote
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1520"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:ProceedsFromDrawdownOfSepa
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1529"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2025-10-01to2026-03-31"
      id="xdx2ixbrl1543"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1544"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2025-10-01to2026-03-31"
      id="xdx2ixbrl1546"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1547"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:DebtDiscountOnWarrantIssuedForNotes
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1553"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfSharesPursuanstToSaveroneExchangeAgreement
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1556"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfShareInAssetAcquisitions
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1559"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:IssuanceOfWarrantsPursuantToExchangeAgreement
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1562"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:NoteIssuedInAssetAcquisition
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1565"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:SharesToBeIssuedRelatedToAssetAcquisitions
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl1568"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-03-31_custom_BannixClassBCommonStockMember"
      id="xdx2ixbrl1712"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2025-10-012026-03-31_custom_VisionWaveMember_custom_ClassBCommonMember"
      id="xdx2ixbrl1732"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2025-10-012026-03-31_custom_VisionWaveTechnologiesMember_custom_ClassBCommonMember"
      id="xdx2ixbrl1734"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:DepositsAssets
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl1753"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-09-30_us-gaap_OfficeEquipmentMember"
      id="xdx2ixbrl1835"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-09-30_custom_DronesMember"
      id="xdx2ixbrl1839"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl1843"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl1847"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl1851"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl1922"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl1926"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl1930"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2026-03-31_custom_AccruedExecutiveCompensationMember"
      id="xdx2ixbrl2070"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:OctoberNoteAtAmortizedCost
      contextRef="AsOf2025-09-30_custom_ConvertibleDebentureMember"
      id="xdx2ixbrl2305"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:NovemberNoteAtAmortizedCost
      contextRef="AsOf2025-09-30_custom_ConvertibleDebentureMember"
      id="xdx2ixbrl2308"
      unitRef="USD"
      xsi:nil="true"/>
    <VWAV:January2026NoteAtAmortizedCost
      contextRef="AsOf2025-09-30_custom_ConvertibleDebentureMember"
      id="xdx2ixbrl2311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2025-10-012025-12-31_custom_WarrantsMember"
      id="xdx2ixbrl2488"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-10-012025-09-30_custom_WarrantsMember"
      id="xdx2ixbrl2490"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2026-01-012026-03-31_custom_WarrantsMember"
      id="xdx2ixbrl2510"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2026-01-012026-03-31_custom_WarrantsMember"
      id="xdx2ixbrl2512"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl2611"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl2613"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2025-10-012025-12-31"
      id="xdx2ixbrl2621"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-10-012025-09-30"
      id="xdx2ixbrl2623"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-10-012025-12-31"
      id="xdx2ixbrl2625"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-10-012025-09-30"
      id="xdx2ixbrl2627"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2026-01-012026-03-31"
      id="xdx2ixbrl2641"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2026-01-012026-03-31"
      id="xdx2ixbrl2643"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="From2025-10-012026-03-31_custom_December312025Member"
      id="xdx2ixbrl2695"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:RestrictedStockExpense
      contextRef="From2025-10-012026-03-31_custom_December312025Member"
      id="xdx2ixbrl2697"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-03-31"
      id="xdx2ixbrl2771"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl2773"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-01-012025-03-31"
      id="xdx2ixbrl2781"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-10-012025-03-31"
      id="xdx2ixbrl2783"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:AmendmentDescription contextRef="From2025-10-01to2026-03-31" id="Fact000013">AMENDMENT
NO. 1 TO</dei:AmendmentDescription>
    <dei:EntityRegistrantName contextRef="From2025-10-01to2026-03-31" id="Fact000014">VisionWave Holdings, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-10-01to2026-03-31" id="Fact000015">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-10-01to2026-03-31" id="Fact000016">99-5002777</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-10-01to2026-03-31" id="Fact000017">300 Delaware Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-10-01to2026-03-31" id="Fact000018">Suite 210 #301</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-10-01to2026-03-31" id="Fact000019">Wilmington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-10-01to2026-03-31" id="Fact000020">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-10-01to2026-03-31" id="Fact000021">19801</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-10-01to2026-03-31" id="Fact000022">302</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-10-01to2026-03-31" id="Fact000023">305.4790</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="From2025-10-012026-03-31_dei_BusinessContactMember"
      id="Fact000024">Douglas Davis</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="From2025-10-012026-03-31_dei_BusinessContactMember"
      id="Fact000025">300 Delaware Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="From2025-10-012026-03-31_dei_BusinessContactMember"
      id="Fact000026">Suite 210 #301</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="From2025-10-012026-03-31_dei_BusinessContactMember"
      id="Fact000027">Wilmington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="From2025-10-012026-03-31_dei_BusinessContactMember"
      id="Fact000028">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="From2025-10-012026-03-31_dei_BusinessContactMember"
      id="Fact000029">19801</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="From2025-10-012026-03-31_dei_BusinessContactMember"
      id="Fact000030">302</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="From2025-10-012026-03-31_dei_BusinessContactMember"
      id="Fact000031">305.4790</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="From2025-10-01to2026-03-31" id="Fact000032">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-10-01to2026-03-31" id="Fact000033">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-10-01to2026-03-31" id="Fact000034">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2025-10-01to2026-03-31" id="Fact000035">false</dei:EntityExTransitionPeriod>
    <us-gaap:Cash
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000043"
      unitRef="USD">2284933</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000044"
      unitRef="USD">3014</us-gaap:Cash>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000046"
      unitRef="USD">189549</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:Supplies
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000049"
      unitRef="USD">98250</us-gaap:Supplies>
    <us-gaap:NotesReceivableGross
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000052"
      unitRef="USD">120000</us-gaap:NotesReceivableGross>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000055"
      unitRef="USD">2692732</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000056"
      unitRef="USD">3014</us-gaap:AssetsCurrent>
    <us-gaap:Investments
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000058"
      unitRef="USD">281</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000059"
      unitRef="USD">10000</us-gaap:Investments>
    <us-gaap:Assets
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000061"
      unitRef="USD">2693013</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000062"
      unitRef="USD">13014</us-gaap:Assets>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000070"
      unitRef="USD">3917834</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000071"
      unitRef="USD">15000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:CustomerDepositsCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000073"
      unitRef="USD">108006</us-gaap:CustomerDepositsCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000076"
      unitRef="USD">994704</us-gaap:TaxesPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000079"
      unitRef="USD">943039</us-gaap:SalesAndExciseTaxPayableCurrent>
    <VWAV:PromissoryNotesEvie
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000082"
      unitRef="USD">1003995</VWAV:PromissoryNotesEvie>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000085"
      unitRef="USD">2434492</VWAV:DueToRelatedParties>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000086"
      unitRef="USD">69133</VWAV:DueToRelatedParties>
    <us-gaap:NotesPayable
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000088"
      unitRef="USD">4861390</us-gaap:NotesPayable>
    <VWAV:DeferredUnderwritersDiscounts
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000091"
      unitRef="USD">225000</VWAV:DeferredUnderwritersDiscounts>
    <VWAV:DeferredUnderwritersDiscount
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000094"
      unitRef="USD">14488460</VWAV:DeferredUnderwritersDiscount>
    <VWAV:DeferredUnderwritersDiscount
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000095"
      unitRef="USD">84133</VWAV:DeferredUnderwritersDiscount>
    <us-gaap:Liabilities
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000097"
      unitRef="USD">14488460</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000098"
      unitRef="USD">84133</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000109"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000111"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000113"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000115"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000117"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000119"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000121"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000123"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000128"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000130"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000132"
      unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000134"
      unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000136"
      unitRef="Shares">14521094</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000138"
      unitRef="Shares">14521094</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000140"
      unitRef="Shares">11000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000142"
      unitRef="Shares">11000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000125"
      unitRef="USD">145211</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000126"
      unitRef="USD">110000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000144"
      unitRef="USD">3168248</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000145"
      unitRef="USD">151000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000147"
      unitRef="USD">-15108906</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000148"
      unitRef="USD">-332119</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000150"
      unitRef="USD">-11795447</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000151"
      unitRef="USD">-71119</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000153"
      unitRef="USD">2693013</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000154"
      unitRef="USD">13014</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000159"
      unitRef="USD">5416619</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000160"
      unitRef="USD">328469</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000162"
      unitRef="USD">156462</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000163"
      unitRef="USD">3650</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000165"
      unitRef="USD">1168108</us-gaap:SellingAndMarketingExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000168"
      unitRef="USD">6741189</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000169"
      unitRef="USD">332119</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000171"
      unitRef="USD">-6741189</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000172"
      unitRef="USD">-332119</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000177"
      unitRef="USD">418</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000180"
      unitRef="USD">59327</us-gaap:InterestExpense>
    <VWAV:ChangeInFairValueOfConvertibleNotesPayables
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000183"
      unitRef="USD">147347</VWAV:ChangeInFairValueOfConvertibleNotesPayables>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000186"
      unitRef="USD">104656</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:OtherIncome
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000189"
      unitRef="USD">193094</us-gaap:OtherIncome>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000192"
      unitRef="USD">-6548095</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000193"
      unitRef="USD">-332119</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000198"
      unitRef="USD">-6548095</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000199"
      unitRef="USD">-332119</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000201"
      unitRef="Shares">11741353</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000203"
      unitRef="Shares">11741353</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-03-202024-09-30"
      decimals="INF"
      id="Fact000205"
      unitRef="Shares">9044585</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-03-202024-09-30"
      decimals="INF"
      id="Fact000207"
      unitRef="Shares">9044585</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000209"
      unitRef="USDPShares">-0.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000211"
      unitRef="USDPShares">-0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-03-202024-09-30"
      decimals="INF"
      id="Fact000213"
      unitRef="USDPShares">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-03-202024-09-30"
      decimals="INF"
      id="Fact000215"
      unitRef="USDPShares">-0.04</us-gaap:EarningsPerShareDiluted>
    <VWAV:IssuanceOfCommonStockInceptionShares
      contextRef="From2024-03-202024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000229"
      unitRef="Shares">4041146</VWAV:IssuanceOfCommonStockInceptionShares>
    <VWAV:IssuanceOfCommonStockInception
      contextRef="From2024-03-202024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000224"
      unitRef="USD">40411</VWAV:IssuanceOfCommonStockInception>
    <VWAV:IssuanceOfCommonStockInception
      contextRef="From2024-03-202024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000225"
      unitRef="USD">-39411</VWAV:IssuanceOfCommonStockInception>
    <VWAV:IssuanceOfCommonStockInception
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000227"
      unitRef="USD">1000</VWAV:IssuanceOfCommonStockInception>
    <VWAV:IssuanceOfCommonStockPurchasingIntellectualPropertiesShares
      contextRef="From2024-03-202024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000236"
      unitRef="Shares">4041146</VWAV:IssuanceOfCommonStockPurchasingIntellectualPropertiesShares>
    <VWAV:IssuanceOfCommonStockPurchasingIntellectualProperties
      contextRef="From2024-03-202024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000231"
      unitRef="USD">40411</VWAV:IssuanceOfCommonStockPurchasingIntellectualProperties>
    <VWAV:IssuanceOfCommonStockPurchasingIntellectualProperties
      contextRef="From2024-03-202024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000232"
      unitRef="USD">-40411</VWAV:IssuanceOfCommonStockPurchasingIntellectualProperties>
    <VWAV:IssuanceOfCommonStockInvestmentByAffiliateShares
      contextRef="From2024-03-202024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000243"
      unitRef="Shares">897135</VWAV:IssuanceOfCommonStockInvestmentByAffiliateShares>
    <VWAV:IssuanceOfCommonStockInvestmentByAffiliate
      contextRef="From2024-03-202024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000238"
      unitRef="USD">8972</VWAV:IssuanceOfCommonStockInvestmentByAffiliate>
    <VWAV:IssuanceOfCommonStockInvestmentByAffiliate
      contextRef="From2024-03-202024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000239"
      unitRef="USD">1028</VWAV:IssuanceOfCommonStockInvestmentByAffiliate>
    <VWAV:IssuanceOfCommonStockInvestmentByAffiliate
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000241"
      unitRef="USD">10000</VWAV:IssuanceOfCommonStockInvestmentByAffiliate>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-03-202024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000250"
      unitRef="Shares">2020573</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-03-202024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000245"
      unitRef="USD">20206</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-03-202024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000246"
      unitRef="USD">229794</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000248"
      unitRef="USD">250000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ProfitLoss
      contextRef="From2024-03-202024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000254"
      unitRef="USD">-332119</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000255"
      unitRef="USD">-332119</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000262"
      unitRef="Shares">11000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000257"
      unitRef="USD">110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000258"
      unitRef="USD">151000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000259"
      unitRef="USD">-332119</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000260"
      unitRef="USD">-71119</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000269"
      unitRef="Shares">2540324</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000264"
      unitRef="USD">-25403</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000265"
      unitRef="USD">143694</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000266"
      unitRef="USD">8228692</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000267"
      unitRef="USD">8346983</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <VWAV:ConversionOfPublicAndPrivateRightsShares
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000276"
      unitRef="Shares">730600</VWAV:ConversionOfPublicAndPrivateRightsShares>
    <VWAV:ConversionOfPublicAndPrivateRights
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000271"
      unitRef="USD">7306</VWAV:ConversionOfPublicAndPrivateRights>
    <VWAV:ConversionOfPublicAndPrivateRights
      contextRef="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000272"
      unitRef="USD">-7306</VWAV:ConversionOfPublicAndPrivateRights>
    <VWAV:IssuanceOfSharesPursuantToStandbyEquityPurchaseAgreementShares
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000283"
      unitRef="Shares">200000</VWAV:IssuanceOfSharesPursuantToStandbyEquityPurchaseAgreementShares>
    <VWAV:IssuanceOfSharesPursuantToStandbyEquityPurchaseAgreement
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000278"
      unitRef="USD">2000</VWAV:IssuanceOfSharesPursuantToStandbyEquityPurchaseAgreement>
    <VWAV:IssuanceOfSharesPursuantToStandbyEquityPurchaseAgreement
      contextRef="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000279"
      unitRef="USD">468000</VWAV:IssuanceOfSharesPursuantToStandbyEquityPurchaseAgreement>
    <VWAV:IssuanceOfSharesPursuantToStandbyEquityPurchaseAgreement
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000281"
      unitRef="USD">470000</VWAV:IssuanceOfSharesPursuantToStandbyEquityPurchaseAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000290"
      unitRef="Shares">22500</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000285"
      unitRef="USD">225</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000286"
      unitRef="USD">52650</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000288"
      unitRef="USD">52875</us-gaap:StockIssuedDuringPeriodValueOther>
    <VWAV:ExerciseOfWarrantsShares
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000297"
      unitRef="Shares">1008</VWAV:ExerciseOfWarrantsShares>
    <VWAV:ExerciseOfWarrants
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000292"
      unitRef="USD">10</VWAV:ExerciseOfWarrants>
    <VWAV:ExerciseOfWarrants
      contextRef="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000293"
      unitRef="USD">11582</VWAV:ExerciseOfWarrants>
    <VWAV:ExerciseOfWarrants
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000295"
      unitRef="USD">11592</VWAV:ExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000304"
      unitRef="Shares">26662</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000299"
      unitRef="USD">267</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000300"
      unitRef="USD">2636016</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000302"
      unitRef="USD">2636283</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000308"
      unitRef="USD">-6548095</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000309"
      unitRef="USD">-6548095</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000316"
      unitRef="Shares">14521094</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000311"
      unitRef="USD">145211</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000312"
      unitRef="USD">3168248</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000313"
      unitRef="USD">-15108906</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000314"
      unitRef="USD">-11795447</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000321"
      unitRef="USD">-6548095</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000322"
      unitRef="USD">-332119</us-gaap:NetIncomeLoss>
    <us-gaap:InterestExpenseDebt
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000327"
      unitRef="USD">38737</us-gaap:InterestExpenseDebt>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000330"
      unitRef="USD">104656</us-gaap:MarketableSecuritiesGainLoss>
    <VWAV:ChangeInFairValueOfConvertibleNotesPayables
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000333"
      unitRef="USD">147347</VWAV:ChangeInFairValueOfConvertibleNotesPayables>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000336"
      unitRef="USD">2636283</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000337"
      unitRef="USD">250000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000342"
      unitRef="USD">185619</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000345"
      unitRef="USD">120000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidSupplies
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000348"
      unitRef="USD">98250</us-gaap:IncreaseDecreaseInPrepaidSupplies>
    <VWAV:IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposit
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000351"
      unitRef="USD">108006</VWAV:IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposit>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000354"
      unitRef="USD">3331878</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000355"
      unitRef="USD">15000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <VWAV:IncreaseDecreaseInDeferredOfferingCosts
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000357"
      unitRef="USD">250000</VWAV:IncreaseDecreaseInDeferredOfferingCosts>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000360"
      unitRef="USD">-1588603</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000361"
      unitRef="USD">69133</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <VWAV:IncreaseDecreaseInExciseTaxPayable
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000363"
      unitRef="USD">54707</VWAV:IncreaseDecreaseInExciseTaxPayable>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000366"
      unitRef="USD">35065</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000369"
      unitRef="USD">-2837894</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000370"
      unitRef="USD">2014</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000375"
      unitRef="USD">114375</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000378"
      unitRef="USD">114375</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000379"
      unitRef="USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000385"
      unitRef="USD">1000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000387"
      unitRef="USD">23846</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000390"
      unitRef="USD">4970000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000393"
      unitRef="USD">11592</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000396"
      unitRef="USD">5005438</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000397"
      unitRef="USD">1000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000399"
      unitRef="USD">2281919</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000400"
      unitRef="USD">3014</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000402"
      unitRef="USD">3014</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000405"
      unitRef="USD">2284933</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000406"
      unitRef="USD">3014</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <VWAV:AccountsPayableAccruedLiabilitiesAndOtherCurrentLiabilitiesCombined
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000420"
      unitRef="USD">8346983</VWAV:AccountsPayableAccruedLiabilitiesAndOtherCurrentLiabilitiesCombined>
    <VWAV:ConversionOfPublicAndPrivateRight
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000423"
      unitRef="USD">7306</VWAV:ConversionOfPublicAndPrivateRight>
    <VWAV:NonCashIssuanceOfShares
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000426"
      unitRef="USD">470000</VWAV:NonCashIssuanceOfShares>
    <VWAV:NonCashIssuanceOfSharesForAdvisoryServices
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000429"
      unitRef="USD">52875</VWAV:NonCashIssuanceOfSharesForAdvisoryServices>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2024-10-012025-09-30" id="Fact000432">&lt;p id="xdx_80A_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zzaL89ODoRng" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 1&#x2014;&lt;span id="xdx_823_zj9QF4vShEq1"&gt;Organization and Business Operations&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;VisionWave Holdings, Inc. (&#x201c;VW Holdings&#x201d;
or the &#x201c;Company&#x201d;) is a Delaware company incorporated in 2024. VW Holdings is the successor to Bannix Acquisition Corp., (&#x201c;Bannix&#x201d;)
a blank check company incorporated in the state of Delaware on January 21, 2021 for the purpose of effecting mergers, capital stock exchange,
asset acquisitions, stock purchases, reorganization or similar business combinations with one or more businesses (&#x201c;Business Combination&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prior to the succession of Bannix by VW Holdings,
on March 26, 2024, Bannix entered into a Business Combination Agreement (the &#x201c;Original Agreement&#x201d;), by and among Bannix, VisionWave
Technologies, Inc., a Nevada corporation (&#x201c;Target&#x201d; or &#x201c;VW Tech.&#x201d;) and the shareholders of Target.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 6, 2024, Bannix entered into a Merger
Agreement and Plan of Reorganization (the &#x201c;Merger Agreement&#x201d;), by and among Bannix, VisionWave Holdings, Inc., a Delaware
corporation and a direct, wholly owned subsidiary of Bannix (&#x201c;VW Holdings&#x201d;), BNIX Merger Sub, Inc., a Delaware corporation
and a direct, wholly owned subsidiary of VisionWave (&#x201c;Parent Merger Sub&#x201d;), BNIX VW Merger Sub, Inc., a Nevada corporation
and direct, wholly owned subsidiary of VisionWave (&#x201c;Company Merger Sub&#x201d;), and Target.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 14, 2025, Bannix closed its proposed merger
with VisionWave Technologies Inc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <VWAV:LiquidityAndCapitalResourcesTextBlock contextRef="From2024-10-012025-09-30" id="Fact000434">&lt;p id="xdx_80E_ecustom--LiquidityAndCapitalResourcesTextBlock_zJvwO2Qo6tQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 2&#x2014;&lt;span id="xdx_82E_zou5jeXW6UP2"&gt;Liquidity, Capital Resources and Going Concern&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s primary sources of liquidity have
been cash from financing activities. The Company had an accumulated deficit of $&lt;span id="xdx_902_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20250930_zj5psX4jPfSk" title="Accumulated deficit"&gt;15,108,906&lt;/span&gt; as of September 30, 2025. As of September 30,
2025, working capital deficit was $&lt;span id="xdx_90E_ecustom--WorkingCapitalDeficit_iI_c20250930_zBJb2ETrdOF6" title="Working capital deficit"&gt;11,795,728&lt;/span&gt; and cash was $&lt;span id="xdx_900_eus-gaap--Cash_iI_c20250930_zP9zhN9fxMp7" title="Cash"&gt;2,284,933&lt;/span&gt;.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company received proceeds of approximately $&lt;span id="xdx_902_ecustom--GrossProceeds_c20241001__20250930_z4WKyOE3pV8i" title="Gross proceeds"&gt;23,846&lt;/span&gt;
as a result of the Reverse Acquisition in September 2025, after giving effect to stockholder redemptions and payment of transaction expenses
in connection with the Reverse Acquisition. The Company received an additional $&lt;span id="xdx_900_ecustom--TransactionEpenses_iI_c20250215_zu7nKAwgsre3" title="Transaction epenses"&gt;308,000&lt;/span&gt; pursuant to the Securities Purchases agreement
entered into on February 15, 2025 and $&lt;span id="xdx_906_ecustom--IssuedConvertiblePromissoryNote_iI_c20250225_zTccLCatzLVe" title="Issued convertible promissory note"&gt;5,000,000&lt;/span&gt; pursuant to the convertible promissory note agreements issued under the Standby Equity
Purchase Agreement referenced below. The Company&#x2019;s future capital requirements will depend on many factors, including the timing
and extent of spending to support further sales and marketing and research and development efforts. In order to finance these opportunities,
the Company will need to raise additional financing. While there can be no assurances, the Company intends to raise such capital through
issuances of additional equity. If additional financing is required from outside sources, the Company may not be able to raise it on terms
acceptable to the Company or at all.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 25, 2025, the Company entered into the Standby
Equity Purchase Agreement (&#x201c;SEPA&#x201d;) with YA II PN, LTD, a Cayman Islands exempt limited partnership (the &#x201c;Investor&#x201d;)
pursuant to which the Company has the right to sell to the Investor up to $50 million of its shares of common stock, subject to certain
limitations and conditions set forth in the SEPA, from time to time during the term of the SEPA, from time to time during the term of
the SEPA.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Going Concern Evaluation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Ordinarily, conditions or events that raise substantial
doubt about an entity&#x2019;s ability to continue as a going concern relate to the entity&#x2019;s ability to meet its obligations as they
become due. The Company evaluated its ability to meet its obligations as they become due within one year from the date that the financial
statements are issued by considering the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 8, 2025, with an effective date of March
31, 2025, the Company entered into a Funding Support Agreement with Stanley Hills, LLC (&#x201c;Stanley Hills&#x201d;), the principal shareholder
of VisionWave Technologies. Pursuant to the agreement, Stanley Hills irrevocably and unconditionally committed to provide financial support
to the Company, sufficient to fund the working capital needs through December 29, 2026. The funding may be provided by Stanley Hills in
the form of direct payments to third parties, advances or intercompany loans, or capital contributions, as mutually determined by the
parties. Unless otherwise agreed in writing, any such advances will be non-interest bearing and repayable only at such time as determined
by the Board of Directors, and only to the extent such repayment would not impair the Company&#x2019;s liquidity or ability to continue
as a going concern. The agreement may not be terminated by Stanley Hills prior to the twelve-month period from the date of release of
the financial statement.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management has determined that the agreement with Stanley Hills, cash receipts from
customer arrangements, resource reallocation initiatives, additional insider investments and financing, along with its existing cash and
committed affiliated support related combinations alleviated the risk about the Company&#x2019;s ability to continue as a going concern
for a reasonable period of time, which is considered to be one year from the issuance of the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;
</VWAV:LiquidityAndCapitalResourcesTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000436"
      unitRef="USD">-15108906</us-gaap:RetainedEarningsAccumulatedDeficit>
    <VWAV:WorkingCapitalDeficit
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000438"
      unitRef="USD">11795728</VWAV:WorkingCapitalDeficit>
    <us-gaap:Cash
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000440"
      unitRef="USD">2284933</us-gaap:Cash>
    <VWAV:GrossProceeds
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000442"
      unitRef="USD">23846</VWAV:GrossProceeds>
    <VWAV:TransactionEpenses
      contextRef="AsOf2025-02-15"
      decimals="0"
      id="Fact000444"
      unitRef="USD">308000</VWAV:TransactionEpenses>
    <VWAV:IssuedConvertiblePromissoryNote
      contextRef="AsOf2025-02-25"
      decimals="0"
      id="Fact000446"
      unitRef="USD">5000000</VWAV:IssuedConvertiblePromissoryNote>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-10-012025-09-30" id="Fact000448">&lt;p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_zxVgc7UDm8md" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 3&#x2014;&lt;span id="xdx_82C_zTlreFFp1M79"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_znRIu5gXIuw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zYPOcptTBkI6"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements
of the Company are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America
(&#x201c;US GAAP&#x201d;) and under the rules of the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;







&lt;p id="xdx_84D_eus-gaap--ConsolidationPolicyTextBlock_zihOSuuzX0g5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_z79mAwjUVwtb"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements
include the accounts of VisionWave Holdings Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated
in consolidation.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zG8ijm4Bk7H2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_ziE98Mnf2kM7"&gt;Segment Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company complies with ASU 2023-07, Segment Reporting
(Topic 280): Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;), which improves reportable segment disclosure
requirements, primarily through enhanced disclosures about significant segment expenses among other disclosure requirements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_zULnraRJ2Sv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z3nGWSiltY78"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is an &#x201c;emerging growth company,&#x201d;
as defined in Section 2(a) of the Securities Act of 1933, as amended, (the &#x201c;Securities Act&#x201d;), as modified by the Jumpstart
our Business Startups Act of 2012, (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being
required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Further, Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison
of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company nor an emerging growth
company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting
standards used.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zqFhjJM6xzMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86A_zPZQKnWM2lKc"&gt;Use of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of these consolidated financial statements
in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses
during the reporting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Making estimates requires management to exercise significant judgement. It is
at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date
of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to
one or more future confirming events. Significant estimates include assumptions made in the valuation of the options, valuation of convertible
notes and recoverability of deferred tax assets. Accordingly, the actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zSL2kaif6bU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86B_zAOZd4gFEj9c"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments that potentially subject the
Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository
Insurance Coverage of $&lt;span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20250930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CreditRiskMember_zb5cvTOJtd8d" title="Federal Depository Insurance coverage"&gt;250,000&lt;/span&gt;. At September 30, 2025 and 2024, the Company had $&lt;span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20250930_z7ty4se4SAaj" title="Federal Depository Insurance coverage"&gt;1,774,899&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20240930_zGeqR6hYTfrl" title="Federal Depository Insurance coverage"&gt;0&lt;/span&gt; deposits in excess of the Federal Depository
Insurance Coverage, respectively. The Company has not experienced losses on these accounts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;







&lt;p id="xdx_840_eus-gaap--BusinessCombinationsPolicy_zGckUbuWam6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_867_zy8A4nn9gFY6"&gt;Business Combinations&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates whether acquired net assets
should be accounted for as a business combination or an asset acquisition by first applying a screen test to determine whether substantially
all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.
If so, the transaction is accounted for as an asset acquisition. If not, the Company applies its judgement to determine whether the acquired
net assets meets the definition of a business by considering if the set includes an acquired input, process, and the ability to create
outputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for business combinations using
the acquisition method when it has obtained control. The Company measures goodwill as the fair value of the consideration transferred
including the fair value of any non-controlling interest recognized, less the net recognized amount of the identifiable assets acquired
and liabilities assumed, all measured at their fair value as of the acquisition date. Transaction costs, other than those associated with
the issuance of debt or equity securities, that the Company incurs in connection with a business combination are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Any contingent consideration is measured at fair value
at the acquisition date. For contingent consideration that does not meet all the criteria for equity classification, such contingent consideration
is required to be recorded at its initial fair value at the acquisition date, and on each balance sheet date thereafter. Changes in the
estimated fair value of liability-classified contingent consideration are recognized on the consolidated statements of operations in the
period of change.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;When the initial accounting for a business combination
has not been finalized by the end of the reporting period in which the transaction occurs, the Company reports provisional amounts. Provisional
amounts are adjusted during the measurement period, which does not exceed one year from the acquisition date. These adjustments, or recognition
of additional assets or liabilities, reflect new information obtained about facts and circumstances that existed at the acquisition date
that, if known, would have affected the amounts recognized at that date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company accounts for certain business combinations
that meet the definition of a reverse merger (also referred to as a reverse recapitalization) in accordance with ASC 805, Business Combinations,
and ASC 810, Consolidation. A reverse merger occurs when the legal acquirer is determined to be the accounting acquiree, and the legal
acquiree is determined to be the accounting acquirer. Accordingly:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No
                                            goodwill or intangible assets are recorded&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            transaction is treated as a capital transaction in substance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            accounting acquirer&#x2019;s assets and liabilities are carried forward at their historical
                                            carrying amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            accounting acquiree&#x2019;s net assets are recognized at fair value, if applicable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 293pt"&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zenkhxEunzEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_zzR4cNOMUZ55"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company considers all cash on hand and in banks, including accounts
in book overdraft positions, certificates of deposit and all short-term investments with an original maturity of three months or less
when purchased to be cash equivalents. The Company did &lt;span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_do_c20240930_zh0Fpj9JiBml" title="Cash equivalents"&gt;no&lt;/span&gt;t have any cash equivalents as of
September 30, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--InvestmentPolicyTextBlock_z8sVKYae4so5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;I&lt;b&gt;nvestments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;

The Company from time to time invests in equity securities. All marketable
equity securities held by the Company are accounted for under &#x201c;Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 320,
&#x201c;&lt;i&gt;Investments&lt;/i&gt; - Debt and Equity Securities.&#x201d; The Company accounts for available-for-sale equity investments at fair
value. From time to time, if the Company determines that the available market price of an available for sale investments is not a reasonable
indicator of the fair value, the Company will determine the best estimate of that fair value which is usually the cost.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_ziz4BsfHrQ15" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_zWhn4bEfE2s2"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of the Company&#x2019;s cash, current
assets and current liabilities approximates the carrying amounts represented in the accompanying consolidated balance sheets, due to their
short-term nature.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fair value is defined as the price which would be
received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
A three-tier fair value hierarchy which prioritizes the inputs used in the valuation methodologies is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 Inputs - Unadjusted quoted prices in active
markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 Inputs - Inputs other than quoted prices included
in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar
assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active,
inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds,
credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 Inputs - Unobservable inputs for determining
the fair values of assets or liabilities that reflect an entity&#x2019;s own assumptions about the assumptions that market participants
would use in pricing the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2025, other than the convertible
notes discussed below, the Company did not hold any financial assets or liabilities that were measured at fair value on a recurring or
nonrecurring basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--ConvertiblenotespayablePolicyTextBlock_zdAnosE2HuIl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86C_z95yAlMFf83g"&gt;Convertible notes payable&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company follows FASB ASC
480, Distinguishing Liabilities from Equity ("ASC 480"), when evaluating the accounting for its convertible instruments. A
financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies
a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as
a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly
on any one of the following: (a) a fixed monetary amount known at inception; (b) variations in something other than the fair value of
the issuer&#x2019;s equity shares; or (c) variations inversely related to changes in the fair value of the issuer&#x2019;s equity shares.
Convertible note instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability
at fair value at each balance sheet date.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;br/&gt;
&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;For convertible debt instruments
that are not considered liabilities under ASC 480 or ASC 815, the Company applies FASB ASC 470, Debt ("ASC 470"), for the accounting
of such instruments, including any premiums or discounts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--OffsettingBalancePolicyTextBlock_zCYcB1iX1js6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_zyUYSfA4tuik"&gt;Offsetting Balances&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with ASC Topic 210 &#x201c;Balance Sheet&#x201d;,
the Company&#x2019;s accounting policy is to offset assets and liabilities when a right of offset exist. Accordingly, the consolidated
balance sheets include transactions with affiliated parties on a net basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;







&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zHRPz5zWU4V1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86A_ztKd1BPRx2F1"&gt;Research and Development Cost&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for research and development
cost (&#x201c;R&amp;amp;D&#x201d;) in accordance with ASC Topic 730, &#x201c;Research and Development&#x201d;. R&amp;amp;D represents costs are expensed
as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--RevenueRecognitionInterest_zNxJ6ZCd0f5b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_868_zUuIU89oBTbf"&gt;Revenue Recognition&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes revenue in accordance with
ASC Topic 606, &lt;i&gt;Revenue from Contracts&lt;/i&gt;. The core principle of the guidance in Topic 606 is that an entity should recognize revenue
to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects
to be entitled in exchange for those goods or services. To achieve the core principle, the Company applied the following five-step model
that requires entities to exercise judgment:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(1) Identify the contracts or agreements with a customer:
The purchase order is considered to be the contract with the customer. The Company&#x2019;s revenue is derived from the customer orders
evidenced by the contract with the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(2) Identifying the performance obligations in the
contract or agreement: The contract with the customer contains a single performance obligation: fulfillment of the customer&#x2019;s order.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(3) Determine the transaction price: The Company&#x2019;s
arrangements pursuant to the contract require a full prepayment from the customer at a fixed price before the shipment of products. The
transaction price is the amount that reflects the consideration which the Company expects to receive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(4) Allocate the transaction price to the separate
performance obligations: All transaction prices are allocated to the single performance obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(5) Recognize revenue as each performance obligation
is satisfied: This performance obligation is satisfied when control of the product is transferred to the customer, which occurred upon
completion of the customer&#x2019;s live testing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company only applies the five-step model to contracts
when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its
clients.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the years ending September 30, 2025 and 2024,
no revenue was recorded.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--CostOfSalesPolicyTextBlock_zVwT6OJepes5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zfdotNvw6tD6"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s cost of goods sold is comprised of costs related to its
commercial revenue, including the cost of sourcing the equipment for sale. During the years ending September 30, 2025 and 2024, no cost
of goods sold was recorded.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zsjAS5ESglQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_zpv3d0EuP23h"&gt;Net Loss Per Share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net income (loss) per share is computed by dividing
the net loss by the weighted average shares outstanding for the year. Diluted loss per share is computed by giving effect to all potential
shares of common stock to the extent dilutive. For the year ended September 30, 2025 and the period from March 20, 2024 (inception) to
September 30, 2024, the Company&#x2019;s diluted weighted-average shares outstanding is equal to basic weighted-average shares, due to
the Company&#x2019;s net loss position. No common stock equivalents were included in the computation of diluted net loss per unit since
such inclusion would have been antidilutive. At September 30, 2025 and 2024, potentially dilutive securities include the public warrants
and the convertible promissory notes.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zIe1v2BUgr23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86A_zZMwVxYcpDji"&gt;Income Taxes&lt;/span&gt;&lt;span style="line-height: 115%"&gt;&lt;sup&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company follows the asset and liability method
of accounting for income taxes under ASC Topic 740, Income Taxes (&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered
or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included
the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;


&lt;p id="xdx_84E_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zfdKeZNeaLL" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_866_z5xyiWzfWAWk"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;In the normal course of business,
the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, which cover a wide range
of matters, including, among others, government investigations, shareholder lawsuits, and non-income tax matters.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;An accrual for a loss contingency
is recognized when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. If a potential
material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent
liability, together with an estimate of the range of possible loss if determinable and material, is disclosed.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--RelatedPartyAndRelatedPartyTransactionsPolicyTextBlock_zAQYp9vchWq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;b&gt;&lt;span id="xdx_86C_zKZvV61tCxdl"&gt;Related party and related-party transactions&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;b&gt;&#160;&lt;br/&gt;
&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Related parties, which can
be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other
party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered
to be related if they are subject to common control or common significant influence, such as a family member or relative, shareholder,
or a related corporation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Transactions involving related
parties cannot be presumed to be carried out on an arm&#x2019;s-length basis, as the requisite conditions of competitive, free-market
dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions
were consummated on terms equivalent to those that prevail in arm&#x2019;s-length transactions unless such representations can be substantiated.
It is not, however, practical to determine the fair value of amounts due to or from related parties due to their related-party nature.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;









&lt;p id="xdx_84A_eus-gaap--IncomeTaxUncertaintiesPolicy_zJUvcyMf6Kqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86E_z60eNnR2rcYg"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows the asset and liability method
of accounting for income taxes under ASC Topic 740, Income Taxes (&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered
or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included
the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC740 prescribes a recognition threshold and a
measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a
tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by
taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax
expense. There were no unrecognized tax benefits as of September 30, 2025 and 2024. Interest and penalties as of $&lt;span id="xdx_908_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_c20240320__20240930_zRwuen4yyxY4" title="Interest and penalties"&gt;35,065&lt;/span&gt;
and $0 was accrued for the year ended September 30, 2025 and the period from March 20, 2024 (inception) to September 30, 2024, respectively. The
Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation
from its position.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_zqzfN1Emnhkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86E_zPYrjZUzpyJl"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Deferred offering costs, which
consist of direct and incremental legal, accounting, consulting, printing, and other third-party fees related to the Company&#x2019;s issuance
of shares, are capitalized as assets in the consolidated balance sheets. The deferred offering costs will be offset against proceeds from
the offering upon issuance of shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--AdvertisingCostsPolicyTextBlock_zAiwmAoWwKKb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_868_zsGQ4XoqyNM9"&gt;Advertising and Promotion&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;All costs associated with &lt;i&gt;advertising
&lt;/i&gt;and promoting products are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--StockBasedCompensationPolicyTextBlock_zpfRD5HlkK72" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_863_z6y8EOsSEY52"&gt;Stock Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company complies with ASC 718 Compensation &#x2014;
Stock Compensation regarding shares granted to directors, officers and vendors of the Company by measuring the grant date fair value of
the award and recognizing the resulting expense over the period during which the employee is required to perform service in exchange for
the award. Equity-based compensation expense is only recognized for awards subject to performance conditions if it is probable that the
performance condition will be achieved. The Company accounts for forfeitures when they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zzdhWMLIRhJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86A_zR3qvfveePSg"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-09, Income
Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which requires disclosure of incremental income tax information
within the rate reconciliation and expanded disclosures of income taxes paid, among other disclosure requirements. ASU 2023-09 is effective
for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company&#x2019;s management does not believe the adoption
of ASU 2023-09 will have a material impact on its financial statements and disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 4, 2024, the FASB issued ASU 2024-03,
Disaggregation of Income Statement Expenses (DISE), requiring additional disclosure of the nature of expenses included in the statements
of operations. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the
face of the statements of operations as well as disclosures about selling expenses. The standard is effective for annual reporting periods
beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s management does not believe that
any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the
Company&#x2019;s consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-10-012025-09-30" id="Fact000450">&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_znRIu5gXIuw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zYPOcptTBkI6"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements
of the Company are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America
(&#x201c;US GAAP&#x201d;) and under the rules of the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;







</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-10-012025-09-30" id="Fact000454">&lt;p id="xdx_84D_eus-gaap--ConsolidationPolicyTextBlock_zihOSuuzX0g5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_z79mAwjUVwtb"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements
include the accounts of VisionWave Holdings Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated
in consolidation.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2024-10-012025-09-30" id="Fact000456">&lt;p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zG8ijm4Bk7H2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_ziE98Mnf2kM7"&gt;Segment Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company complies with ASU 2023-07, Segment Reporting
(Topic 280): Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;), which improves reportable segment disclosure
requirements, primarily through enhanced disclosures about significant segment expenses among other disclosure requirements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <VWAV:EmergingGrowthCompanyStatusPolicyTextBlock contextRef="From2024-10-012025-09-30" id="Fact000458">&lt;p id="xdx_846_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_zULnraRJ2Sv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z3nGWSiltY78"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is an &#x201c;emerging growth company,&#x201d;
as defined in Section 2(a) of the Securities Act of 1933, as amended, (the &#x201c;Securities Act&#x201d;), as modified by the Jumpstart
our Business Startups Act of 2012, (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being
required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Further, Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison
of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company nor an emerging growth
company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting
standards used.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</VWAV:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-10-012025-09-30" id="Fact000460">&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zqFhjJM6xzMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86A_zPZQKnWM2lKc"&gt;Use of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of these consolidated financial statements
in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses
during the reporting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Making estimates requires management to exercise significant judgement. It is
at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date
of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to
one or more future confirming events. Significant estimates include assumptions made in the valuation of the options, valuation of convertible
notes and recoverability of deferred tax assets. Accordingly, the actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-10-012025-09-30" id="Fact000462">&lt;p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zSL2kaif6bU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86B_zAOZd4gFEj9c"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments that potentially subject the
Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository
Insurance Coverage of $&lt;span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20250930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CreditRiskMember_zb5cvTOJtd8d" title="Federal Depository Insurance coverage"&gt;250,000&lt;/span&gt;. At September 30, 2025 and 2024, the Company had $&lt;span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20250930_z7ty4se4SAaj" title="Federal Depository Insurance coverage"&gt;1,774,899&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20240930_zGeqR6hYTfrl" title="Federal Depository Insurance coverage"&gt;0&lt;/span&gt; deposits in excess of the Federal Depository
Insurance Coverage, respectively. The Company has not experienced losses on these accounts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;







</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2025-09-30_us-gaap_CreditRiskMember"
      decimals="0"
      id="Fact000464"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000466"
      unitRef="USD">1774899</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000468"
      unitRef="USD">0</us-gaap:CashFDICInsuredAmount>
    <us-gaap:BusinessCombinationsPolicy contextRef="From2024-10-012025-09-30" id="Fact000472">&lt;p id="xdx_840_eus-gaap--BusinessCombinationsPolicy_zGckUbuWam6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_867_zy8A4nn9gFY6"&gt;Business Combinations&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates whether acquired net assets
should be accounted for as a business combination or an asset acquisition by first applying a screen test to determine whether substantially
all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.
If so, the transaction is accounted for as an asset acquisition. If not, the Company applies its judgement to determine whether the acquired
net assets meets the definition of a business by considering if the set includes an acquired input, process, and the ability to create
outputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for business combinations using
the acquisition method when it has obtained control. The Company measures goodwill as the fair value of the consideration transferred
including the fair value of any non-controlling interest recognized, less the net recognized amount of the identifiable assets acquired
and liabilities assumed, all measured at their fair value as of the acquisition date. Transaction costs, other than those associated with
the issuance of debt or equity securities, that the Company incurs in connection with a business combination are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Any contingent consideration is measured at fair value
at the acquisition date. For contingent consideration that does not meet all the criteria for equity classification, such contingent consideration
is required to be recorded at its initial fair value at the acquisition date, and on each balance sheet date thereafter. Changes in the
estimated fair value of liability-classified contingent consideration are recognized on the consolidated statements of operations in the
period of change.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;When the initial accounting for a business combination
has not been finalized by the end of the reporting period in which the transaction occurs, the Company reports provisional amounts. Provisional
amounts are adjusted during the measurement period, which does not exceed one year from the acquisition date. These adjustments, or recognition
of additional assets or liabilities, reflect new information obtained about facts and circumstances that existed at the acquisition date
that, if known, would have affected the amounts recognized at that date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company accounts for certain business combinations
that meet the definition of a reverse merger (also referred to as a reverse recapitalization) in accordance with ASC 805, Business Combinations,
and ASC 810, Consolidation. A reverse merger occurs when the legal acquirer is determined to be the accounting acquiree, and the legal
acquiree is determined to be the accounting acquirer. Accordingly:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No
                                            goodwill or intangible assets are recorded&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            transaction is treated as a capital transaction in substance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            accounting acquirer&#x2019;s assets and liabilities are carried forward at their historical
                                            carrying amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            accounting acquiree&#x2019;s net assets are recognized at fair value, if applicable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 293pt"&gt;&lt;/p&gt;

</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-10-012025-09-30" id="Fact000474">&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zenkhxEunzEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_zzR4cNOMUZ55"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company considers all cash on hand and in banks, including accounts
in book overdraft positions, certificates of deposit and all short-term investments with an original maturity of three months or less
when purchased to be cash equivalents. The Company did &lt;span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_do_c20240930_zh0Fpj9JiBml" title="Cash equivalents"&gt;no&lt;/span&gt;t have any cash equivalents as of
September 30, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000476"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentPolicyTextBlock contextRef="From2024-10-012025-09-30" id="Fact000478">&lt;p id="xdx_843_eus-gaap--InvestmentPolicyTextBlock_z8sVKYae4so5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;I&lt;b&gt;nvestments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;

The Company from time to time invests in equity securities. All marketable
equity securities held by the Company are accounted for under &#x201c;Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 320,
&#x201c;&lt;i&gt;Investments&lt;/i&gt; - Debt and Equity Securities.&#x201d; The Company accounts for available-for-sale equity investments at fair
value. From time to time, if the Company determines that the available market price of an available for sale investments is not a reasonable
indicator of the fair value, the Company will determine the best estimate of that fair value which is usually the cost.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-10-012025-09-30" id="Fact000480">&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_ziz4BsfHrQ15" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_zWhn4bEfE2s2"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of the Company&#x2019;s cash, current
assets and current liabilities approximates the carrying amounts represented in the accompanying consolidated balance sheets, due to their
short-term nature.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fair value is defined as the price which would be
received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
A three-tier fair value hierarchy which prioritizes the inputs used in the valuation methodologies is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 Inputs - Unadjusted quoted prices in active
markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 Inputs - Inputs other than quoted prices included
in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar
assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active,
inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds,
credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 Inputs - Unobservable inputs for determining
the fair values of assets or liabilities that reflect an entity&#x2019;s own assumptions about the assumptions that market participants
would use in pricing the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2025, other than the convertible
notes discussed below, the Company did not hold any financial assets or liabilities that were measured at fair value on a recurring or
nonrecurring basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <VWAV:ConvertiblenotespayablePolicyTextBlock contextRef="From2024-10-012025-09-30" id="Fact000482">&lt;p id="xdx_843_ecustom--ConvertiblenotespayablePolicyTextBlock_zdAnosE2HuIl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86C_z95yAlMFf83g"&gt;Convertible notes payable&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company follows FASB ASC
480, Distinguishing Liabilities from Equity ("ASC 480"), when evaluating the accounting for its convertible instruments. A
financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies
a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as
a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly
on any one of the following: (a) a fixed monetary amount known at inception; (b) variations in something other than the fair value of
the issuer&#x2019;s equity shares; or (c) variations inversely related to changes in the fair value of the issuer&#x2019;s equity shares.
Convertible note instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability
at fair value at each balance sheet date.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;br/&gt;
&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;For convertible debt instruments
that are not considered liabilities under ASC 480 or ASC 815, the Company applies FASB ASC 470, Debt ("ASC 470"), for the accounting
of such instruments, including any premiums or discounts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</VWAV:ConvertiblenotespayablePolicyTextBlock>
    <VWAV:OffsettingBalancePolicyTextBlock contextRef="From2024-10-012025-09-30" id="Fact000484">&lt;p id="xdx_845_ecustom--OffsettingBalancePolicyTextBlock_zCYcB1iX1js6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_zyUYSfA4tuik"&gt;Offsetting Balances&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with ASC Topic 210 &#x201c;Balance Sheet&#x201d;,
the Company&#x2019;s accounting policy is to offset assets and liabilities when a right of offset exist. Accordingly, the consolidated
balance sheets include transactions with affiliated parties on a net basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;







</VWAV:OffsettingBalancePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-10-012025-09-30" id="Fact000488">&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zHRPz5zWU4V1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86A_ztKd1BPRx2F1"&gt;Research and Development Cost&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for research and development
cost (&#x201c;R&amp;amp;D&#x201d;) in accordance with ASC Topic 730, &#x201c;Research and Development&#x201d;. R&amp;amp;D represents costs are expensed
as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueRecognitionInterest contextRef="From2024-10-012025-09-30" id="Fact000490">&lt;p id="xdx_84E_eus-gaap--RevenueRecognitionInterest_zNxJ6ZCd0f5b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_868_zUuIU89oBTbf"&gt;Revenue Recognition&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes revenue in accordance with
ASC Topic 606, &lt;i&gt;Revenue from Contracts&lt;/i&gt;. The core principle of the guidance in Topic 606 is that an entity should recognize revenue
to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects
to be entitled in exchange for those goods or services. To achieve the core principle, the Company applied the following five-step model
that requires entities to exercise judgment:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(1) Identify the contracts or agreements with a customer:
The purchase order is considered to be the contract with the customer. The Company&#x2019;s revenue is derived from the customer orders
evidenced by the contract with the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(2) Identifying the performance obligations in the
contract or agreement: The contract with the customer contains a single performance obligation: fulfillment of the customer&#x2019;s order.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(3) Determine the transaction price: The Company&#x2019;s
arrangements pursuant to the contract require a full prepayment from the customer at a fixed price before the shipment of products. The
transaction price is the amount that reflects the consideration which the Company expects to receive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(4) Allocate the transaction price to the separate
performance obligations: All transaction prices are allocated to the single performance obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(5) Recognize revenue as each performance obligation
is satisfied: This performance obligation is satisfied when control of the product is transferred to the customer, which occurred upon
completion of the customer&#x2019;s live testing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company only applies the five-step model to contracts
when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its
clients.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the years ending September 30, 2025 and 2024,
no revenue was recorded.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionInterest>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="From2024-10-012025-09-30" id="Fact000492">&lt;p id="xdx_84B_eus-gaap--CostOfSalesPolicyTextBlock_zVwT6OJepes5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zfdotNvw6tD6"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s cost of goods sold is comprised of costs related to its
commercial revenue, including the cost of sourcing the equipment for sale. During the years ending September 30, 2025 and 2024, no cost
of goods sold was recorded.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-10-012025-09-30" id="Fact000494">&lt;p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zsjAS5ESglQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_zpv3d0EuP23h"&gt;Net Loss Per Share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net income (loss) per share is computed by dividing
the net loss by the weighted average shares outstanding for the year. Diluted loss per share is computed by giving effect to all potential
shares of common stock to the extent dilutive. For the year ended September 30, 2025 and the period from March 20, 2024 (inception) to
September 30, 2024, the Company&#x2019;s diluted weighted-average shares outstanding is equal to basic weighted-average shares, due to
the Company&#x2019;s net loss position. No common stock equivalents were included in the computation of diluted net loss per unit since
such inclusion would have been antidilutive. At September 30, 2025 and 2024, potentially dilutive securities include the public warrants
and the convertible promissory notes.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-10-012025-09-30" id="Fact000496">&lt;p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zIe1v2BUgr23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86A_zZMwVxYcpDji"&gt;Income Taxes&lt;/span&gt;&lt;span style="line-height: 115%"&gt;&lt;sup&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company follows the asset and liability method
of accounting for income taxes under ASC Topic 740, Income Taxes (&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered
or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included
the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;


</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="From2024-10-012025-09-30" id="Fact000498">&lt;p id="xdx_84E_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zfdKeZNeaLL" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_866_z5xyiWzfWAWk"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;In the normal course of business,
the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, which cover a wide range
of matters, including, among others, government investigations, shareholder lawsuits, and non-income tax matters.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;An accrual for a loss contingency
is recognized when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. If a potential
material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent
liability, together with an estimate of the range of possible loss if determinable and material, is disclosed.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <VWAV:RelatedPartyAndRelatedPartyTransactionsPolicyTextBlock contextRef="From2024-10-012025-09-30" id="Fact000500">&lt;p id="xdx_84F_ecustom--RelatedPartyAndRelatedPartyTransactionsPolicyTextBlock_zAQYp9vchWq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;b&gt;&lt;span id="xdx_86C_zKZvV61tCxdl"&gt;Related party and related-party transactions&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;b&gt;&#160;&lt;br/&gt;
&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Related parties, which can
be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other
party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered
to be related if they are subject to common control or common significant influence, such as a family member or relative, shareholder,
or a related corporation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Transactions involving related
parties cannot be presumed to be carried out on an arm&#x2019;s-length basis, as the requisite conditions of competitive, free-market
dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions
were consummated on terms equivalent to those that prevail in arm&#x2019;s-length transactions unless such representations can be substantiated.
It is not, however, practical to determine the fair value of amounts due to or from related parties due to their related-party nature.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;









</VWAV:RelatedPartyAndRelatedPartyTransactionsPolicyTextBlock>
    <us-gaap:IncomeTaxUncertaintiesPolicy contextRef="From2024-10-012025-09-30" id="Fact000505">&lt;p id="xdx_84A_eus-gaap--IncomeTaxUncertaintiesPolicy_zJUvcyMf6Kqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86E_z60eNnR2rcYg"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows the asset and liability method
of accounting for income taxes under ASC Topic 740, Income Taxes (&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered
or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included
the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC740 prescribes a recognition threshold and a
measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a
tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by
taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax
expense. There were no unrecognized tax benefits as of September 30, 2025 and 2024. Interest and penalties as of $&lt;span id="xdx_908_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_c20240320__20240930_zRwuen4yyxY4" title="Interest and penalties"&gt;35,065&lt;/span&gt;
and $0 was accrued for the year ended September 30, 2025 and the period from March 20, 2024 (inception) to September 30, 2024, respectively. The
Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation
from its position.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxUncertaintiesPolicy>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000507"
      unitRef="USD">35065</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy contextRef="From2024-10-012025-09-30" id="Fact000509">&lt;p id="xdx_84A_eus-gaap--CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_zqzfN1Emnhkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86E_zPYrjZUzpyJl"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Deferred offering costs, which
consist of direct and incremental legal, accounting, consulting, printing, and other third-party fees related to the Company&#x2019;s issuance
of shares, are capitalized as assets in the consolidated balance sheets. The deferred offering costs will be offset against proceeds from
the offering upon issuance of shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2024-10-012025-09-30" id="Fact000511">&lt;p id="xdx_849_eus-gaap--AdvertisingCostsPolicyTextBlock_zAiwmAoWwKKb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_868_zsGQ4XoqyNM9"&gt;Advertising and Promotion&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;All costs associated with &lt;i&gt;advertising
&lt;/i&gt;and promoting products are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:AdvertisingCostsPolicyTextBlock>
    <VWAV:StockBasedCompensationPolicyTextBlock contextRef="From2024-10-012025-09-30" id="Fact000513">&lt;p id="xdx_849_ecustom--StockBasedCompensationPolicyTextBlock_zpfRD5HlkK72" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_863_z6y8EOsSEY52"&gt;Stock Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company complies with ASC 718 Compensation &#x2014;
Stock Compensation regarding shares granted to directors, officers and vendors of the Company by measuring the grant date fair value of
the award and recognizing the resulting expense over the period during which the employee is required to perform service in exchange for
the award. Equity-based compensation expense is only recognized for awards subject to performance conditions if it is probable that the
performance condition will be achieved. The Company accounts for forfeitures when they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</VWAV:StockBasedCompensationPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-10-012025-09-30" id="Fact000515">&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zzdhWMLIRhJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86A_zR3qvfveePSg"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-09, Income
Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which requires disclosure of incremental income tax information
within the rate reconciliation and expanded disclosures of income taxes paid, among other disclosure requirements. ASU 2023-09 is effective
for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company&#x2019;s management does not believe the adoption
of ASU 2023-09 will have a material impact on its financial statements and disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 4, 2024, the FASB issued ASU 2024-03,
Disaggregation of Income Statement Expenses (DISE), requiring additional disclosure of the nature of expenses included in the statements
of operations. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the
face of the statements of operations as well as disclosures about selling expenses. The standard is effective for annual reporting periods
beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s management does not believe that
any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the
Company&#x2019;s consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <VWAV:RecapitalizationTextBlock contextRef="From2024-10-012025-09-30" id="Fact000517">&lt;p id="xdx_80D_ecustom--RecapitalizationTextBlock_zna0Xa9Z4KQ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 4 &#x2014; &lt;span id="xdx_825_z0ZD564vWOY5"&gt;Recapitalization&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As outlined in Note 1, the Company consummated the
Reverse Acquisition with VisionWave Technologies on July 14, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to and in accordance with the terms set forth
in the Merger Agreement, (a)&#160;Parent Merger Sub merged with and into Bannix, with Bannix continuing as the surviving entity (the &#x201c;Parent
Merger&#x201d;), as a result of which, (i)&#160;Bannix became a wholly owned subsidiary of VW Holdings, and (ii)&#160;each issued and outstanding
share of Bannix immediately prior to the effective time of the Parent Merger (the &#x201c;Parent Merger Effective Time&#x201d;) (other than
shares of Bannix Common Stock that have been redeemed or are owned by Bannix or any of its direct or indirect subsidiaries as treasury
shares and any Dissenting Parent Shares) was automatically cancelled in exchange for one share of common stock, par value $0.001 of VW
Holdings, each Bannix Warrant automatically converted into one warrant to purchase shares of VW Holdings Common Stock on substantially
the same terms and conditions and each Bannix Right automatically converted into the number of shares of VW Holdings Common Stock that
would have been received by the holder of such Bannix Right if it had been converted upon the consummation of a Business Combination in
accordance with Bannix&#x2019;s organizational document and, (b)&#160;immediately following the consummation of the Parent Merger but on
the same day, Company Merger Sub merged with and into Target, with Target continuing as the surviving entity (the &#x201c;Company Merger&#x201d;
and, together with the Parent Merger, the &#x201c;Mergers&#x201d;), as a result of which, (i)&#160;Target became a wholly owned subsidiary
of VW Holdings, and (ii)&#160;each issued and outstanding security of Target immediately prior to the effective time of the Company Merger
(the &#x201c;Company Merger Effective Time&#x201d;) (other than any cancelled Shares or dissenting shares) were no longer be outstanding
and were automatically cancelled in exchange for the issuance to the holder thereof of a substantially equivalent security of VW Holdings.
The Mergers and the other transactions contemplated by the Merger Agreement are hereinafter referred to as the &#x201c;Reverse Acquisition.&#x201d;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Merger Agreement contained representations, warranties
and covenants of each of the parties thereto that are customary for transactions of this type, including, among others, covenants providing
for (i) certain limitations on the operation of the parties&#x2019; respective businesses prior to consummation of the Business Combination,
(ii) the parties&#x2019; efforts to satisfy conditions to consummation of the Business Combination, including by obtaining any necessary
approvals from governmental agencies, (iii) prohibitions on the parties soliciting alternative transactions, (iv) VW Holdings preparing
and filing a registration statement on Form S-4 with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) and taking certain
other actions to obtain the requisite approval of Bannix&#x2019;s stockholders to vote in favor of certain matters, including the adoption
of the Merger Agreement and approval of the Business Combination, at a special meeting to be called for the approval of such matters,
and (v) the protection of, and access to, confidential information of the parties. On May 5, 2025, the SEC declared the Company&#x2019;s
registration statement on Form S-4 to be effective.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As described in the Merger Agreement, VW Holdings
has agreed to adopt an equity incentive plan&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Business Combination was accounted for as a reverse
recapitalization in accordance with GAAP. Under this method of accounting, Bannix, who is the legal acquirer, was treated as the &#x201c;acquired&#x201d;
company for financial reporting purposes and VisionWave Technologies Inc. was treated as the accounting acquirer. VisionWave Technologies
Inc. has been determined to be the accounting acquirer based on evaluation of the following facts and circumstances under the redemption
scenarios:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;VisionWave Technologies Inc.&#x2019;s existing stockholders had more than
69% of the voting interest of VW Holdings under both the no redemption and maximum redemption scenarios;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;VisionWave Technologies Inc.&#x2019;s senior management comprises the senior
management of VW Holdings Inc.;&#160;the directors nominated by VisionWave Technologies represent the majority of the board of directors
of VW Holdings Inc.;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;VisionWave Technologies Inc.&#x2019;s operations comprises the ongoing operations
of VW Holdings Inc.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accordingly, for accounting purposes, the Reverse
Acquisition was treated as the equivalent of a capital transaction in which VisionWave technologies Inc. is issuing stock for the net
assets of Bannix. The net assets of Bannix were stated at historical cost, with no goodwill or other intangible assets recorded. Operations
prior to the Reverse Acquisition were those of VisionWave Technologies, Inc.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Transaction Proceeds&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Upon closing of the Reverse Acquisition, the Company
acquired cash of $&lt;span id="xdx_90D_ecustom--GrossProceeds_c20241001__20250930__us-gaap--RelatedPartyTransactionAxis__custom--ReverseAcquisitionMember_z4yQhVgTaF2d" title="Gross proceeds"&gt;1,169,746&lt;/span&gt; as a result of the Reverse Acquisition, and paid total transaction costs of $&lt;span id="xdx_905_eus-gaap--AssetAcquisitionConsiderationTransferredTransactionCost_c20241001__20250930_zp88fkhABiZ2" title="Transaction costs"&gt;1,145,900&lt;/span&gt;. The following
table reconciles the elements of the Reverse Acquisition to the consolidated statements of cash flows and the consolidated statement of
changes in stockholders&#x2019; deficit for the year ended September 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfconsolidatedStatementsOfCashFlowsAndChangesInStockholdersDeficitTableTextBlock_zaSYz16tCxPg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Recapitalization (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8BE_zY10j3OatGo1"&gt;Schedule
of consolidated statements of cash flows and changes in stockholders deficit&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_491_20241001__20250930_zoFh4ypCJC57" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--CashtrustAndCashNetOfRedemptions_zCDJqVXdCe6l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Cash-trust and cash, net of redemptions&lt;/td&gt;
&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&#160;&lt;/td&gt;
&lt;td style="width: 18%; text-align: right"&gt;1,169,746&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--LessTransactionCostsPaid_zkqAQc4SE2Zf" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less: transaction costs paid&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,145,900&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--NetPayoutInReverseAcquisition_za3CDGkIyWA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net cash acquired in Reverse Acquisition&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;23,846&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--LessLiabilitiesAssumed_zeBVl3AqDe6a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less: Liabilities assumed&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(7,370,764&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--LessPromissoryNoteCombined_zAohPXJWiLw8" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Less: Promissory note assumed&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(1,003,995&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--AddAssetsAcquired_zHv8ThRrKjpl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Add: assets acquired&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,930&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--ReverseAcquistionNet_zIJTP8yitzq3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net liabilities assumed in reverse acquisition&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;(8,346,983&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_8AC_zyrJ3zzCCgp1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The number of shares of Common Stock issued immediately
following the consummation of the Reverse Acquisition were:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfConsummationOfTheReverseAcquisitionTableTextBlock_ztjBcRoCuAyb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Recapitalization (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8BB_zNTDIe9V9Y0g"&gt;Schedule
of consummation of the Reverse Acquisition&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bannix Class A common stock, outstanding prior to the Reverse Acquisition&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--SharesIssued_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--BannixClassACommonStockMember_z2cuS4q2tJQ9" style="width: 18%; text-align: right" title="Shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,623,666&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less: Redemption of Bannix Class A common stock&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--ShareIssued_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--RedemptionClassACommonStockMember_zPBsRBi5syd2" style="border-bottom: Black 1pt solid; text-align: right" title="Shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(83,342&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--SharesIssued_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--TotalBannixClassACommonStockMember_zmg3otCanuC8" style="border-bottom: Black 1pt solid; text-align: right" title="Shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,540,324&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bannix Class B common stock, outstanding prior to the Reverse Acquisition&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--SharesIssued_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--BannixClassBCommonStockMember_zkaa3rGZ4iv5" style="text-align: right" title="Shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0551"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Business Combination shares&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--SharesIssued_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--BusinessCombinationSharesMember_zwb9BLconA4e" style="text-align: right" title="Shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,540,324&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bannix public Rights converted to shares at closing&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--SharesIssued_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--BannixPublicRightsMember_zSOmwgBvPQHk" style="text-align: right" title="Shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;690,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bannix private Rights converted to shares at closing&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--SharesIssued_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--BannixPrivateRightsMember_z8WPPAYtGXD9" style="text-align: right" title="Shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;40,600&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VisionWave Technologies Inc. Shares&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--SharesIssued_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveTechnologiesMember_zuF3gn9FDfA5" style="border-bottom: Black 1pt solid; text-align: right" title="Shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11,000,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Common Stock immediately after the Reverse Acquisition&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--SharesIssued_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--CommonStockReverseMember_zhgYwEOE22Td" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14,270,924&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;




&lt;p id="xdx_8A0_zGrpAiGipdra" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The number of VisionWave Holdings&#x2019; shares was
determined as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfTheNumberOfVisionWaveHoldingsSharesTableTextBlock_zf1Fjfe1zF7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Recapitalization (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8BD_z9pbOXs3rDd2"&gt;Schedule
of the number of VisionWave Holdings shares&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49F_20241001__20250930__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveMember_zo37ZBSDalKc" style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49F_20241001__20250930__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveMember_zp4ZTk3xpVq2" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VisionWave
Technologies Inc. Shares&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VisionWave
Holdings Inc. Shares&lt;br/&gt; after conversion&lt;br/&gt; ratio&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class
A Common&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%; font-size: 12pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ConversionOfStockSharesIssued1_c20241001__20250930__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveMember__us-gaap--StatementClassOfStockAxis__custom--ClassACommonMember_zQ6IZ9COrmb9" style="width: 12%; font-size: 12pt; text-align: right" title="Number shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,722&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--ConversionOfStockSharesIssued1_c20241001__20250930__us-gaap--StatementClassOfStockAxis__custom--ClassACommonMember_zXbVxDle62wa" style="width: 12%; text-align: right" title="Number shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11,000,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class
B Common&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 12pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ConversionOfStockSharesIssued1_c20241001__20250930__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveMember__us-gaap--StatementClassOfStockAxis__custom--ClassBCommonMember_zljcxb3iplRj" style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: right" title="Number shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0569"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ConversionOfStockSharesIssued1_c20241001__20250930__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveTechnologiesMember__us-gaap--StatementClassOfStockAxis__custom--ClassBCommonMember_zEZT6gP64qlh" style="border-bottom: Black 1pt solid; text-align: right" title="Number shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0571"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ConversionOfStockSharesIssued1_c20241001__20250930__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveMember_zZs2VqIBPDDf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="TotalNumber shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,722&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ConversionOfStockSharesIssued1_c20241001__20250930__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveTechnologiesMember_zYVTYsTvNAhd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="TotalNumber shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11,000,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_8AC_zambSCKCRbne" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In exchange, each share of VisionWave Technologies
was converted into &lt;span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20241001__20250930_zLGFfrlj63R8" title="Converted Shares"&gt;4,041&lt;/span&gt; shares of companies common stock&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Public and private placement warrants&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQKX9GeFu2q8" title="Warrants issued"&gt;6,900,000&lt;/span&gt; public warrants issued at the time of
Bannix&#x2019;s initial public offering (the &#x201c;Bannix IPO&#x201d;), and &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zBdVXnTkjod5" title="Warrants issued"&gt;406,000&lt;/span&gt; warrants issued in connection with private placement
at the time of Bannix&#x2019;s initial public offering remained outstanding and became warrants for the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</VWAV:RecapitalizationTextBlock>
    <VWAV:GrossProceeds
      contextRef="From2024-10-012025-09-30_custom_ReverseAcquisitionMember"
      decimals="0"
      id="Fact000521"
      unitRef="USD">1169746</VWAV:GrossProceeds>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000523"
      unitRef="USD">1145900</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <VWAV:ScheduleOfconsolidatedStatementsOfCashFlowsAndChangesInStockholdersDeficitTableTextBlock contextRef="From2024-10-012025-09-30" id="Fact000525">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfconsolidatedStatementsOfCashFlowsAndChangesInStockholdersDeficitTableTextBlock_zaSYz16tCxPg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Recapitalization (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8BE_zY10j3OatGo1"&gt;Schedule
of consolidated statements of cash flows and changes in stockholders deficit&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_491_20241001__20250930_zoFh4ypCJC57" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--CashtrustAndCashNetOfRedemptions_zCDJqVXdCe6l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Cash-trust and cash, net of redemptions&lt;/td&gt;
&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&#160;&lt;/td&gt;
&lt;td style="width: 18%; text-align: right"&gt;1,169,746&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--LessTransactionCostsPaid_zkqAQc4SE2Zf" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less: transaction costs paid&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,145,900&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--NetPayoutInReverseAcquisition_za3CDGkIyWA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net cash acquired in Reverse Acquisition&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;23,846&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--LessLiabilitiesAssumed_zeBVl3AqDe6a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less: Liabilities assumed&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(7,370,764&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--LessPromissoryNoteCombined_zAohPXJWiLw8" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Less: Promissory note assumed&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(1,003,995&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--AddAssetsAcquired_zHv8ThRrKjpl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Add: assets acquired&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,930&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--ReverseAcquistionNet_zIJTP8yitzq3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net liabilities assumed in reverse acquisition&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;(8,346,983&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

</VWAV:ScheduleOfconsolidatedStatementsOfCashFlowsAndChangesInStockholdersDeficitTableTextBlock>
    <VWAV:CashtrustAndCashNetOfRedemptions
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000527"
      unitRef="Shares">1169746</VWAV:CashtrustAndCashNetOfRedemptions>
    <VWAV:LessTransactionCostsPaid
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000529"
      unitRef="Shares">-1145900</VWAV:LessTransactionCostsPaid>
    <VWAV:NetPayoutInReverseAcquisition
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000531"
      unitRef="Shares">23846</VWAV:NetPayoutInReverseAcquisition>
    <VWAV:LessLiabilitiesAssumed
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000533"
      unitRef="Shares">-7370764</VWAV:LessLiabilitiesAssumed>
    <VWAV:LessPromissoryNoteCombined
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000535"
      unitRef="Shares">-1003995</VWAV:LessPromissoryNoteCombined>
    <VWAV:AddAssetsAcquired
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000537"
      unitRef="Shares">3930</VWAV:AddAssetsAcquired>
    <VWAV:ReverseAcquistionNet
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000539"
      unitRef="Shares">-8346983</VWAV:ReverseAcquistionNet>
    <VWAV:ScheduleOfConsummationOfTheReverseAcquisitionTableTextBlock contextRef="From2024-10-012025-09-30" id="Fact000543">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfConsummationOfTheReverseAcquisitionTableTextBlock_ztjBcRoCuAyb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Recapitalization (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8BB_zNTDIe9V9Y0g"&gt;Schedule
of consummation of the Reverse Acquisition&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bannix Class A common stock, outstanding prior to the Reverse Acquisition&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--SharesIssued_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--BannixClassACommonStockMember_z2cuS4q2tJQ9" style="width: 18%; text-align: right" title="Shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,623,666&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less: Redemption of Bannix Class A common stock&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--ShareIssued_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--RedemptionClassACommonStockMember_zPBsRBi5syd2" style="border-bottom: Black 1pt solid; text-align: right" title="Shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(83,342&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--SharesIssued_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--TotalBannixClassACommonStockMember_zmg3otCanuC8" style="border-bottom: Black 1pt solid; text-align: right" title="Shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,540,324&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bannix Class B common stock, outstanding prior to the Reverse Acquisition&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--SharesIssued_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--BannixClassBCommonStockMember_zkaa3rGZ4iv5" style="text-align: right" title="Shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0551"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Business Combination shares&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--SharesIssued_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--BusinessCombinationSharesMember_zwb9BLconA4e" style="text-align: right" title="Shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,540,324&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bannix public Rights converted to shares at closing&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--SharesIssued_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--BannixPublicRightsMember_zSOmwgBvPQHk" style="text-align: right" title="Shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;690,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bannix private Rights converted to shares at closing&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--SharesIssued_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--BannixPrivateRightsMember_z8WPPAYtGXD9" style="text-align: right" title="Shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;40,600&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VisionWave Technologies Inc. Shares&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--SharesIssued_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveTechnologiesMember_zuF3gn9FDfA5" style="border-bottom: Black 1pt solid; text-align: right" title="Shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11,000,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Common Stock immediately after the Reverse Acquisition&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--SharesIssued_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--CommonStockReverseMember_zhgYwEOE22Td" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14,270,924&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;




</VWAV:ScheduleOfConsummationOfTheReverseAcquisitionTableTextBlock>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-09-30_custom_BannixClassACommonStockMember"
      decimals="INF"
      id="Fact000545"
      unitRef="Shares">2623666</us-gaap:SharesIssued>
    <VWAV:ShareIssued
      contextRef="AsOf2025-09-30_custom_RedemptionClassACommonStockMember"
      decimals="INF"
      id="Fact000547"
      unitRef="Shares">-83342</VWAV:ShareIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-09-30_custom_TotalBannixClassACommonStockMember"
      decimals="INF"
      id="Fact000549"
      unitRef="Shares">2540324</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-09-30_custom_BusinessCombinationSharesMember"
      decimals="INF"
      id="Fact000553"
      unitRef="Shares">2540324</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-09-30_custom_BannixPublicRightsMember"
      decimals="INF"
      id="Fact000555"
      unitRef="Shares">690000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-09-30_custom_BannixPrivateRightsMember"
      decimals="INF"
      id="Fact000557"
      unitRef="Shares">40600</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-09-30_custom_VisionWaveTechnologiesMember"
      decimals="INF"
      id="Fact000559"
      unitRef="Shares">11000000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-09-30_custom_CommonStockReverseMember"
      decimals="INF"
      id="Fact000561"
      unitRef="Shares">14270924</us-gaap:SharesIssued>
    <VWAV:ScheduleOfTheNumberOfVisionWaveHoldingsSharesTableTextBlock contextRef="From2024-10-012025-09-30" id="Fact000563">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfTheNumberOfVisionWaveHoldingsSharesTableTextBlock_zf1Fjfe1zF7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Recapitalization (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8BD_z9pbOXs3rDd2"&gt;Schedule
of the number of VisionWave Holdings shares&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49F_20241001__20250930__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveMember_zo37ZBSDalKc" style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49F_20241001__20250930__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveMember_zp4ZTk3xpVq2" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VisionWave
Technologies Inc. Shares&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VisionWave
Holdings Inc. Shares&lt;br/&gt; after conversion&lt;br/&gt; ratio&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class
A Common&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%; font-size: 12pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ConversionOfStockSharesIssued1_c20241001__20250930__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveMember__us-gaap--StatementClassOfStockAxis__custom--ClassACommonMember_zQ6IZ9COrmb9" style="width: 12%; font-size: 12pt; text-align: right" title="Number shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,722&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--ConversionOfStockSharesIssued1_c20241001__20250930__us-gaap--StatementClassOfStockAxis__custom--ClassACommonMember_zXbVxDle62wa" style="width: 12%; text-align: right" title="Number shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11,000,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class
B Common&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 12pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ConversionOfStockSharesIssued1_c20241001__20250930__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveMember__us-gaap--StatementClassOfStockAxis__custom--ClassBCommonMember_zljcxb3iplRj" style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: right" title="Number shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0569"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ConversionOfStockSharesIssued1_c20241001__20250930__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveTechnologiesMember__us-gaap--StatementClassOfStockAxis__custom--ClassBCommonMember_zEZT6gP64qlh" style="border-bottom: Black 1pt solid; text-align: right" title="Number shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0571"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ConversionOfStockSharesIssued1_c20241001__20250930__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveMember_zZs2VqIBPDDf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="TotalNumber shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,722&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ConversionOfStockSharesIssued1_c20241001__20250930__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveTechnologiesMember_zYVTYsTvNAhd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="TotalNumber shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11,000,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

</VWAV:ScheduleOfTheNumberOfVisionWaveHoldingsSharesTableTextBlock>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2024-10-012025-09-30_custom_VisionWaveMember_custom_ClassACommonMember"
      decimals="INF"
      id="Fact000565"
      unitRef="Shares">2722</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2024-10-012025-09-30_custom_ClassACommonMember"
      decimals="INF"
      id="Fact000567"
      unitRef="Shares">11000000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2024-10-012025-09-30_custom_VisionWaveMember"
      decimals="INF"
      id="Fact000573"
      unitRef="Shares">2722</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2024-10-012025-09-30_custom_VisionWaveTechnologiesMember"
      decimals="INF"
      id="Fact000575"
      unitRef="Shares">11000000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000577"
      unitRef="Shares">4041</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2025-09-30_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000579"
      unitRef="Shares">6900000</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2025-09-30_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000581"
      unitRef="Shares">406000</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2024-10-012025-09-30" id="Fact000583">&lt;p id="xdx_80A_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zPwNAzwGIXF1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 5 &#x2014; &lt;span id="xdx_82F_zrNctZeyNLAa"&gt;Accounts Payable &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts payable and accrued liabilities&lt;b&gt;&#160;&lt;/b&gt;consist
of the following as of September 30, 2025 and 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z3DFQlqGrATf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Payable (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_829_zCUOHn9use3b"&gt;Schedule of Accounts payable and accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_497_20250930_zXJqjJ78CLj8" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_495_20240930_z7FP0ZUeSXx2" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--UnderwritersMarketingFee_iI_zXBLlfnVN1Ad" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Underwriter's marketing fee (See Note 10)&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;1,800,000&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0588"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--AccountsPayableCurrent_iI_zTxpprr97bSl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Vendors payable&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;939,192&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0591"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_zJqrWjoovXDf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued compensation expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;359,667&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0594"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--FranchiseTaxPayable_iI_zJjzGA8mxhQ1" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;Franchise tax payable&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;267,323&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0597"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--InsurancePremiumFinancing_iI_zptD2K5xX6Kc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Insurance premium financing&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;71,851&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0600"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_iI_zDn5mA0XcY2d" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued interest expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;49,914&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0603"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--AccountsPayableOtherCurrent_iI_zplsMEfMeRfd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other payables&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;429,887&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,000&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_zuo5Tyb1coB9" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Total&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;3,917,834&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;15,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A8_zStR5pyezaXb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;







</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2024-10-012025-09-30" id="Fact000585">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z3DFQlqGrATf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Payable (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_829_zCUOHn9use3b"&gt;Schedule of Accounts payable and accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_497_20250930_zXJqjJ78CLj8" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_495_20240930_z7FP0ZUeSXx2" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--UnderwritersMarketingFee_iI_zXBLlfnVN1Ad" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Underwriter's marketing fee (See Note 10)&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;1,800,000&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0588"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--AccountsPayableCurrent_iI_zTxpprr97bSl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Vendors payable&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;939,192&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0591"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_zJqrWjoovXDf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued compensation expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;359,667&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0594"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--FranchiseTaxPayable_iI_zJjzGA8mxhQ1" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;Franchise tax payable&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;267,323&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0597"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--InsurancePremiumFinancing_iI_zptD2K5xX6Kc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Insurance premium financing&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;71,851&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0600"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_iI_zDn5mA0XcY2d" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued interest expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;49,914&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0603"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--AccountsPayableOtherCurrent_iI_zplsMEfMeRfd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other payables&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;429,887&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,000&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_zuo5Tyb1coB9" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Total&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;3,917,834&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;15,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <VWAV:UnderwritersMarketingFee
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000587"
      unitRef="USD">1800000</VWAV:UnderwritersMarketingFee>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000590"
      unitRef="USD">939192</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000593"
      unitRef="USD">359667</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <VWAV:FranchiseTaxPayable
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000596"
      unitRef="USD">267323</VWAV:FranchiseTaxPayable>
    <VWAV:InsurancePremiumFinancing
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000599"
      unitRef="USD">71851</VWAV:InsurancePremiumFinancing>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000602"
      unitRef="USD">49914</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000605"
      unitRef="USD">429887</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000606"
      unitRef="USD">15000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000608"
      unitRef="USD">3917834</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000609"
      unitRef="USD">15000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <VWAV:ExciseTaxPayableTextBlock contextRef="From2024-10-012025-09-30" id="Fact000613">&lt;p id="xdx_803_ecustom--ExciseTaxPayableTextBlock_zkuGciau8wLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 6 &#x2014;&lt;span id="xdx_82E_z2atxOnmhrKa"&gt; Excise Tax Payable&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 16, 2022, the Inflation Reduction Act of
2022 (the &#x201c;IR Act&#x201d;) was signed into federal law. The IR Act provides for, among other things, a 1% federal excise tax on certain
repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations
occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which
shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of
the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value
of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions
apply to the excise tax. The U.S. Department of the Treasury (the &#x201c;Treasury&#x201d;) has been given authority to provide regulations
and other guidance to carry out and prevent the abuse or avoidance of the excise tax.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 27, 2022, the Treasury published Notice
2023-2, which provided clarification on some aspects of the application of the excise tax. The notice generally provides that if a publicly
traded U.S. corporation completely liquidates and dissolves, distributions in such complete liquidation and other distributions by such
corporation in the same taxable year in which the final distribution in complete liquidation and dissolution is made are not subject to
the excise tax. Although such notice clarifies certain aspects of the excise tax, the interpretation and operation of aspects of the excise
tax (including its application and operation with respect to SPACs) remain unclear and such interim operating rules are subject to change.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Because the application of this excise tax is not
entirely clear, any redemption or other repurchase effected by the Company, in connection with a Business Combination, extension vote
or otherwise, may be subject to this excise tax. Because any such excise tax would be payable by the Company and not by the redeeming
holders, it could cause a reduction in the value of the Company&#x2019;s Class A common stock, cash available with which to effectuate
a Business Combination or cash available for distribution in a subsequent liquidation. Whether and to what extent the Company would be
subject to the excise tax in connection with a Business Combination will depend on a number of factors, including (i) the structure of
the Business Combination, (ii) the fair market value of the redemptions and repurchases in connection with the Business Combination, (iii)
the nature and amount of any &#x201c;PIPE&#x201d; or other equity issuances in connection with the Business Combination (or any other equity
issuances within the same taxable year of the Business Combination) and (iv) the content of any subsequent regulations, clarifications,
and other guidance issued by the Treasury. Further, the application of the excise tax in respect of distributions pursuant to a liquidation
of a publicly traded U.S. corporation is uncertain and has not been addressed by the Treasury in regulations, and it is possible that
the proceeds held in the Trust Account could be used to pay any excise tax owed by the Company in the event the Company is unable to complete
a Business Combination in the required time and redeem 100% of the remaining Class A common stock in accordance with the Company&#x2019;s
amended and restated certificate of incorporation, in which case the amount that would otherwise be received by the public stockholders
in connection with the Company&#x2019;s liquidation would be reduced.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Any redemption or other repurchase that occurs after
December 31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether and
to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise would
depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business
Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any PIPE or other equity
issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination, but issued within
the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury. In addition,
because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment of the excise
tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business Combination and
in the Company&#x2019;s ability to complete a Business Combination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;During the second quarter of 2024, the Internal
Revenue Service issued final regulations with respect to the timing and payment of the excise tax. These regulations provided that the
filing and payment deadline for any liability incurred during the period from January 1, 2023 to December 31, 2023 would be October 31,
2024. Any amount of such excise tax not paid in full, will be subject to additional interest and penalties which are currently estimated
at 8% interest per annum, a 0.5% underpayment penalty per month or portion of a month up to 25% of the total liability for any amount
that is unpaid from November 1, 2024 until paid in full, and a failure to file penalty of 5% per month.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prior to the consummation of the Reverse Acquisition,
Bannix&#x2019;s common stock exercised their right to redeem their shares for a pro rata portion of the funds in Bannix&#x2019;s Trust Account.
As a result of these redemptions, Bannix estimated the excise tax liability and applicable interest and penalties pursuant to the IR Act.
At the consummation of the Reverse Acquisition, $&lt;span id="xdx_901_eus-gaap--ExciseAndSalesTaxes_c20241001__20250930_z57mtpqiKY71" title="Excise tax interest and penalties"&gt;888,332&lt;/span&gt;, inclusive of excise tax interest and penalties. An additional $&lt;span id="xdx_903_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--BannixCommonStockMember_zumF63EPkjwa" title="Interest of penalties"&gt;54,707&lt;/span&gt; of interest
of penalties is estimated after close and included in the consolidated statement of operations for the year ended September 30, 2025.
As of September 30, 2025, $&lt;span id="xdx_903_ecustom--ExciseTaxLiabilitiesInterestAndPenalties_iI_c20250930_zipWBV2KDF2d" title="Excise tax liabilities  interest and penalties"&gt;943,039&lt;/span&gt; of excise tax liabilities inclusive of interest and penalties is recorded in the consolidated balance
sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</VWAV:ExciseTaxPayableTextBlock>
    <us-gaap:ExciseAndSalesTaxes
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000617"
      unitRef="USD">888332</us-gaap:ExciseAndSalesTaxes>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="AsOf2025-09-30_custom_BannixCommonStockMember"
      decimals="0"
      id="Fact000619"
      unitRef="USD">54707</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <VWAV:ExciseTaxLiabilitiesInterestAndPenalties
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000621"
      unitRef="USD">943039</VWAV:ExciseTaxLiabilitiesInterestAndPenalties>
    <VWAV:PromissoryNoteEvieTextBlock contextRef="From2024-10-012025-09-30" id="Fact000623">&lt;p id="xdx_804_ecustom--PromissoryNoteEvieTextBlock_zczm2umel6V6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 7 &#x2014; &lt;span id="xdx_829_zZqnCyRNNxa8"&gt;Promissory Note - Evie&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prior to the consummation of the Reverse Acquisition,
Bannix issued unsecured promissory notes to Evie Autonomous LTD (&#x201c;Evie&#x201d;) with a principal amount of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20250930_zocOhwvqpky7" title="Principal amount"&gt;1,003,995&lt;/span&gt; (the &#x201c;Evie
Autonomous Extension Notes&#x201d;). The Evie Autonomous Extension Notes bear no interest and are repayable in full upon the earlier of
(a) the date of the consummation of Bannix&#x2019;s initial Business Combination, or (b) the date of Bannix&#x2019;s liquidation. On December
26, 2024 and amended on May 27, 2025, Bannix entered into an agreement to defer payment of the Evie Autonomous Extension Notes. Under
the deferment agreement, these amounts will not become payable until any Pre-Paid Advance issued in connection with the SEPA is repaid
in full (See Note 9). The balance of $&lt;span id="xdx_901_eus-gaap--IncreaseDecreaseInPrepaidAdvertising_c20241001__20250930_zyZzCrI1VHrk" title="Balance of reverse"&gt;1,003,995&lt;/span&gt; was assumed at the close of the Reverse Acquisition. As of September 30, 2025 and 2024,
the balance of $&lt;span id="xdx_905_ecustom--PromissoryNoteBalance_iI_c20250930_zmAH9ztY8CDe" title="Promissory note balance"&gt;1,003,995&lt;/span&gt; and $&lt;span id="xdx_90B_ecustom--PromissoryNoteBalance_iI_c20240930_zRvNNhKScDFe" title="Promissory note balance"&gt;0&lt;/span&gt;, respectively, owing to Evie is reported as promissory notes &#x2013; Evie on the consolidated balance
sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</VWAV:PromissoryNoteEvieTextBlock>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000625"
      unitRef="USD">1003995</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:IncreaseDecreaseInPrepaidAdvertising
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000627"
      unitRef="USD">1003995</us-gaap:IncreaseDecreaseInPrepaidAdvertising>
    <VWAV:PromissoryNoteBalance
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000629"
      unitRef="USD">1003995</VWAV:PromissoryNoteBalance>
    <VWAV:PromissoryNoteBalance
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000631"
      unitRef="USD">0</VWAV:PromissoryNoteBalance>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-10-012025-09-30" id="Fact000633">&lt;p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zeFi1fh194O8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 8 &#x2014; &lt;span id="xdx_822_zcMbHkO2uJO3"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Due to Related Parties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prior to the consummation of the Reverse Acquisition, Bannix entered into various
transactions with related parties to fund working capital needs. A total of $&lt;span id="xdx_908_eus-gaap--IncreaseDecreaseInDueToRelatedParties_c20241001__20250930__us-gaap--RelatedPartyTransactionAxis__custom--BannixClassACommonStockMember_zsHeW6RmdkK2" title="Due to Related Parties"&gt;2,124,212&lt;/span&gt; owing to these related parties was assumed at the
close of the Reverse Acquisition. The table below at September 30, 2024 and September 30, 2025 balances for those
related parties.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_z0hhyvwvNOKf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Related Party Transactions (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;span style="display: none"&gt;&lt;span id="xdx_8B5_zautxQUFYBE4"&gt;Schedule of Due to Related Parties&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Suresh Yezhuvath (3)&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&#160;&lt;/td&gt;
&lt;td id="xdx_987_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SureshYezhuvathMember_zSNhOKbCwRd7" style="width: 12%; text-align: right" title="Due to related parties"&gt;223,960&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_ecustom--DueToRelatedParties_iI_c20250714__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SureshYezhuvathMember_z4OY1nlzKpqa" style="width: 12%; text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0641"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Subash Menon (3)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SubashMenonMember_z8jUAiKbRvi9" style="text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0643"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--DueToRelatedParties_iI_c20250714__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SubashMenonMember_zfwBwfZQ1KFa" style="text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0645"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Bannix Management LLP (3)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_985_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BannixManagementLLPMember_z624hlCFT8r" style="text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0647"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_ecustom--DueToRelatedParties_iI_c20250714__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BannixManagementLLPMember_zZoFmw9aNZL2" style="text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0649"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Instant Fame and affiliated parties (1)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PromissoryNotesMember_zRbk7DZqqdz4" style="text-align: right" title="Due to related parties"&gt;840,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--DueToRelatedParties_iI_c20250714__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PromissoryNotesMember_zanhMkp9b2tg" style="text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0653"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Stanley Hills&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_984_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StanleyHillsMember_zxvB9jrgBuGi" style="text-align: right" title="Due to related parties"&gt;785,252&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_986_ecustom--DueToRelatedParties_iI_c20250714__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StanleyHillsMember_z4FbCRXjeRb6" style="text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0657"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued executive compensation (2)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_987_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccruedExecutiveCompensationMember_zpQGlgVyxxB" style="text-align: right" title="Due to related parties"&gt;250,000&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_985_ecustom--DueToRelatedParties_iI_c20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccruedExecutiveCompensationMember_zLqzyYo9LYi4" style="text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0661"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Anat Attia&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AnatAttiaMember_z4wcaGmd1fja" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties"&gt;335,280&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--DueToRelatedParties_iI_c20250714__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AnatAttiaMember_zbukks2tAzS" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties"&gt;69,133&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98D_ecustom--DueRelatedParties_iI_c20250930_zPsd7DFW6xW4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Due to related parties"&gt;2,434,492&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--DueRelatedParties_iI_c20250714_zTMcobGMcrr2" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Due to related parties"&gt;69,133&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;(1)&#160;Instant Fame and affiliated parties&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Represents unsecured promissory note issued by Bannix
on December 13, 2022 in favor of Instant Fame, in the principal amount of $690,000. In March and April 2023, Bannix issued additional
unsecured promissory notes to Instant Fame for $75,000 for each promissory note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;(2)&#160;Accrued executive compensation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Represents compensation expense owing to executives.
At the close of the reverse acquisition $220,000 and $55,000 were owed to Doug Davis and Erik Klinger, respectively. At September 30,
2025, $25,000, $180,000 and $45,000 were owed to Noam Kenig, Doug Davis and Erik Klinger respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Deferment of payment of related party balances&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 26, 2024 and revised on February 4, 2025, April 19, 2025 and May
25, 2025, the Company entered into an agreement to defer payment of certain related party obligations. Under the deferment agreements,
all amounts owed to the sponsor of Bannix and its affiliates are payable only after any Pre-Paid Advance issued in connection with the
SEPA Pre-Paid Advances is repaid in full (See Note 9).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(3) &lt;i&gt;Transfer of balances&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the quarter ended, upon agreement by and amount
the related parties, $235,333 of balances owing to Bannix Management LLP and $4,737 of balances of Subash Menon was transferred to Stanley
Hill and $200,000 of balances owed to Subash Menon was transferred to Suresh Yezhuvath.&lt;/p&gt;
&lt;p id="xdx_8A1_z2F3oVdCrVp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;VisionWave Technologies related party transactions&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;br/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Stanley Hills, LLC, a corporation controlled by Anat
Attia, paid the entire company expenses for VisionWave Technologies Inc., as well as funded the Company&#x2019;s bank and brokerage accounts,
on behalf of the Company. on April 8, 2025, with an effective date of March 31, 2025, the Company entered into a Funding Support Agreement
with Stanley Hills, LLC (&#x201c;Stanley Hills&#x201d;), the principal shareholder of VisionWave Technologies. Pursuant to the agreement,
Stanley Hills irrevocably and unconditionally committed to provide financial support to the Company, sufficient to fund the working capital
needs through August 13, 2026. The funding may be provided by Stanley Hills in the form of direct payments to third parties, advances
or intercompany loans, or capital contributions, as mutually determined by the parties. Unless otherwise agreed in writing, any such advances
will be non-interest bearing and repayable only at such time as determined by the Board of Directors, and only to the extent such repayment
would not impair the Company&#x2019;s liquidity or ability to continue as a going concern. The agreement may not be terminated by Stanley
Hills prior to the twelve-month period from the date of release of the financial statement.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;br/&gt;
As of September 30, 2025 and 2024, the balance of $785,252
and $&lt;span id="xdx_908_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20231001__20240930_zJLe13RkcEk6"&gt;69,133&lt;/span&gt;,
respectively, owing to Stanley Hills, LLC is included in due to related parties on the consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="From2024-10-012025-09-30_custom_BannixClassACommonStockMember"
      decimals="0"
      id="Fact000635"
      unitRef="USD">2124212</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2024-10-012025-09-30" id="Fact000637">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_z0hhyvwvNOKf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Related Party Transactions (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;span style="display: none"&gt;&lt;span id="xdx_8B5_zautxQUFYBE4"&gt;Schedule of Due to Related Parties&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Suresh Yezhuvath (3)&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&#160;&lt;/td&gt;
&lt;td id="xdx_987_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SureshYezhuvathMember_zSNhOKbCwRd7" style="width: 12%; text-align: right" title="Due to related parties"&gt;223,960&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_ecustom--DueToRelatedParties_iI_c20250714__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SureshYezhuvathMember_z4OY1nlzKpqa" style="width: 12%; text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0641"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Subash Menon (3)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SubashMenonMember_z8jUAiKbRvi9" style="text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0643"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--DueToRelatedParties_iI_c20250714__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SubashMenonMember_zfwBwfZQ1KFa" style="text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0645"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Bannix Management LLP (3)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_985_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BannixManagementLLPMember_z624hlCFT8r" style="text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0647"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_ecustom--DueToRelatedParties_iI_c20250714__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BannixManagementLLPMember_zZoFmw9aNZL2" style="text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0649"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Instant Fame and affiliated parties (1)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PromissoryNotesMember_zRbk7DZqqdz4" style="text-align: right" title="Due to related parties"&gt;840,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--DueToRelatedParties_iI_c20250714__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PromissoryNotesMember_zanhMkp9b2tg" style="text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0653"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Stanley Hills&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_984_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StanleyHillsMember_zxvB9jrgBuGi" style="text-align: right" title="Due to related parties"&gt;785,252&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_986_ecustom--DueToRelatedParties_iI_c20250714__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StanleyHillsMember_z4FbCRXjeRb6" style="text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0657"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued executive compensation (2)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_987_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccruedExecutiveCompensationMember_zpQGlgVyxxB" style="text-align: right" title="Due to related parties"&gt;250,000&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_985_ecustom--DueToRelatedParties_iI_c20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccruedExecutiveCompensationMember_zLqzyYo9LYi4" style="text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0661"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Anat Attia&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AnatAttiaMember_z4wcaGmd1fja" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties"&gt;335,280&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--DueToRelatedParties_iI_c20250714__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AnatAttiaMember_zbukks2tAzS" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties"&gt;69,133&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98D_ecustom--DueRelatedParties_iI_c20250930_zPsd7DFW6xW4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Due to related parties"&gt;2,434,492&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--DueRelatedParties_iI_c20250714_zTMcobGMcrr2" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Due to related parties"&gt;69,133&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;(1)&#160;Instant Fame and affiliated parties&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Represents unsecured promissory note issued by Bannix
on December 13, 2022 in favor of Instant Fame, in the principal amount of $690,000. In March and April 2023, Bannix issued additional
unsecured promissory notes to Instant Fame for $75,000 for each promissory note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;(2)&#160;Accrued executive compensation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Represents compensation expense owing to executives.
At the close of the reverse acquisition $220,000 and $55,000 were owed to Doug Davis and Erik Klinger, respectively. At September 30,
2025, $25,000, $180,000 and $45,000 were owed to Noam Kenig, Doug Davis and Erik Klinger respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Deferment of payment of related party balances&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 26, 2024 and revised on February 4, 2025, April 19, 2025 and May
25, 2025, the Company entered into an agreement to defer payment of certain related party obligations. Under the deferment agreements,
all amounts owed to the sponsor of Bannix and its affiliates are payable only after any Pre-Paid Advance issued in connection with the
SEPA Pre-Paid Advances is repaid in full (See Note 9).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(3) &lt;i&gt;Transfer of balances&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the quarter ended, upon agreement by and amount
the related parties, $235,333 of balances owing to Bannix Management LLP and $4,737 of balances of Subash Menon was transferred to Stanley
Hill and $200,000 of balances owed to Subash Menon was transferred to Suresh Yezhuvath.&lt;/p&gt;
</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-09-30_custom_SureshYezhuvathMember"
      decimals="0"
      id="Fact000639"
      unitRef="USD">223960</VWAV:DueToRelatedParties>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-09-30_custom_PromissoryNotesMember"
      decimals="0"
      id="Fact000651"
      unitRef="USD">840000</VWAV:DueToRelatedParties>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-09-30_custom_StanleyHillsMember"
      decimals="0"
      id="Fact000655"
      unitRef="USD">785252</VWAV:DueToRelatedParties>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-09-30_custom_AccruedExecutiveCompensationMember"
      decimals="0"
      id="Fact000659"
      unitRef="USD">250000</VWAV:DueToRelatedParties>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-09-30_custom_AnatAttiaMember"
      decimals="0"
      id="Fact000663"
      unitRef="USD">335280</VWAV:DueToRelatedParties>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-07-14_custom_AnatAttiaMember"
      decimals="0"
      id="Fact000665"
      unitRef="USD">69133</VWAV:DueToRelatedParties>
    <VWAV:DueRelatedParties
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000667"
      unitRef="USD">2434492</VWAV:DueRelatedParties>
    <VWAV:DueRelatedParties
      contextRef="AsOf2025-07-14"
      decimals="0"
      id="Fact000669"
      unitRef="USD">69133</VWAV:DueRelatedParties>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2023-10-012024-09-30"
      decimals="0"
      id="Fact000672"
      unitRef="USD">69133</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-10-012025-09-30" id="Fact000674">&lt;p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zaFPIHfhoIsi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 9 &#x2014; &lt;span id="xdx_823_zXZqb4QmVHpi"&gt;Convertible Notes Payable&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Securities Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 15, 2025, the Company entered into Securities
Purchase Agreements (the &#x201c;July 2025 SPAs&#x201d;) with two unaffiliated accredited investors (&#x201c;July 2025 Lenders&#x201d;), pursuant
to which the Company issued promissory notes (the &#x201c;July 2025 Notes&#x201d;) to the July 2025 Lenders in the aggregate principal amount
of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_c20250713__20250715_zTdhYGCvgti2" title="Aggregate principal amount"&gt;354,200&lt;/span&gt;, which includes an aggregate original issue discount of $&lt;span id="xdx_904_ecustom--IssuedDiscountConvertibleNotes_iI_c20250715_zwlYHbmsUlCl" title="Issued discount convertible notes"&gt;46,200&lt;/span&gt;, for a purchase price of $&lt;span id="xdx_90B_ecustom--PurchasePrice_iI_c20250715_znhwbwcJC4Ma" title="Purchase price"&gt;308,000&lt;/span&gt;. The Company incurred an
additional $&lt;span id="xdx_90E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c20241001__20250930_zjNZmhBJXj1l" title="Additional fee"&gt;8,000&lt;/span&gt; in fees related to this transaction which is capitalized as part of the debt issuance cost and amortized over the term
of the July 2025 Notes. The July 2025 Notes bear interest at a one-time charge of 12% applied on the issuance date, mature on May 15,
2026, and is repayable in five monthly payments commencing January 15, 2026. The July 2025 Notes are convertible into shares of the Company&#x2019;s
common stock, par value $0.01 per share (the &#x201c;Common Stock&#x201d;), solely upon an event of default, at a conversion price equal
to 75% of the lowest trading price during the ten trading days prior to conversion. The Company also entered into an irrevocable transfer
agent instructions letter with its transfer agent in connection with the July 2025 Notes. The proceeds from the issuances of the July
2025 Notes were used for general working capital purposes. The July 2025 Lenders have piggyback registration rights and have agreed
not to engage in short sales of the Company&#x2019;s common stock during the term of the July 2025 Notes. The July 2025 Notes include customary
representations, warranties, covenants, and default provisions. The Company may prepay the July 2025 Notes within the first 180 days.
The loan pursuant to the July 2025 Notes closed and funded on July 17, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the year ended September 30, 2025 and 2024, total
amortized debt issuance cost of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20250930_z3nAfNMzxz5i" title="Amortized debt issuance cost"&gt;8,737&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20240930_zwl8RZ1MQJ8c" title="Amortized debt issuance cost"&gt;0&lt;/span&gt; was included in interest expense on the accompanying consolidated statements of operations,
respectively. For the year ended September 30, 2025 and 2024, total interest expense $&lt;span id="xdx_902_ecustom--InterestExpenses_c20241001__20250930_zOgsaImyJPTh" title="Interest expense"&gt;10,626&lt;/span&gt; and $&lt;span id="xdx_90E_ecustom--InterestExpenses_c20231001__20240930_zSL7Z0XKji51" title="Interest expense"&gt;0&lt;/span&gt; was included in interest expense on
the accompanying consolidated statements of operations, respectively. At September 30, 2025 and 2024, the balance of the July Notes of
$&lt;span id="xdx_90C_eus-gaap--ConvertibleNotesPayable_iI_c20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zScan7syvD65" title="Convertible notes payable"&gt;308,737&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_c20240930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zhH1zUxRxA57" title="Convertible notes payable"&gt;0&lt;/span&gt;, respectively, recorded in convertible notes payable on the accompanying balance sheets, includes $&lt;span id="xdx_905_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zZNdQCpx6pX7" title="Unamortized debt issuance cost"&gt;45,463&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20240930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zeQiLa9yXs6a" title="Unamortized debt issuance cost"&gt;0&lt;/span&gt;, respectively
of unamortized debt issuance cost.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Standby Equity Purchase Agreement - Pre Paid
Advance&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the SEPA (See Note 11), and
subject to the condition set forth therein, the Investor advanced to the Company in the form of convertible promissory notes (the
&#x201c;Convertible Notes&#x201d;) an aggregate principal amount of $5.0 million (the &#x201c;Pre-Paid Advance&#x201d;). The first
Pre-Paid Advance was disbursed on July 25, 2025 with respect to $&lt;span id="xdx_904_eus-gaap--AdvanceRent_iI_pn3n3_dm_c20250725_zNL6b2wHK3jj"&gt;3.0&lt;/span&gt; million
and the balance of $&lt;span id="xdx_904_eus-gaap--AdvanceRent_iI_pn3n3_dm_c20250911_zYIkr11wDHO4"&gt;2.0&lt;/span&gt; million
was disbursed on September 11, 2025 upon the registration statement registering the resale of the shares of common stock issuable
under the SEPA being declared effective. The purchase price for the Pre-Paid Advance is 94% of the principal amount of the Pre-Paid
Advance. Interest shall accrue on the outstanding balance of any Pre-Paid Advance at an annual rate equal to 6.0%, subject to an
increase to 18% upon an event of default as described in the Convertible Notes. The maturity date is 12-months after the closing of
each tranche of the Pre-Paid Advance. The Investor may convert the Convertible Notes into shares of&#160;the
Company&#x2019;s&#160;common stock&#160;at a conversion price equal to the lower of $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250930_z14m3OoqdU84"&gt;10.00&lt;/span&gt; or
93% of the lowest daily VWAP during the five consecutive trading days immediately preceding the conversion (the &#x201c;Conversion
Price&#x201d;), which in no event may the Conversion Price be lower than $&lt;span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250930__us-gaap--DebtConversionByUniqueDescriptionAxis__custom--ConversionPriceMember_z51Eq9BsYZ52"&gt;1.00&lt;/span&gt; (the
&#x201c;Floor Price&#x201d;) provided, however, that the Floor Price shall be adjusted (downwards only) to equal 20% of the average
VWAP for the five (5) Trading Days immediately prior to the earlier of (i) date of effectiveness of the Registration Statement, (ii)
the six-month anniversary of the date of the SEPA. Notwithstanding the foregoing, the Company may reduce the Floor Price to any
amounts set forth in a written notice to the Holder; provided that such reduction shall be irrevocable and shall not be subject to
increase thereafter. In addition, upon the occurrence and during the continuation of an event of default,&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Convertible Notes is a legal debt obligation
with a variable-share conversion feature that ensures a fixed monetary return to the holder, thus qualifying as a liability under ASC
480-10. the Note remains a liability after issuance and the instrument is remeasured after initial recognition, with changes in fair
value recognized in earnings each reporting period until settlement, modification, or extinguishment, consistent with the liability-classified
model. As of September 30, 2025, the par value of the notes was $&lt;span id="xdx_903_eus-gaap--DebtInstrumentFairValue_iI_c20250930_zsAhNFQurFIg" title="fair value of the notes"&gt;5,000,000&lt;/span&gt; and the fair value of the notes was $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFairValue_iI_c20240930_zJWCA06Kj0Vj" title="fair value of the notes"&gt;4,552,653&lt;/span&gt;. For the year
ended September 30, 2025 and 2024, total interest expense $&lt;span id="xdx_900_eus-gaap--InterestExpense_c20241001__20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zeo5N31OYxGe"&gt;39,288&lt;/span&gt;
and $&lt;span id="xdx_905_eus-gaap--InterestExpense_c20240324__20240930_zgMyRtnhnrm"&gt;0&lt;/span&gt;
was included in interest expense on the accompanying consolidated statement of operations, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;br/&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Convertible notes were valued using unobservable inputs
that are not corroborated by market data (Level 3). The valuation is based on Monte Carlo Simulation to simulate weekly stock prices
through maturity. The enterprise value is then allocated to each class of outstanding shares and convertible notes based on an option
pricing model where the value for each class is driven by the current value and expected volatility of the underlying equity value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/15pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
key assumptions used to value the convertible notes as of September 30, 2025:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ConvertibleDebtTableTextBlock_zw53UpyzC5qk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Notes Payable (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B1_zGnha0tEdb33"&gt;Schedule of key assumptions used to value the convertible notes&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20241001__20250930_znWxumAv0dMd" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--StockholdersEquityOtherShares_z87gdD4EY5vg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Stock Price&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;9.53&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate_dp_zi6JoKruLSbf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Equity Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedDividendRate_dp_z4MuYUupNHk5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Discount Rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_z9sb1O84tKL1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk free rate of return&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.70&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_zpE79mM3HA0b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Term to maturity (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/15pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents changes of the convertible notes with significant unobservable inputs (Level 3) as of September 30, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/15pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfStockByClassTextBlock_zHwkZpC9TRmc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Notes Payable (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B7_zVIF4Ip0vNMi"&gt;Schedule of changes of the convertible notes&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20241001__20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zS7AKPxApHNf" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 12pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible
    Debentures&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ProceedsFromConvertibleDebt_znClnsRC83C9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at October 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24; text-align: right"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0726"&gt;&#x97;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ProceedsFromContributedCapital_zlCoTbFlnjh5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Proceeds
    received&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,700,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ChangeInFairValue_zZ3zLt5EIxGa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(147,347&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--ProceedsFromConvertibleDebts_zrpCOzGunMv8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at September 30, 2025 at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,552,653&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 12pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;July
    notes (at amortized cost)&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zKT5a0EOmg5f" style="border-bottom: Black 1pt solid; color: #0F1E24; text-align: right" title="Amortized cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;308,737&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible
    notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ConvertibleNotesPayables_iI_c20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zhDITnn7oxOi" style="border-bottom: Black 2.5pt double; color: #0F1E24; text-align: right" title="Convertible notes payable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,861,390&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
      contextRef="From2025-07-132025-07-15"
      decimals="0"
      id="Fact000676"
      unitRef="USD">354200</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <VWAV:IssuedDiscountConvertibleNotes
      contextRef="AsOf2025-07-15"
      decimals="0"
      id="Fact000678"
      unitRef="USD">46200</VWAV:IssuedDiscountConvertibleNotes>
    <VWAV:PurchasePrice
      contextRef="AsOf2025-07-15"
      decimals="0"
      id="Fact000680"
      unitRef="USD">308000</VWAV:PurchasePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000682"
      unitRef="USD">8000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000684"
      unitRef="USD">8737</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000686"
      unitRef="USD">0</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <VWAV:InterestExpenses
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000688"
      unitRef="USD">10626</VWAV:InterestExpenses>
    <VWAV:InterestExpenses
      contextRef="From2023-10-012024-09-30"
      decimals="0"
      id="Fact000690"
      unitRef="USD">0</VWAV:InterestExpenses>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2025-09-30_custom_ConvertibleNotesMember"
      decimals="0"
      id="Fact000692"
      unitRef="USD">308737</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2024-09-30_custom_ConvertibleNotesMember"
      decimals="0"
      id="Fact000694"
      unitRef="USD">0</us-gaap:ConvertibleNotesPayable>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="AsOf2025-09-30_custom_ConvertibleNotesMember"
      decimals="0"
      id="Fact000696"
      unitRef="USD">45463</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="AsOf2024-09-30_custom_ConvertibleNotesMember"
      decimals="0"
      id="Fact000698"
      unitRef="USD">0</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:AdvanceRent
      contextRef="AsOf2025-07-25"
      decimals="-3"
      id="Fact000699"
      unitRef="USD">3000000.0</us-gaap:AdvanceRent>
    <us-gaap:AdvanceRent
      contextRef="AsOf2025-09-11"
      decimals="-3"
      id="Fact000700"
      unitRef="USD">2000000.0</us-gaap:AdvanceRent>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000701"
      unitRef="USDPShares">10.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2025-09-30_custom_ConversionPriceMember"
      decimals="INF"
      id="Fact000702"
      unitRef="USDPShares">1.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFairValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000706"
      unitRef="USD">5000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000708"
      unitRef="USD">4552653</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InterestExpense
      contextRef="From2024-10-012025-09-30_custom_ConvertibleNotesMember"
      decimals="0"
      id="Fact000709"
      unitRef="USD">39288</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-03-242024-09-30"
      decimals="0"
      id="Fact000710"
      unitRef="USD">0</us-gaap:InterestExpense>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="From2024-10-012025-09-30" id="Fact000712">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ConvertibleDebtTableTextBlock_zw53UpyzC5qk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Notes Payable (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B1_zGnha0tEdb33"&gt;Schedule of key assumptions used to value the convertible notes&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20241001__20250930_znWxumAv0dMd" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--StockholdersEquityOtherShares_z87gdD4EY5vg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Stock Price&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;9.53&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate_dp_zi6JoKruLSbf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Equity Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedDividendRate_dp_z4MuYUupNHk5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Discount Rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_z9sb1O84tKL1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk free rate of return&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.70&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_zpE79mM3HA0b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Term to maturity (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/15pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents changes of the convertible notes with significant unobservable inputs (Level 3) as of September 30, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/15pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfStockByClassTextBlock_zHwkZpC9TRmc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Notes Payable (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B7_zVIF4Ip0vNMi"&gt;Schedule of changes of the convertible notes&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20241001__20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zS7AKPxApHNf" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 12pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible
    Debentures&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ProceedsFromConvertibleDebt_znClnsRC83C9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at October 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24; text-align: right"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0726"&gt;&#x97;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ProceedsFromContributedCapital_zlCoTbFlnjh5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Proceeds
    received&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,700,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ChangeInFairValue_zZ3zLt5EIxGa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(147,347&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--ProceedsFromConvertibleDebts_zrpCOzGunMv8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at September 30, 2025 at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,552,653&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 12pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;July
    notes (at amortized cost)&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zKT5a0EOmg5f" style="border-bottom: Black 1pt solid; color: #0F1E24; text-align: right" title="Amortized cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;308,737&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible
    notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ConvertibleNotesPayables_iI_c20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zhDITnn7oxOi" style="border-bottom: Black 2.5pt double; color: #0F1E24; text-align: right" title="Convertible notes payable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,861,390&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000714"
      unitRef="Shares">9.53</us-gaap:StockholdersEquityOtherShares>
    <VWAV:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000716"
      unitRef="Ratio">0.520</VWAV:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate>
    <VWAV:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedDividendRate
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000718"
      unitRef="Ratio">0.410</VWAV:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000720"
      unitRef="Ratio">0.0370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2024-10-012025-09-30" id="Fact000722">P0Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="From2024-10-012025-09-30" id="Fact000724">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfStockByClassTextBlock_zHwkZpC9TRmc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Notes Payable (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B7_zVIF4Ip0vNMi"&gt;Schedule of changes of the convertible notes&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20241001__20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zS7AKPxApHNf" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 12pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible
    Debentures&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ProceedsFromConvertibleDebt_znClnsRC83C9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at October 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24; text-align: right"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0726"&gt;&#x97;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ProceedsFromContributedCapital_zlCoTbFlnjh5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Proceeds
    received&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,700,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ChangeInFairValue_zZ3zLt5EIxGa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(147,347&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--ProceedsFromConvertibleDebts_zrpCOzGunMv8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at September 30, 2025 at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,552,653&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 12pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;July
    notes (at amortized cost)&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zKT5a0EOmg5f" style="border-bottom: Black 1pt solid; color: #0F1E24; text-align: right" title="Amortized cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;308,737&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible
    notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="color: #0F1E24; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ConvertibleNotesPayables_iI_c20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zhDITnn7oxOi" style="border-bottom: Black 2.5pt double; color: #0F1E24; text-align: right" title="Convertible notes payable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,861,390&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: #0F1E24; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="From2024-10-012025-09-30_custom_ConvertibleDebenturesMember"
      decimals="0"
      id="Fact000728"
      unitRef="USD">4700000</us-gaap:ProceedsFromContributedCapital>
    <VWAV:ChangeInFairValue
      contextRef="From2024-10-012025-09-30_custom_ConvertibleDebenturesMember"
      decimals="0"
      id="Fact000730"
      unitRef="USD">-147347</VWAV:ChangeInFairValue>
    <VWAV:ProceedsFromConvertibleDebts
      contextRef="From2024-10-012025-09-30_custom_ConvertibleDebenturesMember"
      decimals="0"
      id="Fact000732"
      unitRef="USD">4552653</VWAV:ProceedsFromConvertibleDebts>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2025-09-30_custom_ConvertibleDebenturesMember"
      decimals="0"
      id="Fact000734"
      unitRef="USD">308737</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <VWAV:ConvertibleNotesPayables
      contextRef="AsOf2025-09-30_custom_ConvertibleDebenturesMember"
      decimals="0"
      id="Fact000736"
      unitRef="USD">4861390</VWAV:ConvertibleNotesPayables>
    <VWAV:UnderwritersAgreementTextBlock contextRef="From2024-10-012025-09-30" id="Fact000738">&lt;p id="xdx_809_ecustom--UnderwritersAgreementTextBlock_zk1fwlsq0iLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Note
                                            10 &#x2014; &lt;span id="xdx_827_zLsKjCpWSqnd"&gt;Underwriter&#x2019;s Agreement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Upon completion of
the initial public offering of Bannix IPO, the underwriters are entitled to a deferred underwriting discount of $&lt;span id="xdx_90B_ecustom--DeferredUnderwritingDiscount_iI_c20250930_zAhn9NxxiI22" title="Deferred Underwriting Discount"&gt;225,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;,
solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. Additionally,
the underwriters are entitled to a Business Combination marketing fee of &lt;span id="xdx_90F_ecustom--BusinessCombinationMarketingFeePercentage_iI_dp_c20250930_zRkF5P1a0Ps3" title="Business Combination marketing fee"&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%
of the gross proceeds of the sale of Units in the IPO upon the completion of the Company&#x2019;s initial Business Combination subject
to the terms of the underwriting agreement. At the close of the Reverse Acquisition, the Company assumed $&lt;span id="xdx_90A_ecustom--DeferredUnderwritingDiscount_iI_c20250930_zdhQM0iokpW7" title="Deferred Underwriting Discount"&gt;225,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;of underwriting discount which is included in deferred underwriting discount on the accompanying
balance sheets at September 30, 2025. The amount is due on demand but payable only after the repayment of the SEPA Pre-paid Advances
(See Note 9).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On June 9, 2025, Bannix
entered into an amendment to the underwriting agreement. Pursuant to the amendment, payments of the Business Combination marketing fee
will be modified as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$500,000
                                            &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;shall be paid in cash, deferred until the later
                                            of (i) twelve (12) months after closing or (ii) the date when a key financing facility of
                                            the post-combination company is fully equitized.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$1,300,000
                                            &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;shall be paid in shares of the post-combination
                                            company&#x2019;s common stock, calculated based on the 30-day VWAP immediately following the
                                            closing date. These shares will be subject to piggyback registration rights and a lock-up
                                            that expires upon the termination or full amortization of the referenced financing facility.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;At the close of the
Reverse Acquisition, the Company assumed $&lt;span id="xdx_90C_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20241001__20250930_z53ncLp9L4Zi"&gt;1,800,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;of marketing fees costs which is included in accounts payable and accrued expenses on the
accompanying balance sheets at September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In addition, Bannix
issued the underwriter (and/or its designees) (the &#x201c;Representative&#x201d;) &lt;span id="xdx_90A_eus-gaap--ConversionOfStockSharesIssued1_c20241001__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwriterMember_zHHHH6JQwD2"&gt;393,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;shares of Common Stock for $&lt;span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwriterMember_zwhVhSSv30Rc"&gt;0.01&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;per share (the &#x201c;Representative Shares&#x201d;) upon the consummation of the Bannix IPO.
A balance of $&lt;span id="xdx_900_eus-gaap--CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance_iI_c20250930_zOTjpfMshac9"&gt;3,930
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;outstanding by the Representative for the Representative Shares were assumed at close at
the Reverse Acquisition. As of September 30, 2025 and 2024, the Representative has not yet paid for these shares, and the amount owed
of $&lt;span id="xdx_908_eus-gaap--PrepaidExpenseCurrent_iI_c20240930__us-gaap--RelatedPartyTransactionAxis__custom--BannixClassACommonStockMember_z2aD8QONqvqc"&gt;3,930&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;is included in prepaid expenses on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</VWAV:UnderwritersAgreementTextBlock>
    <VWAV:DeferredUnderwritingDiscount
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000740"
      unitRef="USD">225000</VWAV:DeferredUnderwritingDiscount>
    <VWAV:BusinessCombinationMarketingFeePercentage
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000742"
      unitRef="Ratio">0.035</VWAV:BusinessCombinationMarketingFeePercentage>
    <VWAV:DeferredUnderwritingDiscount
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000744"
      unitRef="USD">225000</VWAV:DeferredUnderwritingDiscount>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000745"
      unitRef="USD">1800000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2024-10-012025-09-30_custom_UnderwriterMember"
      decimals="INF"
      id="Fact000746"
      unitRef="Shares">393000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-09-30_custom_UnderwriterMember"
      decimals="INF"
      id="Fact000747"
      unitRef="USDPShares">0.01</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000748"
      unitRef="USD">3930</us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-09-30_custom_BannixClassACommonStockMember"
      decimals="0"
      id="Fact000749"
      unitRef="USD">3930</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-10-012025-09-30" id="Fact000751">&lt;p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zf2kepP7EQeg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Note
                                            11 &#x2014; &lt;span id="xdx_823_zOytWcFT9aIj"&gt;Commitment and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Standby Equity
Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On July 25, 2025, the
Company entered into the Standby Equity Purchase Agreement (&#x201c;SEPA&#x201d;) with YA II PN, LTD, a Cayman Islands exempt limited partnership
(the &#x201c;Investor&#x201d;) pursuant to which the Company has the right to sell to the Investor up to $50
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;million of its shares of common stock, subject to certain limitations and conditions set
forth in the SEPA, from time to time during the term of the SEPA, from time to time during the term of the SEPA.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Upon the satisfaction
of the conditions to the Investor&#x2019;s purchase obligation set forth in the SEPA, including having a registration statement registering
the resale of the shares of common stock issuable under the SEPA declared effective by the SEC, the Company will have the right, but
not the obligation, from time to time at its discretion until the SEPA is terminated to direct Investor to purchase a specified number
of shares of common stock (&#x201c;Advance&#x201d;) by delivering written notice to Investor (&#x201c;Advance Notice&#x201d;). While there
is no mandatory minimum amount for any Advance, it may not exceed an amount equal to 100% of the average of the daily traded amount during
the five consecutive trading days immediately preceding an Advance Notice.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The shares of common
stock purchased pursuant to an Advance delivered by the Company will be purchased at a price equal to 97% of the lowest daily VWAP of
the shares of common stock during the three consecutive trading days commencing on the date of the delivery of the Advance Notice, other
than the daily VWAP on a day in which the daily VWAP is less than a minimum acceptable price as stated by the Company in the Advance
Notice or there is no VWAP on the subject trading day. The Company may establish a minimum acceptable price in each Advance Notice below
which the Company will not be obligated to make any sales to Investor. &#x201c;VWAP&#x201d; is defined as the daily volume weighted average
price of the shares of common stock for such trading day on the Nasdaq Stock Market during regular trading hours as reported by Bloomberg
L.P.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In connection with
the SEPA, and subject to the condition set forth therein, Investor advanced to the Company in the form of convertible promissory notes
(the &#x201c;Convertible Notes&#x201d;) an aggregate principal amount of $5.0 million (the &#x201c;Pre-Paid Advance&#x201d;) (See Note 9).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Investor, in its
sole discretion and providing that there is a balance remaining outstanding under the Convertible Notes, may deliver a notice under the
SEPA requiring the issuance and sale of shares of common stock to the Investor at the Conversion Price in consideration of an offset
of the Convertible Notes (&#x201c;Investor Advance&#x201d;). The Investor, in its sole discretion, may select the amount of any Pre-Paid
Advance, provided that the number of shares issued does not cause the Investor to exceed the 4.99% ownership limitation, does not exceed
the Exchange Cap or the number of shares of common stock that are registered. As a result of a Pre-Paid Advance, the amounts payable
under the Convertible Notes will be offset by such amount subject to each Investor Advance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company will control
the timing and amount of any sales of shares of common stock to the Investor, except with respect to the Pre-Paid Advances. Actual sales
of shares of common stock to the Investor as a Pre-Paid Advance under the SEPA will depend on a variety of factors to be determined by
the Company from time to time, which may include, among other things, market conditions, the trading price of the Company&#x2019;s common
stock and determinations by the Company as to the appropriate sources of funding for our business and operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The SEPA will automatically
terminate on the earliest to occur of (i) the 24-month anniversary of the date of the SEPA or (ii) the date on which the Investor shall
have made payment of Advances pursuant to the SEPA for shares of common stock equal to $&lt;span id="xdx_90E_eus-gaap--AdvancesOnInventoryPurchases_iI_c20250930_zq5si6lzyc2k"&gt;50,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;.
The Company has the right to terminate the SEPA at no cost or penalty upon five (5) trading days&#x2019; prior written notice to the Investor,
provided that there are no outstanding Advance Notices for which shares of common stock need to be issued and the Company has paid all
amounts owed to the Investor pursuant to the Convertible Notes. The Company and the Investor may also agree to terminate the SEPA by
mutual written consent. Neither the Company nor the Investor may assign or transfer our respective rights and obligations under the SEPA,
and no provision of the SEPA may be modified or waived by us or Investor other than by an instrument in writing signed by both parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;As consideration
for the Investor&#x2019;s commitment to purchase the shares of common stock pursuant the SEPA, the Company paid the Investor, (i) a
structuring fee in the amount of $&lt;span id="xdx_908_ecustom--StructuringFeeAmount_iI_c20250930_zLntCVZ5v4oe" title="Structuring Fee Amount"&gt;30,000&lt;/span&gt; &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;and
(ii) &lt;span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorsMember_zZkAsIAgHR8i"&gt;200,000&lt;/span&gt; &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;shares
of common stock as an equity fee. Further, the Company is required to pay Investor a commitment fee of $&lt;span id="xdx_904_eus-gaap--CommitmentsAndContingencies_iI_c20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorsMember_za5bmeDMokv"&gt;500,000&lt;/span&gt; &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;of
which $&lt;span id="xdx_902_eus-gaap--PayableCommonStockRedeemed_iI_c20250930_zWeH1HhE1J0b"&gt;250,000&lt;/span&gt; &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;shall
be due and payable on the earlier of the effective date of the initial registration statement, or 60 days following the date hereof
and the remaining $250,000 shall be due and payable on the date that is 90 days following the initial due date to be paid by the
issuance of such number of common shares that is equal to the applicable portion of the commitment fee divided by the average of the
daily VWAPs of the common shares during the three trading days immediately prior to the applicable due date. The total consideration
of $&lt;span id="xdx_90E_eus-gaap--DeferredCosts_iI_c20250930_zIH4NxL3VrV3"&gt;1,350,000&lt;/span&gt; &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;is
recorded as  general and administrative expenses in the accompanying statement of operations for the year ended September 30, 2025 and is inclusive of fair value if
$&lt;span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20241001__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorsMember_zUaN2LS7GLH1"&gt;470,000&lt;/span&gt; &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;of
the &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241001__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorsMember_zvijXYlukJye"&gt;200,000&lt;/span&gt; &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;shares
issued and $350,000 consulting fees. At September 30, 2025, $390,000 &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;of
the commitment fee is unpaid and included in accrued expenses on the accompanying balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The SEPA contains customary
representations, warranties, conditions and indemnification obligations of the parties. The representations, warranties and covenants
contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of
the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The net proceeds under
the SEPA to the Company will depend on the frequency and prices at which the Company sells its shares of common stock to Investor. The
Company expects that any proceeds received from such sales to Investor will be used for working capital and general corporate purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The SEPA fails the fixed-for-fixed equity
classification test due to the Exchange Cap requiring shareholder approval, which constitutes a variable settlement contingency outside
the issuer&#x2019;s control. Therefore, equity classification under ASC 815-40 is precluded, and the SEPA must be accounted for as a liability
(or derivative liability, as applicable). While the SEPA has an underlying (the issuer&#x2019;s stock price) and a notional amount (the
$50 million commitment), it does not meet the third characteristic of a derivative because it requires more than a nominal initial net
investment (e.g., the $5 million Pre-Paid Advance in two tranches and related fees). Therefore, the SEPA does not meet the definition
of a derivative under ASC 815-10-15-83. Accordingly, the SEPA should be recorded as non-derivative liability requiring ongoing fair value
remeasurement. As of September 30, 2025, based on management assumptions the SEPA liability was zero.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Joint Venture&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On August 25, 2025,
the Company entered into a Strategic Joint Venture Agreement (the &#x201c;AIPHEX Agreement&#x201d;) with AIPHEX LTD (&#x201c;AIPHEX&#x201d;),
GBT Tokenize Corp. (&#x201c;TOKENIZE&#x201d;), and GBT Technologies, Inc. (&#x201c;GBT&#x201d;). Pursuant to the AIPHEX Agreement, the parties
agreed to form a joint venture limited liability company in the State of Nevada (the &#x201c;JV LLC&#x201d;) for the purpose of collaborating
on certain designated defense and technology projects (the &#x201c;Designated Projects and Background IP&#x201d;). At September 30, 2025,
the JV LLC was neither formed nor funded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Memorandum of Understanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On September 2, 2025,
the Company entered into a Memorandum of Understanding (the &#x201c;MoU&#x201d;) with VEDA Aeronautics Private Limited (&#x201c;VEDA&#x201d;),
a company incorporated under the Companies Act, 2013, of India.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Pursuant to the MoU,
the Company and VEDA intend to collaborate on several Indian Ministry of Defense (&#x201c;MoD&#x201d;) procurement programs (the &#x201c;Programs&#x201d;),
including but not limited to: (a) Drone Kill System (Make-2) &#x2013; interceptor drone development; (b) ALTV (New Generation Light Tank)
&#x2013; 357 tanks, with Company subsystems proposed as onboard modules; (c) FRCV (Main Battle Tank Program) &#x2013; 1,770 main battle
tanks; and (d) T72/T90 Retrofit Program for tanks. Under the MoU, VEDA has invited the Company to supply and develop core subsystems,
including counter-UAS systems, tactical drones, radar technologies, advance protection systems (APS) systems, sensor fusion technologies,
and unmanned platforms for defense and homeland security applications. The parties intend to collaborate in technical proposals, demonstrations,
and joint pursuit of contracts for these Programs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Contingent Commission
Payable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On May 22, 2025, VisionWave
Technologies executed an Addendum to an existing agreement, pursuant to which Raptor LLC was appointed as exclusive sales agent for &lt;span id="xdx_905_eus-gaap--SharesIssued_iI_c20250522_zDbPHCWtCzfh"&gt;280,534&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;TFLM shares (See Note 15) and Raptor LLC will be entitled to a fixed fee of $&lt;span id="xdx_90B_eus-gaap--AccruedSalesCommissionCurrentAndNoncurrent_iI_c20250522_z630nXfFMe35"&gt;50,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;,
payable from the gross proceeds of the share sale of the TFLM shares. As of September 30, 2025, no sale of the TFLM shares has occurred,
and VisionWave Technologies has not granted the required power of attorney over its brokerage account to enable such sales. Accordingly,
the commission obligation to Raptor LLC is considered contingent.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Consulting Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On September 26, 2025,
the Company entered into a Consulting Agreement (the &#x201c;CTMG Agreement&#x201d;) with Crypto Treasury Management Group, LLC (&#x201c;CTMG&#x201d;),
pursuant to which CTMG will provide advisory and strategic services to assist the Company in establishing a digital asset treasury reserve.
The services include, among other things, developing a crypto treasury strategy, recommending custodians, designing staking protocols
(if applicable), assisting with capital formation in collaboration with a licensed securities underwriter, and supporting regulatory
and tax compliance efforts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The CTMG Agreement
has an initial term of two years, subject to earlier termination under certain conditions, including for convenience with 60 days&#x2019;
notice or for material breach. In consideration for the services, the Company has agreed to pay CTMG: (i) a retainer fee of $&lt;span id="xdx_906_eus-gaap--PrepaidTaxes_iI_c20250924_zVX0Mr6zddJc"&gt;50,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;upon signing, which was pre-paid as an advance on September 24, 2025, with an additional
$&lt;span id="xdx_90C_ecustom--AdditionalPrepaidAdvanceFee_iI_c20250924_z1aIIBepYS3h" title="Additional Prepaid Advance Fee"&gt;50,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;due upon execution of binding definitive agreements related to the crypto treasury transaction;
(ii) a success fee of 17 Bitcoin (or cash equivalent) upon successful deployment of at least $20 million into crypto assets for the Company&#x2019;s
treasury; and (iii) &lt;span id="xdx_90B_eus-gaap--SharesIssued_iI_c20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--CryptoAssetsMember_zvN8Qv20T6u9"&gt;250,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;shares of the Company&#x2019;s common stock upon closing of the crypto treasury transaction,
subject to SEC Rule 144 restrictions and inclusion in future registration statements where applicable. The Company will also reimburse
CTMG for pre-approved reasonable expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Litigation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;From time to time,
the Company may be subject to routine litigation, claims or disputes in the ordinary course of business. The Company defends itself vigorously
in all such matters but cannot predict the outcome or effect of any potential litigation, claims or disputes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On September 5, 2025,
Better Works LLC filed an action in the Supreme Court of the State of New York, New York County, captioned Better Works LLC v. VisionWave
Holdings, Inc. and Douglas E. Davis, Index No. 655268/2025. The Summons with Notice asserts claims for breach of contract and seeks (i)
a declaratory judgment regarding affiliate status and the applicability or expiration of certain lock-up provisions relating to private-placement
units exchanged in connection with the Company&#x2019;s business combination, (ii) injunctive relief permitting the plaintiff to sell
such units, and (iii) monetary damages in an amount to be determined. Service of process addressed to VisionWave&#x2019;s Delaware registered
agent was recorded as received on September 9, 2025. On September 30, 2025, counsel for the Company and Mr. Davis served a demand for
the complaint pursuant to CPLR 3012(b), expressly reserving all defenses, including objections to service and personal jurisdiction.
As of the date of this Report, no complaint has been served on the defendants. The Company believes the asserted claims are without merit
and intends to defend the matter vigorously.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Except as described
above, the Company is not a party to any other pending legal proceedings that management believes, individually or in the aggregate,
would have a material adverse effect on the Company&#x2019;s business, financial condition, or results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000755"
      unitRef="USD">50000000</us-gaap:AdvancesOnInventoryPurchases>
    <VWAV:StructuringFeeAmount
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000757"
      unitRef="USD">30000</VWAV:StructuringFeeAmount>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-09-30_custom_InvestorsMember"
      decimals="INF"
      id="Fact000758"
      unitRef="Shares">200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2025-09-30_custom_InvestorsMember"
      decimals="0"
      id="Fact000759"
      unitRef="USD">500000</us-gaap:CommitmentsAndContingencies>
    <us-gaap:PayableCommonStockRedeemed
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000760"
      unitRef="USD">250000</us-gaap:PayableCommonStockRedeemed>
    <us-gaap:DeferredCosts
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000761"
      unitRef="USD">1350000</us-gaap:DeferredCosts>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2024-10-012025-09-30_custom_InvestorsMember"
      decimals="0"
      id="Fact000762"
      unitRef="USD">470000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-10-012025-09-30_custom_InvestorsMember"
      decimals="INF"
      id="Fact000763"
      unitRef="Shares">200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-05-22"
      decimals="INF"
      id="Fact000766"
      unitRef="Shares">280534</us-gaap:SharesIssued>
    <us-gaap:AccruedSalesCommissionCurrentAndNoncurrent
      contextRef="AsOf2025-05-22"
      decimals="0"
      id="Fact000767"
      unitRef="USD">50000</us-gaap:AccruedSalesCommissionCurrentAndNoncurrent>
    <us-gaap:PrepaidTaxes
      contextRef="AsOf2025-09-24"
      decimals="0"
      id="Fact000768"
      unitRef="USD">50000</us-gaap:PrepaidTaxes>
    <VWAV:AdditionalPrepaidAdvanceFee
      contextRef="AsOf2025-09-24"
      decimals="0"
      id="Fact000770"
      unitRef="USD">50000</VWAV:AdditionalPrepaidAdvanceFee>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-09-30_custom_CryptoAssetsMember"
      decimals="INF"
      id="Fact000771"
      unitRef="Shares">250000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-10-012025-09-30" id="Fact000775">&lt;p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zznauGK3p0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Note
                                            12&#x2014; &lt;span id="xdx_82D_zYgHtr8rUwS4"&gt;Stockholder&#x2019;s Deficit&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&#x2014;
The Company is authorized to issue &lt;span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20240930_zNe28RdqzDea"&gt;10,000,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;shares of preferred stock, par value $&lt;span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240930_z9Ho0rGo1Ape"&gt;0.01&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;per share, with such designations, voting and other rights and preferences as may be determined
from time to time by the Company&#x2019;s board of directors. As of September 30, 2025 and 2024, there were no shares of preferred stock
issued or outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&#x2014;
The Company is authorized to issue &lt;span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20240930_z1uhCi32t7Uh"&gt;150,000,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;shares of common stock with par value of $&lt;span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240930_z7KZ25vNOS54"&gt;0.01&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;each. As of September 30, 2025 and 2024, there were &lt;span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20250930_zku9xOulWfvc"&gt;14,521,094
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;and &lt;span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20240930_zkWdCpiQ2Iy1"&gt;11,000,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;shares of Common Stock issued and outstanding, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;As part of the Bannix
IPO, Bannix issued &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20250930_zlFCCJu5uWMf"&gt;6,900,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;warrants to third-party investors where each whole warrant entitles the holder to purchase
one share of the Company&#x2019;s Class A common stock at an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zFiMgpDLSJ5k"&gt;11.50&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;per share (the &#x201c;Public Warrants&#x201d;). Simultaneously with the closing of the IPO,
Bannix completed the private sale of &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zr6MrbEpfNf6"&gt;406,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;Private Placement warrants where each warrant allows the holder to purchase one share of
the Company&#x2019;s Class A common stock at $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zlT09xpevOD"&gt;11.50&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Bannix accounted for
the &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zRH15kLVC65i"&gt;6,900,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;warrants issued in connection with the IPO and private placement in accordance with the guidance
contained in ASC Topic 815 &#x201c;Derivatives and Hedging&#x201d; whereby under that provision, the Private Warrants did not meet the
criteria for equity treatment and were recorded as a liability. Accordingly, Bannix classified the Private Warrants as a liability at
fair value and adjusts them to fair value at each reporting period. The Public Warrants met the classification for equity treatment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The warrants became
exercisable on the later of 12 months from the closing of this offering or upon completion of its initial Business Combination and will
expire five years after the completion of Reverse Acquisition, at 5:00 p.m., Eastern Time, or earlier upon redemption or liquidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Once the warrants become
exercisable, the Company may redeem the warrants:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;in whole
                                            and not in part;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;at a price
                                            of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930_z7y4e3ykA2Me"&gt;0.01&lt;/span&gt;
                                            &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;per warrant;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;upon not
                                            less than 30 days&#x2019; prior written notice of redemption, to each warrant holder; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;







&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;if, and
                                            only if, the reported last sale price of the Public Shares equals or exceeds $&lt;span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20250930_ztfUuaBoUv9g"&gt;18.00&lt;/span&gt;
                                            &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;per share (as adjusted for share subdivisions,
                                            share consolidations, share capitalizations, rights issuances, reorganizations, recapitalizations
                                            and the like) for any 20 trading days within a 30-trading day period ending on the third
                                            trading day prior to the date the Company sends the notice of redemption to the warrant holders.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;if, and
                                            only if, there is a current registration statement in effect with respect to the issuance
                                            of the shares underlying such warrants at the time of redemption and for the entire 30-day
                                            trading period referred to above and continuing each day until the date of redemption.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;At the time of the
Reverse Acquisition, The Private Placement Warrants became identical to the Public Warrants underlying the Units sold in the Bannix
IPO. The Private Placement Warrants were classified as Equity upon close of the Reverse Acquisition. During the year ended September
2025 and the period from March 20, 2024 (inception) to September 30, 2024, 1008 and 0 warrants were exercised. At September 30,
2025, there were &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930_zTOONnvorD2i"&gt;7,304,992&lt;/span&gt; &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;warrants
outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Conversion of
public and private rights&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On July 14, 2025, at
the close of the Reverse Acquisition, &lt;span id="xdx_90E_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20250714__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PublicRightsMember_zda0HzMGH30h"&gt;6,900,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;public rights and &lt;span id="xdx_90D_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20250714__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PrivateRightsMember_zTZ81CLa6n43"&gt;406,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;private rights under Bannix were converted for Common shares on a ten-to-one basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock based compensation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Omnibus Equity Incentive
Plan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On August 5, 2025,
the Board of Directors (the &#x201c;Board&#x201d;) of Bannix adopted Bannix&#x2019;s 2025 Omnibus Equity Incentive Plan (the &#x201c;Plan&#x201d;),
which authorizes the issuance of up to &lt;span id="xdx_909_eus-gaap--SharesIssued_iI_c20250805__us-gaap--SubsidiarySaleOfStockAxis__custom--BoardOfDirectorsMember_zV8PvUfzu8X"&gt;7,000,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;shares of Bannix&#x2019;s common stock, par value $&lt;span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250805__us-gaap--SubsidiarySaleOfStockAxis__custom--BoardOfDirectorsMember_zvFH3h7UPclg"&gt;0.01&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;per share (the &#x201c;Common Stock&#x201d;). The Plan is subject to approval by Bannix&#x2019;s
shareholders within twelve (12) months of the Board&#x2019;s adoption date. If shareholder approval is obtained, the Plan will become
effective as of August 5, 2025. The Plan provides for the grant of various equity-based awards, including non-qualified stock options,
incentive stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards,
performance unit awards, unrestricted stock awards, distribution equivalent rights, or any combination thereof. The Plan is intended
to assist Bannix in attracting, retaining, and incentivizing key management employees, directors, and consultants, and to align their
interests with those of Bannix&#x2019;s shareholders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On August 6, 2025
and September 2, 2025, the Company entered into several employment agreements, pursuant to which the Company granted &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20241001__20250930_z8b72ZWgzLvh"&gt;6,350,000&lt;/span&gt; &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;options
to employees with vesting periods of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20241001__20250930_z92HrF5Q6lq5"&gt;4&lt;/span&gt; &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;years
and exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250806__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--StockOptionMember_z8s2uTzTspi1"&gt;7.2&lt;/span&gt; &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;and
$&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--StockOptionMember_zukCsA7Aa3Ma"&gt;9.09&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;,
respectively. For the year ended September 30, 2025 and the period from March 20, 2024 (inception) to September 30, 2024, total
stock-based compensation related to the employments agreements was $&lt;span id="xdx_90C_eus-gaap--GeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--StockOptionMember_zHkBP5U0FMDh"&gt;511,847&lt;/span&gt; &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;and
$&lt;span id="xdx_907_eus-gaap--GeneralAndAdministrativeExpense_c20240320__20240930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--StockOptionMember_zVeIA78sx8Jj"&gt;0&lt;/span&gt; &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;and
included in general and administrative expense on the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On July 16, 2025, the
Company entered into a consultant non statutory stock option agreement with a vendor, pursuant to which the vendor was granted &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250702__20250716_z4tmLkwzDAUf"&gt;500,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;stock options that vested immediately at an exercise price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250716__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--StockOptionMember_zZm4VajAAlf"&gt;3.27&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;.
For the year ended September 30, 2025 and the period from March 20, 2024 (inception) to September 30, 2024, total stock based compensation
of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20241001__20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--StockOptionMember_ztwCRYIVHjUb"&gt;2,481,283&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;and $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20240320__20240930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--StockOptionMember_zfhyT9o118m5"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;,
respectively, related to this grant was included in general and administrative expense on the accompanying consolidated statements of
operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The assumptions used in the Black-Scholes model during
the years ended September 30, 2025, are set forth in the table immediately below:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfBlackScholesModelTableTextBlock_z6y8g3M7sM2c" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholder's Deficit (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 12pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B1_zU3AfFctOCxh"&gt;Schedule
    of Black-Scholes model&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;June
    30, &lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise
    price&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--StockholdersEquityOtherShares_c20241001__20250930__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zSavwQsDyFM5" title="Exercise price"&gt;3.27&lt;/span&gt;
                                            &#x2013; &lt;span id="xdx_900_eus-gaap--StockholdersEquityOtherShares_c20241001__20250930__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_z3QHIKMd8W7d" title="Exercise price"&gt;9.09&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20241001__20250930__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zHyjwiXlwora" title="Risk-free interest rate"&gt;3.58&lt;/span&gt;
                                            &#x2013; &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20241001__20250930__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_z9y7kS3jYWQa" title="Risk-free interest rate"&gt;3.91&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20241001__20250930__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zNQQfmcoO02" title="Volatility"&gt;101.4&lt;/span&gt; &#x2013; &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20241001__20250930__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_zYHcBbOBHali" title="Volatility"&gt;114.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    life (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20241001__20250930__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zdwZEPWHHd2g" title="Expected life (years)"&gt;3.19&lt;/span&gt;-&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20241001__20250930__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_z2uu8a8IotKf" title="Expected life (years)"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 75%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    yield&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20241001__20250930__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zCeUs1X4dQ1k" title="Expected life (years)"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following is an analysis of the stock option grant
activity:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zrQzUor005Fl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholder's Deficit (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none; font-size: 10pt"&gt;&lt;span id="xdx_8B5_z1OCW0LSABFd"&gt;Schedule
of stock option grant activity&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="2" style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Number&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted
Average Exercise Price&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted
Average Remaining Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at September 30,
2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;&lt;/td&gt;
&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue_iS_c20241001__20250930_zTeTw0IM24Ui" style="font-weight: bold; text-align: right" title="Number of shares  stock option outstanding"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0829"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20241001__20250930_z4dDD5G9pNgl" style="font-weight: bold; text-align: right" title="Weighted Average Exercise Price Beginning balance"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0831"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 30%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 4%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20241001__20250930_zoz0bH4S4Akb" style="width: 17%; text-align: right" title="Number of shares outstanding granted"&gt;&lt;span style="font-size: 10pt"&gt;6,850,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 4%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20241001__20250930_zmyIH65I00f5" style="width: 17%; text-align: right" title="Weighted Average Exercise Price granted"&gt;&lt;span style="font-size: 10pt"&gt;7.42&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 4%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 17%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20241001__20250930_z4HkXZOym3nk" title="Weighted Average Remaining Life Granted"&gt;5.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Expired&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_c20241001__20250930_zc3zGNuweZGc" style="font-weight: bold; text-align: right" title="Number of shares outstanding Expired"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0839"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20241001__20250930_zplsjxb9vdAj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number of shares outstanding exercised"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0841"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at September 30,
2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue_iE_c20241001__20250930_zyqsHQfpmhel" style="text-align: right" title="Number of shares  stock option outstanding"&gt;&lt;span style="font-size: 10pt"&gt;6,850,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20241001__20250930_zHSs59VJFz66" style="text-align: right" title="Weighted Average Exercise Price ending balance"&gt;&lt;span style="font-size: 10pt"&gt;7.42&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20241001__20250930_zB1Ah6vQhcm9" title="Weighted Average Remaining Life Outstanding"&gt;5.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;Exercisable at September 30, 2025&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price ending balance"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Remaining Life"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8A8_zTOZ2k1izRS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company will recognize
the remaining total stock-based compensation of $&lt;span id="xdx_906_eus-gaap--EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_iI_c20250930_zgWAlC55IBA5" title="stock-based compensation"&gt;31,128,519&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;in future periods as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfRecognizeTheRemainingTotalStockBasedCompensationTableTextBlock_zyk7JG0UD7q9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholder's Deficit (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zbYxVf9sCJg6"&gt;Schedule
    of recognize the remaining total stock-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_498_20250930_zq7eFbG1je3e" style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_iI_zGGvgxyPJvZ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 48%; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Remainder
    of 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 38%; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,009,847&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_iI_zt9AoLJCDFUi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,039,388&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_iI_zNQSTgwwqrQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,039,388&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_iI_z0rVmzGAquj7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,039,388&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_iI_zuvm9W7OOyT5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,000,388&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zAtlic2yAhdh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;31,128,519&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A7_z0WS56xquLS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Restricted stock
units (&#x201c;RSUs&#x201d;)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On August 1, 2025,
the Company entered into agreements with three independent directors, pursuant to which each independent directors will be granted
$&lt;span id="xdx_90F_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20250730__20250801_zsEtuALHqfU5"&gt;60,000&lt;/span&gt; &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;of
restricted stock units annually. The restricted stock units will vest after 1 year of service. During the year ended September 30,
2025 and the period from March 20, 2024 (inception) to September 30, 2024, the Company issued &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_c20241001__20250930_zRXD5ijZ1Bq7"&gt;15,735&lt;/span&gt; &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;shares
and 0 shares, respectively to the independent directors pursuant to the agreement and representing $&lt;span id="xdx_90D_eus-gaap--RestrictedStockExpense_c20241001__20250930_zVQwhhn9gWt3" title="Restricted Stock Payable"&gt;60,000&lt;/span&gt; &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;in
restricted stock payable to each independent director. For the year ended September 30, 2025 and the period from March 20, 2024
(inception) to September 30, 2024, the Company recorded stock based compensation expense related to the RSUs of $&lt;span id="xdx_90C_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20241001__20250930_zOfVvoc9ewZ8"&gt;30,000&lt;/span&gt; &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;and
$&lt;span id="xdx_90D_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240320__20240930_zuscRJ3LJWgk"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;,
respectively. At September 30, 2025 and 2024, unearned compensation is $&lt;span id="xdx_904_eus-gaap--DeferredCompensationEquity_iI_c20250930_zhccgTKl58Ed"&gt;150,000&lt;/span&gt;
and $&lt;span id="xdx_90E_eus-gaap--DeferredCompensationEquity_iI_c20240930_ziMESBIrjCVc"&gt;0&lt;/span&gt;, respectively &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;and will be recognized in future years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Issuance of shares
to former directors&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--IssuanceOfSharesToFormerDirectorsDescription_c20250808__20250809_zV3j4ZBMh3sh" title="Issuance Of Shares To Former Directors Description"&gt;On
August 9, 2025, the Company entered into compensation agreements with three former directors, pursuant to which each director will receive
$120,000 payable in cash or shares. Two directors elected to receive a total of $125,000 in shares and on September 10, 2025, total shares
of 10,927 were issued. For the year ended September 30, 2025, total stock based compensation of $125,000 related to the compensation
agreements with three former directors was included in general and administrative expense on the accompanying consolidated statements
of operations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Other share issuances&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;As outlined in Note
9, the Company issued &lt;span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20250725_zb6PpO53T4S8"&gt;200,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;shares of Common stock at a fair value of $&lt;span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_c20241001__20250930_z87suADcCLXd" title="Common Stock Fair Value Issued"&gt;470,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;pursuant to the SEPA.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;At the close of the
Reverse Acquisition, Bannix owed a vendor &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250702__20250725_zQXkziOp6rSj"&gt;22,500&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;shares pursuant to an agreement for the provision of services. On July 25, 2025, the Company
issued the Common Shares to the vendor to satisfy the outstanding obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;









</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000776"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000777"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000778"
      unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000779"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000780"
      unitRef="Shares">14521094</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000781"
      unitRef="Shares">11000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000782"
      unitRef="Shares">6900000</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000783"
      unitRef="USDPShares">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2025-09-30_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000784"
      unitRef="Shares">406000</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000785"
      unitRef="USDPShares">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2025-09-30_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000786"
      unitRef="Shares">6900000</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000787"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000790"
      unitRef="USDPShares">18.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000791"
      unitRef="Shares">7304992</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2025-07-14_custom_PublicRightsMember"
      decimals="INF"
      id="Fact000792"
      unitRef="Shares">6900000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2025-07-14_custom_PrivateRightsMember"
      decimals="INF"
      id="Fact000793"
      unitRef="Shares">406000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-08-05_custom_BoardOfDirectorsMember"
      decimals="INF"
      id="Fact000794"
      unitRef="Shares">7000000</us-gaap:SharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-08-05_custom_BoardOfDirectorsMember"
      decimals="INF"
      id="Fact000795"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000796"
      unitRef="Shares">6350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2024-10-012025-09-30" id="Fact000797">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-08-06_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000798"
      unitRef="USDPShares">7.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000799"
      unitRef="USDPShares">9.09</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000800"
      unitRef="USD">511847</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-03-202024-09-30_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000801"
      unitRef="USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-07-022025-07-16"
      decimals="INF"
      id="Fact000802"
      unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-07-16_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000803"
      unitRef="USDPShares">3.27</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000804"
      unitRef="USD">2481283</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-03-202024-09-30_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000805"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <VWAV:ScheduleOfBlackScholesModelTableTextBlock contextRef="From2024-10-012025-09-30" id="Fact000807">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfBlackScholesModelTableTextBlock_z6y8g3M7sM2c" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholder's Deficit (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 12pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B1_zU3AfFctOCxh"&gt;Schedule
    of Black-Scholes model&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;June
    30, &lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise
    price&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--StockholdersEquityOtherShares_c20241001__20250930__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zSavwQsDyFM5" title="Exercise price"&gt;3.27&lt;/span&gt;
                                            &#x2013; &lt;span id="xdx_900_eus-gaap--StockholdersEquityOtherShares_c20241001__20250930__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_z3QHIKMd8W7d" title="Exercise price"&gt;9.09&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20241001__20250930__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zHyjwiXlwora" title="Risk-free interest rate"&gt;3.58&lt;/span&gt;
                                            &#x2013; &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20241001__20250930__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_z9y7kS3jYWQa" title="Risk-free interest rate"&gt;3.91&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20241001__20250930__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zNQQfmcoO02" title="Volatility"&gt;101.4&lt;/span&gt; &#x2013; &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20241001__20250930__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_zYHcBbOBHali" title="Volatility"&gt;114.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    life (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20241001__20250930__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zdwZEPWHHd2g" title="Expected life (years)"&gt;3.19&lt;/span&gt;-&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20241001__20250930__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_z2uu8a8IotKf" title="Expected life (years)"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 75%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    yield&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20241001__20250930__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zCeUs1X4dQ1k" title="Expected life (years)"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following is an analysis of the stock option grant
activity:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zrQzUor005Fl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholder's Deficit (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none; font-size: 10pt"&gt;&lt;span id="xdx_8B5_z1OCW0LSABFd"&gt;Schedule
of stock option grant activity&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="2" style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Number&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted
Average Exercise Price&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted
Average Remaining Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at September 30,
2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;&lt;/td&gt;
&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue_iS_c20241001__20250930_zTeTw0IM24Ui" style="font-weight: bold; text-align: right" title="Number of shares  stock option outstanding"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0829"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20241001__20250930_z4dDD5G9pNgl" style="font-weight: bold; text-align: right" title="Weighted Average Exercise Price Beginning balance"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0831"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 30%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 4%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20241001__20250930_zoz0bH4S4Akb" style="width: 17%; text-align: right" title="Number of shares outstanding granted"&gt;&lt;span style="font-size: 10pt"&gt;6,850,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 4%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20241001__20250930_zmyIH65I00f5" style="width: 17%; text-align: right" title="Weighted Average Exercise Price granted"&gt;&lt;span style="font-size: 10pt"&gt;7.42&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 4%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 17%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20241001__20250930_z4HkXZOym3nk" title="Weighted Average Remaining Life Granted"&gt;5.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Expired&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_c20241001__20250930_zc3zGNuweZGc" style="font-weight: bold; text-align: right" title="Number of shares outstanding Expired"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0839"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20241001__20250930_zplsjxb9vdAj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number of shares outstanding exercised"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0841"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at September 30,
2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue_iE_c20241001__20250930_zyqsHQfpmhel" style="text-align: right" title="Number of shares  stock option outstanding"&gt;&lt;span style="font-size: 10pt"&gt;6,850,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20241001__20250930_zHSs59VJFz66" style="text-align: right" title="Weighted Average Exercise Price ending balance"&gt;&lt;span style="font-size: 10pt"&gt;7.42&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20241001__20250930_zB1Ah6vQhcm9" title="Weighted Average Remaining Life Outstanding"&gt;5.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;Exercisable at September 30, 2025&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price ending balance"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Remaining Life"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</VWAV:ScheduleOfBlackScholesModelTableTextBlock>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="From2024-10-012025-09-30_custom_BlackScholesModelMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000809"
      unitRef="Shares">3.27</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="From2024-10-012025-09-30_custom_BlackScholesModelMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000811"
      unitRef="Shares">9.09</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-10-012025-09-30_custom_BlackScholesModelMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000813"
      unitRef="Ratio">0.0358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-10-012025-09-30_custom_BlackScholesModelMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000815"
      unitRef="Ratio">0.0391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-10-012025-09-30_custom_BlackScholesModelMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000817"
      unitRef="Ratio">1.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-10-012025-09-30_custom_BlackScholesModelMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000819"
      unitRef="Ratio">1.144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-10-012025-09-30_custom_BlackScholesModelMember_srt_MinimumMember"
      id="Fact000821">P3Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-10-012025-09-30_custom_BlackScholesModelMember_srt_MaximumMember"
      id="Fact000823">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-10-012025-09-30_custom_BlackScholesModelMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000825"
      unitRef="Ratio">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-10-012025-09-30" id="Fact000827">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zrQzUor005Fl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholder's Deficit (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none; font-size: 10pt"&gt;&lt;span id="xdx_8B5_z1OCW0LSABFd"&gt;Schedule
of stock option grant activity&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="2" style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Number&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted
Average Exercise Price&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted
Average Remaining Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at September 30,
2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;&lt;/td&gt;
&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue_iS_c20241001__20250930_zTeTw0IM24Ui" style="font-weight: bold; text-align: right" title="Number of shares  stock option outstanding"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0829"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20241001__20250930_z4dDD5G9pNgl" style="font-weight: bold; text-align: right" title="Weighted Average Exercise Price Beginning balance"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0831"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 30%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 4%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20241001__20250930_zoz0bH4S4Akb" style="width: 17%; text-align: right" title="Number of shares outstanding granted"&gt;&lt;span style="font-size: 10pt"&gt;6,850,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 4%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20241001__20250930_zmyIH65I00f5" style="width: 17%; text-align: right" title="Weighted Average Exercise Price granted"&gt;&lt;span style="font-size: 10pt"&gt;7.42&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 4%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 17%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20241001__20250930_z4HkXZOym3nk" title="Weighted Average Remaining Life Granted"&gt;5.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Expired&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_c20241001__20250930_zc3zGNuweZGc" style="font-weight: bold; text-align: right" title="Number of shares outstanding Expired"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0839"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20241001__20250930_zplsjxb9vdAj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number of shares outstanding exercised"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0841"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at September 30,
2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue_iE_c20241001__20250930_zyqsHQfpmhel" style="text-align: right" title="Number of shares  stock option outstanding"&gt;&lt;span style="font-size: 10pt"&gt;6,850,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20241001__20250930_zHSs59VJFz66" style="text-align: right" title="Weighted Average Exercise Price ending balance"&gt;&lt;span style="font-size: 10pt"&gt;7.42&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20241001__20250930_zB1Ah6vQhcm9" title="Weighted Average Remaining Life Outstanding"&gt;5.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;Exercisable at September 30, 2025&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price ending balance"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Remaining Life"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000833"
      unitRef="Shares">6850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000835"
      unitRef="USDPShares">7.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2024-10-012025-09-30" id="Fact000837">P5Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <VWAV:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000843"
      unitRef="USD">6850000</VWAV:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000845"
      unitRef="USDPShares">7.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2024-10-012025-09-30" id="Fact000847">P5Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000853"
      unitRef="Shares">31128519</us-gaap:EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares>
    <VWAV:ScheduleOfRecognizeTheRemainingTotalStockBasedCompensationTableTextBlock contextRef="From2024-10-012025-09-30" id="Fact000855">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfRecognizeTheRemainingTotalStockBasedCompensationTableTextBlock_zyk7JG0UD7q9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholder's Deficit (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zbYxVf9sCJg6"&gt;Schedule
    of recognize the remaining total stock-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_498_20250930_zq7eFbG1je3e" style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_iI_zGGvgxyPJvZ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 48%; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Remainder
    of 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 38%; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,009,847&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_iI_zt9AoLJCDFUi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,039,388&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_iI_zNQSTgwwqrQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,039,388&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_iI_z0rVmzGAquj7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,039,388&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_iI_zuvm9W7OOyT5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,000,388&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zAtlic2yAhdh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;31,128,519&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</VWAV:ScheduleOfRecognizeTheRemainingTotalStockBasedCompensationTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000857"
      unitRef="USD">2009847</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000859"
      unitRef="USD">8039388</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000861"
      unitRef="USD">8039388</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000863"
      unitRef="USD">8039388</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000865"
      unitRef="USD">5000388</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000867"
      unitRef="USD">31128519</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-07-302025-08-01"
      decimals="0"
      id="Fact000868"
      unitRef="USD">60000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000869"
      unitRef="Shares">15735</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:RestrictedStockExpense
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000871"
      unitRef="USD">60000</us-gaap:RestrictedStockExpense>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000872"
      unitRef="USD">30000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000873"
      unitRef="USD">0</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:DeferredCompensationEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000874"
      unitRef="USD">150000</us-gaap:DeferredCompensationEquity>
    <us-gaap:DeferredCompensationEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000875"
      unitRef="USD">0</us-gaap:DeferredCompensationEquity>
    <VWAV:IssuanceOfSharesToFormerDirectorsDescription contextRef="From2025-08-082025-08-09" id="Fact000877">On
August 9, 2025, the Company entered into compensation agreements with three former directors, pursuant to which each director will receive
$120,000 payable in cash or shares. Two directors elected to receive a total of $125,000 in shares and on September 10, 2025, total shares
of 10,927 were issued. For the year ended September 30, 2025, total stock based compensation of $125,000 related to the compensation
agreements with three former directors was included in general and administrative expense on the accompanying consolidated statements
of operations.</VWAV:IssuanceOfSharesToFormerDirectorsDescription>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-07-25"
      decimals="INF"
      id="Fact000878"
      unitRef="Shares">200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000880"
      unitRef="USD">470000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-07-022025-07-25"
      decimals="INF"
      id="Fact000881"
      unitRef="Shares">22500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <VWAV:GainOnSaleOfMarketableSecuritiesTextBlock contextRef="From2024-10-012025-09-30" id="Fact000886">&lt;p id="xdx_80F_ecustom--GainOnSaleOfMarketableSecuritiesTextBlock_z5MfhlcuuIb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Note
                                            13 &#x2014; &lt;span id="xdx_82E_zP3b0hxm2tXf"&gt;Gain on Sale of Marketable Securities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On June 4, 2024, VW
Tech invested in 10 million shares Avant Technologies, Inc. (&#x201c;AVAI&#x201d;). On February 28, 2025 and March 5, 2025, VW Tech sold
&lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250304__20250305_zgUc8yNoqJZ9"&gt;264,112&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;of AVAI shares for net proceeds of $&lt;span id="xdx_90B_eus-gaap--GainLossOnSaleOfInvestments_c20240603__20240604_zTaRlRmUhoMj"&gt;114,111&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;for a total gain of $104,656 on sale of marketable securities. On April 28, 2025, the Company
sold its remaining holding of &lt;span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250401__20250428_zbIyfi7L6DOa"&gt;9,735,888&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;shares of AVAI, which were recorded at par value of $&lt;span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_c20250428_zVuav3X27jUi"&gt;0.001
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;per share to a third party in exchange for &lt;span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250427__20250428_zEOYWeFjmYe6"&gt;280,534&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;shares of Tofla Megaline Inc. (&#x201c;TFML&#x201d;). The Company determined that the quoted
price of the TFLM shares was not a reliable indicator of fair value at the measurement date as the historical price data indicates that
TFLM shares consistently reflected zero daily trading volume over an extended period. Therefore, the Company measured the TFLM shares
received at par value of $0.001 per share, which was deemed the most reliable and supportable estimate of fair value at the transaction
date under ASC 820.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;As a result of this non-cash exchange, the Company recognized
a loss on sale of the &lt;span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241001__20250930_zfwVs8Br4gz4"&gt;9,735,888&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;share of AVAI of approximately $&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20241001__20250930_z7YTdNfhxWV3"&gt;9,455&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;.
The total gain on sale of AVAI shares of $&lt;span id="xdx_90A_eus-gaap--MarketableSecuritiesGainLoss_c20241001__20250930_zo3mJ74a8I6k"&gt;104,656&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;is recorded in the recorded as gain on sale of marketable securities on the consolidated
statements of operations. At September 30, 2025 and 2024, the total par value of TFML shares of $&lt;span id="xdx_90C_eus-gaap--MarketableSecurities_iI_c20250930_zhOUJXBYqd1c"&gt;281&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;and $&lt;span id="xdx_90B_eus-gaap--MarketableSecurities_iI_c20240930_z9sXHAXCbvCf"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;,
is recorded as investment in marketable securities available for share on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;







</VWAV:GainOnSaleOfMarketableSecuritiesTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-03-042025-03-05"
      decimals="INF"
      id="Fact000887"
      unitRef="Shares">264112</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2024-06-032024-06-04"
      decimals="0"
      id="Fact000888"
      unitRef="USD">114111</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-04-012025-04-28"
      decimals="INF"
      id="Fact000889"
      unitRef="Shares">9735888</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-04-28"
      decimals="INF"
      id="Fact000890"
      unitRef="USDPShares">0.001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2025-04-272025-04-28"
      decimals="INF"
      id="Fact000891"
      unitRef="Shares">280534</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000892"
      unitRef="Shares">9735888</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000893"
      unitRef="USD">9455</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000894"
      unitRef="USD">104656</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000895"
      unitRef="USD">281</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000896"
      unitRef="USD">0</us-gaap:MarketableSecurities>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-10-012025-09-30" id="Fact000900">&lt;p id="xdx_808_eus-gaap--IncomeTaxDisclosureTextBlock_zY6ku4RpBCsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Note
                                            14 &#x2014;&lt;span id="xdx_82D_zIRD0mEWRgKd"&gt; Income Tax&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;b&gt;&lt;span style="font-size: 10pt; line-height: 115%"&gt;&lt;sup&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The income tax provision
for the year ended September 30 2025 and the period from March 20, 2024 (inception) to September 30, 2024 consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zseA7OLoBZr2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Tax (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zNiRS2lQaiAf"&gt;Schedule
of income tax provision&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_497_20241001__20250930_z8zlzQTrfXdd" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_49E_20231001__20240930_zk8DepEsqKo" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;September
30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; width: 56%; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--CurrentFederalTaxExpenseBenefit_ztLehJjABk24" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Federal&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0904"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0905"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_zdwknaMFjbs3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;State&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0907"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0908"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--IncomeTaxProvisionStateCurrent_zXq2y5ypd4uj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Federal&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,145,726&lt;/span&gt;)&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(69,745&lt;/span&gt;)&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--IncomeTaxProvisionStateDeferred_zJv91K2oAkYf" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;State&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0913"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0914"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--ChangeInValuationAllowance_zW1UsrZgH3f3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
in valuation allowance&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,145,726&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;69,745&lt;/span&gt;&lt;/td&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_zZgnw2yaTye8" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax provision&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0919"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0920"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt"&gt;Deferred income tax assets and liabilities result primarily
from temporary differences in the recognition of various expenses for tax and financial statement purposes, and from the recognition of
the tax benefits of net operating loss carryforwards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s net deferred tax assets (liability)
at September 30, 2025 and 2024 are as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfDeferredTaxAssetAndLiabilitiesTableTextBlock_zhf0vaBC1WK3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Tax (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8BD_zSx94PobPrf4"&gt;Schedule of deferred tax assets (liability)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Deferred tax asset (liability)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 30pt; width: 56%; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Research &amp;amp; Development expenses&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ResearchAndDevelopmentExpenses_c20241001__20250930_zr9cDQa9SLJc" style="width: 12%; font-size: 10pt; text-align: right" title="Research &amp;amp; Development expenses"&gt;15,003&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ResearchAndDevelopmentExpenses_c20231001__20240930_zIiImjCD0KD8" style="width: 12%; font-size: 10pt; text-align: right" title="Research &amp;amp; Development expenses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0926"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Stock based compensation&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--EmployeeBenefitsAndSharesBasedCompensation_c20241001__20250930_zXHK99kkqZ9j" style="font-size: 10pt; text-align: right" title="Stock based compensation"&gt;538,487&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--EmployeeBenefitsAndSharesBasedCompensation_c20231001__20240930_zWwwRmZEozHd" style="font-size: 10pt; text-align: right" title="Stock based compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0930"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Net operating loss&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--OperatingIncomeLos_c20241001__20250930_z56YOnVifbdi" style="font-size: 10pt; text-align: right" title="Net operating loss"&gt;728,566&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--OperatingIncomeLos_c20231001__20240930_zdiWdLM5ohVc" style="font-size: 10pt; text-align: right" title="Net operating loss"&gt;69,745&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-indent: -10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amortization of R&amp;amp;D&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AcquisitionCosts_iN_di_c20241001__20250930_zOGoFpXRHFbh" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Amortization of R&amp;amp;D"&gt;(5,251&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AcquisitionCosts_iN_di_c20231001__20240930_zmicH2g2z1Gj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Amortization of R&amp;amp;D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0938"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Total deferred tax asset&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DeferredOtherTaxExpenseBenefit_c20241001__20250930_z7xEW6Bxw2ul" style="font-size: 10pt; text-align: right" title="Total deferred tax asset"&gt;1,276,805&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DeferredOtherTaxExpenseBenefit_c20231001__20240930_zuwI6p0sTlOa" style="font-size: 10pt; text-align: right" title="Total deferred tax asset"&gt;69,745&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ValuationAllowance_iN_di_c20241001__20250930_zlAMUQEqk1T1" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Valuation allowance"&gt;(1,276,805&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ValuationAllowance_iN_di_c20231001__20240930_zMRGRvabjroe" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Valuation allowance"&gt;(69,745&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Deferred tax asset, net of allowance&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DeferredIncomeTaxExpenseBenefit_c20241001__20250930_zYk62Z9Hffz8" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred tax asset, net of allowance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0948"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DeferredIncomeTaxExpenseBenefit_c20231001__20240930_zryfzjSq0Bog" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred tax asset, net of allowance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0950"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company&#x2019;s
net operating loss carryforward as of September 30, 2025 and 2024 amounted to $&lt;span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_c20250930_z8R8TGDb1IJd"&gt;728,566&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;and $&lt;/span&gt;&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_c20240930_zSFSf0mvbkB1"&gt;69,745&lt;/span&gt;,
will be carried forward indefinitely.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In assessing the realization of the deferred tax assets,
management considers whether it is more likely than not that some portion of all of the deferred tax assets will not be realized. The
ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary
differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax
liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the
information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax
assets and has therefore established a full valuation allowance. For the year ended September 30 2025 and the period from March 20, 2024
(inception) to September 30, 2024, the change in the valuation allowance was $1,276,805 and $69,745, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;A reconciliation of
the federal income tax rate to the Company&#x2019;s effective tax rate at September 30 2025 and 2024 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z1ePPjFv7Yo6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Tax (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none; font-size: 10pt"&gt;&lt;span id="xdx_8BC_z5zgGNg7mdvh"&gt;Schedule
of effective tax rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_499_20241001__20250930_zIjFvERXgin1" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_495_20231001__20240930_zfen5JXH3Zmh" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;September
30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zAmp4UybQwIc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Statutory
federal income tax rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_zKGV9sKwgOLl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State
taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0962"&gt;&#x97;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0963"&gt;&#x97;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zU4SCPfkEk71" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
in valuation allowance&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(21&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(21&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zNQYpFPegk23" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax provision&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_8AA_zEvKR34woK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes interest accrued to unrecognized
tax benefits and penalties as income tax expense. There were no penalties or interest accrued as of, nor recognized during the years ended
December 31, 2024 and 2023. As of December 31, 2024 and 2023, the Company has not recorded an amount of gross unrecognized tax benefits
for uncertain tax positions for the current or prior year planned tax filing positions. No unrecognized tax benefits are applicable for
prior periods.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;The Company files
income tax returns in the U.S. federal jurisdiction in various state and local jurisdictions and is subject to examination by the various
taxing authorities, since inception. The Company has not filed its 2023 and 2024 tax returns. At the close of the Reverse Acquisition,
the Company assumed $&lt;span id="xdx_906_eus-gaap--CurrentIncomeTaxExpenseBenefit_c20241001__20250930_zmEnEpL3OkBi"&gt;959,639&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;of income tax expenses inclusive of interest and penalties. The Company has incurred an additional
$&lt;span id="xdx_90B_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_c20241001__20250930_zwu3IUhwj513"&gt;35,065&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;in interest and penalties for its failure to file and pay its taxes from the close of the
Reverse Acquisition to September 30, 2025. Until remedied, the Company will continue to incur these expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2024-10-012025-09-30" id="Fact000902">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zseA7OLoBZr2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Tax (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zNiRS2lQaiAf"&gt;Schedule
of income tax provision&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_497_20241001__20250930_z8zlzQTrfXdd" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_49E_20231001__20240930_zk8DepEsqKo" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;September
30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; width: 56%; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--CurrentFederalTaxExpenseBenefit_ztLehJjABk24" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Federal&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0904"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0905"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_zdwknaMFjbs3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;State&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0907"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0908"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--IncomeTaxProvisionStateCurrent_zXq2y5ypd4uj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Federal&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,145,726&lt;/span&gt;)&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(69,745&lt;/span&gt;)&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--IncomeTaxProvisionStateDeferred_zJv91K2oAkYf" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;State&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0913"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0914"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--ChangeInValuationAllowance_zW1UsrZgH3f3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
in valuation allowance&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,145,726&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;69,745&lt;/span&gt;&lt;/td&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_zZgnw2yaTye8" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax provision&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0919"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0920"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt"&gt;Deferred income tax assets and liabilities result primarily
from temporary differences in the recognition of various expenses for tax and financial statement purposes, and from the recognition of
the tax benefits of net operating loss carryforwards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s net deferred tax assets (liability)
at September 30, 2025 and 2024 are as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfDeferredTaxAssetAndLiabilitiesTableTextBlock_zhf0vaBC1WK3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Tax (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8BD_zSx94PobPrf4"&gt;Schedule of deferred tax assets (liability)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Deferred tax asset (liability)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 30pt; width: 56%; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Research &amp;amp; Development expenses&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ResearchAndDevelopmentExpenses_c20241001__20250930_zr9cDQa9SLJc" style="width: 12%; font-size: 10pt; text-align: right" title="Research &amp;amp; Development expenses"&gt;15,003&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ResearchAndDevelopmentExpenses_c20231001__20240930_zIiImjCD0KD8" style="width: 12%; font-size: 10pt; text-align: right" title="Research &amp;amp; Development expenses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0926"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Stock based compensation&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--EmployeeBenefitsAndSharesBasedCompensation_c20241001__20250930_zXHK99kkqZ9j" style="font-size: 10pt; text-align: right" title="Stock based compensation"&gt;538,487&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--EmployeeBenefitsAndSharesBasedCompensation_c20231001__20240930_zWwwRmZEozHd" style="font-size: 10pt; text-align: right" title="Stock based compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0930"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Net operating loss&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--OperatingIncomeLos_c20241001__20250930_z56YOnVifbdi" style="font-size: 10pt; text-align: right" title="Net operating loss"&gt;728,566&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--OperatingIncomeLos_c20231001__20240930_zdiWdLM5ohVc" style="font-size: 10pt; text-align: right" title="Net operating loss"&gt;69,745&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-indent: -10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amortization of R&amp;amp;D&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AcquisitionCosts_iN_di_c20241001__20250930_zOGoFpXRHFbh" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Amortization of R&amp;amp;D"&gt;(5,251&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AcquisitionCosts_iN_di_c20231001__20240930_zmicH2g2z1Gj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Amortization of R&amp;amp;D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0938"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Total deferred tax asset&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DeferredOtherTaxExpenseBenefit_c20241001__20250930_z7xEW6Bxw2ul" style="font-size: 10pt; text-align: right" title="Total deferred tax asset"&gt;1,276,805&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DeferredOtherTaxExpenseBenefit_c20231001__20240930_zuwI6p0sTlOa" style="font-size: 10pt; text-align: right" title="Total deferred tax asset"&gt;69,745&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ValuationAllowance_iN_di_c20241001__20250930_zlAMUQEqk1T1" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Valuation allowance"&gt;(1,276,805&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ValuationAllowance_iN_di_c20231001__20240930_zMRGRvabjroe" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Valuation allowance"&gt;(69,745&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Deferred tax asset, net of allowance&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DeferredIncomeTaxExpenseBenefit_c20241001__20250930_zYk62Z9Hffz8" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred tax asset, net of allowance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0948"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DeferredIncomeTaxExpenseBenefit_c20231001__20240930_zryfzjSq0Bog" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred tax asset, net of allowance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0950"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company&#x2019;s
net operating loss carryforward as of September 30, 2025 and 2024 amounted to $&lt;span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_c20250930_z8R8TGDb1IJd"&gt;728,566&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;and $&lt;/span&gt;&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_c20240930_zSFSf0mvbkB1"&gt;69,745&lt;/span&gt;,
will be carried forward indefinitely.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In assessing the realization of the deferred tax assets,
management considers whether it is more likely than not that some portion of all of the deferred tax assets will not be realized. The
ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary
differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax
liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the
information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax
assets and has therefore established a full valuation allowance. For the year ended September 30 2025 and the period from March 20, 2024
(inception) to September 30, 2024, the change in the valuation allowance was $1,276,805 and $69,745, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;A reconciliation of
the federal income tax rate to the Company&#x2019;s effective tax rate at September 30 2025 and 2024 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z1ePPjFv7Yo6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Tax (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none; font-size: 10pt"&gt;&lt;span id="xdx_8BC_z5zgGNg7mdvh"&gt;Schedule
of effective tax rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_499_20241001__20250930_zIjFvERXgin1" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_495_20231001__20240930_zfen5JXH3Zmh" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;September
30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zAmp4UybQwIc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Statutory
federal income tax rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_zKGV9sKwgOLl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State
taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0962"&gt;&#x97;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0963"&gt;&#x97;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zU4SCPfkEk71" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
in valuation allowance&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(21&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(21&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zNQYpFPegk23" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax provision&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <VWAV:IncomeTaxProvisionStateCurrent
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000910"
      unitRef="USD">-1145726</VWAV:IncomeTaxProvisionStateCurrent>
    <VWAV:IncomeTaxProvisionStateCurrent
      contextRef="From2023-10-012024-09-30"
      decimals="0"
      id="Fact000911"
      unitRef="USD">-69745</VWAV:IncomeTaxProvisionStateCurrent>
    <VWAV:ChangeInValuationAllowance
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000916"
      unitRef="USD">1145726</VWAV:ChangeInValuationAllowance>
    <VWAV:ChangeInValuationAllowance
      contextRef="From2023-10-012024-09-30"
      decimals="0"
      id="Fact000917"
      unitRef="USD">69745</VWAV:ChangeInValuationAllowance>
    <VWAV:ScheduleOfDeferredTaxAssetAndLiabilitiesTableTextBlock contextRef="From2024-10-012025-09-30" id="Fact000922">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfDeferredTaxAssetAndLiabilitiesTableTextBlock_zhf0vaBC1WK3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Tax (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8BD_zSx94PobPrf4"&gt;Schedule of deferred tax assets (liability)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Deferred tax asset (liability)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 30pt; width: 56%; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Research &amp;amp; Development expenses&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ResearchAndDevelopmentExpenses_c20241001__20250930_zr9cDQa9SLJc" style="width: 12%; font-size: 10pt; text-align: right" title="Research &amp;amp; Development expenses"&gt;15,003&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ResearchAndDevelopmentExpenses_c20231001__20240930_zIiImjCD0KD8" style="width: 12%; font-size: 10pt; text-align: right" title="Research &amp;amp; Development expenses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0926"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Stock based compensation&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--EmployeeBenefitsAndSharesBasedCompensation_c20241001__20250930_zXHK99kkqZ9j" style="font-size: 10pt; text-align: right" title="Stock based compensation"&gt;538,487&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--EmployeeBenefitsAndSharesBasedCompensation_c20231001__20240930_zWwwRmZEozHd" style="font-size: 10pt; text-align: right" title="Stock based compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0930"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Net operating loss&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--OperatingIncomeLos_c20241001__20250930_z56YOnVifbdi" style="font-size: 10pt; text-align: right" title="Net operating loss"&gt;728,566&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--OperatingIncomeLos_c20231001__20240930_zdiWdLM5ohVc" style="font-size: 10pt; text-align: right" title="Net operating loss"&gt;69,745&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-indent: -10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amortization of R&amp;amp;D&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AcquisitionCosts_iN_di_c20241001__20250930_zOGoFpXRHFbh" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Amortization of R&amp;amp;D"&gt;(5,251&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AcquisitionCosts_iN_di_c20231001__20240930_zmicH2g2z1Gj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Amortization of R&amp;amp;D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0938"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Total deferred tax asset&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DeferredOtherTaxExpenseBenefit_c20241001__20250930_z7xEW6Bxw2ul" style="font-size: 10pt; text-align: right" title="Total deferred tax asset"&gt;1,276,805&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DeferredOtherTaxExpenseBenefit_c20231001__20240930_zuwI6p0sTlOa" style="font-size: 10pt; text-align: right" title="Total deferred tax asset"&gt;69,745&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ValuationAllowance_iN_di_c20241001__20250930_zlAMUQEqk1T1" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Valuation allowance"&gt;(1,276,805&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ValuationAllowance_iN_di_c20231001__20240930_zMRGRvabjroe" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Valuation allowance"&gt;(69,745&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;Deferred tax asset, net of allowance&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DeferredIncomeTaxExpenseBenefit_c20241001__20250930_zYk62Z9Hffz8" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred tax asset, net of allowance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0948"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DeferredIncomeTaxExpenseBenefit_c20231001__20240930_zryfzjSq0Bog" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred tax asset, net of allowance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0950"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company&#x2019;s
net operating loss carryforward as of September 30, 2025 and 2024 amounted to $&lt;span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_c20250930_z8R8TGDb1IJd"&gt;728,566&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;and $&lt;/span&gt;&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_c20240930_zSFSf0mvbkB1"&gt;69,745&lt;/span&gt;,
will be carried forward indefinitely.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In assessing the realization of the deferred tax assets,
management considers whether it is more likely than not that some portion of all of the deferred tax assets will not be realized. The
ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary
differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax
liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the
information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax
assets and has therefore established a full valuation allowance. For the year ended September 30 2025 and the period from March 20, 2024
(inception) to September 30, 2024, the change in the valuation allowance was $1,276,805 and $69,745, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;A reconciliation of
the federal income tax rate to the Company&#x2019;s effective tax rate at September 30 2025 and 2024 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z1ePPjFv7Yo6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Tax (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none; font-size: 10pt"&gt;&lt;span id="xdx_8BC_z5zgGNg7mdvh"&gt;Schedule
of effective tax rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_499_20241001__20250930_zIjFvERXgin1" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_495_20231001__20240930_zfen5JXH3Zmh" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;September
30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zAmp4UybQwIc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Statutory
federal income tax rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_zKGV9sKwgOLl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State
taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0962"&gt;&#x97;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0963"&gt;&#x97;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zU4SCPfkEk71" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
in valuation allowance&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(21&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(21&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zNQYpFPegk23" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax provision&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

</VWAV:ScheduleOfDeferredTaxAssetAndLiabilitiesTableTextBlock>
    <VWAV:ResearchAndDevelopmentExpenses
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000924"
      unitRef="USD">15003</VWAV:ResearchAndDevelopmentExpenses>
    <VWAV:EmployeeBenefitsAndSharesBasedCompensation
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000928"
      unitRef="USD">538487</VWAV:EmployeeBenefitsAndSharesBasedCompensation>
    <VWAV:OperatingIncomeLos
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000932"
      unitRef="USD">728566</VWAV:OperatingIncomeLos>
    <VWAV:OperatingIncomeLos
      contextRef="From2023-10-012024-09-30"
      decimals="0"
      id="Fact000934"
      unitRef="USD">69745</VWAV:OperatingIncomeLos>
    <us-gaap:AcquisitionCosts
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000936"
      unitRef="USD">5251</us-gaap:AcquisitionCosts>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000940"
      unitRef="USD">1276805</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="From2023-10-012024-09-30"
      decimals="0"
      id="Fact000942"
      unitRef="USD">69745</us-gaap:DeferredOtherTaxExpenseBenefit>
    <VWAV:ValuationAllowance
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000944"
      unitRef="USD">1276805</VWAV:ValuationAllowance>
    <VWAV:ValuationAllowance
      contextRef="From2023-10-012024-09-30"
      decimals="0"
      id="Fact000946"
      unitRef="USD">69745</VWAV:ValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000951"
      unitRef="USD">728566</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000952"
      unitRef="USD">69745</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-10-012025-09-30" id="Fact000957">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z1ePPjFv7Yo6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Tax (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="display: none; font-size: 10pt"&gt;&lt;span id="xdx_8BC_z5zgGNg7mdvh"&gt;Schedule
of effective tax rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_499_20241001__20250930_zIjFvERXgin1" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_495_20231001__20240930_zfen5JXH3Zmh" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;September
30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zAmp4UybQwIc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Statutory
federal income tax rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_zKGV9sKwgOLl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State
taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0962"&gt;&#x97;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0963"&gt;&#x97;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zU4SCPfkEk71" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
in valuation allowance&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(21&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(21&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zNQYpFPegk23" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax provision&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000959"
      unitRef="Ratio">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-10-012024-09-30"
      decimals="INF"
      id="Fact000960"
      unitRef="Ratio">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000965"
      unitRef="Ratio">-0.21</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-10-012024-09-30"
      decimals="INF"
      id="Fact000966"
      unitRef="Ratio">-0.21</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact000968"
      unitRef="Ratio">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-10-012024-09-30"
      decimals="INF"
      id="Fact000969"
      unitRef="Ratio">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000970"
      unitRef="USD">959639</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000971"
      unitRef="USD">35065</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2024-10-012025-09-30" id="Fact000973">&lt;p id="xdx_807_eus-gaap--SegmentReportingDisclosureTextBlock_zpR7CnBja1rj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Note
                                            15 &#x2014; &lt;span id="xdx_82D_ziMjiMix0Cvi"&gt;Segment Information&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;ASC Topic 280 establishes
standards for companies to report financial statement information about operating segments, products, services, geographic areas, and
major customers. Operating segments are defined as components of an enterprise for which separate financial information is available
that is regularly evaluated by the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), or group, in deciding how to
allocate resources and assess performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The CODM has been identified
as the Chief Financial Officer, who reviews the operating results for the Company as a whole to make decisions about allocating resources
and assessing financial performance. Accordingly, management has determined that the Company only has one operating segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The CODM assesses performance for the single segment
and decides how to allocate resources based on operating loss that also is reported on the consolidated statements of operations. The
measure of segment assets is reported on the consolidated balance sheets as total assets. When evaluating the Company&#x2019;s performance
and making key decisions regarding resource allocation the CODM reviews several key metrics, which include the following:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zpVejNrCrU9f" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt; width: 56%"&gt;&lt;span style="display: none; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zrx2YJEppt69"&gt;Schedule
of Segment Information&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_49A_20241001__20250930_zUBhxjTenWp2" style="text-align: right; width: 12%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_492_20240320__20240930_zuqZHQpKYbf6" style="text-align: right; width: 12%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
the year ended September 30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
the Period from March 20, 2024 (inception) to September 30, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpense_zxjBvhsroTe3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,416,619&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;328,469&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_zbp5OXf1VuH5" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;156,462&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,650&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--BusinessDevelopment_zohdBfZWFbyk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sales
and marketing&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,168,108&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0984"&gt;&#x97;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OtherNonoperatingIncome_iN_di_zXJ9Qzka0Q7h" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6,741,189&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(332,119&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_8A9_zfGPyPLn4gpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The key metrics included in segment profit or loss
reviewed by the CODM are operating costs. The CODM reviews operating costs to manage and forecast cash to ensure enough capital is available
to meet operational needs and fund research and development efforts. The CODM also reviews operating costs to manage, maintain and enforce
all contractual agreements to ensure costs are aligned with all agreements and budget.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2024-10-012025-09-30" id="Fact000975">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zpVejNrCrU9f" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt; width: 56%"&gt;&lt;span style="display: none; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zrx2YJEppt69"&gt;Schedule
of Segment Information&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_49A_20241001__20250930_zUBhxjTenWp2" style="text-align: right; width: 12%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_492_20240320__20240930_zuqZHQpKYbf6" style="text-align: right; width: 12%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
the year ended September 30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
the Period from March 20, 2024 (inception) to September 30, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpense_zxjBvhsroTe3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,416,619&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;328,469&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_zbp5OXf1VuH5" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;156,462&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,650&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--BusinessDevelopment_zohdBfZWFbyk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sales
and marketing&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,168,108&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0984"&gt;&#x97;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OtherNonoperatingIncome_iN_di_zXJ9Qzka0Q7h" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6,741,189&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(332,119&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000977"
      unitRef="USD">5416619</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000978"
      unitRef="USD">328469</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000980"
      unitRef="USD">156462</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000981"
      unitRef="USD">3650</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:BusinessDevelopment
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000983"
      unitRef="USD">1168108</us-gaap:BusinessDevelopment>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000986"
      unitRef="USD">6741189</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2024-03-202024-09-30"
      decimals="0"
      id="Fact000987"
      unitRef="USD">332119</us-gaap:OtherNonoperatingIncome>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-10-012025-09-30" id="Fact000991">&lt;p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zbDoRJFu9Eb4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Note
                                            16&#x2014;&lt;span id="xdx_82C_zrByWHNe6f24"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company evaluated
subsequent events and transactions that occurred after the balance sheet date up to the date of the filing of this report. The Company
did not identify any subsequent events, other than disclosed in the Notes and discussed below, that would have required adjustment or
disclosure in these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;AI Infrastructure
Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On October 5, 2025,
the Company entered into an Order Form (the &#x201c;Agreement&#x201d;) with PVML Ltd., a Tel Aviv&#x2013;based provider of secure data-AI
infrastructure. The Agreement establishes a strategic collaboration to integrate PVML&#x2019;s secure, real-time data-AI infrastructure
with the Company&#x2019;s radar and AI-driven computer-vision technologies to enable secure, autonomous mission-data systems for defense
and homeland-security applications.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The terms of the Agreement
include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The initial
                                            term is twelve (12) months, automatically renewable for successive one-year periods unless
                                            either party gives 60-days&#x2019; prior notice of non-renewal.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
                                            will pay total consideration of $&lt;span id="xdx_901_eus-gaap--AssetAcquisitionConsiderationTransferred_c20241001__20250930_zx5amT2IAqT7"&gt;600,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;,
                                            consisting of (i) a cash component of $&lt;span id="xdx_90B_ecustom--CashComponentPayable_iI_c20250930_zpYBqqmGiy67" title="Cash Component Payable"&gt;250,000&lt;/span&gt;
                                            &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;payable upon execution and (ii) an equity component
                                            valued at $&lt;span id="xdx_903_eus-gaap--DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_iI_c20250930_zj4wboIbo0n6"&gt;350,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;,
                                            to be settled through the issuance of &lt;span id="xdx_901_eus-gaap--SharesIssued_iI_c20250930_zankIdejML6b"&gt;35,000&lt;/span&gt;
                                            &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;shares of the Company&#x2019;s common stock valued
                                            at $&lt;span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--CommonStockMember_zCTNFfkKLdci"&gt;10.00&lt;/span&gt;
                                            &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Agreement
                                            provides for a yearly platform fee covering &lt;span id="xdx_905_ecustom--PlatformFee_iI_pn3n3_dm_c20250930_za89Kkd6jIDb" title="Platform Fee"&gt;2.4&lt;/span&gt;
                                            &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;million PVML Units (&#x201c;PUs&#x201d;) of data-processing
                                            capacity, with usage fees for consumption beyond that level.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Each party
                                            retains ownership of its respective intellectual property, and the Company will own all outputs
                                            and derivatives generated through its use of the PVML platform.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;December 2025
Share Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;On December 15, 2025, in
connection with the closing of the Acquisition (as defined below), the Company (or &#x201c;Buyer&#x201d;) entered into Amendment No. 1
(the &#x201c;Amendment&#x201d;) to the Share Purchase Agreement dated as of December 3, 2025 (the &#x201c;Agreement&#x201d;), with Blade
Ranger Ltd., a company organized under the laws of Israel and listed on the Tel Aviv Stock Exchange under the ticker
&#x201c;BLRN&#x201d; (&#x201c;Seller&#x201d;), and Solar Drone Ltd., an Israeli corporation (the &#x201c;Target Company&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;Pursuant to the Amendment, Section 2.2 of the Agreement
was amended to provide that, in consideration for all of the issued and outstanding shares of the Target Company (the &#x201c;Company Shares&#x201d;),
the Company shall issue and deliver to the Seller (or its designee(s)): (a) 1,500,000 shares of the Company&#x2019;s common stock, $0.01
par value per share (the &#x201c;Buyer Shares&#x201d;); and (b) 300,000 Pre-Funded Common Stock Purchase Warrants (the &#x201c;Initial PFWs&#x201d;),
each exercisable for one share of the Company&#x2019;s common stock on the terms set forth in the form attached as Exhibit A to the Agreement
and filed as Exhibit 4.1 hereto.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;The Amendment also provides for the issuance of additional
Pre-Funded Common Stock Purchase Warrants in the form attached as Exhibit 4.1 hereto (the &#x201c;Additional PFWs&#x201d; and, together
with the Initial PFWs, the &#x201c;Pre-Funded Warrants&#x201d;) if the average daily volume-weighted average price (&#x201c;VWAP&#x201d;)
of the Company&#x2019;s common stock for the five Trading Day period immediately preceding the date of effectiveness of the registration
statement registering the resale of the Buyer Shares and Warrant Shares (as defined below) is less than $12.00 per share. In such event,
the number of Additional PFWs shall equal the difference between (x) $21,600,000 divided by such average daily VWAP and (y) 1,800,000,
to be issued within two Business Days following the effectiveness of such registration statement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;The Pre-Funded Warrants are exercisable immediately
upon issuance at a nominal exercise price of $0.01 per share (with the aggregate exercise price, except for such nominal amount, pre-funded
to the Company) and will remain exercisable until exercised in full, subject to customary adjustments, beneficial ownership limitations
(9.99%), and an exchange cap of 19.99% of the Company&#x2019;s outstanding common stock prior to the initial exercise date unless shareholder
approval is obtained pursuant to Nasdaq Listing Rule 5635. The Warrant Shares issuable upon exercise of the Pre-Funded Warrants are subject
to the registration rights set forth in the Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;On December 15, 2025, the Company completed the acquisition
(the &#x201c;Acquisition&#x201d;) of all of the Company Shares of the Target Company from the Seller pursuant to the Agreement, as amended
by the Amendment described in Item 1.01 above. The Acquisition is material to the Company and constitutes a significant acquisition under
Rule 3-05 of Regulation S-X.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;In consideration for the Company Shares, the Company
issued to the Seller 1,500,000 Buyer Shares and 300,000 Initial PFWs, and may issue Additional PFWs as described in Item 1.01 above. The
Buyer Shares and Initial PFWs were issued in a private placement transaction exempt from the registration requirements of the Securities
Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation
D promulgated thereunder.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;The Target Company is an Israeli corporation engaged
in the development of solar-powered drone technology. The Acquisition is material to the Company and constitutes a significant acquisition
under Rule 3-05 of Regulation S-X, requiring the filing of financial statements of the Target Company. The material terms of the Agreement
were previously disclosed in the Company&#x2019;s Current Report on Form 8-K filed with the Securities and Exchange Commission on December
3, 2025, and are incorporated herein by reference.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company will file the required financial statements
of Solar Drone Ltd. and pro forma financial information related to the Acquisition by amendment to this Current Report on Form 8-K no
later than 71 calendar days after the date that this Current Report on Form 8-K is required to be filed.&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Advance to C.M. Composite Materials Ltd&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;On December 26, 2025, VisionWave Holdings, Inc. advanced
principal in the amount of $398,345 to C.M. Composite Materials Ltd., an Israeli corporation (&#x201c;CM&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;In connection with the advance, CM delivered a Promissory
Note to the Company (the &#x201c; CM Note&#x201d;). The CM Note has a 24-month maturity, with the outstanding principal due and payable
on December 31, 2027, unless repaid earlier. The CM Note does not bear interekenigst unless an event of default occurs, in which case
interest accrues at a rate of 5% per annum, or the maximum rate permitted by applicable law, if lower. The CM Note may be prepaid at any
time without premium or penalty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;The proceeds of the Note were funded on December 26,
2025. The CM Note constitutes a binding and enforceable obligation of CM.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;The CM Note is a stand-alone financial obligation
and is not contingent upon the completion of any acquisition, merger, or other strategic transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Changes to Board of Directors and Officers&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;On December 29, 2025, Noam Kenig resigned as Chief
Executive Officer and as a member of the Board of Directors (the "Board") of the Company, effective immediately for personal
reasons. Mr. Kenig's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations,
policies or practices.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;On December 29, 2025, the Board appointed Douglas
Davis, the Company's current Executive Chairman, to serve as Interim Chief Executive Officer, effective immediately. Mr. Davis will continue
to serve as Executive Chairman while performing the duties of Interim Chief Executive Officer. There are no new compensatory arrangements
entered into with Mr. Davis in connection with this appointment, and no material changes to his existing compensatory arrangements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;On December 29, 2025, the Board appointed Eric Shuss,
who currently serves as a director of the Company, as Independent Lead Director, effective immediately. There are no compensatory arrangements
entered into with Mr. Shuss in connection with this appointment beyond the standard compensatory arrangements for non-employee directors
previously disclosed by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Exercise of the Company warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company received $5,6987,365 Since September 30,
2025 to December 30, 2025 for 495,510 warrants that been exercised paying $11.50 per warrant. As such the Company issued 495,510 shares
for said warrants exercise.&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact000992"
      unitRef="USD">600000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <VWAV:CashComponentPayable
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000994"
      unitRef="USD">250000</VWAV:CashComponentPayable>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000995"
      unitRef="USD">350000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000996"
      unitRef="Shares">35000</us-gaap:SharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember541144343"
      decimals="INF"
      id="Fact000997"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <VWAV:PlatformFee
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000999"
      unitRef="USD">2400000</VWAV:PlatformFee>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001009"
      unitRef="USD">14255720</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001010"
      unitRef="USD">2284933</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001012"
      unitRef="USD">614472</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001013"
      unitRef="USD">189549</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:Supplies
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001015"
      unitRef="USD">98250</us-gaap:Supplies>
    <us-gaap:Supplies
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001016"
      unitRef="USD">98250</us-gaap:Supplies>
    <VWAV:DueFromRelatedParty
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001018"
      unitRef="USD">147500</VWAV:DueFromRelatedParty>
    <VWAV:DueFromRelatedParty
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001019"
      unitRef="USD">120000</VWAV:DueFromRelatedParty>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001021"
      unitRef="USD">15115942</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001022"
      unitRef="USD">2692732</us-gaap:AssetsCurrent>
    <us-gaap:Investments
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001024"
      unitRef="USD">281</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001025"
      unitRef="USD">281</us-gaap:Investments>
    <us-gaap:EquityMethodInvestments
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001027"
      unitRef="USD">2773616</us-gaap:EquityMethodInvestments>
    <us-gaap:AccountsAndNotesReceivableNet
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001030"
      unitRef="USD">3476245</us-gaap:AccountsAndNotesReceivableNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001033"
      unitRef="USD">60121</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001036"
      unitRef="USD">360000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001039"
      unitRef="USD">113915787</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Assets
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001042"
      unitRef="USD">135701992</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001043"
      unitRef="USD">2693013</us-gaap:Assets>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001051"
      unitRef="USD">4284917</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001052"
      unitRef="USD">3917834</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <VWAV:CustomerDeposit
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001054"
      unitRef="USD">108006</VWAV:CustomerDeposit>
    <VWAV:CustomerDeposit
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001055"
      unitRef="USD">108006</VWAV:CustomerDeposit>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001057"
      unitRef="USD">350000</us-gaap:DeferredRevenue>
    <us-gaap:TaxesPayableCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001060"
      unitRef="USD">1043932</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001061"
      unitRef="USD">994704</us-gaap:TaxesPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001063"
      unitRef="USD">1002860</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001064"
      unitRef="USD">943039</us-gaap:SalesAndExciseTaxPayableCurrent>
    <VWAV:PromissoryNotesNetOfUnamortizedDebtIssuanceCost
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001066"
      unitRef="USD">21939203</VWAV:PromissoryNotesNetOfUnamortizedDebtIssuanceCost>
    <VWAV:PromissoryNotesNetOfUnamortizedDebtIssuanceCost
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001067"
      unitRef="USD">1003995</VWAV:PromissoryNotesNetOfUnamortizedDebtIssuanceCost>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001069"
      unitRef="USD">2100316</VWAV:DueToRelatedParties>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001070"
      unitRef="USD">2434492</VWAV:DueToRelatedParties>
    <us-gaap:NotesPayable
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001072"
      unitRef="USD">5625883</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001073"
      unitRef="USD">4861390</us-gaap:NotesPayable>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001075"
      unitRef="USD">375000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <VWAV:DeferredUnderwritersDiscounts
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001078"
      unitRef="USD">225000</VWAV:DeferredUnderwritersDiscounts>
    <VWAV:DeferredUnderwritersDiscounts
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001079"
      unitRef="USD">225000</VWAV:DeferredUnderwritersDiscounts>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001081"
      unitRef="USD">37055117</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001082"
      unitRef="USD">14488460</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001084"
      unitRef="USD">37055117</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001085"
      unitRef="USD">14488460</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001096"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001098"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001100"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001102"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001104"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001106"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001108"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001110"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001115"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001117"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001119"
      unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001121"
      unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001123"
      unitRef="Shares">20347137</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001125"
      unitRef="Shares">20347137</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001127"
      unitRef="Shares">14521094</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001129"
      unitRef="Shares">14521094</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001112"
      unitRef="USD">203470</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001113"
      unitRef="USD">145211</us-gaap:CommonStockValue>
    <VWAV:SharesToBeIssuedRelatedToAcquisition
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001131"
      unitRef="USD">66990000</VWAV:SharesToBeIssuedRelatedToAcquisition>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001134"
      unitRef="USD">66408319</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001135"
      unitRef="USD">3168248</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001137"
      unitRef="USD">-34954914</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001138"
      unitRef="USD">-15108906</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001140"
      unitRef="USD">98646875</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001141"
      unitRef="USD">-11795447</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001143"
      unitRef="USD">135701992</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001144"
      unitRef="USD">2693013</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001151"
      unitRef="USD">2922318</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact001152"
      unitRef="USD">131463</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001153"
      unitRef="USD">7602857</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact001154"
      unitRef="USD">275231</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001156"
      unitRef="USD">271534</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001158"
      unitRef="USD">586609</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001161"
      unitRef="USD">2159439</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact001162"
      unitRef="USD">11490</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001163"
      unitRef="USD">3612611</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact001164"
      unitRef="USD">71445</us-gaap:SellingAndMarketingExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001166"
      unitRef="USD">5702250</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001168"
      unitRef="USD">5821145</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001171"
      unitRef="USD">11055541</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact001172"
      unitRef="USD">142953</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001173"
      unitRef="USD">17623222</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact001174"
      unitRef="USD">346676</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001176"
      unitRef="USD">-11055541</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact001177"
      unitRef="USD">-142953</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001178"
      unitRef="USD">-17623222</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact001179"
      unitRef="USD">-346676</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001186"
      unitRef="USD">18414</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001188"
      unitRef="USD">19402</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001191"
      unitRef="USD">2192375</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001193"
      unitRef="USD">2334917</us-gaap:InterestExpense>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact001197"
      unitRef="USD">114111</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact001199"
      unitRef="USD">114111</us-gaap:MarketableSecuritiesGainLoss>
    <VWAV:ChangeInFairValueOfConvertibleNotesPayable
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001201"
      unitRef="USD">-7634</VWAV:ChangeInFairValueOfConvertibleNotesPayable>
    <VWAV:ChangeInFairValueOfConvertibleNotesPayable
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001203"
      unitRef="USD">279046</VWAV:ChangeInFairValueOfConvertibleNotesPayable>
    <VWAV:ChangeInFairValueOfOtherLiabilities
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001206"
      unitRef="USD">262800</VWAV:ChangeInFairValueOfOtherLiabilities>
    <VWAV:ChangeInFairValueOfOtherLiabilities
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001208"
      unitRef="USD">262800</VWAV:ChangeInFairValueOfOtherLiabilities>
    <us-gaap:OtherIncome
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001211"
      unitRef="USD">48975</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001213"
      unitRef="USD">108975</us-gaap:OtherIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001216"
      unitRef="USD">-1854552</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact001217"
      unitRef="USD">114111</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001218"
      unitRef="USD">-2222786</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact001219"
      unitRef="USD">114111</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001221"
      unitRef="USD">-12910093</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact001222"
      unitRef="USD">-28842</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001223"
      unitRef="USD">-19846008</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact001224"
      unitRef="USD">-232565</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001231"
      unitRef="USD">-12910093</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact001232"
      unitRef="USD">-28842</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001233"
      unitRef="USD">-19846008</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact001234"
      unitRef="USD">-232565</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31"
      decimals="INF"
      id="Fact001236"
      unitRef="Shares">19582298</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31"
      decimals="INF"
      id="Fact001238"
      unitRef="Shares">19582298</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-03-31"
      decimals="INF"
      id="Fact001240"
      unitRef="Shares">11000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-03-31"
      decimals="INF"
      id="Fact001242"
      unitRef="Shares">11000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact001244"
      unitRef="Shares">17343913</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact001246"
      unitRef="Shares">17343913</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-10-012025-03-31"
      decimals="INF"
      id="Fact001248"
      unitRef="Shares">11000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-10-012025-03-31"
      decimals="INF"
      id="Fact001250"
      unitRef="Shares">11000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-012026-03-31"
      decimals="INF"
      id="Fact001252"
      unitRef="USDPShares">-0.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31"
      decimals="INF"
      id="Fact001254"
      unitRef="USDPShares">-0.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-012025-03-31"
      decimals="INF"
      id="Fact001256"
      unitRef="USDPShares">-0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-012025-03-31"
      decimals="INF"
      id="Fact001258"
      unitRef="USDPShares">-0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact001260"
      unitRef="USDPShares">-1.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact001262"
      unitRef="USDPShares">-1.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-10-012025-03-31"
      decimals="INF"
      id="Fact001264"
      unitRef="USDPShares">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-10-012025-03-31"
      decimals="INF"
      id="Fact001266"
      unitRef="USDPShares">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001274"
      unitRef="Shares">14521094</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001268"
      unitRef="USD">145211</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001269"
      unitRef="USD">3168248</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001271"
      unitRef="USD">-15108906</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001272"
      unitRef="USD">-11795447</us-gaap:StockholdersEquity>
    <VWAV:IssuanceOfSharesInAssetAcquisitionsShares
      contextRef="From2025-10-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001282"
      unitRef="Shares">1500000</VWAV:IssuanceOfSharesInAssetAcquisitionsShares>
    <VWAV:IssuanceOfSharesInAssetAcquisitions
      contextRef="From2025-10-012025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001276"
      unitRef="USD">15000</VWAV:IssuanceOfSharesInAssetAcquisitions>
    <VWAV:IssuanceOfSharesInAssetAcquisitions
      contextRef="From2025-10-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001277"
      unitRef="USD">11685000</VWAV:IssuanceOfSharesInAssetAcquisitions>
    <VWAV:IssuanceOfSharesInAssetAcquisitions
      contextRef="From2025-10-012025-12-31"
      decimals="0"
      id="Fact001280"
      unitRef="USD">11700000</VWAV:IssuanceOfSharesInAssetAcquisitions>
    <VWAV:IssuanceOfWarrantsInAssetAcquisitions
      contextRef="From2025-10-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001285"
      unitRef="USD">2340000</VWAV:IssuanceOfWarrantsInAssetAcquisitions>
    <VWAV:IssuanceOfWarrantsInAssetAcquisitions
      contextRef="From2025-10-012025-12-31"
      decimals="0"
      id="Fact001288"
      unitRef="USD">2340000</VWAV:IssuanceOfWarrantsInAssetAcquisitions>
    <VWAV:ExerciseOfWarrantsShares
      contextRef="From2025-10-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001296"
      unitRef="Shares">495509</VWAV:ExerciseOfWarrantsShares>
    <VWAV:ExerciseOfWarrants
      contextRef="From2025-10-012025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001290"
      unitRef="USD">4955</VWAV:ExerciseOfWarrants>
    <VWAV:ExerciseOfWarrants
      contextRef="From2025-10-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001291"
      unitRef="USD">5693399</VWAV:ExerciseOfWarrants>
    <VWAV:ExerciseOfWarrants
      contextRef="From2025-10-012025-12-31"
      decimals="0"
      id="Fact001294"
      unitRef="USD">5698354</VWAV:ExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-10-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001299"
      unitRef="USD">2054847</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-10-012025-12-31"
      decimals="0"
      id="Fact001302"
      unitRef="USD">2054847</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="From2025-10-012025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001307"
      unitRef="USD">-6935915</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-10-012025-12-31"
      decimals="0"
      id="Fact001308"
      unitRef="USD">-6935915</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001316"
      unitRef="Shares">16516603</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001310"
      unitRef="USD">165166</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001311"
      unitRef="USD">24941494</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001313"
      unitRef="USD">-22044821</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001314"
      unitRef="USD">3061839</us-gaap:StockholdersEquity>
    <VWAV:ExerciseOfWarrantsShares
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001324"
      unitRef="Shares">46747</VWAV:ExerciseOfWarrantsShares>
    <VWAV:ExerciseOfWarrants
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001318"
      unitRef="USD">467</VWAV:ExerciseOfWarrants>
    <VWAV:ExerciseOfWarrants
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001319"
      unitRef="USD">537124</VWAV:ExerciseOfWarrants>
    <VWAV:ExerciseOfWarrants
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001322"
      unitRef="USD">537591</VWAV:ExerciseOfWarrants>
    <VWAV:IssuanceOfSharesInAssetAcquisitionShares
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001332"
      unitRef="Shares">3000000</VWAV:IssuanceOfSharesInAssetAcquisitionShares>
    <VWAV:IssuanceOfSharesInAssetAcquisition
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001326"
      unitRef="USD">30000</VWAV:IssuanceOfSharesInAssetAcquisition>
    <VWAV:IssuanceOfSharesInAssetAcquisition
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001327"
      unitRef="USD">28680000</VWAV:IssuanceOfSharesInAssetAcquisition>
    <VWAV:IssuanceOfSharesInAssetAcquisition
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001330"
      unitRef="USD">28710000</VWAV:IssuanceOfSharesInAssetAcquisition>
    <VWAV:IssuanceOfSharesPursuantToSepaShares
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001340"
      unitRef="Shares">233678</VWAV:IssuanceOfSharesPursuantToSepaShares>
    <VWAV:IssuanceOfSharesPursuantToSepa
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001334"
      unitRef="USD">2337</VWAV:IssuanceOfSharesPursuantToSepa>
    <VWAV:IssuanceOfSharesPursuantToSepa
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001335"
      unitRef="USD">1758425</VWAV:IssuanceOfSharesPursuantToSepa>
    <VWAV:IssuanceOfSharesPursuantToSepa
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001338"
      unitRef="USD">1760762</VWAV:IssuanceOfSharesPursuantToSepa>
    <VWAV:IssuanceOfSharesPursuantToSaveroneExchangeAgreementShares
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001348"
      unitRef="Shares">365610</VWAV:IssuanceOfSharesPursuantToSaveroneExchangeAgreementShares>
    <VWAV:IssuanceOfSharesPursuantToSaveroneExchangeAgreement
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001342"
      unitRef="USD">3655</VWAV:IssuanceOfSharesPursuantToSaveroneExchangeAgreement>
    <VWAV:IssuanceOfSharesPursuantToSaveroneExchangeAgreement
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001343"
      unitRef="USD">2720137</VWAV:IssuanceOfSharesPursuantToSaveroneExchangeAgreement>
    <VWAV:IssuanceOfSharesPursuantToSaveroneExchangeAgreement
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001346"
      unitRef="USD">2723792</VWAV:IssuanceOfSharesPursuantToSaveroneExchangeAgreement>
    <VWAV:SharesToBeIssuedRelatedToAssetAcquisition
      contextRef="From2026-01-012026-03-31_custom_SharesToBeIssuedMember"
      decimals="0"
      id="Fact001352"
      unitRef="USD">66990000</VWAV:SharesToBeIssuedRelatedToAssetAcquisition>
    <VWAV:SharesToBeIssuedRelatedToAssetAcquisition
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001354"
      unitRef="USD">66990000</VWAV:SharesToBeIssuedRelatedToAssetAcquisition>
    <VWAV:IssuanceOfWarrantsPursuantToLetterAgreement
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001357"
      unitRef="USD">6986665</VWAV:IssuanceOfWarrantsPursuantToLetterAgreement>
    <VWAV:IssuanceOfWarrantsPursuantToLetterAgreement
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001360"
      unitRef="USD">6986665</VWAV:IssuanceOfWarrantsPursuantToLetterAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001368"
      unitRef="Shares">184499</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001362"
      unitRef="USD">1845</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001363"
      unitRef="USD">784474</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001366"
      unitRef="USD">786319</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001373"
      unitRef="USD">-12910093</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001374"
      unitRef="USD">-12910093</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001382"
      unitRef="Shares">20347137</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001376"
      unitRef="USD">203470</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001377"
      unitRef="USD">66408319</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_SharesToBeIssuedMember"
      decimals="0"
      id="Fact001378"
      unitRef="USD">66990000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001379"
      unitRef="USD">-34954914</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001380"
      unitRef="USD">98646875</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001390"
      unitRef="Shares">11000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001384"
      unitRef="USD">110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001385"
      unitRef="USD">151000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001387"
      unitRef="USD">-332119</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001388"
      unitRef="USD">-71119</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2024-10-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001395"
      unitRef="USD">-203724</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-10-012024-12-31"
      decimals="0"
      id="Fact001396"
      unitRef="USD">-203724</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001404"
      unitRef="Shares">11000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001398"
      unitRef="USD">110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001399"
      unitRef="USD">151000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001401"
      unitRef="USD">-535843</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001402"
      unitRef="USD">-274843</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001409"
      unitRef="USD">-28842</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact001410"
      unitRef="USD">-28842</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001418"
      unitRef="Shares">11000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001412"
      unitRef="USD">110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001413"
      unitRef="USD">151000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001415"
      unitRef="USD">-564685</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact001416"
      unitRef="USD">-303685</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001423"
      unitRef="USD">-19846008</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact001424"
      unitRef="USD">-232565</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <VWAV:FairValueOfOtherLiabilities
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001429"
      unitRef="USD">262800</VWAV:FairValueOfOtherLiabilities>
    <VWAV:ChangeInFairValueOfConvertibleNotesPayable
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001432"
      unitRef="USD">279046</VWAV:ChangeInFairValueOfConvertibleNotesPayable>
    <VWAV:GainOnInvestmentOfMarketableSecurities
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact001436"
      unitRef="USD">114111</VWAV:GainOnInvestmentOfMarketableSecurities>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001438"
      unitRef="USD">1826461</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001441"
      unitRef="USD">2841166</us-gaap:ShareBasedCompensation>
    <VWAV:DepreciationAndAmortizations
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001444"
      unitRef="USD">5821145</VWAV:DepreciationAndAmortizations>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001450"
      unitRef="USD">434092</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseDueFromOtherRelatedParties
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001453"
      unitRef="USD">127862</us-gaap:IncreaseDecreaseDueFromOtherRelatedParties>
    <VWAV:IncreaseDecreaseAdvancesToSupplier
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact001457"
      unitRef="USD">98250</VWAV:IncreaseDecreaseAdvancesToSupplier>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001459"
      unitRef="USD">349501</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact001460"
      unitRef="USD">90000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <VWAV:IncreaseDecreaseInCustomerDeposit
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact001463"
      unitRef="USD">108006</VWAV:IncreaseDecreaseInCustomerDeposit>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001465"
      unitRef="USD">350000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001468"
      unitRef="USD">-334176</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact001469"
      unitRef="USD">190428</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <VWAV:IncreaseDecreaseInStockBasedCompensationLiability
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001471"
      unitRef="USD">637800</VWAV:IncreaseDecreaseInStockBasedCompensationLiability>
    <VWAV:LatePaymentPenaltyOnExciseTaxesPayable
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001474"
      unitRef="USD">59821</VWAV:LatePaymentPenaltyOnExciseTaxesPayable>
    <VWAV:LatePaymentPenaltyOnIncomeTaxesPayable
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001477"
      unitRef="USD">49228</VWAV:LatePaymentPenaltyOnIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001480"
      unitRef="USD">-8790770</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact001481"
      unitRef="USD">-56492</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <VWAV:ProceedsFromSaleOfMarketableSecuritiesNet
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact001487"
      unitRef="USD">114375</VWAV:ProceedsFromSaleOfMarketableSecuritiesNet>
    <VWAV:AdvanceToC.m.CompositeMaterialsLtd
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001489"
      unitRef="USD">3476245</VWAV:AdvanceToC.m.CompositeMaterialsLtd>
    <us-gaap:PaymentsToAcquireOilAndGasPropertyAndEquipment
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001492"
      unitRef="USD">59075</us-gaap:PaymentsToAcquireOilAndGasPropertyAndEquipment>
    <VWAV:DepositOnPropertyPlantAndEquipment
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001495"
      unitRef="USD">-350000</VWAV:DepositOnPropertyPlantAndEquipment>
    <VWAV:CashPaidForEquityMethodInvestment
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001498"
      unitRef="USD">49823</VWAV:CashPaidForEquityMethodInvestment>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001501"
      unitRef="USD">119135</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001504"
      unitRef="USD">-3816008</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact001505"
      unitRef="USD">114375</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001510"
      unitRef="USD">850000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001513"
      unitRef="USD">463680</us-gaap:RepaymentsOfConvertibleDebt>
    <VWAV:ProceedsFromIssuanceOfPromissoryNote
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001516"
      unitRef="USD">16975000</VWAV:ProceedsFromIssuanceOfPromissoryNote>
    <VWAV:RepaymentOfPromissoryNote
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001519"
      unitRef="USD">780461</VWAV:RepaymentOfPromissoryNote>
    <VWAV:ProceedsFromDrawdownOfSepa
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001522"
      unitRef="USD">1760761</VWAV:ProceedsFromDrawdownOfSepa>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001525"
      unitRef="USD">6235945</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001528"
      unitRef="USD">24577565</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001531"
      unitRef="USD">11970787</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact001532"
      unitRef="USD">57883</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001534"
      unitRef="USD">2284933</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001535"
      unitRef="USD">3014</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001537"
      unitRef="USD">14255720</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact001538"
      unitRef="USD">60897</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <VWAV:DebtDiscountOnWarrantIssuedForNotes
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001552"
      unitRef="USD">6986665</VWAV:DebtDiscountOnWarrantIssuedForNotes>
    <VWAV:IssuanceOfSharesPursuanstToSaveroneExchangeAgreement
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001555"
      unitRef="USD">2723792</VWAV:IssuanceOfSharesPursuanstToSaveroneExchangeAgreement>
    <VWAV:IssuanceOfShareInAssetAcquisitions
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001558"
      unitRef="USD">40410000</VWAV:IssuanceOfShareInAssetAcquisitions>
    <VWAV:IssuanceOfWarrantsPursuantToExchangeAgreement
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001561"
      unitRef="USD">2340000</VWAV:IssuanceOfWarrantsPursuantToExchangeAgreement>
    <VWAV:NoteIssuedInAssetAcquisition
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001564"
      unitRef="USD">10000000</VWAV:NoteIssuedInAssetAcquisition>
    <VWAV:SharesToBeIssuedRelatedToAssetAcquisitions
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001567"
      unitRef="USD">66990000</VWAV:SharesToBeIssuedRelatedToAssetAcquisitions>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001570">&lt;p id="xdx_80A_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z0Csr0TuT71h" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 1&#x2014;&lt;span id="xdx_827_zFfbGSUbXKR8"&gt;Organization and Business Operations&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;VisionWave Holdings, Inc. (&#x201c;VW Holdings&#x201d;
or the &#x201c;Company&#x201d;) is a Delaware company incorporated in 2024. VW Holdings is the successor to Bannix Acquisition Corp., (&#x201c;Bannix&#x201d;)
a blank check company incorporated in the state of Delaware on January 21, 2021 for the purpose of effecting mergers, capital stock exchange,
asset acquisitions, stock purchases, reorganization or similar business combinations with one or more businesses (&#x201c;Business Combination&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prior to the succession of Bannix by VW Holdings,
on March 26, 2024, Bannix entered into a Business Combination Agreement (the &#x201c;Original Agreement&#x201d;), by and among Bannix,
VisionWave Technologies, Inc., a Nevada corporation (&#x201c;Target&#x201d; or &#x201c;VW Tech.&#x201d;) and the shareholders of Target.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 6, 2024, Bannix entered into a Merger
Agreement and Plan of Reorganization (the &#x201c;Merger Agreement&#x201d;), by and among Bannix, VW Holdings, a direct, wholly owned subsidiary
of Bannix, BNIX Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of VisionWave (&#x201c;Parent Merger Sub&#x201d;),
BNIX VW Merger Sub, Inc., a Nevada corporation and direct, wholly owned subsidiary of VisionWave (&#x201c;Company Merger Sub&#x201d;),
and Target.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On July 14, 2025, the transaction contemplated by the Merger Agreement
closed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The
                                            Company has two wholly owned subsidiaries: VisionWave Technologies, Inc., Solar Drone Ltd,
                                            acquired on December 15, 2025 pursuant to the Share Purchase Agreement (See Note 9).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <VWAV:LiquidityAndCapitalResourcesTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001572">&lt;p id="xdx_808_ecustom--LiquidityAndCapitalResourcesTextBlock_z16Ih4kNs9Zg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 2&#x2014;&lt;span id="xdx_820_zElpbjBgl26e"&gt;Liquidity, Capital Resources and Going Concern&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s primary sources of liquidity
have been cash from financing activities. For the three and six months ended March 31, 2026, net loss was $&lt;span id="xdx_900_ecustom--NetLoss_iN_pp0d_di_c20260101__20260331_zf6R4E5g7oKk" title="Net loss"&gt;12,910,093&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--NetIncomeLoss_iN_pp0d_di_c20251001__20260331_zuIyxYs6ViYf" title="Net loss"&gt;19,846,008&lt;/span&gt;,
respectively. Cash used in operating activities was $&lt;span id="xdx_908_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pp0d_di_c20251001__20260331_zKRFEFWKjgY9" title="Net cash (used in) provided by operating activities"&gt;8,790,770&lt;/span&gt; for the six months ended March 31, 2026. The Company had an accumulated
deficit of $&lt;span id="xdx_907_ecustom--WorkingCapitalDeficit_iI_c20260331_znTpj2H0i7ti" title="Working capital deficit"&gt;34,954,914&lt;/span&gt; as of March 31, 2026. As of March 31, 2026, working capital deficit was $&lt;span id="xdx_904_ecustom--WorkingCapitalDeficit_iI_c20250331_zg2efh3ILFP4" title="Working capital deficit"&gt;21,939,175&lt;/span&gt; and cash was $&lt;span id="xdx_906_eus-gaap--Cash_iI_c20260331_z7DZdulvX0C9" title="Cash"&gt;14,255,720&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company received proceeds of approximately
$&lt;span id="xdx_908_ecustom--GrossProceeds_c20251001__20260331_zCrQ634P9JRb" title="Gross proceeds"&gt;23,846&lt;/span&gt; as a result of the Reverse Acquisition in September 2025, after giving effect to stockholder redemptions and payment of transaction
expenses in connection with the Reverse Acquisition. The Company received an additional $&lt;span id="xdx_900_ecustom--TransactionEpenses_iI_c20250215_zlbKHiOrWr59" title="Transaction epenses"&gt;308,000&lt;/span&gt; pursuant to the Securities Purchases
agreement entered into on July 15, 2025 and $&lt;span id="xdx_905_ecustom--IssuedConvertiblePromissoryNote_iI_c20250715_zyklQ7SdDFRf" title="Issued convertible promissory note"&gt;5,000,000&lt;/span&gt; pursuant to the convertible promissory note agreements issued under the Standby
Equity Purchase Agreement referenced below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 25, 2025, the Company entered into the
Standby Equity Purchase Agreement (&#x201c;SEPA&#x201d;) with YA II PN, LTD, a Cayman Islands exempt limited partnership (the &#x201c;Investor&#x201d;)
pursuant to which the Company has the right to sell to the Investor up to $50 million of its shares of common stock, subject to certain
limitations and conditions set forth in the SEPA, from time to time during the term of the SEPA, from time to time during the term of
the SEPA. The Company received proceeds of $1,760,761 from draw down during the six months ended March 31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company also received net proceed of $16,975,000
for loan issued during the six months ended March 31, 2026 (See Note 13) and $850,000 from the issuance of convertible notes for the
same periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s future capital requirements
will depend on many factors, including the timing and extent of spending to support further sales and marketing and research and development
efforts. In order to finance these opportunities, the Company will need to raise additional financing. While there can be no assurances,
the Company intends to raise such capital through issuances of additional equity. If additional financing is required from outside sources,
the Company may not be able to raise it on terms acceptable to the Company or at all.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Going Concern Evaluation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Ordinarily,
                                            conditions or events that raise substantial doubt about an entity&#x2019;s ability to continue
                                            as a going concern relate to the entity&#x2019;s ability to meet its obligations as they become
                                            due. The Company evaluated its ability to meet its obligations as they become due within
                                            one year from the date that the unaudited condensed consolidated financial statements are
                                            issued by considering the following:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On
                                            April 8, 2025, with an effective date of March 31, 2025 and as amended on May 20, 2026, the
                                            Company entered into a Funding Support Agreement with Stanley Hills, LLC (&#x201c;Stanley
                                            Hills&#x201d;), the principal shareholder of VisionWave Technologies. Pursuant to the agreement,
                                            Stanley Hills irrevocably and unconditionally committed to provide financial support to the
                                            Company, sufficient to fund the working capital needs through May 20, 2027. The funding may
                                            be provided by Stanley Hills in the form of direct payments to third parties, advances or
                                            intercompany loans, or capital contributions, as mutually determined by the parties. Unless
                                            otherwise agreed in writing, any such advances will be non-interest bearing and repayable
                                            only at such time as determined by the Board of Directors, and only to the extent such repayment
                                            would not impair the Company&#x2019;s liquidity or ability to continue as a going concern.
                                            The agreement may not be terminated by Stanley Hills prior to the twelve-month period from
                                            the date of release of the unaudited condensed consolidated financial statement.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management
                                            has determined that the agreement with Stanley Hills, cash receipts from customer arrangements,
                                            resource reallocation initiatives, additional insider investments and financing, along with
                                            its existing cash and committed affiliated support related combinations alleviated the risk
                                            about the Company&#x2019;s ability to continue as a going concern for a reasonable period
                                            of time, which is considered to be one year from the issuance of the unaudited condensed
                                            consolidated financial statements.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</VWAV:LiquidityAndCapitalResourcesTextBlock>
    <VWAV:NetLoss
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001574"
      unitRef="USD">-12910093</VWAV:NetLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001576"
      unitRef="USD">-19846008</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001578"
      unitRef="USD">-8790770</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <VWAV:WorkingCapitalDeficit
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001580"
      unitRef="USD">34954914</VWAV:WorkingCapitalDeficit>
    <VWAV:WorkingCapitalDeficit
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact001582"
      unitRef="USD">21939175</VWAV:WorkingCapitalDeficit>
    <us-gaap:Cash
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001584"
      unitRef="USD">14255720</us-gaap:Cash>
    <VWAV:GrossProceeds
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001586"
      unitRef="USD">23846</VWAV:GrossProceeds>
    <VWAV:TransactionEpenses
      contextRef="AsOf2025-02-15"
      decimals="0"
      id="Fact001588"
      unitRef="USD">308000</VWAV:TransactionEpenses>
    <VWAV:IssuedConvertiblePromissoryNote
      contextRef="AsOf2025-07-15"
      decimals="0"
      id="Fact001590"
      unitRef="USD">5000000</VWAV:IssuedConvertiblePromissoryNote>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001594">&lt;p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_zvesEdSBtA2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 3&#x2014;&lt;span id="xdx_82E_z4KkxoyLQUxh"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zzsWWppGMhBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&lt;span id="xdx_86E_z6vYLGaEq3fk"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying unaudited condensed consolidated
financial statements as of March 31, 2026 and for the three and six months ended March 31, 2026 and 2025 are unaudited. The accompanying
unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted
in the United States of America (&#x201c;US GAAP&#x201d;) for interim financial statements and Article 10 of Regulation S-X of the United
States Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all the information and footnotes required
by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting
of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six
months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30,
2026. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial
statements as of and for the year ended September 30, 2025 and footnotes thereto filed with the Securities Exchange Commission (&#x201c;SEC&#x201d;)
on Form 10-K on December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All amounts referred to in the notes to the unaudited
condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zZSjqKc4uMy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&lt;span id="xdx_86F_zZ36nUyaF16b"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying unaudited condensed consolidated
financial statements include the accounts of VisionWave Holdings Inc. and its subsidiaries (See Note 1). All intercompany balances and
transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ze1dhyYMNPX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&lt;span id="xdx_868_zrSYRmASLISk"&gt;Segment Reporting&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company complies with ASU 2023-07, Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;), which improves reportable segment
disclosure requirements, primarily through enhanced disclosures about significant segment expenses among other disclosure requirements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_zEzMqZTzyjDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&lt;span id="xdx_86C_zXW3h0yPuR0h"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is an &#x201c;emerging growth company,&#x201d;
as defined in Section 2(a) of the Securities Act of 1933, as amended, (the &#x201c;Securities Act&#x201d;), as modified by the Jumpstart
our Business Startups Act of 2012, (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not
being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Further, Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make
comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company nor an
emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zxR69EvizLEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zoqvgzLdgvP"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of these unaudited condensed consolidated
financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial
statements and the reported amounts of expenses during the reporting periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Making estimates requires management to exercise
significant judgement. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances
that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its
estimate, could change in the near term due to one or more future confirming events. Significant estimates include assumptions made in
the valuation of the options, valuation of convertible notes, fair value of assets acquired including intangible assets, useful life
of intangibles, valuation of warrants and recoverability of deferred tax assets. Accordingly, the actual results could differ from those
estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zg2cM6cK8DDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zn8pqGFCutxd"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments that potentially subject
the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal
Depository Insurance Coverage of $&lt;span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20260331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CreditRiskMember_zED3rChXZYw9" title="Federal Depository Insurance coverage"&gt;250,000&lt;/span&gt;. At March 31, 2026 and September 30, 2025, the Company had $&lt;span id="xdx_90B_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20260331_zaY0h6QktQaj" title="Federal Depository Insurance coverage"&gt;13,732,588&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20250930_zmt8L0xxny95" title="Federal Depository Insurance coverage"&gt;1,774,899&lt;/span&gt; deposits
in excess of the Federal Depository Insurance Coverage, respectively. The Company has not experienced losses on these accounts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--BusinessCombinationsPolicy_zxSbPL02LxWf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zk5MuhxbypO3"&gt;Business Combinations&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates whether acquired net assets
should be accounted for as a business combination or an asset acquisition by first applying a screen test to determine whether substantially
all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.
If so, the transaction is accounted for as an asset acquisition. If not, the Company applies its judgement to determine whether the acquired
net assets meets the definition of a business by considering if the set includes an acquired input, process, and the ability to create
outputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for business combinations
using the acquisition method when it has obtained control. The Company measures goodwill as the fair value of the consideration transferred
including the fair value of any non-controlling interest recognized, less the net recognized amount of the identifiable assets acquired
and liabilities assumed, all measured at their fair value as of the acquisition date. Transaction costs, other than those associated
with the issuance of debt or equity securities, that the Company incurs in connection with a business combination are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Any contingent consideration is measured at fair
value at the acquisition date. For contingent consideration that does not meet all the criteria for equity classification, such contingent
consideration is required to be recorded at its initial fair value at the acquisition date, and on each balance sheet date thereafter.
Changes in the estimated fair value of liability-classified contingent consideration are recognized on the consolidated statements of
operations in the period of change.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;When the initial accounting for a business combination
has not been finalized by the end of the reporting period in which the transaction occurs, the Company reports provisional amounts. Provisional
amounts are adjusted during the measurement period, which does not exceed one year from the acquisition date. These adjustments, or recognition
of additional assets or liabilities, reflect new information obtained about facts and circumstances that existed at the acquisition date
that, if known, would have affected the amounts recognized at that date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for certain business combinations
that meet the definition of a reverse merger (also referred to as a reverse recapitalization) in accordance with ASC 805, Business Combinations,
and ASC 810, Consolidation. A reverse merger occurs when the legal acquirer is determined to be the accounting acquiree, and the legal
acquiree is determined to be the accounting acquirer. Accordingly:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No
                                            goodwill or intangible assets are recorded&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            transaction is treated as a capital transaction in substance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            accounting acquirer&#x2019;s assets and liabilities are carried forward at their historical
                                            carrying amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            accounting acquiree&#x2019;s net assets are recognized at fair value, if applicable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z57twQjssal9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_z1FcInqLMGJh"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers all cash on hand and in
banks, including accounts in book overdraft positions, certificates of deposit and all short-term investments with an original maturity
of three months or less when purchased to be cash equivalents. Cash equivalents was $&lt;span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20260331_zurbg4qw3VJh" title="Cash equivalents"&gt;&lt;span id="xdx_90C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20250930_zrqL8OabSqOf" title="Cash equivalents"&gt;15,723&lt;/span&gt;&lt;/span&gt; at March 31, 2026 and September 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p id="xdx_849_eus-gaap--InvestmentPolicyTextBlock_zSOCEVIyI9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zUtn61ImjlG9"&gt;Investments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company from time to time invests in equity
securities. All marketable equity securities held by the Company are accounted for under &#x201c;Accounting Standards Codification (&#x201c;ASC&#x201d;)
Topic 320, &#x201c;&lt;i&gt;Investments&lt;/i&gt; - Debt and Equity Securities.&#x201d; The Company accounts for available-for-sale equity investments
at fair value. From time to time, if the Company determines that the available market price of an available for sale investments is not
a reasonable indicator of the fair value, the Company will determine the best estimate of that fair value which is usually the cost.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--EquityMethodInvestmentsPolicy_zFlITE8TG2l3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zluxFZeZsGw9"&gt;Equity Method Investment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for investments in entities
in which the Company has significant influence over the entity&#x2019;s financial and operating policies, but does not control, using
the equity method of accounting. The equity method investment is initially recorded at cost and subsequently increased for capital contributions
and allocations of net income and decreased for capital distributions and allocations of net loss. Equity in net income (loss) from the
equity method investment is allocated based on the Company&#x2019;s economic interest. The equity method investment is reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If it is determined that a loss
in value of the equity method investment is other than temporary, an impairment loss is measured based on the excess of the carrying
amount of an investment over its estimated fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z0PGXKnv2wC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zl0Wj4jJyBdg"&gt;Property and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The value of property and equipment that were
acquired as part of the Asset Acquisition (See Note 9) are recorded at a relative fair value assessed at the time of the acquisition
less depreciation. Any additional property and equipment acquired, and any expenditures that extend the life of such assets are recorded
at historical cost, including direct acquisition costs, less depreciation and impairment losses. Historical cost includes expenditures
that are directly attributable to the acquisition of the items.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Subsequent costs are included in the asset&#x2019;s
carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated
with the item will flow to VisionWave and the cost of the item can be measured reliably. All other repairs and maintenance costs are
charged to profit or loss during the financial period in which they are incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--DepreciationDepletionAndAmortizationPolicyTextBlock_zKINoQK0cR08" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zPqSbjJRxUX6"&gt;Depreciation and amortization&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation for equipment and other assets is
computed using the straight-line method at rates calculated to depreciate the cost of the assets, less their anticipated residual values,
if any, over their estimated useful lives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Capitalized intellectual property costs include
those acquired in the asset acquisitions including a propriety drone system.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The estimated useful life of used to determine depreciation and amortization
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfDepreciationForEquipmentAndOtherAssetsTableTextBlock_zhLa93WfA1lg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_ziFwjijpfwCd" style="display: none"&gt;Schedule of Depreciation for equipment and other assets&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 45%; text-align: left; text-indent: -10pt"&gt;Computer and accessories&lt;/td&gt;
&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 43%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndAccessoriesMember_zJQqmb0HQDI6" title="Estimated useful lives"&gt;3&lt;/span&gt; years&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Drones&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DronesMember_zhiLXIl1dodf" title="Estimated useful lives"&gt;3&lt;/span&gt; years&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Intellectual property&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--IntellectualPropertyMember_zi6ZjowPIqBk" title="Estimated useful lives"&gt;5&lt;/span&gt; years&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A1_zSewIE9zaoIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;An item of property and equipment is derecognized
upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. The gain or loss arising
on the disposal or retirement of an asset is determined as the difference between the sales proceeds and the carrying amount of the asset
and is recognized in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates the carrying value of property
and equipment and finite-lived intangible assets whenever a change in circumstances indicates that the net carrying value may not be
recoverable from the entity-specific undiscounted future cash flows expected to result from our use of and eventual disposition of a
long-lived asset or asset group. Events or circumstances that could trigger an impairment review of a long-lived asset or asset group
include, but are not limited to: (i) a significant decrease in the market price of the asset, (ii) a significant adverse change in the
extent or manner that the asset is used or in its physical condition, (iii) a significant adverse change in legal factors or in the business
climate that could affect the value of the asset, (iv) an accumulation of costs significantly in excess of original expectation for the
acquisition or construction of the asset, (v) a current period operating or cash flow loss combined with a history of operating or cash
flow losses or a forecast of continuing losses associated with the use of the asset and (vi) a more-likely-than-not expectation that
the asset will be sold or disposed of significantly before the end of its previously estimated useful life. If an impairment exists,
the net carrying values are reduced to fair values. The Company estimates the fair values of these long-lived assets by performing a
discounted future cash flow analysis for the remaining useful life of the asset, or the remaining useful life of the primary asset in
the case of an asset group. An individual asset within an asset group is not impaired below its estimated fair value. There were no impairments
recorded for the three and six months ended March 31, 2026 and 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_znheae1Lx0fe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z1QYQu9F6vXj"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of the Company&#x2019;s cash, current
assets and current liabilities approximates the carrying amounts represented in the accompanying unaudited condensed consolidated balance
sheets, due to their short-term nature.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fair value is defined as the price which would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. A three-tier fair value hierarchy which prioritizes the inputs used in the valuation methodologies is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 Inputs - Unadjusted quoted prices in active
markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 Inputs - Inputs other than quoted prices
included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices
for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are
not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment
speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 Inputs - Unobservable inputs for determining
the fair values of assets or liabilities that reflect an entity&#x2019;s own assumptions about the assumptions that market participants
would use in pricing the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As
                                            of March 31, 2026, other than the convertible notes discussed below, the Company did not
                                            hold any financial assets or liabilities that were measured at fair value on a recurring
                                            or nonrecurring basis.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--ConvertiblenotespayablePolicyTextBlock_zyOHHRlmjaxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zueyLSyYbvzi"&gt;Convertible Notes Payable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For convertible debt instruments that are not
considered liabilities under ASC 480 or ASC 815, the Company applies FASB ASC 470, Debt (&#x201c;ASC 470&#x201d;), for the accounting of
such instruments, including any premiums or discounts. Debt issuance costs consist primarily of original issue discount (OID) and legal
fees. These costs are netted off with the related loan and are being amortized to interest expense over the term of the related debt
facilities using effective interest method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company may elect the fair value option for
certain financial instruments that meet the required criteria under ASC 825, Financial Instruments. The Company elected the fair value
option for its SEPA related convertible notes, which met the required criteria under ASC 825, Financial Instruments. Issuance fees incurred
on instruments for which the fair value option was elected are not deferred and are recognized as an expense when incurred in the consolidated
statement of operations. The portion of the change in fair value attributable to instrument-specific credit risk, if any, is recognized
in other comprehensive income, with the remainder recognized in earnings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--OffsettingBalancePolicyTextBlock_zTbR7qnRf6Rh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zVNTGRdxwWs"&gt;Offsetting Balances&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with ASC Topic 210 &#x201c;Balance
Sheet&#x201d;, the Company&#x2019;s accounting policy is to offset assets and liabilities when a right of offset exists. Accordingly, the
unaudited condensed consolidated balance sheets include transactions with affiliated parties on a net basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zfQLYXjU5Le1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_z7MM2lPvpZ4a"&gt;Research and Development Cost&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for research and development
cost (&#x201c;R&amp;amp;D&#x201d;) in accordance with ASC Topic 730, &#x201c;Research and Development&#x201d;. R&amp;amp;D represents costs are expensed
as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zrlVgbOcWtIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zYiE0tBuVYV6"&gt;Net Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net loss per share is computed by dividing
the net loss by the weighted average shares outstanding for the year. Diluted loss per share is computed by giving effect to all potential
shares of common stock to the extent dilutive. For the three and six months ended March 31, 2026 and 2025, the Company&#x2019;s diluted
weighted-average shares outstanding is equal to basic weighted-average shares, due to the Company&#x2019;s net loss position. No common
stock equivalents were included in the computation of diluted net loss per unit since such inclusion would have been antidilutive. At
March 31, 2026 and 2025, potentially dilutive securities include the public warrants, stock options and the convertible promissory notes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zz7Da6k9NGT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zzQ4EhXHJUu6"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In the normal course of business, the Company
is subject to loss contingencies, such as legal proceedings and claims arising out of its business, which cover a wide range of matters,
including, among others, government investigations, shareholder lawsuits, and no income tax matters.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;An accrual for a loss contingency is recognized
when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. If a potential material loss
contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability,
together with an estimate of the range of possible loss if determinable and material, is disclosed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--RelatedPartyAndRelatedPartyTransactionsPolicyTextBlock_zMRWP3U2VrB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zGcP4cUfq6Y"&gt;Related party and related-party transactions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Related parties, which can be a corporation or
individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise
significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if
they are subject to common control or common significant influence, such as a family member or relative, shareholder, or a related corporation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Transactions involving related parties cannot
be presumed to be carried out on an arm&#x2019;s-length basis, as the requisite conditions of competitive, free-market dealings may not
exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated
on terms equivalent to those that prevail in arm&#x2019;s-length transactions unless such representations can be substantiated. It is
not, however, practical to determine the fair value of amounts due to or from related parties due to their related-party nature.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--IncomeTaxUncertaintiesPolicy_zFxgEHWpDn4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zhcENS0opqhg"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows the asset and liability method
of accounting for income taxes under ASC Topic 740, Income Taxes (&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered
or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included
the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be
realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC 740 prescribes a recognition threshold and
a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax
return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized
tax benefits as of March 31, 2026 and September 30, 2025. Interest and penalties related to Bannix Acquisition for the three and six
months ended March 31, 2026 were $&lt;span id="xdx_906_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_c20260101__20260331_z8AYQyTrv0h1" title="Interest and penalties"&gt;24,462&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_c20251001__20260331_zOI9rr1x4utj" title="Interest and penalties"&gt;49,228&lt;/span&gt;, respectively. There were no interest and penalties related to Bannix Acquisition
for the three and six months ended March 31, 2025. The Company is currently not aware of any issues under review that could result in
significant payments, accruals or material deviation from its position.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--AdvertisingCostsPolicyTextBlock_zydZFPSlnSdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zo1bEIdqXl05"&gt;Advertising and Promotion&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;All costs associated with advertising and promoting products are expensed
as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--StockBasedCompensationPolicyTextBlock_ztWfG0r7b3P5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zpOcD7jtpTS2"&gt;Stock Based Compensation &lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company complies with ASC 718 Compensation
&#x2014; Stock Compensation regarding shares granted to directors, officers and vendors of the Company by measuring the grant date fair
value of the award and recognizing the resulting expense over the period during which the employee is required to perform service in
exchange for the award. Equity-based compensation expense is only recognized for awards subject to performance conditions if it is probable
that the performance condition will be achieved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has elected to account for forfeitures
as they occur rather than estimating expected forfeitures at the grant date. Accordingly, stock-based compensation expense is adjusted
in the period in which awards are forfeited.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zNVgZinhn4N8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zy0gaU82ArTh"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 4, 2024, the FASB issued ASU 2024-03,
Disaggregation of Income Statement Expenses (DISE), requiring additional disclosure of the nature of expenses included in the statements
of operations. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the
face of the statements of operations as well as disclosures about selling expenses. The standard is effective for annual reporting periods
beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027. The
Company is currently assessing the impact this standard will have on its unaudited condensed consolidated financial statements and related
disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s management does not believe
that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect
on the Company&#x2019;s unaudited condensed consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001596">&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zzsWWppGMhBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&lt;span id="xdx_86E_z6vYLGaEq3fk"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying unaudited condensed consolidated
financial statements as of March 31, 2026 and for the three and six months ended March 31, 2026 and 2025 are unaudited. The accompanying
unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted
in the United States of America (&#x201c;US GAAP&#x201d;) for interim financial statements and Article 10 of Regulation S-X of the United
States Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all the information and footnotes required
by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting
of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six
months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30,
2026. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial
statements as of and for the year ended September 30, 2025 and footnotes thereto filed with the Securities Exchange Commission (&#x201c;SEC&#x201d;)
on Form 10-K on December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All amounts referred to in the notes to the unaudited
condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001600">&lt;p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zZSjqKc4uMy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&lt;span id="xdx_86F_zZ36nUyaF16b"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying unaudited condensed consolidated
financial statements include the accounts of VisionWave Holdings Inc. and its subsidiaries (See Note 1). All intercompany balances and
transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001602">&lt;p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ze1dhyYMNPX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&lt;span id="xdx_868_zrSYRmASLISk"&gt;Segment Reporting&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company complies with ASU 2023-07, Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;), which improves reportable segment
disclosure requirements, primarily through enhanced disclosures about significant segment expenses among other disclosure requirements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <VWAV:EmergingGrowthCompanyStatusPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001604">&lt;p id="xdx_842_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_zEzMqZTzyjDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&lt;span id="xdx_86C_zXW3h0yPuR0h"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is an &#x201c;emerging growth company,&#x201d;
as defined in Section 2(a) of the Securities Act of 1933, as amended, (the &#x201c;Securities Act&#x201d;), as modified by the Jumpstart
our Business Startups Act of 2012, (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not
being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Further, Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make
comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company nor an
emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</VWAV:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2025-10-01to2026-03-31" id="Fact001606">&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zxR69EvizLEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zoqvgzLdgvP"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of these unaudited condensed consolidated
financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial
statements and the reported amounts of expenses during the reporting periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Making estimates requires management to exercise
significant judgement. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances
that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its
estimate, could change in the near term due to one or more future confirming events. Significant estimates include assumptions made in
the valuation of the options, valuation of convertible notes, fair value of assets acquired including intangible assets, useful life
of intangibles, valuation of warrants and recoverability of deferred tax assets. Accordingly, the actual results could differ from those
estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2025-10-01to2026-03-31" id="Fact001610">&lt;p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zg2cM6cK8DDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zn8pqGFCutxd"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments that potentially subject
the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal
Depository Insurance Coverage of $&lt;span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20260331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CreditRiskMember_zED3rChXZYw9" title="Federal Depository Insurance coverage"&gt;250,000&lt;/span&gt;. At March 31, 2026 and September 30, 2025, the Company had $&lt;span id="xdx_90B_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20260331_zaY0h6QktQaj" title="Federal Depository Insurance coverage"&gt;13,732,588&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20250930_zmt8L0xxny95" title="Federal Depository Insurance coverage"&gt;1,774,899&lt;/span&gt; deposits
in excess of the Federal Depository Insurance Coverage, respectively. The Company has not experienced losses on these accounts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2026-03-31_us-gaap_CreditRiskMember"
      decimals="0"
      id="Fact001612"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001614"
      unitRef="USD">13732588</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001616"
      unitRef="USD">1774899</us-gaap:CashFDICInsuredAmount>
    <us-gaap:BusinessCombinationsPolicy contextRef="From2025-10-01to2026-03-31" id="Fact001618">&lt;p id="xdx_84D_eus-gaap--BusinessCombinationsPolicy_zxSbPL02LxWf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zk5MuhxbypO3"&gt;Business Combinations&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates whether acquired net assets
should be accounted for as a business combination or an asset acquisition by first applying a screen test to determine whether substantially
all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.
If so, the transaction is accounted for as an asset acquisition. If not, the Company applies its judgement to determine whether the acquired
net assets meets the definition of a business by considering if the set includes an acquired input, process, and the ability to create
outputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for business combinations
using the acquisition method when it has obtained control. The Company measures goodwill as the fair value of the consideration transferred
including the fair value of any non-controlling interest recognized, less the net recognized amount of the identifiable assets acquired
and liabilities assumed, all measured at their fair value as of the acquisition date. Transaction costs, other than those associated
with the issuance of debt or equity securities, that the Company incurs in connection with a business combination are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Any contingent consideration is measured at fair
value at the acquisition date. For contingent consideration that does not meet all the criteria for equity classification, such contingent
consideration is required to be recorded at its initial fair value at the acquisition date, and on each balance sheet date thereafter.
Changes in the estimated fair value of liability-classified contingent consideration are recognized on the consolidated statements of
operations in the period of change.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;When the initial accounting for a business combination
has not been finalized by the end of the reporting period in which the transaction occurs, the Company reports provisional amounts. Provisional
amounts are adjusted during the measurement period, which does not exceed one year from the acquisition date. These adjustments, or recognition
of additional assets or liabilities, reflect new information obtained about facts and circumstances that existed at the acquisition date
that, if known, would have affected the amounts recognized at that date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for certain business combinations
that meet the definition of a reverse merger (also referred to as a reverse recapitalization) in accordance with ASC 805, Business Combinations,
and ASC 810, Consolidation. A reverse merger occurs when the legal acquirer is determined to be the accounting acquiree, and the legal
acquiree is determined to be the accounting acquirer. Accordingly:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No
                                            goodwill or intangible assets are recorded&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            transaction is treated as a capital transaction in substance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            accounting acquirer&#x2019;s assets and liabilities are carried forward at their historical
                                            carrying amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            accounting acquiree&#x2019;s net assets are recognized at fair value, if applicable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001620">&lt;p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z57twQjssal9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_z1FcInqLMGJh"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers all cash on hand and in
banks, including accounts in book overdraft positions, certificates of deposit and all short-term investments with an original maturity
of three months or less when purchased to be cash equivalents. Cash equivalents was $&lt;span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20260331_zurbg4qw3VJh" title="Cash equivalents"&gt;&lt;span id="xdx_90C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20250930_zrqL8OabSqOf" title="Cash equivalents"&gt;15,723&lt;/span&gt;&lt;/span&gt; at March 31, 2026 and September 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001622"
      unitRef="USD">15723</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001624"
      unitRef="USD">15723</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001628">&lt;p id="xdx_849_eus-gaap--InvestmentPolicyTextBlock_zSOCEVIyI9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zUtn61ImjlG9"&gt;Investments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company from time to time invests in equity
securities. All marketable equity securities held by the Company are accounted for under &#x201c;Accounting Standards Codification (&#x201c;ASC&#x201d;)
Topic 320, &#x201c;&lt;i&gt;Investments&lt;/i&gt; - Debt and Equity Securities.&#x201d; The Company accounts for available-for-sale equity investments
at fair value. From time to time, if the Company determines that the available market price of an available for sale investments is not
a reasonable indicator of the fair value, the Company will determine the best estimate of that fair value which is usually the cost.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="From2025-10-01to2026-03-31" id="Fact001630">&lt;p id="xdx_84D_eus-gaap--EquityMethodInvestmentsPolicy_zFlITE8TG2l3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zluxFZeZsGw9"&gt;Equity Method Investment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for investments in entities
in which the Company has significant influence over the entity&#x2019;s financial and operating policies, but does not control, using
the equity method of accounting. The equity method investment is initially recorded at cost and subsequently increased for capital contributions
and allocations of net income and decreased for capital distributions and allocations of net loss. Equity in net income (loss) from the
equity method investment is allocated based on the Company&#x2019;s economic interest. The equity method investment is reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If it is determined that a loss
in value of the equity method investment is other than temporary, an impairment loss is measured based on the excess of the carrying
amount of an investment over its estimated fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001632">&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z0PGXKnv2wC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zl0Wj4jJyBdg"&gt;Property and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The value of property and equipment that were
acquired as part of the Asset Acquisition (See Note 9) are recorded at a relative fair value assessed at the time of the acquisition
less depreciation. Any additional property and equipment acquired, and any expenditures that extend the life of such assets are recorded
at historical cost, including direct acquisition costs, less depreciation and impairment losses. Historical cost includes expenditures
that are directly attributable to the acquisition of the items.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Subsequent costs are included in the asset&#x2019;s
carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated
with the item will flow to VisionWave and the cost of the item can be measured reliably. All other repairs and maintenance costs are
charged to profit or loss during the financial period in which they are incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001634">&lt;p id="xdx_845_eus-gaap--DepreciationDepletionAndAmortizationPolicyTextBlock_zKINoQK0cR08" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zPqSbjJRxUX6"&gt;Depreciation and amortization&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation for equipment and other assets is
computed using the straight-line method at rates calculated to depreciate the cost of the assets, less their anticipated residual values,
if any, over their estimated useful lives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Capitalized intellectual property costs include
those acquired in the asset acquisitions including a propriety drone system.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The estimated useful life of used to determine depreciation and amortization
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfDepreciationForEquipmentAndOtherAssetsTableTextBlock_zhLa93WfA1lg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_ziFwjijpfwCd" style="display: none"&gt;Schedule of Depreciation for equipment and other assets&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 45%; text-align: left; text-indent: -10pt"&gt;Computer and accessories&lt;/td&gt;
&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 43%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndAccessoriesMember_zJQqmb0HQDI6" title="Estimated useful lives"&gt;3&lt;/span&gt; years&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Drones&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DronesMember_zhiLXIl1dodf" title="Estimated useful lives"&gt;3&lt;/span&gt; years&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Intellectual property&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--IntellectualPropertyMember_zi6ZjowPIqBk" title="Estimated useful lives"&gt;5&lt;/span&gt; years&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A1_zSewIE9zaoIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;An item of property and equipment is derecognized
upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. The gain or loss arising
on the disposal or retirement of an asset is determined as the difference between the sales proceeds and the carrying amount of the asset
and is recognized in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates the carrying value of property
and equipment and finite-lived intangible assets whenever a change in circumstances indicates that the net carrying value may not be
recoverable from the entity-specific undiscounted future cash flows expected to result from our use of and eventual disposition of a
long-lived asset or asset group. Events or circumstances that could trigger an impairment review of a long-lived asset or asset group
include, but are not limited to: (i) a significant decrease in the market price of the asset, (ii) a significant adverse change in the
extent or manner that the asset is used or in its physical condition, (iii) a significant adverse change in legal factors or in the business
climate that could affect the value of the asset, (iv) an accumulation of costs significantly in excess of original expectation for the
acquisition or construction of the asset, (v) a current period operating or cash flow loss combined with a history of operating or cash
flow losses or a forecast of continuing losses associated with the use of the asset and (vi) a more-likely-than-not expectation that
the asset will be sold or disposed of significantly before the end of its previously estimated useful life. If an impairment exists,
the net carrying values are reduced to fair values. The Company estimates the fair values of these long-lived assets by performing a
discounted future cash flow analysis for the remaining useful life of the asset, or the remaining useful life of the primary asset in
the case of an asset group. An individual asset within an asset group is not impaired below its estimated fair value. There were no impairments
recorded for the three and six months ended March 31, 2026 and 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock>
    <VWAV:ScheduleOfDepreciationForEquipmentAndOtherAssetsTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001636">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfDepreciationForEquipmentAndOtherAssetsTableTextBlock_zhLa93WfA1lg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_ziFwjijpfwCd" style="display: none"&gt;Schedule of Depreciation for equipment and other assets&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 45%; text-align: left; text-indent: -10pt"&gt;Computer and accessories&lt;/td&gt;
&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 43%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndAccessoriesMember_zJQqmb0HQDI6" title="Estimated useful lives"&gt;3&lt;/span&gt; years&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Drones&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DronesMember_zhiLXIl1dodf" title="Estimated useful lives"&gt;3&lt;/span&gt; years&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Intellectual property&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--IntellectualPropertyMember_zi6ZjowPIqBk" title="Estimated useful lives"&gt;5&lt;/span&gt; years&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</VWAV:ScheduleOfDepreciationForEquipmentAndOtherAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2026-03-31_custom_ComputerAndAccessoriesMember"
      id="Fact001638">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2026-03-31_custom_DronesMember"
      id="Fact001640">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2026-03-31_us-gaap_IntellectualPropertyMember"
      id="Fact001642">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2025-10-01to2026-03-31" id="Fact001646">&lt;p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_znheae1Lx0fe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z1QYQu9F6vXj"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of the Company&#x2019;s cash, current
assets and current liabilities approximates the carrying amounts represented in the accompanying unaudited condensed consolidated balance
sheets, due to their short-term nature.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fair value is defined as the price which would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. A three-tier fair value hierarchy which prioritizes the inputs used in the valuation methodologies is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 Inputs - Unadjusted quoted prices in active
markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 Inputs - Inputs other than quoted prices
included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices
for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are
not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment
speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 Inputs - Unobservable inputs for determining
the fair values of assets or liabilities that reflect an entity&#x2019;s own assumptions about the assumptions that market participants
would use in pricing the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As
                                            of March 31, 2026, other than the convertible notes discussed below, the Company did not
                                            hold any financial assets or liabilities that were measured at fair value on a recurring
                                            or nonrecurring basis.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <VWAV:ConvertiblenotespayablePolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001648">&lt;p id="xdx_84B_ecustom--ConvertiblenotespayablePolicyTextBlock_zyOHHRlmjaxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zueyLSyYbvzi"&gt;Convertible Notes Payable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For convertible debt instruments that are not
considered liabilities under ASC 480 or ASC 815, the Company applies FASB ASC 470, Debt (&#x201c;ASC 470&#x201d;), for the accounting of
such instruments, including any premiums or discounts. Debt issuance costs consist primarily of original issue discount (OID) and legal
fees. These costs are netted off with the related loan and are being amortized to interest expense over the term of the related debt
facilities using effective interest method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company may elect the fair value option for
certain financial instruments that meet the required criteria under ASC 825, Financial Instruments. The Company elected the fair value
option for its SEPA related convertible notes, which met the required criteria under ASC 825, Financial Instruments. Issuance fees incurred
on instruments for which the fair value option was elected are not deferred and are recognized as an expense when incurred in the consolidated
statement of operations. The portion of the change in fair value attributable to instrument-specific credit risk, if any, is recognized
in other comprehensive income, with the remainder recognized in earnings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</VWAV:ConvertiblenotespayablePolicyTextBlock>
    <VWAV:OffsettingBalancePolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001652">&lt;p id="xdx_849_ecustom--OffsettingBalancePolicyTextBlock_zTbR7qnRf6Rh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zVNTGRdxwWs"&gt;Offsetting Balances&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with ASC Topic 210 &#x201c;Balance
Sheet&#x201d;, the Company&#x2019;s accounting policy is to offset assets and liabilities when a right of offset exists. Accordingly, the
unaudited condensed consolidated balance sheets include transactions with affiliated parties on a net basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</VWAV:OffsettingBalancePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2025-10-01to2026-03-31" id="Fact001654">&lt;p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zfQLYXjU5Le1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_z7MM2lPvpZ4a"&gt;Research and Development Cost&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for research and development
cost (&#x201c;R&amp;amp;D&#x201d;) in accordance with ASC Topic 730, &#x201c;Research and Development&#x201d;. R&amp;amp;D represents costs are expensed
as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001656">&lt;p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zrlVgbOcWtIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zYiE0tBuVYV6"&gt;Net Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net loss per share is computed by dividing
the net loss by the weighted average shares outstanding for the year. Diluted loss per share is computed by giving effect to all potential
shares of common stock to the extent dilutive. For the three and six months ended March 31, 2026 and 2025, the Company&#x2019;s diluted
weighted-average shares outstanding is equal to basic weighted-average shares, due to the Company&#x2019;s net loss position. No common
stock equivalents were included in the computation of diluted net loss per unit since such inclusion would have been antidilutive. At
March 31, 2026 and 2025, potentially dilutive securities include the public warrants, stock options and the convertible promissory notes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001658">&lt;p id="xdx_845_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zz7Da6k9NGT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zzQ4EhXHJUu6"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In the normal course of business, the Company
is subject to loss contingencies, such as legal proceedings and claims arising out of its business, which cover a wide range of matters,
including, among others, government investigations, shareholder lawsuits, and no income tax matters.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;An accrual for a loss contingency is recognized
when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. If a potential material loss
contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability,
together with an estimate of the range of possible loss if determinable and material, is disclosed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <VWAV:RelatedPartyAndRelatedPartyTransactionsPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001660">&lt;p id="xdx_84F_ecustom--RelatedPartyAndRelatedPartyTransactionsPolicyTextBlock_zMRWP3U2VrB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zGcP4cUfq6Y"&gt;Related party and related-party transactions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Related parties, which can be a corporation or
individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise
significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if
they are subject to common control or common significant influence, such as a family member or relative, shareholder, or a related corporation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Transactions involving related parties cannot
be presumed to be carried out on an arm&#x2019;s-length basis, as the requisite conditions of competitive, free-market dealings may not
exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated
on terms equivalent to those that prevail in arm&#x2019;s-length transactions unless such representations can be substantiated. It is
not, however, practical to determine the fair value of amounts due to or from related parties due to their related-party nature.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</VWAV:RelatedPartyAndRelatedPartyTransactionsPolicyTextBlock>
    <us-gaap:IncomeTaxUncertaintiesPolicy contextRef="From2025-10-01to2026-03-31" id="Fact001664">&lt;p id="xdx_843_eus-gaap--IncomeTaxUncertaintiesPolicy_zFxgEHWpDn4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zhcENS0opqhg"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows the asset and liability method
of accounting for income taxes under ASC Topic 740, Income Taxes (&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered
or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included
the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be
realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC 740 prescribes a recognition threshold and
a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax
return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized
tax benefits as of March 31, 2026 and September 30, 2025. Interest and penalties related to Bannix Acquisition for the three and six
months ended March 31, 2026 were $&lt;span id="xdx_906_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_c20260101__20260331_z8AYQyTrv0h1" title="Interest and penalties"&gt;24,462&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_c20251001__20260331_zOI9rr1x4utj" title="Interest and penalties"&gt;49,228&lt;/span&gt;, respectively. There were no interest and penalties related to Bannix Acquisition
for the three and six months ended March 31, 2025. The Company is currently not aware of any issues under review that could result in
significant payments, accruals or material deviation from its position.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxUncertaintiesPolicy>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001666"
      unitRef="USD">24462</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001668"
      unitRef="USD">49228</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001670">&lt;p id="xdx_840_eus-gaap--AdvertisingCostsPolicyTextBlock_zydZFPSlnSdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zo1bEIdqXl05"&gt;Advertising and Promotion&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;All costs associated with advertising and promoting products are expensed
as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:AdvertisingCostsPolicyTextBlock>
    <VWAV:StockBasedCompensationPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001672">&lt;p id="xdx_843_ecustom--StockBasedCompensationPolicyTextBlock_ztWfG0r7b3P5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zpOcD7jtpTS2"&gt;Stock Based Compensation &lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company complies with ASC 718 Compensation
&#x2014; Stock Compensation regarding shares granted to directors, officers and vendors of the Company by measuring the grant date fair
value of the award and recognizing the resulting expense over the period during which the employee is required to perform service in
exchange for the award. Equity-based compensation expense is only recognized for awards subject to performance conditions if it is probable
that the performance condition will be achieved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has elected to account for forfeitures
as they occur rather than estimating expected forfeitures at the grant date. Accordingly, stock-based compensation expense is adjusted
in the period in which awards are forfeited.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</VWAV:StockBasedCompensationPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001674">&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zNVgZinhn4N8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zy0gaU82ArTh"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 4, 2024, the FASB issued ASU 2024-03,
Disaggregation of Income Statement Expenses (DISE), requiring additional disclosure of the nature of expenses included in the statements
of operations. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the
face of the statements of operations as well as disclosures about selling expenses. The standard is effective for annual reporting periods
beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027. The
Company is currently assessing the impact this standard will have on its unaudited condensed consolidated financial statements and related
disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s management does not believe
that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect
on the Company&#x2019;s unaudited condensed consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <VWAV:RecapitalizationTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001678">&lt;p id="xdx_801_ecustom--RecapitalizationTextBlock_z3KHTCTqHUPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 4 &#x2014; &lt;span id="xdx_820_zOCjZGu7uXWb"&gt;Recapitalization&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As outlined in Note 1, the Company consummated
the Reverse Acquisition with VisionWave Technologies on July 14, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to and in accordance with the terms set
forth in the Merger Agreement, (a) Parent Merger Sub merged with and into Bannix, with Bannix continuing as the surviving entity (the
&#x201c;Parent Merger&#x201d;), as a result of which, (i) Bannix became a wholly owned subsidiary of VW Holdings, and (ii) each issued
and outstanding share of Bannix immediately prior to the effective time of the Parent Merger (the &#x201c;Parent Merger Effective Time&#x201d;)
(other than shares of Bannix Common Stock that have been redeemed or are owned by Bannix or any of its direct or indirect subsidiaries
as treasury shares and any Dissenting Parent Shares) was automatically cancelled in exchange for one share of common stock, par value
$&lt;span id="xdx_901_ecustom--CommonStockParOrStatedValuePerShares_iI_c20250714_zon9HelYW0p2" title="Common stock par value"&gt;0.001&lt;/span&gt; of VW Holdings, each Bannix Warrant automatically converted into one warrant to purchase shares of VW Holdings Common Stock on
substantially the same terms and conditions and each Bannix Right automatically converted into the number of shares of VW Holdings Common
Stock that would have been received by the holder of such Bannix Right if it had been converted upon the consummation of a Business Combination
in accordance with Bannix&#x2019;s organizational document and, (b) immediately following the consummation of the Parent Merger but on
the same day, Company Merger Sub merged with and into Target, with Target continuing as the surviving entity (the &#x201c;Company Merger&#x201d;
and, together with the Parent Merger, the &#x201c;Mergers&#x201d;), as a result of which, (i) Target became a wholly owned subsidiary of
VW Holdings, and (ii) each issued and outstanding security of Target immediately prior to the effective time of the Company Merger (the
&#x201c;Company Merger Effective Time&#x201d;) (other than any cancelled Shares or dissenting shares) were no longer be outstanding and
were automatically cancelled in exchange for the issuance to the holder thereof of a substantially equivalent security of VW Holdings.
The Mergers and the other transactions contemplated by the Merger Agreement are hereinafter referred to as the &#x201c;Reverse Acquisition.&#x201d;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Merger Agreement contained representations,
warranties and covenants of each of the parties thereto that are customary for transactions of this type, including, among others, covenants
providing for (i) certain limitations on the operation of the parties&#x2019; respective businesses prior to consummation of the Business
Combination, (ii) the parties&#x2019; efforts to satisfy conditions to consummation of the Business Combination, including by obtaining
any necessary approvals from governmental agencies, (iii) prohibitions on the parties soliciting alternative transactions, (iv) VW Holdings
preparing and filing a registration statement on Form S-4 with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) and taking
certain other actions to obtain the requisite approval of Bannix&#x2019;s stockholders to vote in favor of certain matters, including
the adoption of the Merger Agreement and approval of the Business Combination, at a special meeting to be called for the approval of
such matters, and (v) the protection of, and access to, confidential information of the parties. On May 5, 2025, the SEC declared the
Company&#x2019;s registration statement on Form S-4 to be effective.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As described in the Merger Agreement, VW Holdings has agreed to adopt
an equity incentive plan&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Business Combination was accounted for as
a reverse recapitalization in accordance with GAAP. Under this method of accounting, Bannix, who is the legal acquirer, was treated as
the &#x201c;acquired&#x201d; company for financial reporting purposes and VisionWave Technologies Inc. was treated as the accounting acquirer.
VisionWave Technologies Inc. has been determined to be the accounting acquirer based on evaluation of the following facts and circumstances
under the redemption scenarios:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;VisionWave Technologies Inc.&#x2019;s
                                            existing stockholders had more than 69% of the voting interest of VW Holdings under both
                                            the no redemption and maximum redemption scenarios;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;







&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;VisionWave Technologies Inc.&#x2019;s
                                            senior management comprises the senior management of VW Holdings Inc.; the directors nominated
                                            by VisionWave Technologies represent the majority of the board of directors of VW Holdings
                                            Inc.;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;VisionWave Technologies Inc.&#x2019;s
                                            operations comprise the ongoing operations of VW Holdings Inc.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accordingly, for accounting purposes, the Reverse
Acquisition was treated as the equivalent of a capital transaction in which VisionWave technologies Inc. is issuing stock for the net
assets of Bannix. The net assets of Bannix were stated at historical cost, with no goodwill or other intangible assets recorded. Operations
prior to the Reverse Acquisition were those of VisionWave Technologies, Inc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Transaction Proceeds&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Upon closing of the Reverse Acquisition, the Company
acquired cash of $&lt;span id="xdx_904_ecustom--GrossProceeds_c20251001__20260331__us-gaap--RelatedPartyTransactionAxis__custom--ReverseAcquisitionMember_zB1G4LJJRRpe" title="Gross proceeds"&gt;1,169,746&lt;/span&gt; as a result of the Reverse Acquisition, and paid total transaction costs of $&lt;span id="xdx_90B_eus-gaap--AssetAcquisitionConsiderationTransferredTransactionCost_c20251001__20260331_zGGr81XBu2ri" title="Transaction costs"&gt;1,145,900&lt;/span&gt;. The following table
reconciles the elements of the Reverse Acquisition to the consolidated statements of cash flows and the consolidated statement of changes
in stockholders&#x2019; deficit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfconsolidatedStatementsOfCashFlowsAndChangesInStockholdersDeficitTableTextBlock_znsFVptQ1bZb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Recapitalization (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z3ph20wdK9wi" style="display: none"&gt;Schedule
of consolidated statements of cash flows and changes in stockholders deficit&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_498_20251001__20260331_zmOVpseuXDkd" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--CashtrustAndCashNetOfRedemptions_z8kktahnP9y7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Cash-trust and cash, net of redemptions&lt;/td&gt;
&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 18%; text-align: right"&gt;1,169,746&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--LessTransactionCostsPaid_zOaLzn7WSIt9" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less: transaction costs paid&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,145,900&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--NetPayoutInReverseAcquisition_z8ALDZVDgLqi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net payout in Reverse Acquisition&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;23,846&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--LessLiabilitiesAssumed_zNFDT1a5wty" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less: Liabilities assumed&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(7,370,764&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--LessPromissoryNoteCombined_zZFwVvaPx6se" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less: Promissory note combined&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(1,003,995&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--AddAssetsAcquired_z24qRNyRwQtc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Add: assets acquired&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,930&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--ReverseAcquistionNet_zqZkymlfmBGd" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Reverse acquisition, net&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(8,346,983&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AF_z2vr4hyvEGA5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The number of shares of Common Stock issued immediately following the
consummation of the Reverse Acquisition were:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfConsummationOfTheReverseAcquisitionTableTextBlock_zKyv163yFhwj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Recapitalization (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_z6cD3VRBx3D4" style="display: none"&gt;Schedule of consummation of the Reverse Acquisition&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Bannix Class A common stock, outstanding prior
to the Reverse Acquisition&lt;/td&gt;
&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--SharesIssued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--BannixClassACommonStockMember_zBgnHydgWMxj" style="width: 18%; text-align: right" title="Shares issued"&gt;2,623,666&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less: Redemption of Bannix Class A common stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--ShareIssued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--RedemptionClassACommonStockMember_zUB7B7XgDX73" style="border-bottom: Black 1pt solid; text-align: right" title="Shares issued"&gt;(83,342&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--SharesIssued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--TotalBannixClassACommonStockMember_z79FP30Nkou4" style="text-align: right" title="Shares issued"&gt;2,540,324&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Bannix Class B common stock, outstanding prior to the
Reverse Acquisition&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--SharesIssued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--BannixClassBCommonStockMember_zP5PFVoaRwZf" style="border-bottom: Black 1pt solid; text-align: right" title="Shares issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1712"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Business Combination shares&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--SharesIssued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--BusinessCombinationSharesMember_zjvW2OHVi8V1" style="text-align: right" title="Shares issued"&gt;2,540,324&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Bannix public Rights converted to shares at closing&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--SharesIssued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--BannixPublicRightsMember_z4rn1ifTVP3k" style="text-align: right" title="Shares issued"&gt;690,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Bannix private Rights converted to shares at closing&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--SharesIssued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--BannixPrivateRightsMember_ztHMkzpiaX9j" style="text-align: right" title="Shares issued"&gt;40,600&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;VisionWave Technologies Inc. Shares&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--SharesIssued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveTechnologiesMember_z2QSMpYiWE63" style="text-align: right" title="Shares issued"&gt;11,000,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Common Stock immediately after the Reverse Acquisition&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--SharesIssued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--CommonStockReverseMember_zBSjPkRocqs" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares issued"&gt;14,270,924&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A2_z7sJJMiUm8h" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The number of VisionWave Holdings&#x2019; shares was determined as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfTheNumberOfVisionWaveHoldingsSharesTableTextBlock_zvoksvzPmc68" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Recapitalization (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BB_zagtbPd2J4f1" style="display: none"&gt;Schedule of the number of VisionWave Holdings shares&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;VisionWave Technologies Inc. Shares&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;VisionWave Holdings Inc. Shares after
conversion ratio&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Class A Common&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ConversionOfStockSharesIssued1_c20251001__20260331__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveMember__us-gaap--StatementClassOfStockAxis__custom--ClassACommonMember_zq5c5nbd2Lo3" style="width: 12%; text-align: right" title="Number shares issued"&gt;2,722&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--ConversionOfStockSharesIssued1_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassACommonMember_zFivmqSXF78l" style="width: 12%; text-align: right" title="Number shares issued"&gt;2,540,324&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Class B Common&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ConversionOfStockSharesIssued1_c20251001__20260331__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveMember__us-gaap--StatementClassOfStockAxis__custom--ClassBCommonMember_zxmjUjeTsMM5" style="text-align: right" title="Number shares issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1732"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ConversionOfStockSharesIssued1_c20251001__20260331__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveTechnologiesMember__us-gaap--StatementClassOfStockAxis__custom--ClassBCommonMember_zm3h3gzTaoR6" style="text-align: right" title="Number shares issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1734"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ConversionOfStockSharesIssued1_c20251001__20260331__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveMember_zbcd37vCMXk5" style="border-bottom: Black 2.5pt double; text-align: right" title="TotalNumber shares issued"&gt;2,722&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ConversionOfStockSharesIssued1_c20251001__20260331__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveTechnologiesMember_zNAq1AoeF9gg" style="border-bottom: Black 2.5pt double; text-align: right" title="TotalNumber shares issued"&gt;2,540,324&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A2_zCApnRczG466" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In exchange, each share of VisionWave Technologies
was converted into &lt;span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_c20251001__20260331_zA1XDCNee4te" title="Converted Shares"&gt;4,041&lt;/span&gt; shares of the Company&#x2019;s common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Public and private placement warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zKrSQFEDbPWk" title="Warrants issued"&gt;6,900,000&lt;/span&gt; public warrants issued at the time
of Bannix&#x2019;s initial public offering (the &#x201c;Bannix IPO&#x201d;), and &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zV0C4I2VRiea" title="Warrants issued"&gt;406,000&lt;/span&gt; warrants issued in connection with private placement
at the time of Bannix&#x2019;s initial public offering remained outstanding and became warrants for the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</VWAV:RecapitalizationTextBlock>
    <VWAV:CommonStockParOrStatedValuePerShares
      contextRef="AsOf2025-07-14"
      decimals="INF"
      id="Fact001680"
      unitRef="USDPShares">0.001</VWAV:CommonStockParOrStatedValuePerShares>
    <VWAV:GrossProceeds
      contextRef="From2025-10-012026-03-31_custom_ReverseAcquisitionMember"
      decimals="0"
      id="Fact001684"
      unitRef="USD">1169746</VWAV:GrossProceeds>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001686"
      unitRef="USD">1145900</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <VWAV:ScheduleOfconsolidatedStatementsOfCashFlowsAndChangesInStockholdersDeficitTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001688">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfconsolidatedStatementsOfCashFlowsAndChangesInStockholdersDeficitTableTextBlock_znsFVptQ1bZb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Recapitalization (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z3ph20wdK9wi" style="display: none"&gt;Schedule
of consolidated statements of cash flows and changes in stockholders deficit&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_498_20251001__20260331_zmOVpseuXDkd" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--CashtrustAndCashNetOfRedemptions_z8kktahnP9y7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Cash-trust and cash, net of redemptions&lt;/td&gt;
&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 18%; text-align: right"&gt;1,169,746&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--LessTransactionCostsPaid_zOaLzn7WSIt9" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less: transaction costs paid&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,145,900&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--NetPayoutInReverseAcquisition_z8ALDZVDgLqi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net payout in Reverse Acquisition&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;23,846&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--LessLiabilitiesAssumed_zNFDT1a5wty" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less: Liabilities assumed&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(7,370,764&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--LessPromissoryNoteCombined_zZFwVvaPx6se" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less: Promissory note combined&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(1,003,995&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--AddAssetsAcquired_z24qRNyRwQtc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Add: assets acquired&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,930&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--ReverseAcquistionNet_zqZkymlfmBGd" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Reverse acquisition, net&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(8,346,983&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</VWAV:ScheduleOfconsolidatedStatementsOfCashFlowsAndChangesInStockholdersDeficitTableTextBlock>
    <VWAV:CashtrustAndCashNetOfRedemptions
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact001690"
      unitRef="Shares">1169746</VWAV:CashtrustAndCashNetOfRedemptions>
    <VWAV:LessTransactionCostsPaid
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact001692"
      unitRef="Shares">-1145900</VWAV:LessTransactionCostsPaid>
    <VWAV:NetPayoutInReverseAcquisition
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact001694"
      unitRef="Shares">23846</VWAV:NetPayoutInReverseAcquisition>
    <VWAV:LessLiabilitiesAssumed
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact001696"
      unitRef="Shares">-7370764</VWAV:LessLiabilitiesAssumed>
    <VWAV:LessPromissoryNoteCombined
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact001698"
      unitRef="Shares">-1003995</VWAV:LessPromissoryNoteCombined>
    <VWAV:AddAssetsAcquired
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact001700"
      unitRef="Shares">3930</VWAV:AddAssetsAcquired>
    <VWAV:ReverseAcquistionNet
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact001702"
      unitRef="Shares">-8346983</VWAV:ReverseAcquistionNet>
    <VWAV:ScheduleOfConsummationOfTheReverseAcquisitionTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001704">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfConsummationOfTheReverseAcquisitionTableTextBlock_zKyv163yFhwj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Recapitalization (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_z6cD3VRBx3D4" style="display: none"&gt;Schedule of consummation of the Reverse Acquisition&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Bannix Class A common stock, outstanding prior
to the Reverse Acquisition&lt;/td&gt;
&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--SharesIssued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--BannixClassACommonStockMember_zBgnHydgWMxj" style="width: 18%; text-align: right" title="Shares issued"&gt;2,623,666&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less: Redemption of Bannix Class A common stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--ShareIssued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--RedemptionClassACommonStockMember_zUB7B7XgDX73" style="border-bottom: Black 1pt solid; text-align: right" title="Shares issued"&gt;(83,342&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--SharesIssued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--TotalBannixClassACommonStockMember_z79FP30Nkou4" style="text-align: right" title="Shares issued"&gt;2,540,324&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Bannix Class B common stock, outstanding prior to the
Reverse Acquisition&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--SharesIssued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--BannixClassBCommonStockMember_zP5PFVoaRwZf" style="border-bottom: Black 1pt solid; text-align: right" title="Shares issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1712"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Business Combination shares&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--SharesIssued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--BusinessCombinationSharesMember_zjvW2OHVi8V1" style="text-align: right" title="Shares issued"&gt;2,540,324&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Bannix public Rights converted to shares at closing&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--SharesIssued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--BannixPublicRightsMember_z4rn1ifTVP3k" style="text-align: right" title="Shares issued"&gt;690,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Bannix private Rights converted to shares at closing&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--SharesIssued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--BannixPrivateRightsMember_ztHMkzpiaX9j" style="text-align: right" title="Shares issued"&gt;40,600&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;VisionWave Technologies Inc. Shares&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--SharesIssued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveTechnologiesMember_z2QSMpYiWE63" style="text-align: right" title="Shares issued"&gt;11,000,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Common Stock immediately after the Reverse Acquisition&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--SharesIssued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--CommonStockReverseMember_zBSjPkRocqs" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares issued"&gt;14,270,924&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</VWAV:ScheduleOfConsummationOfTheReverseAcquisitionTableTextBlock>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-03-31_custom_BannixClassACommonStockMember"
      decimals="INF"
      id="Fact001706"
      unitRef="Shares">2623666</us-gaap:SharesIssued>
    <VWAV:ShareIssued
      contextRef="AsOf2026-03-31_custom_RedemptionClassACommonStockMember"
      decimals="INF"
      id="Fact001708"
      unitRef="Shares">-83342</VWAV:ShareIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-03-31_custom_TotalBannixClassACommonStockMember"
      decimals="INF"
      id="Fact001710"
      unitRef="Shares">2540324</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-03-31_custom_BusinessCombinationSharesMember"
      decimals="INF"
      id="Fact001714"
      unitRef="Shares">2540324</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-03-31_custom_BannixPublicRightsMember"
      decimals="INF"
      id="Fact001716"
      unitRef="Shares">690000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-03-31_custom_BannixPrivateRightsMember"
      decimals="INF"
      id="Fact001718"
      unitRef="Shares">40600</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-03-31_custom_VisionWaveTechnologiesMember"
      decimals="INF"
      id="Fact001720"
      unitRef="Shares">11000000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-03-31_custom_CommonStockReverseMember"
      decimals="INF"
      id="Fact001722"
      unitRef="Shares">14270924</us-gaap:SharesIssued>
    <VWAV:ScheduleOfTheNumberOfVisionWaveHoldingsSharesTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001726">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfTheNumberOfVisionWaveHoldingsSharesTableTextBlock_zvoksvzPmc68" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Recapitalization (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BB_zagtbPd2J4f1" style="display: none"&gt;Schedule of the number of VisionWave Holdings shares&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;VisionWave Technologies Inc. Shares&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;VisionWave Holdings Inc. Shares after
conversion ratio&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Class A Common&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ConversionOfStockSharesIssued1_c20251001__20260331__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveMember__us-gaap--StatementClassOfStockAxis__custom--ClassACommonMember_zq5c5nbd2Lo3" style="width: 12%; text-align: right" title="Number shares issued"&gt;2,722&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--ConversionOfStockSharesIssued1_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassACommonMember_zFivmqSXF78l" style="width: 12%; text-align: right" title="Number shares issued"&gt;2,540,324&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Class B Common&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ConversionOfStockSharesIssued1_c20251001__20260331__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveMember__us-gaap--StatementClassOfStockAxis__custom--ClassBCommonMember_zxmjUjeTsMM5" style="text-align: right" title="Number shares issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1732"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ConversionOfStockSharesIssued1_c20251001__20260331__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveTechnologiesMember__us-gaap--StatementClassOfStockAxis__custom--ClassBCommonMember_zm3h3gzTaoR6" style="text-align: right" title="Number shares issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1734"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ConversionOfStockSharesIssued1_c20251001__20260331__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveMember_zbcd37vCMXk5" style="border-bottom: Black 2.5pt double; text-align: right" title="TotalNumber shares issued"&gt;2,722&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ConversionOfStockSharesIssued1_c20251001__20260331__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveTechnologiesMember_zNAq1AoeF9gg" style="border-bottom: Black 2.5pt double; text-align: right" title="TotalNumber shares issued"&gt;2,540,324&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</VWAV:ScheduleOfTheNumberOfVisionWaveHoldingsSharesTableTextBlock>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2025-10-012026-03-31_custom_VisionWaveMember_custom_ClassACommonMember"
      decimals="INF"
      id="Fact001728"
      unitRef="Shares">2722</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2025-10-012026-03-31_custom_ClassACommonMember"
      decimals="INF"
      id="Fact001730"
      unitRef="Shares">2540324</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2025-10-012026-03-31_custom_VisionWaveMember"
      decimals="INF"
      id="Fact001736"
      unitRef="Shares">2722</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2025-10-012026-03-31_custom_VisionWaveTechnologiesMember"
      decimals="INF"
      id="Fact001738"
      unitRef="Shares">2540324</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact001740"
      unitRef="Shares">4041</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2026-03-31_us-gaap_IPOMember"
      decimals="INF"
      id="Fact001742"
      unitRef="Shares">6900000</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2026-03-31_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001744"
      unitRef="Shares">406000</us-gaap:ClassOfWarrantOrRightUnissued>
    <VWAV:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001746">&lt;p id="xdx_80E_ecustom--PrepaidExpensesAndOtherCurrentAssetsTextBlock_zFukaxpfd6Uj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 5 &#x2014; &lt;span id="xdx_821_zMvN0CpIHHR8"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prepaid expenses and other current assets consisted
of the following as of March 31, 2026 and September 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zGVuZL2D2ia2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses and Other Current Assets (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_zDfsOOwlyS5e" style="display: none"&gt;Schedule of Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_499_20260331_zfo4iQw4MlX9" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_491_20250930_z36tlMY6mIVa" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--PrepaidReinsurancePremiums_iI_zwjSBUdRNkMh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Insurance premium&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;30,886&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;83,833&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DepositsAssets_iI_zkilKd7B57Al" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Deposit on asset&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1753"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;10,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--PrepaidConsultingFees_iI_z7qRxgnocED9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Prepaid consulting fees&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;400,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;50,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssets_iI_zH7thEw6ZHib" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other prepaid expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;66,088&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;261&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--LegalRetainer_iI_zUkrevd03B8l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Legal retainer&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;85,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;35,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--OtherCurrentAssets_iI_zBjkbEEcXDa6" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other current assets&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;28,568&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;6,525&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--DueFromUnderwriters_iI_z0bntvwHEK2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Due from underwriters&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,930&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,930&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--OtherPrepaidExpenseCurrent_iI_zOHbja67B9oe" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;614,472&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;189,549&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</VWAV:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001748">&lt;table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zGVuZL2D2ia2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses and Other Current Assets (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_zDfsOOwlyS5e" style="display: none"&gt;Schedule of Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_499_20260331_zfo4iQw4MlX9" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_491_20250930_z36tlMY6mIVa" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--PrepaidReinsurancePremiums_iI_zwjSBUdRNkMh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Insurance premium&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;30,886&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;83,833&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DepositsAssets_iI_zkilKd7B57Al" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Deposit on asset&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1753"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;10,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--PrepaidConsultingFees_iI_z7qRxgnocED9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Prepaid consulting fees&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;400,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;50,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssets_iI_zH7thEw6ZHib" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other prepaid expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;66,088&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;261&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--LegalRetainer_iI_zUkrevd03B8l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Legal retainer&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;85,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;35,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--OtherCurrentAssets_iI_zBjkbEEcXDa6" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other current assets&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;28,568&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;6,525&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--DueFromUnderwriters_iI_z0bntvwHEK2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Due from underwriters&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,930&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,930&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--OtherPrepaidExpenseCurrent_iI_zOHbja67B9oe" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;614,472&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;189,549&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidReinsurancePremiums
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001750"
      unitRef="USD">30886</us-gaap:PrepaidReinsurancePremiums>
    <us-gaap:PrepaidReinsurancePremiums
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001751"
      unitRef="USD">83833</us-gaap:PrepaidReinsurancePremiums>
    <us-gaap:DepositsAssets
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001754"
      unitRef="USD">10000</us-gaap:DepositsAssets>
    <VWAV:PrepaidConsultingFees
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001756"
      unitRef="USD">400000</VWAV:PrepaidConsultingFees>
    <VWAV:PrepaidConsultingFees
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001757"
      unitRef="USD">50000</VWAV:PrepaidConsultingFees>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001759"
      unitRef="USD">66088</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001760"
      unitRef="USD">261</us-gaap:PrepaidExpenseAndOtherAssets>
    <VWAV:LegalRetainer
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001762"
      unitRef="USD">85000</VWAV:LegalRetainer>
    <VWAV:LegalRetainer
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001763"
      unitRef="USD">35000</VWAV:LegalRetainer>
    <VWAV:OtherCurrentAssets
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001765"
      unitRef="USD">28568</VWAV:OtherCurrentAssets>
    <VWAV:OtherCurrentAssets
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001766"
      unitRef="USD">6525</VWAV:OtherCurrentAssets>
    <VWAV:DueFromUnderwriters
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001768"
      unitRef="USD">3930</VWAV:DueFromUnderwriters>
    <VWAV:DueFromUnderwriters
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001769"
      unitRef="USD">3930</VWAV:DueFromUnderwriters>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001771"
      unitRef="USD">614472</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001772"
      unitRef="USD">189549</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001774">&lt;p id="xdx_801_eus-gaap--EquityMethodInvestmentsDisclosureTextBlock_zL3m3QLxNFZe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 6 &#x2014; &lt;span id="xdx_824_zs7jQg6ntuf2"&gt;Equity Method Investment&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 26, 2026, the Company entered into
a definitive Exchange Agreement (the &#x201c;Exchange Agreement&#x201d;) with SaverOne 2014 Ltd., an Israeli company whose American Depositary
Shares are listed on The Nasdaq Stock Market (&#x201c;SaverOne&#x201d;). The Exchange Agreement replaced and superseded the previously
disclosed non-binding Letter of Intent dated December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Exchange Agreement provides for a three-stage
equity exchange and strategic collaboration providing for the Company to acquire up to approximately 51% of SaverOne&#x2019;s issued and
outstanding ordinary shares on a fully diluted basis, subject to milestone achievement and applicable regulatory approvals. In exchange,
the Exchange Agreement provides SaverOne with the ability to acquire VisionWave common stock with an aggregate economic value of up to
$&lt;span id="xdx_902_ecustom--AggregateEconomicValue_iI_pn3n3_dm_c20250126_z1XBGZoOFsa6" title="Aggregate economic value"&gt;7&lt;/span&gt; million, subject to staged issuance, price-based adjustments, and compliance with Nasdaq listing rules.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The transaction establishes SaverOne as the core
operating platform for VisionWave&#x2019;s radio-frequency (RF) defense and security technologies, supported by a non-exclusive, worldwide
license to certain VisionWave RF intellectual property for defense and security applications.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Staged Exchange Structure&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Stage 1:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;SaverOne issues VisionWave ordinary shares representing
19.99% of SaverOne&#x2019;s outstanding share capital (fully diluted), in exchange for VisionWave common stock valued at approximately
$&lt;span id="xdx_904_eus-gaap--CommonStockValue_iI_pn3n3_dm_c20260126__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveStage1Member_z965vf2C15wc" title="Common stock value"&gt;2.74&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Stage 2:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Upon achievement of the first operational integration
milestone, SaverOne issues VisionWave ordinary shares representing 19.99% of SaverOne&#x2019;s outstanding share capital (fully diluted),
in exchange for VisionWave common stock valued at approximately $&lt;span id="xdx_90E_eus-gaap--CommonStockValue_iI_pn3n3_dm_c20260126__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveStage2Member_zAI81n5CPJff" title="Common stock value"&gt;2.74 &lt;/span&gt;million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Stage 3:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Upon achievement of a commercial or defense pilot
milestone, SaverOne issues VisionWave ordinary shares representing 11.02% of SaverOne&#x2019;s outstanding share capital (fully diluted)
resulting in VisionWave owning approximately 51% of SaverOne in exchange for VisionWave common stock valued at approximately $&lt;span id="xdx_904_eus-gaap--CommonStockValue_iI_pn3n3_dm_c20260126__us-gaap--RelatedPartyTransactionAxis__custom--VisionWaveStage3Member_zIy1HsT0G6rj" title="Common stock value"&gt;1.51&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The number of VisionWave shares of common stock
issued in each stage is determined based on a five-day VWAP immediately preceding the applicable closing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Additional Provisions&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Exchange Agreement also includes, among other things:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#x25cf; Board representation rights for VisionWave at SaverOne&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#x25cf; Registration rights for resale of VisionWave shares of
common stock&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#x25cf; Use-of-proceeds covenants tied to RF platform development&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#x25cf; Value-protection mechanisms subject to Nasdaq compliance&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#x25cf; Mutual non-competition provisions within the defined
field of use&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The transaction remains subject to milestone certifications, regulatory
approvals, and customary closing conditions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At the close of stage 1 of the agreement, the
Company issued &lt;span id="xdx_900_eus-gaap--SharesIssued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--Stage1Member_zqApTz8pXOl8" title="Shares issued"&gt;365,610&lt;/span&gt; shares valued at $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20251001__20260331_zPIumLhZplp9" title="Share value"&gt;2,723,792&lt;/span&gt; to SaverOne in exchange for &lt;span id="xdx_901_ecustom--SharesExchanged_iI_c20260331_zkzlpNiuDMj7" title="Shares exchanged"&gt;148,584&lt;/span&gt; shares of SaverOne. During the three months ended
March 31, 2026, the Company purchased an additional &lt;span id="xdx_90F_eus-gaap--StockRepurchasedDuringPeriodShares_c20260101__20260331_zkhqKHwtP4Lj" title="Purchased additional shares"&gt;17,569&lt;/span&gt; shares of SaverOne costing $&lt;span id="xdx_90E_eus-gaap--StockRepurchasedDuringPeriodValue_c20260101__20260331_zM9zP2h54x6c" title="Purchased additional cost"&gt;49,824&lt;/span&gt; for a shareholding in SaverOne of 22.20%
at March 31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;SaverOne is accounted for as an equity method
investment at March 31, 2026, pursuant to ASC 323. The Company determined that the value protection mechanism liability has a value of
$&lt;span id="xdx_906_ecustom--ProtectionMechanismLiability_iI_c20260331_z7fmVPtXjVu6" title="Protection mechanism liability"&gt;0&lt;/span&gt; at March 31, 2026 as it is assessed on a stage-by-stage basis and stage 1 did not trigger a liability. The investment in SaverOne
of $&lt;span id="xdx_905_eus-gaap--EquityMethodInvestmentAggregateCost_iI_c20260331_zCGStMSZcCz1" title="Investment"&gt;2,773,616&lt;/span&gt; is included in Equity method investments on the March 31, 2026 unaudited condensed consolidated balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;








&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, the Company issued the corresponding
156,686 to management at the Stage 1 Closing pursuant to Schedule 1.7 of the January 26, 2026 Agreement, including the applicable portion
of the $3 million pool (39.1877%).The total fair value of the shares of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_c20260125__20260126_zcOc8qYhRQli" title="Stock based compensation"&gt;1,167,311&lt;/span&gt; at issuance date was included in stock based compensation
on the accompanying unaudited condensed consolidated statements of operations.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <VWAV:AggregateEconomicValue
      contextRef="AsOf2025-01-26"
      decimals="-3"
      id="Fact001776"
      unitRef="USD">7000000</VWAV:AggregateEconomicValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-01-26_custom_VisionWaveStage1Member"
      decimals="-3"
      id="Fact001780"
      unitRef="USD">2740000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-01-26_custom_VisionWaveStage2Member"
      decimals="-3"
      id="Fact001782"
      unitRef="USD">2740000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-01-26_custom_VisionWaveStage3Member"
      decimals="-3"
      id="Fact001784"
      unitRef="USD">1510000</us-gaap:CommonStockValue>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-03-31_custom_Stage1Member"
      decimals="INF"
      id="Fact001786"
      unitRef="Shares">365610</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001788"
      unitRef="USD">2723792</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <VWAV:SharesExchanged
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001790"
      unitRef="Shares">148584</VWAV:SharesExchanged>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2026-01-012026-03-31"
      decimals="INF"
      id="Fact001792"
      unitRef="Shares">17569</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001794"
      unitRef="USD">49824</us-gaap:StockRepurchasedDuringPeriodValue>
    <VWAV:ProtectionMechanismLiability
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001796"
      unitRef="USD">0</VWAV:ProtectionMechanismLiability>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001798"
      unitRef="USD">2773616</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:ShareBasedCompensation
      contextRef="From2026-01-252026-01-26"
      decimals="0"
      id="Fact001802"
      unitRef="USD">1167311</us-gaap:ShareBasedCompensation>
    <VWAV:NoteReceivableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001804">&lt;p id="xdx_807_ecustom--NoteReceivableTextBlock_zv8T1J0ZOyvc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 7 &#x2014; &lt;span id="xdx_827_zTqSTyQ35Xs4"&gt;Note Receivable&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Advance to C.M. Composite Materials Ltd&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 26, 2025, the Company advanced principal
in the amount of $&lt;span id="xdx_90A_eus-gaap--PaymentsToAcquireNotesReceivable_c20251225__20251226_zpBg7YuqH42a"&gt;398,245&lt;/span&gt; to C.M. Composite Materials Ltd., an Israeli corporation (&#x201c;CM&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the advance, CM delivered a
Promissory Note to the Company (the &#x201c;CM Note&#x201d;). The CM Note has a 24-month maturity, with the outstanding principal due and
payable on December 31, 2027, unless repaid earlier. The CM Note does not bear interest unless an event of default occurs, in which case
interest accrues at a rate of &lt;span id="xdx_90F_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20251226_ztKv1lJkySi9" title="Accrues interest rate"&gt;5&lt;/span&gt;% per annum, or the maximum rate permitted by applicable law, if lower. The CM Note may be prepaid at
any time without premium or penalty. The CM Note is a stand-alone financial obligation and is not contingent upon the completion of any
acquisition, merger, or other strategic transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 22, 2026, the Company entered into
an additional Promissory Note with CM for an amount of $&lt;span id="xdx_90D_eus-gaap--PaymentsToAcquireNotesReceivable_c20260121__20260122_zVvA7EXzJLUb"&gt;200,000&lt;/span&gt; to CM (the &#x201c;Second Note&#x201d;). The Second Note has a 24-month
maturity, with the outstanding principal due and payable on January 30, 2028, unless repaid earlier. The Second Note does not bear interest
unless an event of default occurs, in which case interest accrues at a rate of &lt;span id="xdx_903_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20260122_zs0tg1mU3Frg" title="Accrues interest rate"&gt;5&lt;/span&gt;% per annum, or the maximum rate permitted by applicable
law, if lower. The Second Note may be prepaid at any time without premium or penalty. The proceeds of the Note were funded on January
26, 2026. The Second Note constitutes a binding and enforceable obligation of CM. The Note is a stand-alone financial obligation and
is not contingent upon the completion of any acquisition, merger, or other strategic transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 4, 2026, the Company entered into
an additional Promissory Note with CM for an amount of $&lt;span id="xdx_90E_eus-gaap--PaymentsToAcquireNotesReceivable_c20260203__20260204_zymnRq9yUCY9"&gt;500,000&lt;/span&gt; (the &#x201c;Third Note&#x201d;). The Third Note has a 24-month maturity,
with the outstanding principal due and payable on December 31, 2027, unless repaid earlier. The Third Note does not bear interest unless
an event of default occurs, in which case interest accrues at a rate of &lt;span id="xdx_90E_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20260204_zNkl9QEyvbdi" title="Accrues interest rate"&gt;5&lt;/span&gt;% per annum, or the maximum rate permitted by applicable law,
if lower. The Third Note may be prepaid at any time without premium or penalty. The proceeds of the Third Note were funded on February
4, 2026. The Third Note constitutes a binding and enforceable obligation of CM. The Third Note is a stand-alone financial obligation
and is not contingent upon the completion of any acquisition, merger, or other strategic transaction. The note was satisfied from funding
pursuant to the funding agreement with Stanley Hills, LLC (See Note 2).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2026, CM entered into a settlement
agreement with a vendor who alleged failure to meet contractual obligation in the sum of approximately 12 million Israeli Shekels following
a failed motion to appoint a receiver by that said vendor. Pursuant to the agreement, CM is expected to make monthly payments to liquidate
the obligation and regular court appearances. The Company evaluated the current financial position of CM and determined that there is
not an increased credit risk nor is the collectability of the CM Note uncertain, due to past profitability of CM.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The CM Notes described herein remain fully enforceable
regardless of whether any contemplated transaction is completed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2026, total advances to C.M. Composite
Materials Ltd. of $&lt;span id="xdx_903_eus-gaap--AccountsAndNotesReceivableNet_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--CompositeMaterialsMember_zAB5LYI0vJcf" title="Notes receivable"&gt;1,098,245&lt;/span&gt; is included in notes receivable on the unaudited condensed consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Side Letter Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 11, 2026, the Company entered into a
Side Letter with C.M., Giza Zinger Even Mezzanine, Limited Partnership (&#x201c;Giza&#x201d;), and Matania (Mati) Moskovitch. This Side
Letter supplements and addresses obligations under the Company&#x2019;s previously disclosed Investment and Share Purchase Agreement (SPA)
and Loan Agreement, both dated February 20, 2026. Under the Side Letter, the Company acknowledges an existing settlement agreement between
Giza, Mati, and CM, and agrees that CM&#x2019;s performance and payments under that settlement do not constitute a breach or event of
default under the SPA or Loan Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the Side Letter, the Company has irrevocably
committed to providing aggregate funding of at least $&lt;span id="xdx_90B_ecustom--AggregateValue_iI_pn3n3_dm_c20260311_z5gtsMup2jod" title="Aggregate value"&gt;5.0&lt;/span&gt; million to CM. This funding commitment is specifically allocated as $1.5 million
for working capital and $3.5 million for the establishment and operation of a new facility outside of Israel. Additionally, the agreement
requires that CM&#x2019;s activities outside Israel must be conducted directly by CM rather than through subsidiaries, unless those entities
are pledged to Giza.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Until CM&#x2019;s obligations to Giza are fully
satisfied, the Company has agreed not to exercise its conversion rights under the Loan Agreement (the Note) to convert amounts into equity
of CM without Giza&#x2019;s prior written consent. Furthermore, the parties agreed not to take actions that would result in the dilution
of CM&#x2019;s shareholders, including the issuance of new equity, options, warrants, or convertible securities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Side Letter also stipulates that any shares
of the Company to be issued to the shareholder (Mati) in connection with the SPA will be deposited with an approved Israeli trustee.
These shares will be held in a dedicated securities account in Israel for the purpose of securing CM&#x2019;s obligations to Giza.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_907_ecustom--SharePurchaseAgreementDescription_c20251001__20260331_ztpUTjYAB3zl" title="Share Purchase Agreement description"&gt;As stated in Note 18, pursuant to the Investment
and Share Purchase Agreement, the Company agreed to provide loans to the Target Company as additional consideration under the Share Purchase
Agreement. The Loan Agreement provides for a secured loan facility in an aggregate principal amount of up to $5,000,000 (the &#x201c;Commitment&#x201d;).
The Company is obligated to make an initial advance of up to $1,500,000 within ten (10) Business Days following the Effective Date (subject
to satisfaction of conditions precedent), to be used for general working capital purposes consistent with the Target Company&#x2019;s
ordinary course of business. Subsequent advances of the remaining up to $3,500,000 may be made in one or more tranches upon mutual written
agreement of the parties, solely for working capital or the establishment and operation of a new facility outside Israel, with each tranche
subject to the Company&#x2019;s reasonable approval and minimum amounts (generally not less than $250,000 unless otherwise agreed). Proceeds
of subsequent advances are to be used exclusively to operate, develop, certify, market, and commercialize the Target Company&#x2019;s
technologies and products in global markets, including the United States.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The advances were made pursuant to a promissory
note with a 24-month maturity, bearing no interest unless an event of default occurs (then at 5% per annum or the lower legal maximum),
prepayable without penalty, and not contingent on any acquisition or strategic transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Any loan pursuant to the Loan Agreement will bear
simple interest at 12% per annum (or such lower rate as mutually agreed in writing, but not exceeding prevailing market rates for similar
loans as determined in good faith by the Company), calculated on a 360-day year basis for actual days elapsed. The loan will mature three
(3) years after the Effective Date. The obligations under the Loan Agreement are secured by a first-priority security interest in substantially
all assets of the Target Company (including accounts, inventory, equipment, general intangibles, intellectual property, and proceeds
thereof).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended March 31, 2026,
the Company advanced to the Target a total of $&lt;span id="xdx_909_eus-gaap--LongTermInvestmentsAndReceivablesNet_iI_c20260331_zmt4L8m7755i" title="Notes receivable"&gt;2,378,000&lt;/span&gt; which is included in note receivable at March 31, 2026 on the unaudited condensed
consolidated balance sheets. For the three and six months ended March 31, 2026, interest income of $&lt;span id="xdx_904_ecustom--InterestIncome_c20260101__20260331_zU1c1UtXkET4" title="Interest income"&gt;13,851&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--InterestIncomeOther_c20251001__20260331_zAhOKV7RP64h" title="Interest income"&gt;0&lt;/span&gt; is accrued and included
in interest income on the unaudited condensed consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;





</VWAV:NoteReceivableTextBlock>
    <us-gaap:PaymentsToAcquireNotesReceivable
      contextRef="From2025-12-252025-12-26"
      decimals="0"
      id="Fact001805"
      unitRef="USD">398245</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="AsOf2025-12-26"
      decimals="INF"
      id="Fact001807"
      unitRef="Ratio">0.05</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:PaymentsToAcquireNotesReceivable
      contextRef="From2026-01-212026-01-22"
      decimals="0"
      id="Fact001808"
      unitRef="USD">200000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="AsOf2026-01-22"
      decimals="INF"
      id="Fact001810"
      unitRef="Ratio">0.05</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:PaymentsToAcquireNotesReceivable
      contextRef="From2026-02-032026-02-04"
      decimals="0"
      id="Fact001811"
      unitRef="USD">500000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="AsOf2026-02-04"
      decimals="INF"
      id="Fact001813"
      unitRef="Ratio">0.05</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:AccountsAndNotesReceivableNet
      contextRef="AsOf2026-03-31_custom_CompositeMaterialsMember"
      decimals="0"
      id="Fact001815"
      unitRef="USD">1098245</us-gaap:AccountsAndNotesReceivableNet>
    <VWAV:AggregateValue
      contextRef="AsOf2026-03-11"
      decimals="-3"
      id="Fact001818"
      unitRef="USD">5000000.0</VWAV:AggregateValue>
    <VWAV:SharePurchaseAgreementDescription contextRef="From2025-10-01to2026-03-31" id="Fact001820">As stated in Note 18, pursuant to the Investment
and Share Purchase Agreement, the Company agreed to provide loans to the Target Company as additional consideration under the Share Purchase
Agreement. The Loan Agreement provides for a secured loan facility in an aggregate principal amount of up to $5,000,000 (the &#x201c;Commitment&#x201d;).
The Company is obligated to make an initial advance of up to $1,500,000 within ten (10) Business Days following the Effective Date (subject
to satisfaction of conditions precedent), to be used for general working capital purposes consistent with the Target Company&#x2019;s
ordinary course of business. Subsequent advances of the remaining up to $3,500,000 may be made in one or more tranches upon mutual written
agreement of the parties, solely for working capital or the establishment and operation of a new facility outside Israel, with each tranche
subject to the Company&#x2019;s reasonable approval and minimum amounts (generally not less than $250,000 unless otherwise agreed). Proceeds
of subsequent advances are to be used exclusively to operate, develop, certify, market, and commercialize the Target Company&#x2019;s
technologies and products in global markets, including the United States.</VWAV:SharePurchaseAgreementDescription>
    <us-gaap:LongTermInvestmentsAndReceivablesNet
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001822"
      unitRef="USD">2378000</us-gaap:LongTermInvestmentsAndReceivablesNet>
    <VWAV:InterestIncome
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001824"
      unitRef="USD">13851</VWAV:InterestIncome>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001826"
      unitRef="USD">0</us-gaap:InterestIncomeOther>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001829">&lt;p id="xdx_801_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zQqlvZnUb2M7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 8 &#x2014; &lt;span id="xdx_82B_zo89md9FBRS6"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Property and equipment, net consisted of the following at March 31,
2026 and September 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6FTII0oOJf9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment, Net (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_zMVCD2WgyeRg" style="display: none"&gt;Schedule of Property and equipment&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Computer Equipment&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z23ZSCTpoR7j" style="width: 12%; text-align: right" title="Total property and equipment"&gt;60,341&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zSNphIi1Vpk9" style="width: 12%; text-align: right" title="Total property and equipment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1835"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Drones&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DronesMember_z8dsI3q39dfc" style="border-bottom: Black 1pt solid; text-align: right" title="Total property and equipment"&gt;7,122&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DronesMember_zZiAjhvM96u8" style="border-bottom: Black 1pt solid; text-align: right" title="Total property and equipment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1839"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total cost&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331_z8FWGX2x1foh" style="text-align: right" title="Total property and equipment"&gt;67,463&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250930_ziWid3tm8fel" style="text-align: right" title="Total property and equipment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1843"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Accumulated depreciation&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_di_c20260331_zXZY8F2IVL9k" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation"&gt;(7,342&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_di_c20250930_zjSIVWJwepO" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right" title="Accumulated depreciation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1847"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Net book value&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20260331_z31iRIAUonXl" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;60,121&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20250930_zIoUNGPkbU14" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1851"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation expense was $&lt;span id="xdx_90C_eus-gaap--Depreciation_pp0p0_c20260101__20260331_zsNvaIM2A2od" title="Depreciation expense"&gt;5,360&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--Depreciation_pp0p0_c20250101__20250331_zR9TpeX9PNEc" title="Depreciation expense"&gt;0&lt;/span&gt; for the
three months ended March 31, 2026 and 2025, respectively, and $&lt;span id="xdx_90E_eus-gaap--Depreciation_pp0p0_c20251001__20260331_zoi9JXNMtt2" title="Depreciation expense"&gt;7,342&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--Depreciation_pp0p0_c20241001__20250331_zrbHIqAyZEW8" title="Depreciation expense"&gt;0&lt;/span&gt; for the six months ended March 31, 2026 and 2025, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2026 and September 30, 2025, $&lt;span id="xdx_902_eus-gaap--Deposits_iI_c20260331_zrsc2MYp7pHi" title="Deposit"&gt;360,000&lt;/span&gt;
and $&lt;span id="xdx_90E_eus-gaap--Deposits_iI_c20250930_zw1bBfHb0JSh" title="Deposit"&gt;0&lt;/span&gt; deposit on boat purchase is included in other non-current assets on the accompanying unaudited condensed consolidated balance
sheets.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001831">&lt;table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6FTII0oOJf9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment, Net (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_zMVCD2WgyeRg" style="display: none"&gt;Schedule of Property and equipment&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Computer Equipment&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z23ZSCTpoR7j" style="width: 12%; text-align: right" title="Total property and equipment"&gt;60,341&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zSNphIi1Vpk9" style="width: 12%; text-align: right" title="Total property and equipment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1835"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Drones&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DronesMember_z8dsI3q39dfc" style="border-bottom: Black 1pt solid; text-align: right" title="Total property and equipment"&gt;7,122&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DronesMember_zZiAjhvM96u8" style="border-bottom: Black 1pt solid; text-align: right" title="Total property and equipment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1839"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total cost&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331_z8FWGX2x1foh" style="text-align: right" title="Total property and equipment"&gt;67,463&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250930_ziWid3tm8fel" style="text-align: right" title="Total property and equipment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1843"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Accumulated depreciation&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_di_c20260331_zXZY8F2IVL9k" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation"&gt;(7,342&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_di_c20250930_zjSIVWJwepO" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right" title="Accumulated depreciation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1847"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Net book value&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20260331_z31iRIAUonXl" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;60,121&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20250930_zIoUNGPkbU14" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1851"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      id="Fact001833"
      unitRef="USD">60341</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_custom_DronesMember"
      decimals="0"
      id="Fact001837"
      unitRef="USD">7122</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001841"
      unitRef="USD">67463</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001845"
      unitRef="USD">7342</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001849"
      unitRef="USD">60121</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001853"
      unitRef="USD">5360</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact001855"
      unitRef="USD">0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001857"
      unitRef="USD">7342</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact001859"
      unitRef="USD">0</us-gaap:Depreciation>
    <us-gaap:Deposits
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001861"
      unitRef="USD">360000</us-gaap:Deposits>
    <us-gaap:Deposits
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001863"
      unitRef="USD">0</us-gaap:Deposits>
    <us-gaap:AssetAcquisitionTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001865">&lt;p id="xdx_808_eus-gaap--AssetAcquisitionTextBlock_zD8J9ZRt3E28" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 9 &#x2014; &lt;span id="xdx_824_z7B1kvkpTOb"&gt;Asset Acquisitions&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Solar Drone&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 3, 2025, the Company entered into
a Share Purchase Agreement (the &#x201c;Solar Drone Agreement&#x201d;) with BladeRanger Ltd., a company organized under the laws of Israel
and listed on the Tel Aviv Stock Exchange under the ticker &#x201c;BLRN&#x201d; (&#x201c;BladeRanger&#x201d;), and, solely for purposes of
acknowledgment and certain covenants therein, Solar Drone Ltd., an Israeli corporation engaged in the development of solar-powered drone
technology (the &#x201c;Solar Drone&#x201d;). &lt;span id="xdx_907_ecustom--AssetAcquisitionDescription_c20251001__20260331_zS6LtMbMmMig" title="Asset acquisition description"&gt;On December 15, 2025, the Company entered into Amendment No. 1 to the Solar Drone Agreement
to provide that, in consideration for all of the issued and outstanding shares of Solar Drone, the Company shall issue and deliver to
BladeRanger (or its designee(s)) 1,500,000 shares of the Company&#x2019;s common stock (the &#x201c;Company Shares&#x201d;) valuated at
$11,700,000 and 300,000 Pre-Funded Common Stock Purchase Warrants (the &#x201c;Initial PFWs&#x201d;) valued at $2,340,000. Further, the
Company has agreed that if the average daily volume-weighted average price (&#x201c;VWAP&#x201d;) of the Company&#x2019;s common stock for
the five Trading Day period immediately preceding the date of effectiveness of the registration statement registering the resale of the
Company Shares is less than $12.00 per share, Pre-Funded Common Stock Purchase Warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase
a number of additional shares of the Company&#x2019;s common stock (the &#x201c;Warrant Shares&#x201d;) equivalent to the difference between
$21,600,000 and the aggregate value of the Company Shares based on such VWAP, such that the aggregate consideration has a value of $21,600,000.
The Company has determined that the value of these contingent Warrant Shares was $0 at acquisition date and March 31, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluated this acquisition under ASC
805, Business Combinations. ASC 805 requires that an acquirer determine whether it has acquired a business. If the criteria of ASC 805
are met, a transaction would be accounted for as a business combination and the purchase price is allocated to the respective net assets
and liabilities assumed based on their fair values and a determination is made whether any goodwill results from the transaction. The
Company concluded that the acquired set of assets did not meet the US GAAP definition of a business as substantially all of the fair
value of the gross assets acquired are concentrated in a single identifiable asset or group of similar identifiable assets and consequently
accounted for the purchase as an asset acquisition. The Company allocated the total consideration transferred on the date of the acquisition
to the assets and liabilities acquired on a relative fair value basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the acquisition date fair value of the
assets acquired and the liabilities assumed:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfFairValueOfTheAssetsAcquiredAndTheLiabilitiesAssumedTableTextBlock_z6yPIYzOVzA6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Asset Acquisition (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zitJMR3QYsi4" style="display: none"&gt;Schedule
of fair value of the assets acquired and the liabilities assumed&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_498_20260331__us-gaap--RelatedPartyTransactionAxis__custom--AcquisitionFairValueMember_zdZ3LcvL5MAb" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amounts Recognized as of &#x200b;&#x200b;&#x200b;&#x200b;
Acquisition Date&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_zc5dIjzdQ7Rd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Total Consideration&lt;/td&gt;
&lt;td style="width: 10%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right"&gt;14,040,000&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--Cash_iI_zsZLe6l8T0yb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Cash&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;119,135&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_z5ahQzOgSb0b" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other Receivables&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;831&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_iI_zYtFYNR5V0X7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed Assets (a)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;8,387&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_iI_zockAbQgZTVa" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Intangible assets (b)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;14,029,591&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherPayables_iI_zNcCQb661ZF7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other Payables&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(17,582&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDueToRelatedParty_iI_ztsaRPobsFje" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Due to related party (c)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(100,362&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zRmspJ2c0F2l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net assets acquired&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;14,040,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(a) Fixed asset consists primarily of drones and
computer equipment acquired by the Company. The fair value of fixed assets was estimated to equal the replacement cost.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(b) Intangible assets consist of intellectual
property related drone technology and are recorded at estimated fair values based on the allocation of the total consideration transferred
on the date of the acquisition to the assets and liabilities acquired on a relative fair value basis. (See Note 10).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(c) Intercompany balance with VisionWave Holdings
Inc. eliminated in consolidation.&lt;/p&gt;

&lt;p id="xdx_8A4_zbiVJK8PEbQh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;QuantumSpeed&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 5, 2026, the Company entered into an
Asset Purchase Agreement with Adrian Holdings S.R.L. to acquire all right, title, and interest in specific intellectual property assets
related to QuantumSpeed technology. The acquired assets will be assigned to QuantumSpeed Inc., a wholly-owned subsidiary of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate consideration for the intellectual
property consists of a $&lt;span id="xdx_90A_ecustom--AggregatePromissoryNoteValue_iI_pn3n3_dm_c20260105_zacHX8lgv3Ai" title="Aggregate Promissory note value"&gt;10&lt;/span&gt; million promissory note (the &#x201c;Adrian Note&#x201d;) and up to 10,000,000 shares of the Company&#x2019;s
common stock. Upon closing, the Company issued &lt;span id="xdx_90A_eus-gaap--SharesIssued_iI_c20260105__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdrianNoteMember_zz6X9QzEnAlc" title="Shares issued"&gt;3,000,000&lt;/span&gt; shares of common stock valued at $&lt;span id="xdx_909_eus-gaap--CommonStockValue_iI_c20260105__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdrianNoteMember_zndDrThYYore" title="Common stock value"&gt;28,710,000&lt;/span&gt; and executed the $10 million Adrian
Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The issuance of the remaining &lt;span id="xdx_90A_ecustom--RemainingSharesIssued_iI_c20260105_zkIORDmINS9b" title="Remaining shares issued"&gt;7,000,000&lt;/span&gt; shares
with a fair value of $&lt;span id="xdx_907_ecustom--ContingentFairValue_iI_c20260105_zXPDoCQ02RXc" title="Contingent fair value"&gt;66,900,000&lt;/span&gt; is contingent upon receiving shareholder approval, as required by Nasdaq listing rules. The Company
is obligated to use commercially reasonable efforts to obtain this approval no later than nine months following the closing date. The
7,000,000 shares were accounted for as equity and included in shares to be issued in asset acquisition on the accompanying unaudited
condensed consolidated statements of changes in equity (deficit).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If shareholder approval is not obtained within
the nine-month period, the Company is required to transfer 60% of its equity interest in QuantumSpeed Inc. back to the seller, free and
clear of all encumbrances. In such an event, the seller&#x2019;s security interest in the equity would be released, and the seller would
retain full ownership of the initial &lt;span id="xdx_90E_eus-gaap--SharesIssued_iI_c20260105__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--QuantumSpeedMember_zSluj5VhiJnb" title="Shares issued"&gt;3,000,000&lt;/span&gt; closing shares and the $10 million promissory note. No alternative consideration will
be provided in lieu of the unissued contingent share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluated this acquisition under ASC
805, Business Combinations. ASC 805 requires that an acquirer determine whether it has acquired a business. If the criteria of ASC 805
are met, a transaction would be accounted for as a business combination and the purchase price is allocated to the respective net assets
and liabilities assumed based on their fair values and a determination is made whether any goodwill results from the transaction. The
Company concluded that the acquired asset did not meet the US GAAP definition of a business as substantially all of the fair value of
the gross assets acquired are concentrated in a single identifiable asset and consequently accounted for the purchase as an asset acquisition.
The Company allocated the total consideration transferred on the date of the acquisition to the single intellectual property acquired
on a relative fair value basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the acquisition date fair value of the
asset acquired:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_zYxgVnMnxzH7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Asset Acquisition (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;span id="xdx_8B0_zdwQ4ZKRvko6" style="display: none"&gt;Schedule of acquisition date fair value of the
asset &lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20251231__us-gaap--RelatedPartyTransactionAxis__custom--QuantumSpeedMember_zWqbY8HHbKB7" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amounts Recognized as of &#x200b;&#x200b;&#x200b;&#x200b;&#x200b;
Acquisition Date&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_zhRT7KazkyGl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Total Consideration&lt;/td&gt;
&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;105,700,000&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_ecustom--IntellectualPropertyQuantumspeed_iI_zDe8XEI9bVYh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Intellectual Property (QuantumSpeed)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;105,700,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zR8T6ykTn7yc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Asset acquired&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;105,700,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p id="xdx_8A4_zgyiI1jOVPFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:AssetAcquisitionTextBlock>
    <VWAV:AssetAcquisitionDescription contextRef="From2025-10-01to2026-03-31" id="Fact001867">On December 15, 2025, the Company entered into Amendment No. 1 to the Solar Drone Agreement
to provide that, in consideration for all of the issued and outstanding shares of Solar Drone, the Company shall issue and deliver to
BladeRanger (or its designee(s)) 1,500,000 shares of the Company&#x2019;s common stock (the &#x201c;Company Shares&#x201d;) valuated at
$11,700,000 and 300,000 Pre-Funded Common Stock Purchase Warrants (the &#x201c;Initial PFWs&#x201d;) valued at $2,340,000. Further, the
Company has agreed that if the average daily volume-weighted average price (&#x201c;VWAP&#x201d;) of the Company&#x2019;s common stock for
the five Trading Day period immediately preceding the date of effectiveness of the registration statement registering the resale of the
Company Shares is less than $12.00 per share, Pre-Funded Common Stock Purchase Warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase
a number of additional shares of the Company&#x2019;s common stock (the &#x201c;Warrant Shares&#x201d;) equivalent to the difference between
$21,600,000 and the aggregate value of the Company Shares based on such VWAP, such that the aggregate consideration has a value of $21,600,000.
The Company has determined that the value of these contingent Warrant Shares was $0 at acquisition date and March 31, 2026.</VWAV:AssetAcquisitionDescription>
    <VWAV:ScheduleOfFairValueOfTheAssetsAcquiredAndTheLiabilitiesAssumedTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001871">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfFairValueOfTheAssetsAcquiredAndTheLiabilitiesAssumedTableTextBlock_z6yPIYzOVzA6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Asset Acquisition (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zitJMR3QYsi4" style="display: none"&gt;Schedule
of fair value of the assets acquired and the liabilities assumed&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_498_20260331__us-gaap--RelatedPartyTransactionAxis__custom--AcquisitionFairValueMember_zdZ3LcvL5MAb" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amounts Recognized as of &#x200b;&#x200b;&#x200b;&#x200b;
Acquisition Date&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_zc5dIjzdQ7Rd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Total Consideration&lt;/td&gt;
&lt;td style="width: 10%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right"&gt;14,040,000&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--Cash_iI_zsZLe6l8T0yb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Cash&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;119,135&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_z5ahQzOgSb0b" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other Receivables&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;831&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_iI_zYtFYNR5V0X7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed Assets (a)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;8,387&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_iI_zockAbQgZTVa" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Intangible assets (b)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;14,029,591&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherPayables_iI_zNcCQb661ZF7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other Payables&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(17,582&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDueToRelatedParty_iI_ztsaRPobsFje" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Due to related party (c)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(100,362&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zRmspJ2c0F2l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net assets acquired&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;14,040,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(a) Fixed asset consists primarily of drones and
computer equipment acquired by the Company. The fair value of fixed assets was estimated to equal the replacement cost.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(b) Intangible assets consist of intellectual
property related drone technology and are recorded at estimated fair values based on the allocation of the total consideration transferred
on the date of the acquisition to the assets and liabilities acquired on a relative fair value basis. (See Note 10).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(c) Intercompany balance with VisionWave Holdings
Inc. eliminated in consolidation.&lt;/p&gt;

</VWAV:ScheduleOfFairValueOfTheAssetsAcquiredAndTheLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="AsOf2026-03-31_custom_AcquisitionFairValueMember"
      decimals="0"
      id="Fact001873"
      unitRef="USD">14040000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:Cash
      contextRef="AsOf2026-03-31_custom_AcquisitionFairValueMember"
      decimals="0"
      id="Fact001875"
      unitRef="USD">119135</us-gaap:Cash>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="AsOf2026-03-31_custom_AcquisitionFairValueMember"
      decimals="0"
      id="Fact001877"
      unitRef="USD">831</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <VWAV:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets
      contextRef="AsOf2026-03-31_custom_AcquisitionFairValueMember"
      decimals="0"
      id="Fact001879"
      unitRef="USD">8387</VWAV:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets>
    <VWAV:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets
      contextRef="AsOf2026-03-31_custom_AcquisitionFairValueMember"
      decimals="0"
      id="Fact001881"
      unitRef="USD">14029591</VWAV:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets>
    <VWAV:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherPayables
      contextRef="AsOf2026-03-31_custom_AcquisitionFairValueMember"
      decimals="0"
      id="Fact001883"
      unitRef="USD">-17582</VWAV:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherPayables>
    <VWAV:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDueToRelatedParty
      contextRef="AsOf2026-03-31_custom_AcquisitionFairValueMember"
      decimals="0"
      id="Fact001885"
      unitRef="USD">-100362</VWAV:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDueToRelatedParty>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="AsOf2026-03-31_custom_AcquisitionFairValueMember"
      decimals="0"
      id="Fact001887"
      unitRef="USD">14040000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <VWAV:AggregatePromissoryNoteValue
      contextRef="AsOf2026-01-05"
      decimals="-3"
      id="Fact001889"
      unitRef="USD">10000000</VWAV:AggregatePromissoryNoteValue>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-01-05_custom_AdrianNoteMember"
      decimals="INF"
      id="Fact001891"
      unitRef="Shares">3000000</us-gaap:SharesIssued>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-01-05_custom_AdrianNoteMember"
      decimals="0"
      id="Fact001893"
      unitRef="USD">28710000</us-gaap:CommonStockValue>
    <VWAV:RemainingSharesIssued
      contextRef="AsOf2026-01-05"
      decimals="INF"
      id="Fact001895"
      unitRef="Shares">7000000</VWAV:RemainingSharesIssued>
    <VWAV:ContingentFairValue
      contextRef="AsOf2026-01-05"
      decimals="0"
      id="Fact001897"
      unitRef="USD">66900000</VWAV:ContingentFairValue>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-01-05_custom_QuantumSpeedMember"
      decimals="INF"
      id="Fact001899"
      unitRef="Shares">3000000</us-gaap:SharesIssued>
    <us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001902">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_zYxgVnMnxzH7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Asset Acquisition (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;span id="xdx_8B0_zdwQ4ZKRvko6" style="display: none"&gt;Schedule of acquisition date fair value of the
asset &lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20251231__us-gaap--RelatedPartyTransactionAxis__custom--QuantumSpeedMember_zWqbY8HHbKB7" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amounts Recognized as of &#x200b;&#x200b;&#x200b;&#x200b;&#x200b;
Acquisition Date&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_zhRT7KazkyGl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Total Consideration&lt;/td&gt;
&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;105,700,000&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_ecustom--IntellectualPropertyQuantumspeed_iI_zDe8XEI9bVYh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Intellectual Property (QuantumSpeed)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;105,700,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zR8T6ykTn7yc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Asset acquired&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;105,700,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="AsOf2025-12-31_custom_QuantumSpeedMember"
      decimals="0"
      id="Fact001904"
      unitRef="USD">105700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <VWAV:IntellectualPropertyQuantumspeed
      contextRef="AsOf2025-12-31_custom_QuantumSpeedMember"
      decimals="0"
      id="Fact001906"
      unitRef="USD">105700000</VWAV:IntellectualPropertyQuantumspeed>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="AsOf2025-12-31_custom_QuantumSpeedMember"
      decimals="0"
      id="Fact001908"
      unitRef="USD">105700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001910">&lt;p id="xdx_80A_eus-gaap--IntangibleAssetsDisclosureTextBlock_z7iQLQ814RK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 10 &#x2014; &lt;span id="xdx_82E_zwN4Jzv9mYtg"&gt;Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As noted in Notes 9, on December 15, 2025 and
January 5, 2026, the Company acquired intellectual property from the acquisition of Solar Drone and QuantumSpeed, respectively. Solar
Drone is a drone-based industrial technology platform providing automated cleaning and inspection solutions for utility-scale solar installations
and high-voltage electrical infrastructure. The core asset is a proprietary, field-proven drone system that replaces manual, ground-based,
and helicopter-based maintenance with autonomous drone operations, improving energy output, safety, and operational reliability while
reducing costs and downtime.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;QuantumSpeed is currently in a proof-of-concept
and system architecture phase, where core mathematical, algorithmic, and architectural principles have been defined and validated at
a prototype level.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At acquisition dates, the fair value of Solar
Drone intellectual property was $&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--SolarDroneMember_zKbQuAs56pR9" title="Intangible assets"&gt;14,029,591&lt;/span&gt; and the fair value of QuantumSpeed intellectual property was $&lt;span id="xdx_907_ecustom--FairValueOfQuantumspeedIntellectualProperty_iI_c20260331_z5eRIxq7zR16" title="fair value of QuantumSpeed intellectual property"&gt;105,700,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zS7xKPm50Dyh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure -  Intangible Assets (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_zWU6cI9er6X9" style="display: none"&gt;Schedule of fair value of intellectual property&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Estimated Useful Life (years)&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Intellectual property&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260331_z8EMThc27Gv" title="Estimated Useful Life (years), Intellectual property"&gt;5&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20260331_zjgfjEnwofhd" style="width: 11%; text-align: right" title="Intellectual property"&gt;119,729,591&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20250930_zMVMxkjXOIn3" style="width: 11%; text-align: right" title="Intellectual property"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1922"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Accumulated amortization&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20260331_zgidzcGODHi" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization"&gt;(5,813,804&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20250930_zEA1JfZPZyJ4" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right" title="Accumulated amortization"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1926"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Net book value&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20260331_zaNts1HXQZ3a" style="border-bottom: Black 2.5pt double; text-align: right" title="Net book value"&gt;113,915,787&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20250930_zKAV7TphKLki" style="border-bottom: Black 2.5pt double; text-align: right" title="Net book value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1930"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AE_z8pEZQiwLbK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Amortization of the intangible asset during the
three and six months ended March 31, 2026 was $&lt;span id="xdx_908_eus-gaap--AmortizationOfIntangibleAssets_c20260101__20260331_zPyrvnLLm244" title="Amortization of the intangible asset"&gt;5,696,891&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20251001__20260331_zqBLh7JTp2m1" title="Amortization of the intangible asset"&gt;5,813,804&lt;/span&gt;, respectively, and there were no amortization during the three
and six months ended March 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The future amortization of the intangible asset is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;span id="xdx_8B7_zsXDFzXmN7Af" style="display: none"&gt;Schedule of future amortization of the intangible
    asset&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20260331_zdh1QVx3mrEh" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: left"&gt;Fiscal Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zShgjTOpl8if" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 52%; text-align: left; text-indent: -10pt"&gt;Remainder of 2026&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 35%; text-align: right"&gt;11,972,959&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_z9Sbrmox9xi3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2027&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,945,918&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zc9dgIk7OOY3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,945,918&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zhZmO1RT91U7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,945,918&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zxIkxeldA5Yd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,945,918&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zES6bsveGSle" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,159,156&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zQenXnOCYRr8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total unamortized intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;113,915,787&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zSket6SMVbM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2026-03-31_custom_SolarDroneMember"
      decimals="0"
      id="Fact001912"
      unitRef="USD">14029591</us-gaap:FiniteLivedIntangibleAssetsGross>
    <VWAV:FairValueOfQuantumspeedIntellectualProperty
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001914"
      unitRef="USD">105700000</VWAV:FairValueOfQuantumspeedIntellectualProperty>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001916">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zS7xKPm50Dyh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure -  Intangible Assets (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_zWU6cI9er6X9" style="display: none"&gt;Schedule of fair value of intellectual property&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Estimated Useful Life (years)&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Intellectual property&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260331_z8EMThc27Gv" title="Estimated Useful Life (years), Intellectual property"&gt;5&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20260331_zjgfjEnwofhd" style="width: 11%; text-align: right" title="Intellectual property"&gt;119,729,591&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20250930_zMVMxkjXOIn3" style="width: 11%; text-align: right" title="Intellectual property"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1922"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Accumulated amortization&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20260331_zgidzcGODHi" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization"&gt;(5,813,804&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20250930_zEA1JfZPZyJ4" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right" title="Accumulated amortization"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1926"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Net book value&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20260331_zaNts1HXQZ3a" style="border-bottom: Black 2.5pt double; text-align: right" title="Net book value"&gt;113,915,787&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20250930_zKAV7TphKLki" style="border-bottom: Black 2.5pt double; text-align: right" title="Net book value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1930"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="AsOf2026-03-31" id="Fact001918">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001920"
      unitRef="USD">119729591</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001924"
      unitRef="USD">-5813804</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001928"
      unitRef="USD">113915787</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact001932"
      unitRef="USD">5696891</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001934"
      unitRef="USD">5813804</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001936"
      unitRef="USD">11972959</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001938"
      unitRef="USD">23945918</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001940"
      unitRef="USD">23945918</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001942"
      unitRef="USD">23945918</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001944"
      unitRef="USD">23945918</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001946"
      unitRef="USD">6159156</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001948"
      unitRef="USD">113915787</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001952">&lt;p id="xdx_802_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z90LlAzxzJAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 11 &#x2014; &lt;span id="xdx_826_zJtUSdKudz54"&gt;Accounts Payable and Accrued Expenses&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Accounts payable and accrued liabilities consist of the following as
of March 31, 2026 and September 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zDioRhZCBRe4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Payable and Accrued Expenses (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BB_z2bdJgglNuBe" style="display: none"&gt;Schedule of Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_497_20260331_zFdfWQs2oebc" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49C_20250930_z0TCt1Gf71Q5" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--UnderwritersMarketingFee_iI_ztaO2RHrekC6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Underwriter&#x2019;s marketing fee (See Note
17)&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;1,800,000&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;1,800,000&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--AccountsPayableCurrent_iI_zNeQJDuR5UMe" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Vendors payable&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,353,790&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;939,192&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_zBWal7YIbGg4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued compensation expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;187,001&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;359,667&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--FranchiseTaxPayable_iI_zTZy0a96M0pd" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Franchise tax payable&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;367,323&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;267,323&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--InsurancePremiumFinancing_iI_zy0xjjfSZe7b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Insurance premium financing&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;17,957&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;71,851&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_iI_z5oAwmI3ePa" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued interest expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;545,713&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;49,914&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--AccountsPayableOtherCurrent_iI_zQKpsqYjZgi3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Other payables and accrued expenses&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13,133&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;429,887&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_zVBXXaRpaMG7" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,284,917&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,917,834&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001954">&lt;table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zDioRhZCBRe4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Payable and Accrued Expenses (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BB_z2bdJgglNuBe" style="display: none"&gt;Schedule of Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_497_20260331_zFdfWQs2oebc" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49C_20250930_z0TCt1Gf71Q5" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--UnderwritersMarketingFee_iI_ztaO2RHrekC6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Underwriter&#x2019;s marketing fee (See Note
17)&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;1,800,000&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;1,800,000&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--AccountsPayableCurrent_iI_zNeQJDuR5UMe" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Vendors payable&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,353,790&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;939,192&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_zBWal7YIbGg4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued compensation expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;187,001&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;359,667&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--FranchiseTaxPayable_iI_zTZy0a96M0pd" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Franchise tax payable&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;367,323&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;267,323&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--InsurancePremiumFinancing_iI_zy0xjjfSZe7b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Insurance premium financing&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;17,957&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;71,851&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_iI_z5oAwmI3ePa" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued interest expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;545,713&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;49,914&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--AccountsPayableOtherCurrent_iI_zQKpsqYjZgi3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Other payables and accrued expenses&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13,133&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;429,887&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_zVBXXaRpaMG7" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,284,917&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,917,834&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <VWAV:UnderwritersMarketingFee
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001956"
      unitRef="USD">1800000</VWAV:UnderwritersMarketingFee>
    <VWAV:UnderwritersMarketingFee
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001957"
      unitRef="USD">1800000</VWAV:UnderwritersMarketingFee>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001959"
      unitRef="USD">1353790</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001960"
      unitRef="USD">939192</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001962"
      unitRef="USD">187001</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001963"
      unitRef="USD">359667</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <VWAV:FranchiseTaxPayable
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001965"
      unitRef="USD">367323</VWAV:FranchiseTaxPayable>
    <VWAV:FranchiseTaxPayable
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001966"
      unitRef="USD">267323</VWAV:FranchiseTaxPayable>
    <VWAV:InsurancePremiumFinancing
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001968"
      unitRef="USD">17957</VWAV:InsurancePremiumFinancing>
    <VWAV:InsurancePremiumFinancing
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001969"
      unitRef="USD">71851</VWAV:InsurancePremiumFinancing>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001971"
      unitRef="USD">545713</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001972"
      unitRef="USD">49914</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001974"
      unitRef="USD">13133</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001975"
      unitRef="USD">429887</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001977"
      unitRef="USD">4284917</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001978"
      unitRef="USD">3917834</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <VWAV:ExciseTaxPayableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact001980">&lt;p id="xdx_80E_ecustom--ExciseTaxPayableTextBlock_zzZSi9HDWEna" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 12 &#x2014; &lt;span id="xdx_828_zUNNPoNhhf9j"&gt;Excise Tax Payable&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 16, 2022, the Inflation Reduction Act
of 2022 (the &#x201c;IR Act&#x201d;) was signed into federal law. The IR Act provides for, among other things, a 1% federal excise tax
on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded
foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its
shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased
at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the
fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In
addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#x201c;Treasury&#x201d;) has been given
authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 27, 2022, the Treasury published Notice
2023-2, which provided clarification on some aspects of the application of the excise tax. The notice generally provides that if a publicly
traded U.S. corporation completely liquidates and dissolves, distributions in such complete liquidation and other distributions by such
corporation in the same taxable year in which the final distribution in complete liquidation and dissolution is made are not subject
to the excise tax. Although such notice clarifies certain aspects of the excise tax, the interpretation and operation of aspects of the
excise tax (including its application and operation with respect to SPACs) remain unclear and such interim operating rules are subject
to change.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Because the application of this excise tax is
not entirely clear, any redemption or other repurchase effected by the Company, in connection with a Business Combination, extension
vote or otherwise, may be subject to this excise tax. Because any such excise tax would be payable by the Company and not by the redeeming
holders, it could cause a reduction in the value of the Company&#x2019;s Class A common stock, cash available with which to effectuate
a Business Combination or cash available for distribution in a subsequent liquidation. Whether and to what extent the Company would be
subject to the excise tax in connection with a Business Combination&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Any redemption or other repurchase that occurs
after December 31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether
and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise
would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business
Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any PIPE or other equity
issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination, but issued within
the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury. In addition,
because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment of the
excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business Combination
and in the Company&#x2019;s ability to complete a Business Combination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the second quarter of 2024, the Internal
Revenue Service issued final regulations with respect to the timing and payment of the excise tax. These regulations provided that the
filing and payment deadline for any liability incurred during the period from January 1, 2023 to December 31, 2023 would be October 31,
2024. Any amount of such excise tax not paid in full, will be subject to additional interest and penalties which are currently estimated
at 8% interest per annum, a 0.5% underpayment penalty per month or portion of a month up to 25% of the total liability for any amount
that is unpaid from November 1, 2024 until paid in full, and a failure to file penalty of 5% per month.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prior to the consummation of the Reverse Acquisition,
Bannix&#x2019;s common stockholders exercised their right to redeem their shares for a pro rata portion of the funds in Bannix&#x2019;s
Trust Account. As a result of these redemptions, Bannix estimated the excise tax liability and applicable interest and penalties pursuant
to the IR Act. At the consummation of the Reverse Acquisition, $&lt;span id="xdx_90F_eus-gaap--ExciseAndSalesTaxes_c20251001__20260331_zwCtc0TqHrYl" title="Excise tax interest and penalties"&gt;888,332&lt;/span&gt; of excise tax liability, inclusive of excise tax interest and
penalties, is assumed. For the three months ended March 31, 2026 and 2025, $&lt;span id="xdx_909_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--BannixCommonStockMember_zZi34vvfoDQ4" title="Interest of penalties"&gt;26,207&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_c20250331__us-gaap--RelatedPartyTransactionAxis__custom--BannixCommonStockMember_z7JSJiQzN6Eb" title="Interest of penalties"&gt;0&lt;/span&gt;, respectively of interest and penalties is
estimated on the excise tax balance and included in general and administrative expenses on the unaudited condensed consolidated statements
of operations. For the six months ended March 31, 2026 and 2025, $&lt;span id="xdx_908_eus-gaap--GeneralAndAdministrativeExpense_c20251001__20260331__us-gaap--RelatedPartyTransactionAxis__custom--BannixMember_zzF4etfnT1m6" title="General and administrative expenses"&gt;59,821&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--GeneralAndAdministrativeExpense_c20241001__20250331__us-gaap--RelatedPartyTransactionAxis__custom--BannixMember_z5CcDVxsWlNj" title="General and administrative expenses"&gt;0&lt;/span&gt;, respectively, of interest and penalties is estimated
on the excise tax balance and included in general and administrative expenses on the unaudited condensed consolidated statements of operations.
As of March 31, 2026 and September 30, 2025, $&lt;span id="xdx_90B_ecustom--ExciseTaxLiabilitiesInterestAndPenalties_iI_c20260331_zK3QntQJcKWd" title="Excise tax liabilities  interest and penalties"&gt;1,002,860&lt;/span&gt; and $&lt;span id="xdx_90E_ecustom--ExciseTaxLiabilitiesInterestAndPenalties_iI_c20250930_z7rZM1cKAwT3" title="Excise tax liabilities  interest and penalties"&gt;943,039&lt;/span&gt; of excise tax liabilities, respectively, inclusive of interest and
penalties is recorded in the unaudited condensed consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







</VWAV:ExciseTaxPayableTextBlock>
    <us-gaap:ExciseAndSalesTaxes
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact001984"
      unitRef="USD">888332</us-gaap:ExciseAndSalesTaxes>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="AsOf2026-03-31_custom_BannixCommonStockMember"
      decimals="0"
      id="Fact001986"
      unitRef="USD">26207</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="AsOf2025-03-31_custom_BannixCommonStockMember"
      decimals="0"
      id="Fact001988"
      unitRef="USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-10-012026-03-31_custom_BannixMember"
      decimals="0"
      id="Fact001990"
      unitRef="USD">59821</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-10-012025-03-31_custom_BannixMember"
      decimals="0"
      id="Fact001992"
      unitRef="USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <VWAV:ExciseTaxLiabilitiesInterestAndPenalties
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact001994"
      unitRef="USD">1002860</VWAV:ExciseTaxLiabilitiesInterestAndPenalties>
    <VWAV:ExciseTaxLiabilitiesInterestAndPenalties
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001996"
      unitRef="USD">943039</VWAV:ExciseTaxLiabilitiesInterestAndPenalties>
    <VWAV:PromissoryNoteTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002000">&lt;p id="xdx_804_ecustom--PromissoryNoteTextBlock_zyBcqVfiMCHe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 13 &#x2014; &lt;span id="xdx_828_zskKeVUjW3Wb"&gt;Promissory Notes&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Evie Autonomous &lt;i&gt;LTD &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prior to the consummation of the Reverse Acquisition,
Bannix issued unsecured promissory notes to Evie Autonomous LTD (&#x201c;Evie&#x201d;) with a principal amount of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20260331_zAuyTRw1sfLh" title="Principal amount"&gt;1,003,995&lt;/span&gt; (the &#x201c;Evie
Autonomous Extension Notes&#x201d;). The Evie Autonomous Extension Notes bear no interest and are repayable in full upon the earlier of
(a) the date of the consummation of Bannix&#x2019;s initial Business Combination, or (b) the date of Bannix&#x2019;s liquidation. On December
26, 2024 and amended on May 27, 2025, Bannix entered into an agreement to defer payment of the Evie Autonomous Extension Notes. Under
the deferment agreement, these amounts will not become payable until any Pre-Paid Advance issued in connection with the SEPA is repaid
in full (See Note 19). The balance of $&lt;span id="xdx_904_eus-gaap--IncreaseDecreaseInPrepaidAdvertising_c20251001__20260331_zfNUf7qScHL6" title="Balance of reverse"&gt;1,003,995&lt;/span&gt; was assumed at the close of the Reverse Acquisition. As of March 31, 2026 and September
30, 2025, the balance of $&lt;span id="xdx_905_ecustom--PromissoryNoteBalance_iI_c20260331_zsrItWRsrPgf" title="Promissory note balance"&gt;1,003,995&lt;/span&gt;, owing to Evie is reported as promissory notes &#x2013; Evie on the accompanying unaudited condensed
consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;YA II PN&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_905_ecustom--LetterAgreementDescription_c20260225__20260226_zEpzBvX4l9Q4" title="Letter Agreement description"&gt;On February 26, 2026, VisionWave Holdings Inc.
(the &#x201c;Company&#x201d;) entered into a Letter Agreement (the &#x201c;Letter Agreement&#x201d;) with YA II PN, Ltd. (the &#x201c;Investor&#x201d;),
pursuant to which the Investor agreed to provide the Company with a $20,000,000 senior loan (the &#x201c;Loan&#x201d;) on the terms and
conditions set forth therein. The Loan is evidenced by a Promissory Note (the &#x201c;YA II PN Note&#x201d;) in the original principal
amount of $20,000,000, bearing 0% interest per annum (increasing to 18% upon an Event of Default as defined therein). The Note was issued
at an original issue discount of 15%, resulting in gross proceeds to the Company of $17,000,000 (prior to deduction of a $25,000 structuring
and due diligence fee), or $16,975,000 net cash received.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The YA II PN Note matures 12 months from issuance
and requires monthly amortization payments of $&lt;span id="xdx_902_eus-gaap--AmortizationOfDeferredLoanOriginationFeesNet_c20251001__20260331_z3wLUVul1HI5" title="Amortization payments"&gt;2,500,000&lt;/span&gt; of principal (plus a 2% Payment Premium on such principal amount) beginning
on the 60th day following issuance and continuing on the same day of each successive month thereafter until maturity (each an &#x201c;Installment
Date&#x201d;). The Company may satisfy any Installment Amount in cash or, at its election, by delivering an Advance Notice under the Company&#x2019;s
existing Standby Equity Purchase Agreement dated July 25, 2025, as amended (the &#x201c;SEPA&#x201d;), subject to a 30-day repayment waterfall
in favor of the Investor.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has the right to optionally redeem
all or any portion of the outstanding principal at any time at 105% of the principal amount redeemed plus accrued and unpaid interest.
Upon an uncured Event of Default, the Investor may convert all or any portion of the outstanding principal, accrued interest, and other
amounts due into Common Stock at a conversion price equal to 90% of the lowest daily VWAP during the 10 consecutive Trading Days immediately
prior to the conversion date, subject to a 4.99% beneficial ownership blocker, and a floor price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Concurrently with the issuance of the YA II PN
Note, the Company issued to the Investor a warrant (the &#x201c;Warrant&#x201d;) to purchase &lt;span id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_c20251001__20260630_zVcvaj1ExDoc" title="Shares issued"&gt;1,333,333&lt;/span&gt; shares of Common Stock at an exercise
price of $&lt;span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember_zC2CXVhkO7fa" title="Exercise price per share"&gt;9.00&lt;/span&gt; per share, exercisable for a term of five years from issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The obligations under the Note are guaranteed
by each subsidiary of the Company pursuant to a Global Guaranty Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Letter Agreement contains customary representations,
warranties, covenants (including restrictions on variable rate transactions, additional indebtedness without consent, and use of proceeds),
and events of default. The Company is not required to register the shares issuable upon conversion of the Note but has agreed to register
the shares issuable upon exercise of the Warrant. The Investor has demand registration rights covering all shares of common stock underlying
the Note. Upon written demand, the Company must file a resale registration statement within 45 calendar days, use commercially reasonable
efforts to cause it to become effective promptly, and address any Rule 415 limitations through pro-rata reductions and successive filings
as necessary. In addition, the Company shall, at its sole cost and expense, file with the SEC on or before the date that is 90 calendar
days after the closing date file a registration statement on Form S-1 registering the resale of all of the shares of common stock issuable
upon exercise of the Warrant (the &#x201c;Warrant Registration Statement&#x201d;). The Company shall use its commercially reasonable efforts
to cause the Warrant Registration Statement to be declared effective as soon as practicable after the filing thereof. The registration
statement was filed on April 16, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Total debt issuance cost of $&lt;span id="xdx_90B_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20251001__20260331_zVJebfFJ7yu8"&gt;10,411,665&lt;/span&gt; includes
the $3,000,000 OID, $&lt;span id="xdx_905_eus-gaap--LegalFees_c20251001__20260331_zRWCrHvsBhX8"&gt;25,000&lt;/span&gt; legal fees and $&lt;span id="xdx_908_ecustom--Warrants_iI_c20260331_zlPqUpEGa0Yi" title="Warrants"&gt;6,986,665&lt;/span&gt; warrants value at issuance date and $400,000 payment premium. Debt issuance cost
is amortized over the term of the Note using the effective interest rate method. During the three months ended March 31, 2026, $&lt;span id="xdx_90E_ecustom--RepaidOnYaIiPnNote_c20260101__20260331_zwNm82pYfoei" title="Repaid On YaIi Pn Note"&gt;780,461&lt;/span&gt;
was repaid on the &#160;YA II PN Note. For the three months and six months ended March 31, 2026, total amortized debt issuance cost of
$&lt;span id="xdx_90D_eus-gaap--PaymentsOfDebtIssuanceCosts_c20251001__20260331_zQpTPldCqF8g"&gt;1,727,334&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--PaymentsOfDebtIssuanceCosts_c20241001__20250331_zPlbZWVzbY2l"&gt;1,727,334&lt;/span&gt; was included in interest expense on the accompanying unaudited condensed consolidated statements of operations.
At March 31, 2026 and September 30, 2025, the balance of the YA II PN Notes of $10,935,208 and $0, respectively, recorded in promissory
notes - YA II PN on the accompanying unaudited condensed consolidated balance sheets, includes $8,684,331 and $0, respectively of unamortized
debt issuance cost.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Adrian Note&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As stated in Note 9, on January 5, 2026, the Company
issued a $10 million promissory note pursuant to the Adrian Asset Purchase Agreement (the &#x201c;Adrian Note&#x201d;). The loan accrues
interest at a rate of 12% per annum with a 1% reduction in the interest rate for every $1,000,000 of payment. The loan matures on January
5, 2027. For the three and six months ended March 31, 2026 and 2025, interest expense of $&lt;span id="xdx_904_eus-gaap--InterestExpense_c20251001__20260331__us-gaap--RelatedPartyTransactionAxis__custom--AdrianNoteMember_zTqMCBZszXHf" title="Interest expense"&gt;279,452 &lt;/span&gt;on the Adrian Note is included in interest
expense on the accompanying unaudited condensed consolidated statements of operations. At March 31, 2026, the balance of the Adrian Note
of $&lt;span id="xdx_90A_eus-gaap--LoansPayable_iI_c20260331_zsuz7uWzXHZf" title="Loan payable"&gt;10,000,000&lt;/span&gt; is included in loan payable on the accompanying unaudited condensed consolidated balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</VWAV:PromissoryNoteTextBlock>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002002"
      unitRef="USD">1003995</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:IncreaseDecreaseInPrepaidAdvertising
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002004"
      unitRef="USD">1003995</us-gaap:IncreaseDecreaseInPrepaidAdvertising>
    <VWAV:PromissoryNoteBalance
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002006"
      unitRef="USD">1003995</VWAV:PromissoryNoteBalance>
    <VWAV:LetterAgreementDescription contextRef="From2026-02-252026-02-26" id="Fact002008">On February 26, 2026, VisionWave Holdings Inc.
(the &#x201c;Company&#x201d;) entered into a Letter Agreement (the &#x201c;Letter Agreement&#x201d;) with YA II PN, Ltd. (the &#x201c;Investor&#x201d;),
pursuant to which the Investor agreed to provide the Company with a $20,000,000 senior loan (the &#x201c;Loan&#x201d;) on the terms and
conditions set forth therein. The Loan is evidenced by a Promissory Note (the &#x201c;YA II PN Note&#x201d;) in the original principal
amount of $20,000,000, bearing 0% interest per annum (increasing to 18% upon an Event of Default as defined therein). The Note was issued
at an original issue discount of 15%, resulting in gross proceeds to the Company of $17,000,000 (prior to deduction of a $25,000 structuring
and due diligence fee), or $16,975,000 net cash received.</VWAV:LetterAgreementDescription>
    <us-gaap:AmortizationOfDeferredLoanOriginationFeesNet
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002010"
      unitRef="USD">2500000</us-gaap:AmortizationOfDeferredLoanOriginationFeesNet>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2025-10-012026-06-30"
      decimals="INF"
      id="Fact002012"
      unitRef="Shares">1333333</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002014"
      unitRef="USDPShares">9.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002017"
      unitRef="USD">10411665</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:LegalFees
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002018"
      unitRef="USD">25000</us-gaap:LegalFees>
    <VWAV:Warrants
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002020"
      unitRef="USD">6986665</VWAV:Warrants>
    <VWAV:RepaidOnYaIiPnNote
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact002022"
      unitRef="USD">780461</VWAV:RepaidOnYaIiPnNote>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002023"
      unitRef="USD">1727334</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact002024"
      unitRef="USD">1727334</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:InterestExpense
      contextRef="From2025-10-012026-03-31_custom_AdrianNoteMember"
      decimals="0"
      id="Fact002026"
      unitRef="USD">279452</us-gaap:InterestExpense>
    <us-gaap:LoansPayable
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002028"
      unitRef="USD">10000000</us-gaap:LoansPayable>
    <VWAV:WarrantsTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002030">&lt;p id="xdx_80E_ecustom--WarrantsTextBlock_zqSKVYxXj7tl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 14 &#x2014; &lt;span id="xdx_828_zokaXN4rpm9g"&gt;Warrants &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As stated in Note 13, concurrently with the issuance
of the YA II PN Note, the Company issued to the Investor the Warrant to purchase &lt;span id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_c20251001__20260630_zjMgFPPA12C1" title="Shares issued"&gt;1,333,333&lt;/span&gt; shares of Common Stock at an exercise price
of $9.00 per share, exercisable for a term of five years from issuance. The Company accounted for the Warrant in accordance with the
guidance contained in ASC 815 whereby under that provision these warrants met the criteria for equity treatment. As such, these warrants
are recorded at fair value at issuance date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company utilized a Monte Carlo Simulation
model to estimate the fair values of the February 26, 2026 of the Warrants, which incorporated significant inputs that were not observable
in the market, and thus represents a Level 3 measurement as defined in ASC 820. The unobservable inputs utilized for measuring the fair
value of the contingent consideration reflect management&#x2019;s own assumptions about the assumptions that market participants would
use in valuing the contingent consideration. The Company determined the fair value by using the below key inputs to the Monte Carlo Simulation
Model.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_zp3OktSnmNma" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details )"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_zN09EuQTCQN1" style="display: none"&gt;Schedule of fair value of key inputs to the Monte Carlo
Simulation Model&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;February 26, 2026&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Stock Price&lt;/td&gt;
&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--SharePrice_iI_c20260226_zp7Qmt79Y7Vc" style="width: 18%; text-align: right" title="Stock Price"&gt;7.96&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Exercise Price&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260226_z2G0mVbb2fS6" style="text-align: right" title="Exercise Price"&gt;9.00&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LongDurationContractsAssumptionsByProductAndGuaranteeVolatilityRate_iI_dp_c20260226_zs65UCfGKBT2" title="Volatility"&gt;73.0&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk free rate of return&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--RiskFreeRateOfReturn_iI_c20260226_zY8Q0UdCFLFd" title="Risk free rate of return"&gt;3.54&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Term to maturity (years)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentTerm_dtY_c20260225__20260226_zItjA4esXNG" title="Term to maturity (Years)"&gt;5.00&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Term to financing (years)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--TermToFinancingYears_dtY_c20260225__20260226_zRVCTYZOjOB7" title="Term to financing (years)"&gt;2.50&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p id="xdx_8A8_zS2jquWRppne" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of the Warrants on February 26,
2026 of $&lt;span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_c20260225__20260226_znj0aDEyWdbl" title="Fair value of Warrants"&gt;6,986,665&lt;/span&gt;, was included as debt issuance cost related to the YA II PN Notes (See Note 13).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







</VWAV:WarrantsTextBlock>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2025-10-012026-06-30"
      decimals="INF"
      id="Fact002032"
      unitRef="Shares">1333333</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002034">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_zp3OktSnmNma" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details )"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_zN09EuQTCQN1" style="display: none"&gt;Schedule of fair value of key inputs to the Monte Carlo
Simulation Model&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;February 26, 2026&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Stock Price&lt;/td&gt;
&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--SharePrice_iI_c20260226_zp7Qmt79Y7Vc" style="width: 18%; text-align: right" title="Stock Price"&gt;7.96&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Exercise Price&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260226_z2G0mVbb2fS6" style="text-align: right" title="Exercise Price"&gt;9.00&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LongDurationContractsAssumptionsByProductAndGuaranteeVolatilityRate_iI_dp_c20260226_zs65UCfGKBT2" title="Volatility"&gt;73.0&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk free rate of return&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--RiskFreeRateOfReturn_iI_c20260226_zY8Q0UdCFLFd" title="Risk free rate of return"&gt;3.54&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Term to maturity (years)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentTerm_dtY_c20260225__20260226_zItjA4esXNG" title="Term to maturity (Years)"&gt;5.00&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Term to financing (years)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--TermToFinancingYears_dtY_c20260225__20260226_zRVCTYZOjOB7" title="Term to financing (years)"&gt;2.50&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2026-02-26"
      decimals="INF"
      id="Fact002036"
      unitRef="USDPShares">7.96</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2026-02-26"
      decimals="INF"
      id="Fact002038"
      unitRef="USDPShares">9.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:LongDurationContractsAssumptionsByProductAndGuaranteeVolatilityRate
      contextRef="AsOf2026-02-26"
      decimals="INF"
      id="Fact002040"
      unitRef="Ratio">0.730</us-gaap:LongDurationContractsAssumptionsByProductAndGuaranteeVolatilityRate>
    <VWAV:RiskFreeRateOfReturn
      contextRef="AsOf2026-02-26"
      decimals="INF"
      id="Fact002042"
      unitRef="Ratio">3.54</VWAV:RiskFreeRateOfReturn>
    <us-gaap:DebtInstrumentTerm contextRef="From2026-02-252026-02-26" id="Fact002044">P5Y</us-gaap:DebtInstrumentTerm>
    <VWAV:TermToFinancingYears contextRef="From2026-02-252026-02-26" id="Fact002046">P2Y6M</VWAV:TermToFinancingYears>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2026-02-252026-02-26"
      decimals="0"
      id="Fact002048"
      unitRef="USD">6986665</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002052">&lt;p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_znrDeZhtwDi7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 15 &#x2014; &lt;span id="xdx_82E_zA8WdYG6nRDd"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Due to Related Parties&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prior to the consummation of the Reverse Acquisition,
Bannix entered into various transactions with related parties to fund working capital needs. A total of $&lt;span id="xdx_90B_eus-gaap--IncreaseDecreaseInDueToRelatedParties_c20251001__20260331__us-gaap--RelatedPartyTransactionAxis__custom--BannixClassACommonStockMember_zcaxgGIhwZbb" title="Due to Related Parties"&gt;2,124,212&lt;/span&gt; owing to these related
parties was assumed at the close of the Reverse Acquisition. The following table summarizes the related party balances as of March 31,
2026, and September 30, 2025,&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_z1PzQ2cCy9C5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Related Party Transactions (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B5_zXLYjMl3Y6k1" style="display: none"&gt;Schedule of Due to Related Parties&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Suresh Yezhuvath&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_ecustom--DueToRelatedParties_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SureshYezhuvathMember_zngoioFZ6eT8" style="width: 12%; text-align: right" title="Due to related parties"&gt;223,960&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_988_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SureshYezhuvathMember_zwUHbBqGw4O5" style="width: 12%; text-align: right" title="Due to related parties"&gt;223,960&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Instant Fame and affiliated parties (1)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_ecustom--DueToRelatedParties_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PromissoryNotesMember_zgL3l5cr87ql" style="text-align: right" title="Due to related parties"&gt;840,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PromissoryNotesMember_zfhU58FNbLYh" style="text-align: right" title="Due to related parties"&gt;840,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Stanley Hills (3)(4)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--DueToRelatedParties_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StanleyHillsMember_znYENI95kRTc" style="text-align: right" title="Due to related parties"&gt;785,252&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StanleyHillsMember_zYEwnlihkYx8" style="text-align: right" title="Due to related parties"&gt;785,252&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued executive compensation (2)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_985_ecustom--DueToRelatedParties_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccruedExecutiveCompensationMember_zGfvdv9EkNhh" style="text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2070"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccruedExecutiveCompensationMember_zvDBOw7d3bgc" style="text-align: right" title="Due to related parties"&gt;250,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Anat Attia&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_ecustom--DueToRelatedParties_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AnatAttiaMember_zWEp6avSRDik" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties"&gt;251,104&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_987_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AnatAttiaMember_zrbLaYQu9Ep7" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties"&gt;335,280&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--DueRelatedParties_iI_c20260331_zcIiW6G5CrI4" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties"&gt;2,100,316&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_986_ecustom--DueRelatedParties_iI_c20250930_zMNKnEvw8yze" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties"&gt;2,434,492&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;(1) Instant Fame and affiliated parties&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Represents unsecured promissory note issued by
Bannix on December 13, 2022 in favor of Instant Fame, in the principal amount of $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentIssuedPrincipal_c20221212__20221213_zbWNYN8VZzr4" title="Principal amount"&gt;690,000&lt;/span&gt;. In March and April 2023, Bannix issued additional
unsecured promissory notes to Instant Fame for $75,000 for each promissory note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;(2) Accrued executive compensation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_902_ecustom--AccruedExecutiveCompensationDescription_c20251001__20260331_zO75KUqOCAxh" title="Accrued executive compensation description"&gt;Represents compensation expense owing to executives.
At the close of the reverse acquisition $220,000 and $55,000 were owed to Doug Davis and Erik Klinger, respectively. At September 30,
2025, $180,000, $25,000 and $45,000 were owed to Doug Davis, Noam Kenig and Erik Klinger, respectively&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;(3) Transfer of balances&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_903_ecustom--TransferOfBalancesDescription_c20241001__20250930_zXqHKoAV3U48" title="Transfer of balances description"&gt;During the year ended September 30, 2025, upon
agreement by and amount the related parties, $235,333 of balances owing to Bannix Management LLP and $4,737 of balances of Subash Menon
was transferred to Stanley Hills and $200,000 of balances owed to Subash Menon was transferred to Suresh Yezhuvath&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;(4) VisionWave Technologies related party transactions&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Stanley Hills, LLC, a corporation wholly owned
by Anat Attia, paid the entire company expenses for VisionWave Technologies Inc., as well as funded the Company&#x2019;s bank and brokerage
accounts, on behalf of the Company. On April 8, 2025, with an effective date of March 31, 2025 and as amended on May 20, 2026, the Company
entered into a Funding Support Agreement with Stanley Hills, LLC (&#x201c;Stanley Hills&#x201d;), the principal shareholder of VisionWave
Technologies. Pursuant to the agreement, Stanley Hills irrevocably and unconditionally committed to provide financial support to the
Company, sufficient to fund the working capital needs through February 17, 2027. The funding may be provided by Stanley Hills in the
form of direct payments to third parties, advances or intercompany loans, or capital contributions, as mutually determined by the parties.
Unless otherwise agreed in writing, any such advances will be non-interest bearing and repayable only at such time as determined by the
Board of Directors, and only to the extent such repayment would not impair the Company&#x2019;s liquidity or ability to continue as a
going concern. The agreement may not be terminated by Stanley Hills prior to the twelve-month period from the date of release of the
financial statement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 19, 2026, the Company and Yorkville
Advisors amended the SEPA to provide that the prepaid advance would no longer constitute an advance under the SEPA but instead be evidenced
by stand-alone promissory notes. During the three and six month ended March 31, 2026, Stanley Hills provided funding of $&lt;span id="xdx_901_eus-gaap--RepaymentsOfSecuredDebt_c20251001__20260331_z0ghgjul0YDj" title="Partial payment"&gt;500,000&lt;/span&gt; to the
Company. During the three and six months ended March 31, 2026, the Company made a partial payment of $&lt;span id="xdx_90C_eus-gaap--PaymentsToFundPolicyLoans_c20251001__20260331_zf9vNltRyl4c" title="Additional funding"&gt;500,000&lt;/span&gt; to Stanley Hills, LLC,
respectively; the deferral agreement remains in effect and was not amended, and Yorkville Advisors has not delivered any notice of default
under the SEPA or the related promissory notes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three and six months ended March 31,
2026, a total of $&lt;span id="xdx_900_ecustom--RepaidAmount_c20260101__20260331_zxDYPhtZL9Qa" title="Repaid amount"&gt;500,000&lt;/span&gt; and $&lt;span id="xdx_900_ecustom--RepaidAmount_c20251001__20260331_zelbyLaUM7A8" title="Repaid amount"&gt;270,000&lt;/span&gt; was repaid on the Stanley Hill and Anat Attia balances, respectively. During the three and six
months ended March 31, 2026, Anat Attia paid $&lt;span id="xdx_90C_eus-gaap--PaymentsForDeposits_c20251001__20260331_zlDC3Pbd0LK7" title="Paid expenses"&gt;81,824&lt;/span&gt; of expenses on behalf of the Company and advanced the Company $100,000. As of March
31, 2026 and September 30, 2025, the balance of $785,252 owing to Stanley Hills, LLC is included in due to related parties on the unaudited
condensed consolidated balance sheets. As of March 31, 2026 and September 30, 2025, the balance of $&lt;span id="xdx_90D_eus-gaap--PrepaidTaxes_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--StanleyHillsLLCMember_z4tqh21dYXxj"&gt;251,104&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--PrepaidTaxes_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--StanleyHillsLLCMember_zDCsjQJhs0Ii"&gt;335,280&lt;/span&gt;, respectively,
owing to Anat Attia is included in due to related parties on the unaudited condensed consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Due from related party&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended September 30, 2025, the
Company advanced against compensation $&lt;span id="xdx_90D_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z6ALDC7tQ2if"&gt;120,000&lt;/span&gt; to the Executive Chairman and acting CEO. For the three and six months ended March 31,
2026, the Company advanced to that executive an additional $0 and $27,500 against compensation, respectively. As of March 31, 2026 and
September 30, 2025, $&lt;span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20251001__20260331_zUNVFEba4yDc"&gt;147,500&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20241001__20250930_zgMbJ4ElAFSe"&gt;120,000&lt;/span&gt; is advanced against compensation to the executive Chairman and acting CEO and reported in due
from related party balance on the unaudited condensed consolidated balance sheets, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="From2025-10-012026-03-31_custom_BannixClassACommonStockMember"
      decimals="0"
      id="Fact002054"
      unitRef="USD">2124212</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002056">&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_z1PzQ2cCy9C5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Related Party Transactions (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B5_zXLYjMl3Y6k1" style="display: none"&gt;Schedule of Due to Related Parties&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Suresh Yezhuvath&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_ecustom--DueToRelatedParties_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SureshYezhuvathMember_zngoioFZ6eT8" style="width: 12%; text-align: right" title="Due to related parties"&gt;223,960&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_988_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SureshYezhuvathMember_zwUHbBqGw4O5" style="width: 12%; text-align: right" title="Due to related parties"&gt;223,960&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Instant Fame and affiliated parties (1)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_ecustom--DueToRelatedParties_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PromissoryNotesMember_zgL3l5cr87ql" style="text-align: right" title="Due to related parties"&gt;840,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PromissoryNotesMember_zfhU58FNbLYh" style="text-align: right" title="Due to related parties"&gt;840,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Stanley Hills (3)(4)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--DueToRelatedParties_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StanleyHillsMember_znYENI95kRTc" style="text-align: right" title="Due to related parties"&gt;785,252&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StanleyHillsMember_zYEwnlihkYx8" style="text-align: right" title="Due to related parties"&gt;785,252&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued executive compensation (2)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_985_ecustom--DueToRelatedParties_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccruedExecutiveCompensationMember_zGfvdv9EkNhh" style="text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2070"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccruedExecutiveCompensationMember_zvDBOw7d3bgc" style="text-align: right" title="Due to related parties"&gt;250,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Anat Attia&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_ecustom--DueToRelatedParties_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AnatAttiaMember_zWEp6avSRDik" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties"&gt;251,104&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_987_ecustom--DueToRelatedParties_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AnatAttiaMember_zrbLaYQu9Ep7" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties"&gt;335,280&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--DueRelatedParties_iI_c20260331_zcIiW6G5CrI4" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties"&gt;2,100,316&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_986_ecustom--DueRelatedParties_iI_c20250930_zMNKnEvw8yze" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties"&gt;2,434,492&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2026-03-31_custom_SureshYezhuvathMember"
      decimals="0"
      id="Fact002058"
      unitRef="USD">223960</VWAV:DueToRelatedParties>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-09-30_custom_SureshYezhuvathMember"
      decimals="0"
      id="Fact002060"
      unitRef="USD">223960</VWAV:DueToRelatedParties>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2026-03-31_custom_PromissoryNotesMember"
      decimals="0"
      id="Fact002062"
      unitRef="USD">840000</VWAV:DueToRelatedParties>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-09-30_custom_PromissoryNotesMember"
      decimals="0"
      id="Fact002064"
      unitRef="USD">840000</VWAV:DueToRelatedParties>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2026-03-31_custom_StanleyHillsMember"
      decimals="0"
      id="Fact002066"
      unitRef="USD">785252</VWAV:DueToRelatedParties>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-09-30_custom_StanleyHillsMember"
      decimals="0"
      id="Fact002068"
      unitRef="USD">785252</VWAV:DueToRelatedParties>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-09-30_custom_AccruedExecutiveCompensationMember"
      decimals="0"
      id="Fact002072"
      unitRef="USD">250000</VWAV:DueToRelatedParties>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2026-03-31_custom_AnatAttiaMember"
      decimals="0"
      id="Fact002074"
      unitRef="USD">251104</VWAV:DueToRelatedParties>
    <VWAV:DueToRelatedParties
      contextRef="AsOf2025-09-30_custom_AnatAttiaMember"
      decimals="0"
      id="Fact002076"
      unitRef="USD">335280</VWAV:DueToRelatedParties>
    <VWAV:DueRelatedParties
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002078"
      unitRef="USD">2100316</VWAV:DueRelatedParties>
    <VWAV:DueRelatedParties
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact002080"
      unitRef="USD">2434492</VWAV:DueRelatedParties>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="From2022-12-122022-12-13"
      decimals="0"
      id="Fact002082"
      unitRef="USD">690000</us-gaap:DebtInstrumentIssuedPrincipal>
    <VWAV:AccruedExecutiveCompensationDescription contextRef="From2025-10-01to2026-03-31" id="Fact002084">Represents compensation expense owing to executives.
At the close of the reverse acquisition $220,000 and $55,000 were owed to Doug Davis and Erik Klinger, respectively. At September 30,
2025, $180,000, $25,000 and $45,000 were owed to Doug Davis, Noam Kenig and Erik Klinger, respectively</VWAV:AccruedExecutiveCompensationDescription>
    <VWAV:TransferOfBalancesDescription contextRef="From2024-10-012025-09-30" id="Fact002086">During the year ended September 30, 2025, upon
agreement by and amount the related parties, $235,333 of balances owing to Bannix Management LLP and $4,737 of balances of Subash Menon
was transferred to Stanley Hills and $200,000 of balances owed to Subash Menon was transferred to Suresh Yezhuvath</VWAV:TransferOfBalancesDescription>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002090"
      unitRef="USD">500000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:PaymentsToFundPolicyLoans
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002092"
      unitRef="USD">500000</us-gaap:PaymentsToFundPolicyLoans>
    <VWAV:RepaidAmount
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact002094"
      unitRef="USD">500000</VWAV:RepaidAmount>
    <VWAV:RepaidAmount
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002096"
      unitRef="USD">270000</VWAV:RepaidAmount>
    <us-gaap:PaymentsForDeposits
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002098"
      unitRef="USD">81824</us-gaap:PaymentsForDeposits>
    <us-gaap:PrepaidTaxes
      contextRef="AsOf2026-03-31_custom_StanleyHillsLLCMember"
      decimals="0"
      id="Fact002099"
      unitRef="USD">251104</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="AsOf2025-09-30_custom_StanleyHillsLLCMember"
      decimals="0"
      id="Fact002100"
      unitRef="USD">335280</us-gaap:PrepaidTaxes>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-10-012025-09-30_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact002101"
      unitRef="USD">120000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002102"
      unitRef="USD">147500</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact002103"
      unitRef="USD">120000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002105">&lt;p id="xdx_802_eus-gaap--DebtDisclosureTextBlock_zccupIrtUfEi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 16 &#x2014; &lt;span id="xdx_821_z4CI9X1jbiA2"&gt;Convertible Notes Payable&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Securities Purchase Agreements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 15, 2025, the Company entered into Securities
Purchase Agreements (the &#x201c;July 2025 SPAs&#x201d;) with two unaffiliated accredited investors (&#x201c;July 2025 Lenders&#x201d;),
pursuant to which the Company issued promissory notes (the &#x201c;July 2025 Notes&#x201d;) to the July 2025 Lenders in the aggregate principal
amount of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_c20250713__20250715_zDQToQ7MHe1i" title="Aggregate principal amount"&gt;354,200&lt;/span&gt;, which includes an aggregate original issue discount of $&lt;span id="xdx_904_ecustom--IssuedDiscountConvertibleNotes_iI_c20250715_zSEvKv4IU51b" title="Issued discount convertible notes"&gt;46,200&lt;/span&gt;, for a purchase price of $&lt;span id="xdx_90B_ecustom--PurchasePrice_iI_c20250715_zBJr8EzON2N2" title="Purchase price"&gt;308,000&lt;/span&gt;. The Company incurred
an additional $&lt;span id="xdx_905_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c20251001__20260331_ziXvZLLl8Qua" title="Additional fee"&gt;8,000&lt;/span&gt; in fees related to this transaction which is capitalized as part of the debt issuance cost and amortized over the
term of the July 2025 Notes. The July 2025 Notes bear interest at a one-time charge of 12% applied on the issuance date, mature on May
15, 2026, and is repayable in five monthly payments commencing January 15, 2026. The July 2025 Notes are convertible into shares of the
Company&#x2019;s common stock, par value $0.01 per share (the &#x201c;Common Stock&#x201d;), solely upon an event of default, at a conversion
price equal to 75% of the lowest trading price during the ten trading days prior to conversion. The Company also entered into an irrevocable
transfer agent instructions letter with its transfer agent in connection with the July 2025 Notes. The proceeds from the issuances of
the July 2025 Notes were used for general working capital purposes. The July 2025 Lenders have piggyback registration rights and have
agreed not to engage in short sales of the Company&#x2019;s common stock during the term of the July 2025 Notes. The July 2025 Notes include
customary representations, warranties, covenants, and default provisions. The Company may prepay the July 2025 Notes within the first
180 days. The loan pursuant to the July 2025 Notes closed and funded on July 17, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three and six months ended March 31,
2026, the Company repaid $&lt;span id="xdx_90C_eus-gaap--RepaymentsOfConvertibleDebt_pp0d_c20260101__20260331__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_znqPFzokMO35"&gt;147,644&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--RepaymentsOfConvertibleDebt_pp0d_c20251001__20260331__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_zoM5xo6Ygpok"&gt;297,528&lt;/span&gt;, respectively on the July 2025 Notes. For the three months ended March 31, 2026 and 2025,
total amortized debt issuance cost of $&lt;span id="xdx_90B_eus-gaap--PaymentsOfDebtIssuanceCosts_c20260101__20260331_zs9ltAvXbN1d" title="Total amortized debt issuance cost"&gt;16,293&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--PaymentsOfDebtIssuanceCosts_c20250101__20250331_zsenhOpjfk7h" title="Total amortized debt issuance cost"&gt;0&lt;/span&gt; was included in interest expense on the accompanying unaudited condensed consolidated
statements of operations, respectively. For the six months ended March 31, 2026 and 2025 total amortized debt issuance cost of $&lt;span id="xdx_90C_eus-gaap--PaymentsOfDebtIssuanceCosts_c20251001__20260331__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_zi8K0057AG3i" title="Total amortized debt issuance cost"&gt;32,586&lt;/span&gt;
and $&lt;span id="xdx_902_eus-gaap--PaymentsOfDebtIssuanceCosts_c20241001__20250331__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_zdgG82gMfJn4" title="Total amortized debt issuance cost"&gt;0&lt;/span&gt; was included in interest expense on the accompanying unaudited condensed consolidated statements of operations, respectively.
For the three months ended March 31, 2026 and 2025, total interest expense $&lt;span id="xdx_907_eus-gaap--InterestExpense_c20260101__20260331__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_z3p7LFEVxWU8" title="Interest expense"&gt;12,751&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--InterestExpense_c20250101__20250331__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_zpvRer98u7ra" title="Interest expense"&gt;0&lt;/span&gt; was included in interest expense on the accompanying
unaudited condensed consolidated statements of operations, respectively. For the six months ended March 31, 2026 and 2025, total interest
expense $&lt;span id="xdx_908_eus-gaap--InterestExpense_c20251001__20260331__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_zHZlnVTUyczk" title="Interest expense"&gt;25,502&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--InterestExpense_c20241001__20250331__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_z6LGOOzSFGN3" title="Interest expense"&gt;0&lt;/span&gt; was included in interest expense on the accompanying unaudited condensed consolidated statements of operations,
respectively. At March 31, 2026 and September 30, 2025, the balance of the July Notes of $&lt;span id="xdx_90A_eus-gaap--ConvertibleNotesPayable_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_z0GTKqrVrvgi"&gt;43,795&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--ConvertibleNotesPayable_iI_c20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zwYJ7ybny36f"&gt;308,737&lt;/span&gt;, respectively, recorded
in convertible notes payable on the accompanying unaudited condensed consolidated balance sheets, includes $&lt;span id="xdx_905_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zVtbCjpYF6R4"&gt;12,877&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zXStu7NyFjzd"&gt;45,463&lt;/span&gt;, respectively
of unamortized debt issuance cost.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 6, 2025, the Company entered into a
Securities Purchase Agreement (the &#x201c;October 2025 SPA&#x201d;) with an unaffiliated accredited investor, pursuant to which the Company
issued a promissory note (the &#x201c;October 2025 Note&#x201d;) to the investor in the aggregate principal amount of $&lt;span id="xdx_903_eus-gaap--DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_c20251004__20251006_zdsg4gHTa36" title="Aggregate principal amount"&gt;296,700&lt;/span&gt;, which includes
an aggregate original issue discount of $&lt;span id="xdx_90A_ecustom--IssuedDiscountConvertibleNotes_iI_c20251006_zv8F3SeabJci" title="Issued discount convertible notes"&gt;38,700&lt;/span&gt;, for a purchase price of $&lt;span id="xdx_901_ecustom--PurchasePrice_iI_c20251006_zgL7PbSg6kGl" title="Purchase price"&gt;258,000&lt;/span&gt;. The Company incurred an additional $&lt;span id="xdx_903_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c20251004__20251006_zWg9yU1eEhwj" title="Additional fee"&gt;8,000&lt;/span&gt; in fees
related to this transaction which is capitalized as part of the debt issuance cost and amortized over the term of the October 2025 Note.
The October 2025 Note bear interest at a one-time charge of 12% applied on the issuance date, mature on July 30, 2026, and is repayable
in five monthly payments commencing March 30, 2026. The October 2025 Note is convertible into shares of the Company&#x2019;s common stock,
par value $0.01 per share, solely upon an event of default, at a conversion price equal to 75% of the lowest trading price during the
ten trading days prior to conversion. The Company also entered into an irrevocable transfer agent instructions letter with its transfer
agent in connection with the October 2025 Note. The proceeds from the issuances of the October 2025 Note were used for general working
capital purposes. The October 2025 investor have piggyback registration rights and have agreed not to engage in short sales of the Company&#x2019;s
common stock during the term of the October 2025 Note. The October 2025 Note include customary representations, warranties, covenants,
and default provisions. The Company may prepay the October 2025 Notes within the first 180 days.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the three ended March 31, 2026 and 2025, total
amortized debt issuance cost of $&lt;span id="xdx_90C_eus-gaap--PaymentsOfDebtIssuanceCosts_c20260101__20260331__us-gaap--FinancialInstrumentAxis__us-gaap--DebtMember_zJImVn0PXT08" title="Total amortized debt issuance cost"&gt;14,012&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--PaymentsOfDebtIssuanceCosts_c20250101__20250331__us-gaap--FinancialInstrumentAxis__us-gaap--DebtMember_zVA9hQZAQrBa" title="Total amortized debt issuance cost"&gt;0&lt;/span&gt;, respectively, was included in interest expense on the accompanying unaudited condensed
consolidated statements of operations. For the six months ended March 31, 2026 and 2025, total amortized debt issuance cost of $&lt;span id="xdx_90C_eus-gaap--PaymentsOfDebtIssuanceCosts_c20251001__20260331__us-gaap--FinancialInstrumentAxis__us-gaap--DebtMember_zKSA45KurLba" title="Total amortized debt issuance cost"&gt;28,024&lt;/span&gt;
and $&lt;span id="xdx_907_eus-gaap--PaymentsOfDebtIssuanceCosts_c20241001__20250331__us-gaap--FinancialInstrumentAxis__us-gaap--DebtMember_zglYwnDQsGab" title="Total amortized debt issuance cost"&gt;0&lt;/span&gt;, respectively, was included in interest expense on the accompanying unaudited condensed consolidated statements of operations.
For the three and six months ended March 31, 2026 and 2025, total interest expense $&lt;span id="xdx_90F_ecustom--InterestExpenses_c20260101__20260331__us-gaap--FinancialInstrumentAxis__us-gaap--DebtMember_zoS1p2g3Ruk5" title="Interest expense"&gt;10,681&lt;/span&gt; and $&lt;span id="xdx_903_ecustom--InterestExpenses_c20250101__20250331__us-gaap--FinancialInstrumentAxis__us-gaap--DebtMember_z4uLTKZx7V64" title="Interest expense"&gt;0&lt;/span&gt;, respectively, and $&lt;span id="xdx_909_ecustom--InterestExpenses_c20251001__20260331__us-gaap--FinancialInstrumentAxis__us-gaap--DebtMember_zAZTgWMsHIS4" title="Interest expense"&gt;24,693&lt;/span&gt; and $&lt;span id="xdx_90E_ecustom--InterestExpenses_c20241001__20250331__us-gaap--FinancialInstrumentAxis__us-gaap--DebtMember_zCoISJEMRsUj" title="Interest expense"&gt;0&lt;/span&gt;,
respectively, was included in interest expense on the accompanying unaudited condensed consolidated statements of operations. At March
31, 2026 and September 30, 2025, the balance of the October Notes of $&lt;span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FinancialInstrumentAxis__us-gaap--DebtMember_zNnxLsHDsuk2" title="Convertible notes payable"&gt;111,871&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ConvertibleNotesPayable_iI_c20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FinancialInstrumentAxis__us-gaap--DebtMember_zT2qUeJjRDJ2" title="Convertible notes payable"&gt;0&lt;/span&gt;, respectively, recorded in convertible notes payable
on the accompanying unaudited condensed balance sheets, includes $&lt;span id="xdx_902_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FinancialInstrumentAxis__us-gaap--DebtMember_zAeukjBfFzQl" title="Unamortized debt issuance cost"&gt;18,677&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FinancialInstrumentAxis__us-gaap--DebtMember_zhN7gR3wIeKh" title="Unamortized debt issuance cost"&gt;0&lt;/span&gt;, respectively of unamortized debt issuance cost.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 12, 2025, the Company entered into
a Securities Purchase Agreement (the &#x201c;November 2025 SPA&#x201d;) with an unaffiliated accredited investor, pursuant to which the
Company issued a promissory note (the &#x201c;November 2025 Note&#x201d;) to the November 2025 investor in the aggregate principal amount
of $&lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_c20251110__20251112_zQnlBZBWfj8l" title="Aggregate principal amount"&gt;354,200&lt;/span&gt;, which includes an aggregate original issue discount of $&lt;span id="xdx_900_ecustom--IssuedDiscountConvertibleNotes_iI_c20251112_zQKOWESOvFN4" title="Issued discount convertible notes"&gt;46,200&lt;/span&gt;, for a purchase price of $&lt;span id="xdx_90D_ecustom--PurchasePrice_iI_c20251112_zKpbB3TZ1bm3" title="Purchase price"&gt;308,000&lt;/span&gt;. The Company incurred an
additional $&lt;span id="xdx_902_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c20251110__20251112_zOuOVZ0RugP" title="Additional fee"&gt;8,000&lt;/span&gt; in fees related to this transaction which is capitalized as part of the debt issuance cost and amortized over the term
of the November 2025 Note. The November 2025 Note bear interest at a one-time charge of 12% applied on the issuance date, mature on September
15, 2026, and is repayable in five monthly payments commencing May 15, 2026. The November 2025 Note is convertible into shares of the
Company&#x2019;s common stock, par value $0.01 per share (the &#x201c;Common Stock&#x201d;), solely upon an event of default, at a conversion
price equal to 75% of the lowest trading price during the ten trading days prior to conversion. The Company also entered into an irrevocable
transfer agent instructions letter with its transfer agent in connection with the November 2025 Notes. The proceeds from the issuances
of the November 2025 Notes were used for general working capital purposes. The investor has piggyback registration rights and have agreed
not to engage in short sales of the Company&#x2019;s common stock during the term of the November 2025 Note. The November 2025 Note include
customary representations, warranties, covenants, and default provisions. The Company may prepay the November 2025 Note within the first
180 days.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the three and six months ended March 31, 2026
and 2025, total amortized debt issuance cost of $&lt;span id="xdx_90E_eus-gaap--PaymentsOfDebtIssuanceCosts_c20260101__20260331__us-gaap--FinancialInstrumentAxis__custom--Debt1Member_zoD2JoL5vW29" title="Amortized debt issuance cost"&gt;17,533&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--PaymentsOfDebtIssuanceCosts_c20250101__20250331__us-gaap--FinancialInstrumentAxis__custom--Debt1Member_zh5AU2pIbhv8" title="Amortized debt issuance cost"&gt;0&lt;/span&gt;, respectively, and $&lt;span id="xdx_903_eus-gaap--PaymentsOfDebtIssuanceCosts_c20251001__20260331__us-gaap--FinancialInstrumentAxis__custom--Debt1Member_z41uegU62TEi" title="Amortized debt issuance cost"&gt;24,174&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--PaymentsOfDebtIssuanceCosts_c20241001__20250331__us-gaap--FinancialInstrumentAxis__custom--Debt1Member_zCxeYQHaEzX4" title="Amortized debt issuance cost"&gt;0&lt;/span&gt;, respectively, was included in interest
expense on the accompanying unaudited condensed consolidated statements of operations. For the three and six months ended March 31, 2026
and 2025, total interest expense $&lt;span id="xdx_905_ecustom--InterestExpenses_c20260101__20260331__us-gaap--FinancialInstrumentAxis__custom--Debt1Member_zFCwPaU0dQB2" title="Interest expense"&gt;12,751&lt;/span&gt; and $&lt;span id="xdx_90E_ecustom--InterestExpenses_c20250101__20250331__us-gaap--FinancialInstrumentAxis__custom--Debt1Member_zEkGHe9U8Upf" title="Interest expense"&gt;0&lt;/span&gt;, respectively, and $&lt;span id="xdx_901_ecustom--InterestExpenses_c20251001__20260331__us-gaap--FinancialInstrumentAxis__custom--Debt1Member_zE79TVfUH39c" title="Interest expense"&gt;23,909&lt;/span&gt; and $&lt;span id="xdx_902_ecustom--InterestExpenses_c20241001__20250331__us-gaap--FinancialInstrumentAxis__custom--Debt1Member_zSCFnHDcDTa9" title="Interest expense"&gt;0&lt;/span&gt;, respectively, was included in interest expense on
the accompanying unaudited condensed consolidated statements of operations. At March 31, 2026 and September 30, 2025, the balance of
the November Notes of $&lt;span id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FinancialInstrumentAxis__custom--Debt1Member_zjoVkM5YgPl9" title="Convertible notes payable"&gt;324,174&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_c20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FinancialInstrumentAxis__custom--Debt1Member_zo5oI2HSsTr4" title="Convertible notes payable"&gt;0&lt;/span&gt;, respectively, recorded in convertible notes payable on the accompanying balance sheets, includes
$&lt;span id="xdx_90C_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FinancialInstrumentAxis__custom--Debt1Member_z1KPWeCf9ew5" title="Unamortized debt issuance cost"&gt;30,026&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FinancialInstrumentAxis__custom--Debt1Member_zDC0nMFZb242" title="Unamortized debt issuance cost"&gt;0&lt;/span&gt;, respectively of unamortized debt issuance cost.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Standby Equity Purchase Agreement - Pre-Paid Advance&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the SEPA (See Note 19), and
subject to the condition set forth therein, the Investor advanced to the Company in the form of convertible promissory notes (the &#x201c;Convertible
Notes&#x201d;) an aggregate principal amount of $5.0 million (the &#x201c;Pre-Paid Advance&#x201d;). The first Pre-Paid Advance was disbursed
on July 25, 2025 with respect to $&lt;span id="xdx_90C_eus-gaap--AdvanceRent_iI_pn3n3_dm_c20250725_zagnmEW48kmj"&gt;3.0&lt;/span&gt; million and the balance of $&lt;span id="xdx_902_eus-gaap--AdvanceRent_iI_pn3n3_dm_c20250911_zuH0s7az7m98"&gt;2.0 &lt;/span&gt;million was disbursed on September 11, 2025 upon the registration
statement registering the resale of the shares of common stock issuable under the SEPA being declared effective. The purchase price for
the Pre-Paid Advance is 94% of the principal amount of the Pre-Paid Advance. Interest shall accrue on the outstanding balance of any
Pre-Paid Advance at an annual rate equal to 6.0%, subject to an increase to 18% upon an event of default as described in the Convertible
Notes. The maturity date is 12-months after the closing of each tranche of the Pre-Paid Advance. The Investor may convert the Convertible
Notes into shares of the Company&#x2019;s common stock at a conversion price equal to the lower of $10.00 or 93% of the lowest daily VWAP
during the five consecutive trading days immediately preceding the conversion (the &#x201c;Conversion Price&#x201d;), which in no event
may the Conversion Price be lower than $&lt;span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20260331__us-gaap--DebtConversionByUniqueDescriptionAxis__custom--ConversionPriceMember_z0clAdAGiNac"&gt;1.00&lt;/span&gt; (the &#x201c;Floor Price&#x201d;) provided, however, that the Floor Price shall be adjusted
(downwards only) to equal 20% of the average VWAP for the five (5) Trading Days immediately prior to the earlier of (i) date of effectiveness
of the Registration Statement, (ii) the six-month anniversary of the date of the SEPA. Notwithstanding the foregoing, the Company may
reduce the Floor Price to any amounts set forth in a written notice to the Holder; provided that such reduction shall be irrevocable
and shall not be subject to increase thereafter. In addition, upon the occurrence and during the continuation of an event of default,
the Convertible Notes shall become immediately due and payable and the Company shall pay to the Investor the principal and interest due
thereunder. In no event shall Investor be allowed to effect a conversion if such conversion, along with all other shares of common stock
beneficially owned by Investor and its affiliates would exceed 4.99% of the outstanding shares of the common stock of the Company. If
any time on or after the issuance of the Convertible Notes (i) the daily VWAP is less than the Floor Price for five trading days during
a period of seven consecutive trading days (&#x201c;Floor Price Trigger&#x201d;), or (ii) the Company has issued in excess of 99% of the
shares of common stock available under the Exchange Cap, where applicable ( &#x201c;Exchange Cap Trigger&#x201d; and collectively with
the Floor Price Trigger, the &#x201c;Trigger&#x201d;), then the Company shall make monthly payments to Investor beginning on the seventh
trading day after the Trigger and continuing monthly in the amount of $&lt;span id="xdx_90C_eus-gaap--StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount1_c20251001__20260331_zJFGiv9LSIB7" title="Trigger amount"&gt;750,000&lt;/span&gt; plus an &lt;span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_dp_c20251001__20260331_zF3CG8fqnki9" title="Unpaid interest percent"&gt;5.0&lt;/span&gt;% premium and accrued and unpaid interest.
The Exchange Cap Trigger will not apply in the event the Company has obtained the approval from its stockholders in accordance with the
rules of Nasdaq Stock Market for the issuance of shares of common stock pursuant to the transactions contemplated in the Convertible
Note and the SEPA in excess of 19.99% of the aggregate number of shares of common stock issued and outstanding as of the effective date
of the SEPA (the &#x201c;Exchange Cap&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Convertible Notes is a legal debt obligation
with a variable-share conversion feature and the Company elected to account for the Convertible Notes at fair value under ASC 825. The
Note remains a liability after issuance and the instrument is remeasured after initial recognition, with changes in fair value recognized
in earnings each reporting period until settlement, modification, or extinguishment, consistent with the liability-classified model.
As of March 31, 2026 and September 30, 2025, the par value of the notes was $&lt;span id="xdx_903_eus-gaap--DebtInstrumentFairValue_iI_c20260331_ziUcLzHOpnCg" title="fair value of the notes"&gt;5,000,000 &lt;/span&gt;and the fair value of the notes was $&lt;span id="xdx_90C_ecustom--FairValueOfNotes_iI_c20260331_zSkVJm1VeHs4" title="Fair value of  notes"&gt;4,831,699&lt;/span&gt;
and $&lt;span id="xdx_907_ecustom--FairValueOfNotes_iI_c20250930_zJkOQu5MS21l" title="Fair value of  notes"&gt;4,552,653&lt;/span&gt;, respectively. For the three months ended March 31, 2026 and 2025, total interest expense $&lt;span id="xdx_901_eus-gaap--InterestExpense_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zMJciqbY2Lgl"&gt;75,616&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--InterestExpense_c20250101__20250331__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zfMbTVOPEie"&gt;0&lt;/span&gt;, respectively,
was included in interest expense on the accompanying unaudited condensed consolidated statements of operations. For the six months ended
March 31, 2026 and 2025, total interest expense $&lt;span id="xdx_906_eus-gaap--InterestExpense_c20251001__20260331__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zUE3YXA7QWgg"&gt;150,411&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--InterestExpense_c20241001__20250331__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zuHWLoyWrNWd"&gt;0&lt;/span&gt; respectively, was included in interest expense on the accompanying unaudited
condensed consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;January 2026 Notes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 9, 2026, the Company issued promissory
notes (the &#x201c;January 2026 Notes&#x201d;) to two investors in the aggregate principal amount of $&lt;span id="xdx_904_ecustom--AggregatePrincipalAmount_iI_c20260109_z1oMBjXLl5T8" title="Aggregate principal amount"&gt;354,200&lt;/span&gt;, which includes an aggregate
original issue discount of $&lt;span id="xdx_902_ecustom--AggregateOriginalIssueDiscount_iI_c20260109_zMblxZTC1De7" title="Aggregate original issue discount"&gt;46,200&lt;/span&gt;, for a purchase price of $&lt;span id="xdx_904_ecustom--PurchasePrice_iI_c20260109_zbWWDT9BYpLc" title="Purchase price"&gt;293,000&lt;/span&gt;. The Company incurred an additional $&lt;span id="xdx_907_ecustom--AdditionalFees_iI_c20260109_znam1SNluuAe" title="Additional fees"&gt;8,000&lt;/span&gt; in fees related to this
transaction which is capitalized as part of the debt issuance cost and amortized over the term of the January 2026 Notes. The January
2026 Notes bear interest at a one-time charge of 12% applied on the issuance date, mature on November 15, 2026, and is repayable in five
monthly payments commencing July 15, 2026. The January 2026 Notes are convertible into shares of the Company&#x2019;s common stock, par
value $0.01 per share, solely upon an event of default, at a conversion price equal to 75% of the lowest trading price during the ten
trading days prior to conversion. The Company also entered into an irrevocable transfer agent instructions letter with its transfer agent
in connection with the January 2026 Notes. The proceeds from the issuances of the January 2026 Notes were used for general working capital
purposes. The investors have piggyback registration rights and have agreed not to engage in short sales of the Company&#x2019;s common
stock during the term of the January 2026 Notes. The January 2026 Notes include customary representations, warranties, covenants, and
default provisions. The Company may prepay the January 2026 Notes within the first 180 days.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluated the embedded conversion
features and other terms of the January 2026 Notes under applicable accounting guidance, including ASC 815, Derivatives and Hedging.
The conversion feature is exercisable solely upon an event of default and, accordingly, the Company concluded that bifurcation of the
embedded conversion feature was not required as of issuance. The January 2026 Notes were therefore initially recorded at their principal
amount, net of unamortized original issue discount and debt issuance costs. As the notes were not elected under the fair value option
of ASC 825, the Company accounts for the January 2026 Notes at amortized cost and no recurring fair value measurement is required.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the three ended March 31, 2026 and 2025, total
amortized debt issuance cost of $&lt;span id="xdx_907_eus-gaap--PaymentsOfDebtIssuanceCosts_c20260101__20260331__us-gaap--FinancialInstrumentAxis__custom--January2026NotesMember_zvhBnTsM56pg" title="Amortized debt issuance cost"&gt;14,344&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--PaymentsOfDebtIssuanceCosts_c20250101__20250331__us-gaap--FinancialInstrumentAxis__custom--January2026NotesMember_zVdXMmudAZ1c" title="Amortized debt issuance cost"&gt;0&lt;/span&gt;, respectively, was included in interest expense on the accompanying unaudited condensed
consolidated statements of operations. For the six months ended March 31, 2026 and 2025, total amortized debt issuance cost of $&lt;span id="xdx_90F_eus-gaap--PaymentsOfDebtIssuanceCosts_c20251001__20260331__us-gaap--FinancialInstrumentAxis__custom--January2026NotesMember_zOuFXj3pkCNa" title="Amortized debt issuance cost"&gt;14,344&lt;/span&gt;
and $&lt;span id="xdx_909_eus-gaap--PaymentsOfDebtIssuanceCosts_c20241001__20250331__us-gaap--FinancialInstrumentAxis__custom--January2026NotesMember_zrAN1Rw7Iwl4" title="Amortized debt issuance cost"&gt;0&lt;/span&gt;, respectively, was included in interest expense on the accompanying unaudited condensed consolidated statements of operations.
For the three and six months ended March 31, 2026 and 2025, total interest expense $&lt;span id="xdx_905_ecustom--InterestExpenses_c20260101__20260331__us-gaap--FinancialInstrumentAxis__custom--January2026NotesMember_zlNe7mnGexE9" title="Interest expense"&gt;10,626&lt;/span&gt; and $&lt;span id="xdx_900_ecustom--InterestExpenses_c20250101__20250331__us-gaap--FinancialInstrumentAxis__custom--January2026NotesMember_zftqEIsFP98e" title="Interest expense"&gt;0&lt;/span&gt;, respectively, and $&lt;span id="xdx_909_ecustom--InterestExpenses_c20251001__20260331__us-gaap--FinancialInstrumentAxis__custom--January2026NotesMember_ztXHDuZC2g05" title="Interest expense"&gt;10,626&lt;/span&gt; and $&lt;span id="xdx_90F_ecustom--InterestExpenses_c20241001__20250331__us-gaap--FinancialInstrumentAxis__custom--January2026NotesMember_zNOR2gbQ1hNf" title="Interest expense"&gt;0&lt;/span&gt;,
respectively, was included in interest expense on the accompanying unaudited condensed consolidated statements of operations. At March
31, 2026 and September 30, 2025, the balance of the October Notes of $&lt;span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FinancialInstrumentAxis__custom--January2026NotesMember_zNJxDhbeam7i" title="Convertible notes payable"&gt;314,344&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_c20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FinancialInstrumentAxis__custom--January2026NotesMember_zW9fjW54mZG8" title="Convertible notes payable"&gt;0&lt;/span&gt;, respectively, recorded in convertible notes payable
on the accompanying balance sheets, includes $&lt;span id="xdx_909_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FinancialInstrumentAxis__custom--January2026NotesMember_zP7h4mwDjSDc" title="Unamortized debt issuance cost"&gt;39,856&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FinancialInstrumentAxis__custom--January2026NotesMember_z9LQF0tSMOK8" title="Unamortized debt issuance cost"&gt;0&lt;/span&gt;, respectively of unamortized debt issuance cost.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table presents changes of the convertible
notes with significant unobservable inputs (Level 3) for the three and six months ended March 31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--SignificantUnobservableInputsConvertibleDebtTableTextBlock_zRzMLvTnRvS4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Notes Payable (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B5_z5crKGFUuEFe" style="display: none"&gt;Schedule of unobservable inputs of convertible notes&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Convertible Notes&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Convertible Notes balance at September 30,
2025&lt;/td&gt;
&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ConvertibleNotesPayable_iS_c20251001__20251231_zGcb6eK72w53" style="width: 18%; text-align: right" title="Convertible notes beginning balance"&gt;4,552,653&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Change in fair value&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_c20251001__20251231_zZ2lCTI1ca33" style="text-align: right" title="Change in fair value"&gt;286,680&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Convertible Notes balance at December 31, 2025&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ConvertibleNotesPayable_iS_c20260101__20260331_zKjBrEOFABH5" style="text-align: right" title="Convertible notes beginning balance"&gt;4,839,333&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Change in fair value&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_c20260101__20260331_zLWGiPxoGXf3" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(7,634&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Convertible Notes balance at March 31, 2026&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--ConvertibleNotesPayable_iE_c20260101__20260331_z9jWqCA8pNs5" style="border-bottom: Black 2.5pt double; text-align: right" title="Convertible notes ending balance"&gt;4,831,699&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AF_zrm3Q3liiy29" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Convertible notes were valued using unobservable
inputs that are not corroborated by market data (Level 3). The valuation is based on Monte Carlo Simulation to simulate weekly stock
prices through maturity. The enterprise value is then allocated to each class of outstanding shares and convertible notes based on an
option pricing model where the value for each class is driven by the current value and expected volatility of the underlying equity value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The key assumptions used to value the convertible notes as of March
31, 2026 and September 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ConvertibleDebtTableTextBlock_zo6TEoNt2TB4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Notes Payable (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B5_zDYYLr92FgN1" style="display: none"&gt;Schedule of key assumptions used to value the convertible
notes&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-indent: -10pt"&gt;Stock Price&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--StockholdersEquityOtherShares_c20251001__20260331_zdHM3CLYlona" style="width: 12%; text-align: right" title="Stock Price"&gt;4.74&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--StockholdersEquityOtherShares_c20241001__20250930_z7jlhc2mQmvf" style="width: 12%; text-align: right" title="Stock Price"&gt;9.53&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Equity Volatility&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20251001__20260331_zroL44i7Gg5c" title="Equity Volatility"&gt;59&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20241001__20250930_znWHgB5vMoxb" title="Equity Volatility"&gt;52&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Discount Rate&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20251001__20260331_zy2rCnJevby1" title="Discount Rate"&gt;45&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20241001__20250930_zNBiOT7brvRc" title="Discount Rate"&gt;41&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk free rate of return&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20251001__20260331__srt--RangeAxis__srt--MaximumMember_zWEO7WfX6DUa" title="Risk free rate of return"&gt;3.67&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20251001__20260331__srt--RangeAxis__srt--MinimumMember_zjCnWwz0n2B1" title="Risk free rate of return"&gt;3.68&lt;/span&gt; %&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20241001__20250930_zOH9C4sOdlz6" title="Risk free rate of return"&gt;3.70&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Term to maturity (years)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20251001__20260331__srt--RangeAxis__srt--MaximumMember_zqilu958Zcmh" title="Term to maturity (years)"&gt;0.32&lt;/span&gt;-&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20251001__20260331__srt--RangeAxis__srt--MinimumMember_zaWD2nVwMtai" title="Term to maturity (years)"&gt;0.45&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20241001__20250930_zuBCumfMWeI1" title="Term to maturity (years)"&gt;0.82&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p id="xdx_8AB_zZIwhEvItvbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table presents balance of the convertible
notes with significant unobservable inputs (Level 3) as of March 31, 2026 and September 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfUnobservableInputsConvertibleNotesTableTexxtBlock_zSZl2f89lcr" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Notes Payable (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;span id="xdx_8BE_z60tacX1GyE6" style="display: none"&gt;Schedule of balance of the convertible
notes with significant unobservable inputs&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49E_20260331__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zjSaBPuGstej" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_499_20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zBZh4BYykb95" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--ConvertibleNotesAtFairValue_iI_zL5YmZqCB375" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Convertible notes (at fair value)&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;4,831,699&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;4,552,653&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--JulyNotesAtAmortizedCost_iI_zrpQpXYCKKq7" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;July Notes (at amortized cost)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;43,795&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;308,737&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--OctoberNoteAtAmortizedCost_iI_z9nlfjQMaji2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;October Note (at amortized cost)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;111,871&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2305"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--NovemberNoteAtAmortizedCost_iI_z2FwsfVPWfT2" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;November Note (at amortized cost)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;324,174&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2308"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--January2026NoteAtAmortizedCost_iI_z9EkB5UR7W7c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;January 2026 Note (at amortized cost))&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;314,344&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2311"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--BalanceConvertibleNotesPayable_iI_zWw50R2Xp5Gj" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Balance, Convertible notes payable&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,625,883&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,861,390&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A0_zMU8PnT6WU1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
      contextRef="From2025-07-132025-07-15"
      decimals="0"
      id="Fact002107"
      unitRef="USD">354200</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <VWAV:IssuedDiscountConvertibleNotes
      contextRef="AsOf2025-07-15"
      decimals="0"
      id="Fact002109"
      unitRef="USD">46200</VWAV:IssuedDiscountConvertibleNotes>
    <VWAV:PurchasePrice
      contextRef="AsOf2025-07-15"
      decimals="0"
      id="Fact002111"
      unitRef="USD">308000</VWAV:PurchasePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002113"
      unitRef="USD">8000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2026-01-012026-03-31_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="Fact002114"
      unitRef="USD">147644</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2025-10-012026-03-31_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="Fact002115"
      unitRef="USD">297528</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact002117"
      unitRef="USD">16293</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact002119"
      unitRef="USD">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2025-10-012026-03-31_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="Fact002121"
      unitRef="USD">32586</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-10-012025-03-31_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="Fact002123"
      unitRef="USD">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:InterestExpense
      contextRef="From2026-01-012026-03-31_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="Fact002125"
      unitRef="USD">12751</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-01-012025-03-31_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="Fact002127"
      unitRef="USD">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-10-012026-03-31_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="Fact002129"
      unitRef="USD">25502</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-10-012025-03-31_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="Fact002131"
      unitRef="USD">0</us-gaap:InterestExpense>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2026-03-31_custom_ConvertibleNotesMember"
      decimals="0"
      id="Fact002132"
      unitRef="USD">43795</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2025-09-30_custom_ConvertibleNotesMember"
      decimals="0"
      id="Fact002133"
      unitRef="USD">308737</us-gaap:ConvertibleNotesPayable>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="AsOf2026-03-31_custom_ConvertibleNotesMember"
      decimals="0"
      id="Fact002134"
      unitRef="USD">12877</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="AsOf2025-09-30_custom_ConvertibleNotesMember"
      decimals="0"
      id="Fact002135"
      unitRef="USD">45463</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
      contextRef="From2025-10-042025-10-06"
      decimals="0"
      id="Fact002139"
      unitRef="USD">296700</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <VWAV:IssuedDiscountConvertibleNotes
      contextRef="AsOf2025-10-06"
      decimals="0"
      id="Fact002141"
      unitRef="USD">38700</VWAV:IssuedDiscountConvertibleNotes>
    <VWAV:PurchasePrice
      contextRef="AsOf2025-10-06"
      decimals="0"
      id="Fact002143"
      unitRef="USD">258000</VWAV:PurchasePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2025-10-042025-10-06"
      decimals="0"
      id="Fact002145"
      unitRef="USD">8000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2026-01-012026-03-31_us-gaap_DebtMember"
      decimals="0"
      id="Fact002147"
      unitRef="USD">14012</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2025-01-012025-03-31_us-gaap_DebtMember"
      decimals="0"
      id="Fact002149"
      unitRef="USD">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2025-10-012026-03-31_us-gaap_DebtMember"
      decimals="0"
      id="Fact002151"
      unitRef="USD">28024</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-10-012025-03-31_us-gaap_DebtMember"
      decimals="0"
      id="Fact002153"
      unitRef="USD">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <VWAV:InterestExpenses
      contextRef="From2026-01-012026-03-31_us-gaap_DebtMember"
      decimals="0"
      id="Fact002155"
      unitRef="USD">10681</VWAV:InterestExpenses>
    <VWAV:InterestExpenses
      contextRef="From2025-01-012025-03-31_us-gaap_DebtMember"
      decimals="0"
      id="Fact002157"
      unitRef="USD">0</VWAV:InterestExpenses>
    <VWAV:InterestExpenses
      contextRef="From2025-10-012026-03-31_us-gaap_DebtMember"
      decimals="0"
      id="Fact002159"
      unitRef="USD">24693</VWAV:InterestExpenses>
    <VWAV:InterestExpenses
      contextRef="From2024-10-012025-03-31_us-gaap_DebtMember"
      decimals="0"
      id="Fact002161"
      unitRef="USD">0</VWAV:InterestExpenses>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2026-03-31_custom_ConvertibleNotesMember_us-gaap_DebtMember"
      decimals="0"
      id="Fact002163"
      unitRef="USD">111871</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2025-09-30_custom_ConvertibleNotesMember_us-gaap_DebtMember"
      decimals="0"
      id="Fact002165"
      unitRef="USD">0</us-gaap:ConvertibleNotesPayable>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="AsOf2026-03-31_custom_ConvertibleNotesMember_us-gaap_DebtMember"
      decimals="0"
      id="Fact002167"
      unitRef="USD">18677</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="AsOf2025-09-30_custom_ConvertibleNotesMember_us-gaap_DebtMember"
      decimals="0"
      id="Fact002169"
      unitRef="USD">0</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
      contextRef="From2025-11-102025-11-12"
      decimals="0"
      id="Fact002171"
      unitRef="USD">354200</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <VWAV:IssuedDiscountConvertibleNotes
      contextRef="AsOf2025-11-12"
      decimals="0"
      id="Fact002173"
      unitRef="USD">46200</VWAV:IssuedDiscountConvertibleNotes>
    <VWAV:PurchasePrice
      contextRef="AsOf2025-11-12"
      decimals="0"
      id="Fact002175"
      unitRef="USD">308000</VWAV:PurchasePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2025-11-102025-11-12"
      decimals="0"
      id="Fact002177"
      unitRef="USD">8000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2026-01-012026-03-31_custom_Debt1Member"
      decimals="0"
      id="Fact002179"
      unitRef="USD">17533</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2025-01-012025-03-31_custom_Debt1Member"
      decimals="0"
      id="Fact002181"
      unitRef="USD">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2025-10-012026-03-31_custom_Debt1Member"
      decimals="0"
      id="Fact002183"
      unitRef="USD">24174</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-10-012025-03-31_custom_Debt1Member"
      decimals="0"
      id="Fact002185"
      unitRef="USD">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <VWAV:InterestExpenses
      contextRef="From2026-01-012026-03-31_custom_Debt1Member"
      decimals="0"
      id="Fact002187"
      unitRef="USD">12751</VWAV:InterestExpenses>
    <VWAV:InterestExpenses
      contextRef="From2025-01-012025-03-31_custom_Debt1Member"
      decimals="0"
      id="Fact002189"
      unitRef="USD">0</VWAV:InterestExpenses>
    <VWAV:InterestExpenses
      contextRef="From2025-10-012026-03-31_custom_Debt1Member"
      decimals="0"
      id="Fact002191"
      unitRef="USD">23909</VWAV:InterestExpenses>
    <VWAV:InterestExpenses
      contextRef="From2024-10-012025-03-31_custom_Debt1Member"
      decimals="0"
      id="Fact002193"
      unitRef="USD">0</VWAV:InterestExpenses>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2026-03-31_custom_ConvertibleNotesMember_custom_Debt1Member"
      decimals="0"
      id="Fact002195"
      unitRef="USD">324174</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2025-09-30_custom_ConvertibleNotesMember_custom_Debt1Member"
      decimals="0"
      id="Fact002197"
      unitRef="USD">0</us-gaap:ConvertibleNotesPayable>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="AsOf2026-03-31_custom_ConvertibleNotesMember_custom_Debt1Member"
      decimals="0"
      id="Fact002199"
      unitRef="USD">30026</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="AsOf2025-09-30_custom_ConvertibleNotesMember_custom_Debt1Member"
      decimals="0"
      id="Fact002201"
      unitRef="USD">0</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:AdvanceRent
      contextRef="AsOf2025-07-25"
      decimals="-3"
      id="Fact002204"
      unitRef="USD">3000000.0</us-gaap:AdvanceRent>
    <us-gaap:AdvanceRent
      contextRef="AsOf2025-09-11"
      decimals="-3"
      id="Fact002205"
      unitRef="USD">2000000.0</us-gaap:AdvanceRent>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2026-03-31_custom_ConversionPriceMember"
      decimals="INF"
      id="Fact002206"
      unitRef="USDPShares">1.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002208"
      unitRef="USD">750000</us-gaap:StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact002210"
      unitRef="Ratio">0.050</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentFairValue
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002212"
      unitRef="USD">5000000</us-gaap:DebtInstrumentFairValue>
    <VWAV:FairValueOfNotes
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002214"
      unitRef="USD">4831699</VWAV:FairValueOfNotes>
    <VWAV:FairValueOfNotes
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact002216"
      unitRef="USD">4552653</VWAV:FairValueOfNotes>
    <us-gaap:InterestExpense
      contextRef="From2026-01-012026-03-31_custom_ConvertibleNotesMember"
      decimals="0"
      id="Fact002217"
      unitRef="USD">75616</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-01-012025-03-31_custom_ConvertibleNotesMember"
      decimals="0"
      id="Fact002218"
      unitRef="USD">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-10-012026-03-31_custom_ConvertibleNotesMember"
      decimals="0"
      id="Fact002219"
      unitRef="USD">150411</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-10-012025-03-31_custom_ConvertibleNotesMember"
      decimals="0"
      id="Fact002220"
      unitRef="USD">0</us-gaap:InterestExpense>
    <VWAV:AggregatePrincipalAmount
      contextRef="AsOf2026-01-09"
      decimals="0"
      id="Fact002224"
      unitRef="USD">354200</VWAV:AggregatePrincipalAmount>
    <VWAV:AggregateOriginalIssueDiscount
      contextRef="AsOf2026-01-09"
      decimals="0"
      id="Fact002226"
      unitRef="USD">46200</VWAV:AggregateOriginalIssueDiscount>
    <VWAV:PurchasePrice
      contextRef="AsOf2026-01-09"
      decimals="0"
      id="Fact002228"
      unitRef="USD">293000</VWAV:PurchasePrice>
    <VWAV:AdditionalFees
      contextRef="AsOf2026-01-09"
      decimals="0"
      id="Fact002230"
      unitRef="USD">8000</VWAV:AdditionalFees>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2026-01-012026-03-31_custom_January2026NotesMember"
      decimals="0"
      id="Fact002232"
      unitRef="USD">14344</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2025-01-012025-03-31_custom_January2026NotesMember"
      decimals="0"
      id="Fact002234"
      unitRef="USD">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2025-10-012026-03-31_custom_January2026NotesMember"
      decimals="0"
      id="Fact002236"
      unitRef="USD">14344</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-10-012025-03-31_custom_January2026NotesMember"
      decimals="0"
      id="Fact002238"
      unitRef="USD">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <VWAV:InterestExpenses
      contextRef="From2026-01-012026-03-31_custom_January2026NotesMember"
      decimals="0"
      id="Fact002240"
      unitRef="USD">10626</VWAV:InterestExpenses>
    <VWAV:InterestExpenses
      contextRef="From2025-01-012025-03-31_custom_January2026NotesMember"
      decimals="0"
      id="Fact002242"
      unitRef="USD">0</VWAV:InterestExpenses>
    <VWAV:InterestExpenses
      contextRef="From2025-10-012026-03-31_custom_January2026NotesMember"
      decimals="0"
      id="Fact002244"
      unitRef="USD">10626</VWAV:InterestExpenses>
    <VWAV:InterestExpenses
      contextRef="From2024-10-012025-03-31_custom_January2026NotesMember"
      decimals="0"
      id="Fact002246"
      unitRef="USD">0</VWAV:InterestExpenses>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2026-03-31_custom_ConvertibleNotesMember_custom_January2026NotesMember"
      decimals="0"
      id="Fact002248"
      unitRef="USD">314344</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2025-09-30_custom_ConvertibleNotesMember_custom_January2026NotesMember"
      decimals="0"
      id="Fact002250"
      unitRef="USD">0</us-gaap:ConvertibleNotesPayable>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="AsOf2026-03-31_custom_ConvertibleNotesMember_custom_January2026NotesMember"
      decimals="0"
      id="Fact002252"
      unitRef="USD">39856</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="AsOf2025-09-30_custom_ConvertibleNotesMember_custom_January2026NotesMember"
      decimals="0"
      id="Fact002254"
      unitRef="USD">0</us-gaap:UnamortizedDebtIssuanceExpense>
    <VWAV:SignificantUnobservableInputsConvertibleDebtTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002256">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--SignificantUnobservableInputsConvertibleDebtTableTextBlock_zRzMLvTnRvS4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Notes Payable (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B5_z5crKGFUuEFe" style="display: none"&gt;Schedule of unobservable inputs of convertible notes&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Convertible Notes&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Convertible Notes balance at September 30,
2025&lt;/td&gt;
&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ConvertibleNotesPayable_iS_c20251001__20251231_zGcb6eK72w53" style="width: 18%; text-align: right" title="Convertible notes beginning balance"&gt;4,552,653&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Change in fair value&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_c20251001__20251231_zZ2lCTI1ca33" style="text-align: right" title="Change in fair value"&gt;286,680&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Convertible Notes balance at December 31, 2025&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ConvertibleNotesPayable_iS_c20260101__20260331_zKjBrEOFABH5" style="text-align: right" title="Convertible notes beginning balance"&gt;4,839,333&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Change in fair value&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_c20260101__20260331_zLWGiPxoGXf3" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(7,634&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Convertible Notes balance at March 31, 2026&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--ConvertibleNotesPayable_iE_c20260101__20260331_z9jWqCA8pNs5" style="border-bottom: Black 2.5pt double; text-align: right" title="Convertible notes ending balance"&gt;4,831,699&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</VWAV:SignificantUnobservableInputsConvertibleDebtTableTextBlock>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact002258"
      unitRef="USD">4552653</us-gaap:ConvertibleNotesPayable>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="From2025-10-012025-12-31"
      decimals="0"
      id="Fact002260"
      unitRef="USD">286680</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact002262"
      unitRef="USD">4839333</us-gaap:ConvertibleNotesPayable>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact002264"
      unitRef="USD">-7634</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002266"
      unitRef="USD">4831699</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002270">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ConvertibleDebtTableTextBlock_zo6TEoNt2TB4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Notes Payable (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B5_zDYYLr92FgN1" style="display: none"&gt;Schedule of key assumptions used to value the convertible
notes&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-indent: -10pt"&gt;Stock Price&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--StockholdersEquityOtherShares_c20251001__20260331_zdHM3CLYlona" style="width: 12%; text-align: right" title="Stock Price"&gt;4.74&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--StockholdersEquityOtherShares_c20241001__20250930_z7jlhc2mQmvf" style="width: 12%; text-align: right" title="Stock Price"&gt;9.53&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Equity Volatility&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20251001__20260331_zroL44i7Gg5c" title="Equity Volatility"&gt;59&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20241001__20250930_znWHgB5vMoxb" title="Equity Volatility"&gt;52&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Discount Rate&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20251001__20260331_zy2rCnJevby1" title="Discount Rate"&gt;45&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20241001__20250930_zNBiOT7brvRc" title="Discount Rate"&gt;41&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk free rate of return&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20251001__20260331__srt--RangeAxis__srt--MaximumMember_zWEO7WfX6DUa" title="Risk free rate of return"&gt;3.67&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20251001__20260331__srt--RangeAxis__srt--MinimumMember_zjCnWwz0n2B1" title="Risk free rate of return"&gt;3.68&lt;/span&gt; %&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20241001__20250930_zOH9C4sOdlz6" title="Risk free rate of return"&gt;3.70&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Term to maturity (years)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20251001__20260331__srt--RangeAxis__srt--MaximumMember_zqilu958Zcmh" title="Term to maturity (years)"&gt;0.32&lt;/span&gt;-&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20251001__20260331__srt--RangeAxis__srt--MinimumMember_zaWD2nVwMtai" title="Term to maturity (years)"&gt;0.45&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20241001__20250930_zuBCumfMWeI1" title="Term to maturity (years)"&gt;0.82&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact002272"
      unitRef="Shares">4.74</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact002274"
      unitRef="Shares">9.53</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact002276"
      unitRef="Ratio">0.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact002278"
      unitRef="Ratio">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact002280"
      unitRef="Ratio">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact002282"
      unitRef="Ratio">0.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-10-012026-03-31_srt_MaximumMember"
      decimals="INF"
      id="Fact002284"
      unitRef="Ratio">0.0367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-10-012026-03-31_srt_MinimumMember"
      decimals="INF"
      id="Fact002286"
      unitRef="Ratio">0.0368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact002288"
      unitRef="Ratio">0.0370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-10-012026-03-31_srt_MaximumMember"
      id="Fact002290">P0Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-10-012026-03-31_srt_MinimumMember"
      id="Fact002292">P0Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2024-10-012025-09-30" id="Fact002294">P0Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <VWAV:ScheduleOfUnobservableInputsConvertibleNotesTableTexxtBlock contextRef="From2025-10-01to2026-03-31" id="Fact002296">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfUnobservableInputsConvertibleNotesTableTexxtBlock_zSZl2f89lcr" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Notes Payable (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;span id="xdx_8BE_z60tacX1GyE6" style="display: none"&gt;Schedule of balance of the convertible
notes with significant unobservable inputs&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49E_20260331__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zjSaBPuGstej" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_499_20250930__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zBZh4BYykb95" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--ConvertibleNotesAtFairValue_iI_zL5YmZqCB375" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Convertible notes (at fair value)&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;4,831,699&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;4,552,653&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--JulyNotesAtAmortizedCost_iI_zrpQpXYCKKq7" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;July Notes (at amortized cost)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;43,795&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;308,737&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--OctoberNoteAtAmortizedCost_iI_z9nlfjQMaji2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;October Note (at amortized cost)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;111,871&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2305"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--NovemberNoteAtAmortizedCost_iI_z2FwsfVPWfT2" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;November Note (at amortized cost)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;324,174&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2308"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--January2026NoteAtAmortizedCost_iI_z9EkB5UR7W7c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;January 2026 Note (at amortized cost))&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;314,344&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2311"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--BalanceConvertibleNotesPayable_iI_zWw50R2Xp5Gj" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Balance, Convertible notes payable&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,625,883&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,861,390&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</VWAV:ScheduleOfUnobservableInputsConvertibleNotesTableTexxtBlock>
    <VWAV:ConvertibleNotesAtFairValue
      contextRef="AsOf2026-03-31_custom_ConvertibleDebentureMember"
      decimals="0"
      id="Fact002298"
      unitRef="USD">4831699</VWAV:ConvertibleNotesAtFairValue>
    <VWAV:ConvertibleNotesAtFairValue
      contextRef="AsOf2025-09-30_custom_ConvertibleDebentureMember"
      decimals="0"
      id="Fact002299"
      unitRef="USD">4552653</VWAV:ConvertibleNotesAtFairValue>
    <VWAV:JulyNotesAtAmortizedCost
      contextRef="AsOf2026-03-31_custom_ConvertibleDebentureMember"
      decimals="0"
      id="Fact002301"
      unitRef="USD">43795</VWAV:JulyNotesAtAmortizedCost>
    <VWAV:JulyNotesAtAmortizedCost
      contextRef="AsOf2025-09-30_custom_ConvertibleDebentureMember"
      decimals="0"
      id="Fact002302"
      unitRef="USD">308737</VWAV:JulyNotesAtAmortizedCost>
    <VWAV:OctoberNoteAtAmortizedCost
      contextRef="AsOf2026-03-31_custom_ConvertibleDebentureMember"
      decimals="0"
      id="Fact002304"
      unitRef="USD">111871</VWAV:OctoberNoteAtAmortizedCost>
    <VWAV:NovemberNoteAtAmortizedCost
      contextRef="AsOf2026-03-31_custom_ConvertibleDebentureMember"
      decimals="0"
      id="Fact002307"
      unitRef="USD">324174</VWAV:NovemberNoteAtAmortizedCost>
    <VWAV:January2026NoteAtAmortizedCost
      contextRef="AsOf2026-03-31_custom_ConvertibleDebentureMember"
      decimals="0"
      id="Fact002310"
      unitRef="USD">314344</VWAV:January2026NoteAtAmortizedCost>
    <VWAV:BalanceConvertibleNotesPayable
      contextRef="AsOf2026-03-31_custom_ConvertibleDebentureMember"
      decimals="0"
      id="Fact002313"
      unitRef="USD">5625883</VWAV:BalanceConvertibleNotesPayable>
    <VWAV:BalanceConvertibleNotesPayable
      contextRef="AsOf2025-09-30_custom_ConvertibleDebentureMember"
      decimals="0"
      id="Fact002314"
      unitRef="USD">4861390</VWAV:BalanceConvertibleNotesPayable>
    <VWAV:UnderwritersAgreementTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002316">&lt;p id="xdx_802_ecustom--UnderwritersAgreementTextBlock_zLXUYKFQDR5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 17 &#x2014; &lt;span id="xdx_82F_zkYPwLCeR96e"&gt;Underwriter&#x2019;s Agreement&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Upon completion of the initial public offering
of Bannix IPO, the underwriters are entitled to a deferred underwriting discount of $&lt;span id="xdx_901_ecustom--DeferredUnderwritingDiscount_iI_c20260331_zQMyReJiYf7c" title="Deferred Underwriting Discount"&gt;225,000&lt;/span&gt;, solely in the event that the Company completes
a Business Combination, subject to the terms of the underwriting agreement. Additionally, the underwriters are entitled to a Business
Combination marketing fee of &lt;span id="xdx_90A_ecustom--BusinessCombinationMarketingFeePercentage_iI_dp_c20260331_ztfFJWxAxKjk" title="Business Combination marketing fee"&gt;3.5&lt;/span&gt;% of the gross proceeds of the sale of Units in the IPO upon the completion of the Company&#x2019;s initial
Business Combination subject to the terms of the underwriting agreement. At the close of the Reverse Acquisition, the Company assumed
$&lt;span id="xdx_90B_ecustom--DeferredUnderwritingDiscount_iI_c20260331_zKZxzrbXTDRi" title="Deferred Underwriting Discount"&gt;225,000&lt;/span&gt; of underwriting discount which is included in deferred underwriting discount on the accompanying unaudited condensed consolidated
balance sheets at March 31, 2026 and September 30, 2025. The amount is due on demand but payable only after the repayment of the SEPA
Pre-paid Advances (See Note 19).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On June 9, 2025, Bannix entered into an amendment to the underwriting
agreement. Pursuant to the amendment, payments of the Business Combination marketing fee will be modified as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;$&lt;span id="xdx_90F_ecustom--CahPaid_iI_c20260331_zQ3cRTr6u856" title="Cah Paid"&gt;500,000&lt;/span&gt; shall be paid in cash, deferred
                                            until the later of (i) twelve (12) months after closing or (ii) the date when a key financing
                                            facility of the post-combination company is fully equitized.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;$&lt;span id="xdx_909_ecustom--CahPaidPostCombination_iI_c20260331_zJgVaMLNzrrd" title="Cah Paid Post Combination"&gt;1,300,000&lt;/span&gt; shall be paid in shares
                                            of the post-combination company&#x2019;s common stock, calculated based on the 30-day VWAP
                                            immediately following the closing date. These shares will be subject to piggyback registration
                                            rights and a lock-up that expires upon the termination or full amortization of the referenced
                                            financing facility.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At the close of the Reverse Acquisition, the Company
assumed $&lt;span id="xdx_902_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20251001__20260331_zOsYTt7LdNPi"&gt;1,800,000&lt;/span&gt; of marketing fees costs which is included in accounts payable and accrued expenses on the accompanying unaudited condensed
consolidated balance sheets at March 31, 2026 and September 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, Bannix issued the underwriter (and/or
its designees) (the &#x201c;Representative&#x201d;) &lt;span id="xdx_90A_eus-gaap--ConversionOfStockSharesIssued1_c20251001__20260331__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwriterMember_zkyhT2oVxo0l"&gt;393,000&lt;/span&gt; shares of Common Stock for $0.01 per share (the &#x201c;Representative Shares&#x201d;)
upon the consummation of the Bannix IPO. A balance of $&lt;span id="xdx_904_eus-gaap--CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance_iI_c20260331_zncj2thghjUc"&gt;3,930&lt;/span&gt; outstanding by the Representative for the Representative Shares were assumed
at close at the Reverse Acquisition. As of March 31, 2026 and September 30, 2025, the Representative has not yet paid for these shares,
and the amount owed of $&lt;span id="xdx_908_eus-gaap--PrepaidExpenseCurrent_iI_c20250930__us-gaap--RelatedPartyTransactionAxis__custom--BannixClassACommonStockMember_zVhVxOwnlwW5"&gt;3,930&lt;/span&gt; is included in prepaid expenses on the unaudited condensed consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</VWAV:UnderwritersAgreementTextBlock>
    <VWAV:DeferredUnderwritingDiscount
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002318"
      unitRef="USD">225000</VWAV:DeferredUnderwritingDiscount>
    <VWAV:BusinessCombinationMarketingFeePercentage
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002320"
      unitRef="Ratio">0.035</VWAV:BusinessCombinationMarketingFeePercentage>
    <VWAV:DeferredUnderwritingDiscount
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002322"
      unitRef="USD">225000</VWAV:DeferredUnderwritingDiscount>
    <VWAV:CahPaid
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002324"
      unitRef="USD">500000</VWAV:CahPaid>
    <VWAV:CahPaidPostCombination
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002326"
      unitRef="USD">1300000</VWAV:CahPaidPostCombination>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002327"
      unitRef="USD">1800000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2025-10-012026-03-31_custom_UnderwriterMember"
      decimals="INF"
      id="Fact002330"
      unitRef="Shares">393000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002331"
      unitRef="USD">3930</us-gaap:CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-09-30_custom_BannixClassACommonStockMember"
      decimals="0"
      id="Fact002332"
      unitRef="USD">3930</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002334">&lt;p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zUsd57p6lUbk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 18 &#x2014; &lt;span id="xdx_828_ziOnSd1RAhV"&gt;Commitment and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Standby Equity Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 25, 2025, the Company entered into the
Standby Equity Purchase Agreement (&#x201c;SEPA&#x201d;) with YA II PN, LTD, a Cayman Islands exempt limited partnership (the &#x201c;Investor&#x201d;)
pursuant to which the Company has the right to sell to the Investor up to $50 million of its shares of common stock, subject to certain
limitations and conditions set forth in the SEPA, from time to time during the term of the SEPA, from time to time during the term of
the SEPA.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Upon the satisfaction of the conditions to the
Investor&#x2019;s purchase obligation set forth in the SEPA, including having a registration statement registering the resale of the shares
of common stock issuable under the SEPA declared effective by the SEC, the Company will have the right, but not the obligation, from
time to time at its discretion until the SEPA is terminated to direct Investor to purchase a specified number of shares of common stock
(&#x201c;Advance&#x201d;) by delivering written notice to Investor (&#x201c;Advance Notice&#x201d;). While there is no mandatory minimum
amount for any Advance, it may not exceed an amount equal to 100% of the average of the daily traded amount during the five consecutive
trading days immediately preceding an Advance Notice.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The shares of common stock purchased pursuant
to an Advance delivered by the Company will be purchased at a price equal to 97% of the lowest daily VWAP of the shares of common stock
during the three consecutive trading days commencing on the date of the delivery of the Advance Notice, other than the daily VWAP on
a day in which the daily VWAP is less than a minimum acceptable price as stated by the Company in the Advance Notice or there is no VWAP
on the subject trading day. The Company may establish a minimum acceptable price in each Advance Notice below which the Company will
not be obligated to make any sales to Investor. &#x201c;VWAP&#x201d; is defined as the daily volume weighted average price of the shares
of common stock for such trading day on the Nasdaq Stock Market during regular trading hours as reported by Bloomberg L.P.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In
                                            connection with the SEPA, and subject to the condition set forth therein, Investor advanced
                                            to the Company in the form of convertible promissory notes (the &#x201c;Convertible Notes&#x201d;)
                                            an aggregate principal amount of $5 million (the &#x201c;Pre-Paid Advance&#x201d;) (See Note
                                            17).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Investor, in its sole discretion and providing
that there is a balance remaining outstanding under the Convertible Notes, may deliver a notice under the SEPA requiring the issuance
and sale of shares of common stock to the Investor at the Conversion Price in consideration of an offset of the Convertible Notes (&#x201c;Investor
Advance&#x201d;). The Investor, in its sole discretion, may select the amount of any Pre-Paid Advance, provided that the number of shares
issued does not cause the Investor to exceed the 4.99% ownership limitation, does not exceed the Exchange Cap or the number of shares
of common stock that are registered. As a result of a Pre-Paid Advance, the amounts payable under the Convertible Notes will be offset
by such amount subject to each Investor Advance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company will control the timing and amount
of any sales of shares of common stock to the Investor, except with respect to the Pre-Paid Advances. Actual sales of shares of common
stock to the Investor as a Pre-Paid Advance under the SEPA will depend on a variety of factors to be determined by the Company from time
to time, which may include, among other things, market conditions, the trading price of the Company&#x2019;s common stock and determinations
by the Company as to the appropriate sources of funding for our business and operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The SEPA will automatically terminate on the earliest
to occur of (i) the 24-month anniversary of the date of the SEPA or (ii) the date on which the Investor shall have made payment of Advances
pursuant to the SEPA for shares of common stock equal to $&lt;span id="xdx_901_eus-gaap--AdvancesOnInventoryPurchases_iI_c20260331_zGEuP52iIYek"&gt;50,000,000&lt;/span&gt;. The Company has the right to terminate the SEPA at no cost or penalty
upon five (5) trading days&#x2019; prior written notice to the Investor, provided that there are no outstanding Advance Notices for which
shares of common stock need to be issued and the Company has paid all amounts owed to the Investor pursuant to the Convertible Notes.
The Company and the Investor may also agree to terminate the SEPA by mutual written consent. Neither the Company nor the Investor may
assign or transfer our respective rights and obligations under the SEPA, and no provision of the SEPA may be modified or waived by us
or Investor other than by an instrument in writing signed by both parties.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As consideration for the Investor&#x2019;s commitment
to purchase the shares of common stock pursuant the SEPA, the Company paid the Investor, (i) a structuring fee in the amount of $&lt;span id="xdx_907_ecustom--StructuringFeeAmount_iI_c20260331_z3r7lwSHUwV5" title="Structuring Fee Amount"&gt;30,000&lt;/span&gt;
and (ii) &lt;span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorsMember_ztHAAOMli23i"&gt;200,000&lt;/span&gt; shares of common stock as an equity fee. Further, the Company is required to pay Investor a commitment fee of $&lt;span id="xdx_903_eus-gaap--CommitmentsAndContingencies_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorsMember_zKJfT7wiTYK9" title="Commitments contingencies"&gt;500,000&lt;/span&gt;
of which $&lt;span id="xdx_90B_eus-gaap--PayableCommonStockRedeemed_iI_c20260331_zQiQ70OCcRNh"&gt;250,000&lt;/span&gt; shall be due and payable on the earlier of the effective date of the initial registration statement, or 60 days following
the date hereof and the remaining $250,000 shall be due and payable on the date that is 90 days following the initial due date to be
paid by the issuance of such number of common shares that is equal to the applicable portion of the commitment fee divided by the average
of the daily VWAPs of the common shares during the three trading days immediately prior to the applicable due date. The total consideration
of $&lt;span id="xdx_90E_eus-gaap--DeferredCosts_iI_c20260331_zWiCuk0vOP27"&gt;1,350,000&lt;/span&gt; is recorded as general and administrative expenses in the statement of operations for the year ended September 30, 2025
and is inclusive of fair value of $&lt;span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20251001__20260331__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorsMember_z9Yfd7hhpwx5"&gt;470,000&lt;/span&gt; of the &lt;span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251001__20260331__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorsMember_zwiVfaeL2yvj"&gt;200,000&lt;/span&gt; shares issued and $&lt;span id="xdx_90A_ecustom--ConsultingFees_iI_c20260331_zyuve46EoEAc" title="Consulting fees"&gt;350,000&lt;/span&gt; consulting fees. At March 31, 2026 and September
30, 2025, $&lt;span id="xdx_902_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_c20241001__20250930_zpgCij7Fr6Th"&gt;140,000&lt;/span&gt; of the commitment fee is unpaid and included in accrued expenses on the accompanying unaudited condensed consolidated
balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The SEPA contains customary representations, warranties,
conditions and indemnification obligations of the parties. The representations, warranties and covenants contained in such agreements
were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements
and may be subject to limitations agreed upon by the contracting parties.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The net proceeds under the SEPA to the Company
will depend on the frequency and prices at which the Company sells its shares of common stock to Investor. The Company expects that any
proceeds received from such sales to Investor will be used for working capital and general corporate purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The SEPA fails the fixed-for-fixed equity classification
test due to the Exchange Cap requiring shareholder approval, which constitutes a variable settlement contingency outside the issuer&#x2019;s
control. Therefore, equity classification under ASC 815-40 is precluded, and the SEPA must be accounted for as a liability (or derivative
liability, as applicable). While the SEPA has an underlying (the issuer&#x2019;s stock price) and a notional amount (the $50 million commitment),
it does not meet the third characteristic of a derivative because it requires more than a nominal initial net investment (e.g., the $5
million Pre-Paid Advance in two tranches and related fees). Therefore, the SEPA does not meet the definition of a derivative under ASC
815-10-15-83. Accordingly, the SEPA should be recorded as nonderivative liability requiring ongoing fair value remeasurement. As of March
31, 2026 and September 30, 2025, based on management assumptions the SEPA liability was zero.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Amendment to SEPA&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 19, 2026, the Company entered into
an amendment to the Standby Equity Purchase Agreement, dated as of July 25, 2025 (the &#x201c;SEPA Amendment No. 1&#x201d;), by and between
the Company and YA II PN, Ltd. (the &#x201c;Investor&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Amendment amends the SEPA to, among other things:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(i) remove the Investor&#x2019;s ability to deliver
Investor Notices, which previously allowed the Investor to require the Company to issue and sell shares of Common Stock to the Investor
in offset of amounts outstanding under the Promissory Notes;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(ii) modify the conditions under which an amortization
event may occur, providing that no amortization event shall be deemed to have occurred due to a Registration Event ( prior to July 15,
2026 (the &#x201c;Rule 144 Date&#x201d;), and after the Rule 144 date, no such amortization event shall occur so long as the Company remains
current on its filings with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) and the Investor is able to rely on Rule 144
under the Securities Act of 1933, as amended, to resell shares of Common Stock issuable under the Promissory Notes;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(iii) cancel the Investor&#x2019;s obligation to
fund an additional $&lt;span id="xdx_903_ecustom--AdditionalPrincipalAmount_iI_c20250911_zaCGG4LBMUmd" title="Additional principal amount"&gt;2,000,000&lt;/span&gt; in principal amount to the Company as set forth in a letter agreement dated September 11, 2025, between
the Company and the Investor (provided that subsequent fundings on the same or different terms may be mutually agreed by the parties
in the future and documented in writing); and (iv) require the Company to use its best efforts to promptly respond to comments from the
staff of the SEC regarding the Company&#x2019;s initial Registration Statement on Form S-1 (File No. 333-289952) and seek effectiveness
of such Registration Statement as soon as reasonably practicable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three and six months ended March 31,
2026, the Company issued &lt;span id="xdx_90C_eus-gaap--ConversionOfStockSharesIssued1_c20251001__20260331_zTVtOfufaMp7" title="Shares issued"&gt;233,678&lt;/span&gt; shares under the SEPA for total proceeds of $&lt;span id="xdx_900_ecustom--TotalProceeds_c20260101__20260331_zH6nYLricJJ8" title="Total proceeds"&gt;1,760,672&lt;/span&gt;, of which $&lt;span id="xdx_90E_ecustom--TotalProceeds_c20251001__20260331_zyyu306eSJia" title="Total proceeds"&gt;780,462&lt;/span&gt; was applied to the YA II PN
Notes (See Note 13).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Joint Venture&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 25, 2025, the Company entered into a
Strategic Joint Venture Agreement (the &#x201c;AIPHEX Agreement&#x201d;) with AIPHEX LTD (&#x201c;AIPHEX&#x201d;), GBT Tokenize Corp. (&#x201c;TOKENIZE&#x201d;),
and GBT Technologies, Inc. (&#x201c;GBT&#x201d;). Pursuant to the AIPHEX Agreement, the parties agreed to form a joint venture limited
liability company in the State of Nevada (the &#x201c;JV LLC&#x201d;) for the purpose of collaborating on certain designated defense and
technology projects (the &#x201c;Designated Projects and Background IP&#x201d;). The Company does not intend to pursue this agreement but
to date of this report has not formalized a cancellation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Memorandum of Understanding&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 2, 2025, the Company entered into
a Memorandum of Understanding (the &#x201c;MoU&#x201d;) with VEDA Aeronautics Private Limited (&#x201c;VEDA&#x201d;), a company incorporated
under the Companies Act, 2013, of India.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the MoU, the Company and VEDA intend
to collaborate on several Indian Ministry of Defense (&#x201c;MoD&#x201d;) procurement programs (the &#x201c;Programs&#x201d;), including
but not limited to: (a) Drone Kill System (Make-2) &#x2013; interceptor drone development; (b) ALTV (New Generation Light Tank) &#x2013;
357 tanks, with Company subsystems proposed as onboard modules; (c) FRCV (Main Battle Tank Program) &#x2013; 1,770 main battle tanks;
and (d) T72/T90 Retrofit Program for tanks. Under the MoU, VEDA has invited the Company to supply and develop core subsystems, including
counter-UAS systems, tactical drones, radar technologies, advance protection systems (APS) systems, sensor fusion technologies, and unmanned
platforms for defense and homeland security applications. The parties intend to collaborate in technical proposals, demonstrations, and
joint pursuit of contracts for these Programs. The Company does not intend to pursue this MOU but to date of this report has not formalized
a cancellation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Contingent Commission Payable&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 22, 2025, VisionWave Technologies executed
an Addendum to an existing agreement, pursuant to which Raptor LLC was appointed as exclusive sales agent for &lt;span id="xdx_905_eus-gaap--SharesIssued_iI_c20250522_z59lMltKknv1"&gt;280,534&lt;/span&gt; TFLM shares (See
Note 20) and Raptor LLC will be entitled to a fixed fee of $&lt;span id="xdx_90B_eus-gaap--AccruedSalesCommissionCurrentAndNoncurrent_iI_c20250522_zDhJ4ZNBRukl"&gt;50,000&lt;/span&gt;, payable from the gross proceeds of the share sale of the TFLM shares.
As of March 31, 2026, no sale of the TFLM shares has occurred, and VisionWave Technologies has not granted the required power of attorney
over its brokerage account to enable such sales. Accordingly, the commission obligation to Raptor LLC is considered contingent.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Consulting Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 26, 2025, the Company entered into
a Consulting Agreement (the &#x201c;CTMG Agreement&#x201d;) with Crypto Treasury Management Group, LLC (&#x201c;CTMG&#x201d;), pursuant to
which CTMG will provide advisory and strategic services to assist the Company in establishing a digital asset treasury reserve. The services
include, among other things, developing a crypto treasury strategy, recommending custodians, designing staking protocols (if applicable),
assisting with capital formation in collaboration with a licensed securities underwriter, and supporting regulatory and tax compliance
efforts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The CTMG Agreement has an initial term of two
years, subject to earlier termination under certain conditions, including for convenience with 60 days&#x2019; notice or for material
breach. In consideration for the services, the Company has agreed to pay CTMG: (i) a retainer fee of $&lt;span id="xdx_906_eus-gaap--PrepaidTaxes_iI_c20250924_zjvJSVum3Kr7"&gt;50,000&lt;/span&gt; upon signing, which was
pre-paid as an advance on September 24, 2025, with an additional $&lt;span id="xdx_90C_ecustom--AdditionalPrepaidAdvanceFee_iI_c20250924_zpR5X10bjum4" title="Additional Prepaid Advance Fee"&gt;50,000&lt;/span&gt; due upon execution of binding definitive agreements related
to the crypto treasury transaction; (ii) a success fee of 17 Bitcoin (or cash equivalent) upon successful deployment of at least $20
million into crypto assets for the Company&#x2019;s treasury; and (iii) &lt;span id="xdx_904_eus-gaap--SharesIssued_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__custom--CryptoAssetsMember_zd539mwsXoG"&gt;250,000&lt;/span&gt; shares of the Company&#x2019;s common stock upon closing
of the crypto treasury transaction, subject to SEC Rule 144 restrictions and inclusion in future registration statements where applicable.
The Company will also reimburse CTMG for pre-approved reasonable expenses. For the three and six months ended March 31, 2026, no additional
costs were incurred under this agreement. The Company does not intend to pursue this agreement due to market changes, but to date of
this report has not formalized a cancellation&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Litigation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;From time to time, the Company may be subject
to routine litigation, claims or disputes in the ordinary course of business. The Company defends itself vigorously in all such matters
but cannot predict the outcome or effect of any potential litigation, claims or disputes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Better Works LLC&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 5, 2025, Better Works LLC filed an
action in the Supreme Court of the State of New York, New York County, captioned Better Works LLC v. VisionWave Holdings, Inc. and Douglas
E. Davis, Index No. 655268/2025. The Summons with Notice asserts claims for breach of contract and seeks (i) a declaratory judgment regarding
affiliate status and the applicability or expiration of certain lock-up provisions relating to private-placement units exchanged in connection
with the Company&#x2019;s business combination, (ii) injunctive relief permitting the plaintiff to sell such units, and (iii) monetary
damages in an amount to be determined. Service of process addressed to VisionWave&#x2019;s Delaware registered agent was recorded as received
on September 9, 2025. On September 30, 2025, counsel for the Company and Mr. Davis served a demand for the complaint pursuant to CPLR
3012(b), expressly reserving all defenses, including objections to service and personal jurisdiction. As of the date of this Report,
no complaint has been served on the defendants. The Company believes the asserted claims are without merit and intends to defend the
matter vigorously.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;i&gt;Maxim Group LLC&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 17, 2026, Maxim Group LLC filed a complaint
against VisionWave Holdings, Inc. in the Supreme Court of the State of New York, County of New York, alleging breach of contract and
seeking damages related to certain financing transactions completed by the Company in July 2025 and February 2026 pursuant to an engagement
agreement dated April 9, 2025. Maxim alleges entitlement to placement fees and declaratory relief in connection with financings involving
YA II PN, Ltd., a fund managed by Yorkville Advisors Global, LP. The action includes claims for alleged unpaid fees of approximately
$1.33 million, declaratory relief concerning alleged tail rights and rights of first refusal, attorneys&#x2019; fees, interest, and other
relief. The action was filed under an unassigned New York County index number as of the filing date. The Company believes the asserted
claims are without merit and intends to defend the matter vigorously.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Also on April 17, 2026, the Company filed a
separate action against Maxim Group LLC in the Supreme Court of the State of New York, County of New York, asserting claims for breach
of contract, declaratory judgment, and unjust enrichment. The Company alleges, among other things, that Maxim did not identify or place
the relevant financing transactions, was not entitled to compensation under the parties&#x2019; agreement, and wrongfully invoiced the
Company for fees related to the July 2025 and February 2026 financings. The Company seeks, among other relief, repayment of approximately
$&lt;span id="xdx_90D_eus-gaap--ProceedsFromRepaymentsOfDebt_c20260416__20260417_z5ySk26mrQP5" title="Repayment"&gt;210,000&lt;/span&gt; previously paid to Maxim, rescission of an additional invoice of approximately $1.4 million, declaratory relief regarding the
parties&#x2019; rights under the agreement, damages, restitution, interest, and costs. The Company believes Maxim&#x2019;s claims are without
merit and intends to vigorously defend against them while aggressively pursuing its own claims. This action was also filed under an unassigned
New York County index number as of the filing date. At this early stage of the proceedings, the Company is unable to reasonably estimate
the ultimate outcome or potential loss, if any, associated with these matters.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i&gt;Pre-litigation disputes with former employees&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company is involved in certain pre-litigation
disputes with former employees, former executives, and other individuals associated with the Company arising primarily from organizational
changes implemented following the departure of the Company&#x2019;s former Chief Executive Officer in late December 2025. Such matters
include allegations relating to severance, unpaid compensation, notice-period pay, equity awards, and related contractual and employment
matters. Certain individuals have asserted claims through counsel, and the parties have engaged in correspondence and preliminary settlement
discussions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company disputes the allegations and claims
asserted in these matters and intends to vigorously defend its positions. As of the date of this Quarterly Report, no formal lawsuits,
arbitrations, or other legal proceedings have been filed with respect to these matters. Due to the early stage of these disputes, the
absence of formal proceedings, and the inherent uncertainty surrounding such matters, the Company is unable to reasonably estimate the
possible loss or range of loss, if any, that may result from these matters. Accordingly, no liability has been accrued in the accompanying
condensed consolidated financial statements.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Except as described above, the Company is not
a party to any other pending legal proceedings that management believes, individually or in the aggregate, would have a material adverse
effect on the Company&#x2019;s business, financial condition, or results of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;AI Infrastructure Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 5, 2025, the Company entered into an
Order Form (the &#x201c; PVML Agreement&#x201d;) with PVML Ltd., a Tel Aviv&#x2013;based provider of secure data-AI infrastructure. The
Agreement establishes a strategic collaboration to integrate PVML&#x2019;s secure, real-time data-AI infrastructure with the Company&#x2019;s
radar and AI-driven computer-vision technologies to enable secure, autonomous mission-data systems for defense and homeland-security
applications.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The terms of the PVML Agreement include:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The initial term is twelve (12) months,
                                            automatically renewable for successive one-year periods unless either party gives 60-days&#x2019;
                                            prior notice of non-renewal.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The Company will pay total consideration
                                            of $&lt;span id="xdx_905_eus-gaap--BusinessCombinationConsiderationTransferred1_c20251001__20260331_zryYgbX4RGKd" title="Consisting"&gt;600,000&lt;/span&gt;, consisting of (i) a cash component of $&lt;span id="xdx_909_eus-gaap--OtherNoncashIncomeTaxExpense_c20251001__20260331_zP7C5mYhUuZi" title="Cash component"&gt;250,000&lt;/span&gt; payable upon execution and (ii)
                                            an equity component valued at $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_c20251001__20260331_zIL4wcPhRe4l" title="Equity component value"&gt;350,000&lt;/span&gt;, to be settled through the issuance of&lt;span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260331_zaZNhWJQqpYl" title="Issuance of shares"&gt; 35,000&lt;/span&gt; shares
                                            of the Company&#x2019;s common stock valued at $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20260331_z1h1YX4pi7Kd" title="Share price"&gt;10.00 &lt;/span&gt;per share.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The PVML Agreement provides for a
                                            yearly platform fee covering 2.4 million PVML Units (&#x201c;PUs&#x201d;) of data-processing
                                            capacity, with usage fees for consumption beyond that level.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Each party retains ownership of its
                                            respective intellectual property, and the Company will own all outputs and derivatives generated
                                            through its use of the PVML platform.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company paid $&lt;span id="xdx_902_ecustom--PaidAgreementToCompany_c20251001__20260331_z07myZoaxpvk" title="Paid agreement to company"&gt;250,000&lt;/span&gt; under this agreement.
As of March 31, 2026, the Company has not issued shares for the equity component and the total value of $&lt;span id="xdx_90E_eus-gaap--RepurchaseAgreementsInterestExpenseAmount_c20251001__20260331_zpugaFNKcdL2" title="Paid agreement to company"&gt;350,000&lt;/span&gt; is included in stock-based
compensation liability on the unaudited condensed consolidated balance sheets. Subsequent to quarter-end, the parties continue to discuss
the timing and scope of the pilot phase of the arrangement. The Company will issue the shares or otherwise resolve the equity consideration
in accordance with the agreement or any future written amendment between the parties.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The United States and global markets are experiencing
volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and the Israel-Hamas
conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (&#x201c;NATO&#x201d;) deployed additional
military forces to eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various
sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial
institutions from the Society for Worldwide Interbank Financial Telecommunication payment system. Certain countries, including the United
States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical
tensions among a number of nations. The invasion of Ukraine by Russia and the Israel-Hamas conflict and the resulting measures that have
been taken&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our operations are located, in part, in Israel,
a region that has experienced ongoing political instability, armed conflicts, terrorist activities, and military tensions. The current
and potential escalation of hostilities involving Israel, Iran, the United States, and various regional actors could materially and adversely
affect our business, operations, financial condition, and results of operations. Since October 2023, military activity in the region
has intensified, including direct and indirect hostilities involving Israel and Iran. Any further escalation into a broader regional
conflict or war, including direct military confrontation between the United States and Iran or expanded attacks against Israel, could
disrupt our operations, infrastructure, personnel, suppliers, service providers, and customers. Such events may result in temporary closures
of facilities, workforce disruptions due to military reserve duty call-ups, delays in product development or delivery, cybersecurity
incidents, interruptions to communication and transportation networks, and reduced productivity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, regional instability may negatively
impact global and local economic conditions, including causing volatility in financial markets, inflationary pressures, increased energy
and shipping costs, disruptions in international trade and supply chains, and reduced access to capital markets. The continuation or
expansion of geopolitical tensions could also adversely affect investor sentiment and the market price of our securities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our operations in Israel are also subject to risks
associated with missile attacks, terrorist activities, civil unrest, and other security incidents, which may require us to suspend or
limit operations and could adversely affect.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Any of the above-mentioned factors, or any other
negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine,
the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely affect the Company&#x2019;s operations in the future
or with future capital raising activities. The Company has not been affected so far by these conflicts or US tariffs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Letter of Engagement with the National Oil Company of Liberia&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 18, 2026, the Company entered into a
Letter of Engagement (the &#x201c;LOE&#x201d;) with the National Oil Company of Liberia (&#x201c;NOCAL&#x201d;). The LOE relates to offshore
petroleum Blocks LB-4 and LB-5 located in the Liberia Basin and establishes a framework for the Company to advance toward the execution
of a Production Sharing Contract (&#x201c;PSC&#x201d;) with the Government of Liberia. The execution of a PSC is subject to prequalification
by the Liberia Petroleum Regulatory Authority, regulatory approvals, and legislative ratification.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under the LOE, the Company has been granted exclusive,
non-transferable rights to pursue the Blocks for an eight-month period from the date of execution, during which NOCAL is prohibited from
negotiating or granting rights in the Blocks to third parties. While the LOE does not constitute a final award of petroleum rights, it
contains binding provisions including confidentiality, exclusivity, and specified financial obligations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In connection with the LOE, the Company is subject to the following
near-term and contingent financial obligations:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Initial Signing Bonus:&lt;/b&gt; The
                                            Company is required to pay a binding initial signing bonus of $300,000 per block (totaling
                                            $600,000) within 60 days of the execution of the LOE. This amount is fully refundable without
                                            interest if the Blocks are not awarded to the Company for reasons not attributable to its
                                            own actions&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;







&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Data Licensing (Contingent):&lt;/b&gt;
                                            Following the execution of a PSC, the Company would be required to license seismic data for
                                            a minimum of $1,000,000 per block within 120 days&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;PSC Signature Bonus (Contingent):
                                            &lt;/b&gt;Upon execution and legislative ratification of a PSC, the Company would be obligated
                                            to pay a signature bonus of $1,000,000 per block within 90 days&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The contemplated PSC would include a multi-phase
exploration program spanning approximately seven years. It also contemplates certain carried and participating interests, including a
10% carried interest to NOCAL, a 10% carried interest to the Government of Liberia, a 5% carried interest to citizens, and up to 5% participation
by a local Liberian company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company notes that there is no assurance a
PSC will be executed or that the Company will ultimately be awarded the Blocks. The initiative is exploratory in nature and involves
significant geopolitical, regulatory, and operational risks.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Strategic Joint Venture Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 9, 2026, the Company entered into a
Strategic Joint Venture Agreement (the &#x201c;JV Agreement&#x201d;) with BOCA JOM, LLC (&#x201c;BOCA&#x201d;), GBT Tokenize Corp. (&#x201c;TOKENIZE&#x201d;),
and GBT Technologies, Inc. (&#x201c;GBT&#x201d;). The parties agreed to form a Nevada limited liability company (the &#x201c;JV LLC&#x201d;)
to develop, commercialize, and manage designated electronic design automation (EDA), defense, and high-security technology projects.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Capital Contributions and Valuation &lt;/i&gt;To
fund and resource the JV LLC, the parties agreed to specific capital and asset contributions. TOKENIZE will contribute its intellectual
property portfolio along with 897,102 shares of the Company&#x2019;s common stock, and GBT will contribute 2,020,500 shares of the Company&#x2019;s
common stock. BOCA will contribute the designated projects. Additionally, both the Company and BOCA will provide non-exclusive licenses
granting the JV LLC rights to use certain background intellectual property solely for the designated projects.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All contributions of the Company&#x2019;s securities
are subject to compliance with applicable securities laws and Nasdaq Listing Rules, including any requisite shareholder approval. To
facilitate the negotiation of equity ownership percentages, the parties utilized an internal reference value of $1.0 billion. The Company
explicitly notes that this internal value is not a statement of the JV LLC&#x2019;s actual fair market value, was reached without an independent
third-party valuation, and should not be relied upon as an indication of value for the JV LLC, its assets, or the Company&#x2019;s interest
therein.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Governance&lt;/i&gt;&lt;b&gt;:&lt;/b&gt; The JV LLC will be governed
by a three-member board, with specific governance and deadlock resolution mechanisms to be established in a separate operating agreement.
TOKENIZE and GBT will not participate in the management or governance of the JV LLC. Additionally, the JV Agreement permits the Company
to appoint a director to BOCA&#x2019;s board; any reciprocal appointment of a BOCA designee to the Company&#x2019;s board remains subject
to approval by the Company&#x2019;s independent directors, compliance with Nasdaq rules, and, if applicable, shareholder approval.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Intellectual Property, Term, and Termination:
&lt;/b&gt;Any intellectual property developed by the JV LLC (&#x201c;Foreground IP&#x201d;) will be wholly owned by the JV LLC, while each party
retains ownership of its independently developed background IP. The JV Agreement has an initial term of seven years and contains customary
termination rights, including if required regulatory approvals (e.g., CFIUS or export controls) are denied. Furthermore, if no designated
project generates revenue within twelve months following the formation of the JV LLC, the JV Agreement may be terminated, and contributed
consideration may be returned, subject to board-level fiduciary determinations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended March 31, 2026,
JV LLC was formed and funded by all parties except the Company. Since an operating agreement is not yet adopted for JV LLC, the transaction
is not deemed to be closed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Acquisition of Junko Solar Ltd&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 11, 2026, SolarDrone Ltd., an Israeli
subsidiary of the Company, entered into a Consulting and Share Purchase Agreement to acquire a 51% controlling interest in Junko Solar
Ltd., an Israeli company engaged in solar panel maintenance and cleaning services. As part of the transaction, Junko Solar Ltd. is transferring
its related operational activities, customer relationships, business opportunities, and operational assets to SolarDrone, which will
manage and operate the business going forward.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The transaction was based on a pre-money valuation
of $400,000 for Junko Solar Ltd. The aggregate purchase price for the 51% interest is $204,000, payable in cash in three equal installments
of $68,000: (i) upon execution of the agreement, (ii) within 35 days of execution, and (iii) within 35 days thereafter. The transfer
of the shares representing the 51% ownership to SolarDrone (or its designated affiliate) was triggered upon the payment of the first
installment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the acquisition, Mr. Amos Cohen,
the seller and former controlling shareholder of Junko Solar Ltd., was appointed as Chief Executive Officer and a director of SolarDrone
Ltd. Under a concurrent consulting arrangement, Mr. Cohen will provide management and strategic services to SolarDrone for a monthly
fee of &lt;span id="xdx_908_ecustom--MonthlyFee_iI_c20260311_zuyoRdg4GSp3" title="Monthly fee"&gt;50,000&lt;/span&gt; N.I.S. (New Israeli Shekels), plus applicable value-added tax (VAT).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 31, 2026, the Company has transferred
the first installment of $&lt;span id="xdx_902_ecustom--FirstInstallment_iI_c20260331_z0lQhBt9YpFf" title="First installment"&gt;68,000&lt;/span&gt; but no transfer of ownership had taken place. As of March 31, 2026, the transaction is not deemed to
be closed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Bitcoin mining acceleration and orchestration platform&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 17, 2026, the Company entered into
a Statement of Work (the &#x201c;SOW&#x201d;) with a third-party vendor for the development, validation, and deployment of a custom qSpeed-Mine&#x2122;
Bitcoin mining acceleration and orchestration platform. The SOW has a total contract value of $&lt;span id="xdx_90F_eus-gaap--ContractualObligation_iI_pn3n3_dm_c20260217_zeIm4g5kKlYb" title="Total contract"&gt;10&lt;/span&gt; million and represents a commitment
for custom software and systems development to enhance the Company&#x2019;s Bitcoin mining operations. At March 31, 2026, the $&lt;span id="xdx_908_eus-gaap--DeferredRevenue_iI_c20260331_zNB6rEa9b3pe" title="Deferred revenue"&gt;350,000&lt;/span&gt;
payment upon execution was recorded as deferred revenue on the accompanying unaudited condensed consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Scope and Structure&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The SOW provides for the design, validation, and
deployment of a production-grade software acceleration layer, fleet orchestration/control plane, observability tools, security hardening,
and deployment engineering optimized for Bitcoin (SHA-256d) mining across up to approximately 1,000 nodes/machines. The engagement is
structured with objective technical milestones and acceptance criteria, and payments are contingent upon successful delivery and acceptance
of each milestone. The expected program duration is approximately 32 weeks.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Payment Milestones&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The SOW provides for the following milestone-based payment structure:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;$350,000 was paid upon execution of the SOW;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Approximately $1 million is payable
                                            through completion and acceptance of the proof-of-concept (&#x201c;POC&#x201d;) milestone;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Approximately $6 million is payable
                                            upon completion and acceptance of successive intermediate milestones, including scaled deployment
                                            and operational validation; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;Approximately $3 million is payable upon final delivery and full
                                            program acceptance.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If milestone execution proceeds as planned, the
SOW is structured to generate not less than the full $10.0 million in revenue during calendar year 2026, subject to milestone completion
and acceptance of which there is no guarantee. Revenue is expected to be recognized in accordance with applicable accounting standards
based on milestone achievement and acceptance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Additional Terms&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All deliverables under the SOW are owned by the
Company, reinforcing the Company&#x2019;s proprietary rights in the QuantumSpeed&#x2122; platform. The SOW does not obligate the counterparty
to continue beyond accepted milestones and does not include minimum purchase or volume commitments beyond the defined milestone structure.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;C.M. Composite Materials Ltd Investment and Share Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 20, 2026 (the &#x201c;Effective Date&#x201d;),
the Company entered into two related definitive agreements in connection with a strategic investment and acquisition transaction involving
C.M. Composite Materials Ltd., an Israeli corporation with registration number 513931980 (the &#x201c;Target Company&#x201d;): (i) an Investment
and Share Purchase Agreement (the &#x201c;Share Purchase Agreement&#x201d;), dated as of February 20, 2026, by and among the Company (as
Buyer), Matania (Mati) Moskovich (as Seller), and the Target Company (solely for purposes of acknowledgment and certain covenants); and
(ii) a Loan Agreement (the &#x201c;Loan Agreement&#x201d;), dated as of February 20, 2026, by and between the Company (as Lender) and the
Target Company (as Borrower).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the Share Purchase Agreement, the
Company agreed to acquire from the Seller 10.2 ordinary shares of the Target Company (the &#x201c;Purchased Shares&#x201d;), representing
51% of the issued and outstanding ordinary shares of the Target Company (which has 20 outstanding ordinary shares out of &lt;span id="xdx_900_ecustom--OrdinarySharesAuthorized_iI_c20260220_zGC7DkL5Jhcd" title="Ordinary shares authorized"&gt;30,000&lt;/span&gt; authorized
ordinary shares, par value 0.1 NIS per share). In consideration therefore, the Company agreed to issue to the Seller 250,000 shares of
the Company&#x2019;s common stock, $0.01 par value per share (the &#x201c;Buyer Shares&#x201d;), valued at $&lt;span id="xdx_90D_ecustom--OrdinarySharesValue_iI_c20260220_zl2mZxatgpy6" title="Ordinary shares value"&gt;2,500,000&lt;/span&gt; based on the parties&#x2019;
agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The transaction is structured as a private placement
exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), and/or Rule
506 of Regulation D promulgated thereunder. The Seller was granted certain registration rights with respect to the Buyer Shares. The
Company has also agreed to provide loans to the Target Company as additional consideration under the Share Purchase Agreement. The Loan
Agreement provides for a secured loan facility in an aggregate principal amount of up to $&lt;span id="xdx_902_ecustom--AggregatePrincipalAmount_iI_c20260220_zgQMM2K2gXAl" title="Aggregate principal amount"&gt;5,000,000 &lt;/span&gt;(the &#x201c;Commitment&#x201d;). The
Company is obligated to make an initial advance of up to $1,500,000 within ten (10) Business Days following the Effective Date (subject
to satisfaction of conditions precedent), to be used for general working capital purposes consistent with the Target Company&#x2019;s
ordinary course of business. Subsequent advances of the remaining up to $3,500,000 may be made in one or more tranches upon mutual written
agreement of the parties, solely for working capital or the establishment and operation of a new facility outside Israel, with each tranche
subject to the Company&#x2019;s reasonable approval and minimum amounts (generally not less than $250,000 unless otherwise agreed). Proceeds
of subsequent advances are to be used exclusively to operate, develop, certify, market, and commercialize the Target Company&#x2019;s
technologies and products in global markets, including the United States. This Loan Agreement expands upon the Company&#x2019;s prior
financial support to the Target Company including previous advances.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The advances were made pursuant to a promissory
note with a 24-month maturity, bearing no interest unless an event of default occurs (then at 5% per annum or the lower legal maximum),
prepayable without penalty, and not contingent on any acquisition or strategic transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Any loan pursuant to the Loan Agreement will bear
simple interest at 12% per annum (or such lower rate as mutually agreed in writing, but not exceeding prevailing market rates for similar
loans as determined in good faith by the Company), calculated on a 360-day year basis for actual days elapsed. The loan will mature three
(3) years after the Effective Date. The obligations under the Loan Agreement are secured by a first-priority security interest in substantially
all assets of the Target Company (including accounts, inventory, equipment, general intangibles, intellectual property, and proceeds
thereof). The Loan Agreement is evidenced by a promissory note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 26, 2026, the Company entered into
the First Amendment (the &#x201c;Amendment&#x201d;) to the Investment and Share Purchase Agreement, dated as of February 20, 2026 (the
&#x201c;SPA&#x201d;), by and among the Company (&#x201c;Buyer&#x201d;), Matania (Mati) Moskovich (the &#x201c;Seller&#x201d;), and, solely
for purposes of acknowledgment and certain covenants therein, C.M. Composite Materials Ltd., an Israeli limited liability company (the
&#x201c;CM Company&#x201d;). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the SPA. The Amendment
adds a new recital to the SPA emphasizing that the sole purpose of the Company entering into the SPA is to facilitate and enable the
establishment of a joint venture in India between the CM Company (and/or FBM) and Belrise Industries Limited (or its affiliate) as contemplated
by that certain Memorandum of Understanding dated February 16, 2026 (the &#x201c;Belrise MOU&#x201d;), and that the execution and performance
of definitive agreements with Belrise Industries Limited (the &#x201c;Belrise JV Agreements&#x201d;) is a critical and indispensable component
of the overall transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Amendment provides that the Company&#x2019;s
obligation to consummate the purchase of the Purchased Shares and the other transactions contemplated by the SPA is expressly conditioned
upon the satisfaction (or waiver by the Company in its sole and absolute discretion) of the following condition precedent (the &#x201c;Belrise
Condition&#x201d;): (a) the CM Company and FBM Composite Materials Ltd. shall have duly executed and delivered the Belrise JV Agreements
substantially in the form and on the terms contemplated by the Belrise MOU; and (b) the Belrise JV Agreements shall be in full force
and effect and shall not have been&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;terminated, amended, or modified in any respect
materially adverse to the CM Company or the Company without the prior written consent of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Seller acknowledges that the Belrise Condition
is material, and failure to satisfy it entitles the Company to terminate the SPA without liability. The Amendment amends and restates
Section 2.3 of the SPA to provide that the Closing shall take place remotely no later than June 30, 2026 (or such later date as mutually
agreed), provided that in no event shall the Closing occur unless and until the Belrise Condition has been satisfied (or waived by the
Company). The Amendment also permits termination by the Company if the Belrise Condition has not been satisfied (or waived by the Company)
on or before March 31, 2026 (the &#x201c;Belrise Long-Stop Date&#x201d;), provided that the Company may not terminate if it is then in
material breach of its obligations under the SPA. Except as expressly amended by the Amendment, the SPA remains in full force and effect.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;At March 31, 2026, the transaction was not consummated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Acquisition of VisionWave IL, Ltd.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 18, 2026, the Company acquired 100% of
the issued and outstanding shares of VisionWave IL Ltd., an Israeli private shell limited company (&#x201c;VisionWave Israel&#x201d;),
for nominal consideration.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Further, on March 18, 2026, VisionWave Israel
appointed Khdoura Sabbagh as Chief Executive Officer and its sole director and entered into an Employment Agreement with Mr. Sabbagh,
pursuant to which Mr. Sabbagh was appointed Chief Executive Officer of VisionWave Israel. Under the Employment Agreement, Mr. Sabbagh
will receive an annual base salary of $&lt;span id="xdx_90C_ecustom--AnnualBaseSalary_iI_c20260318_z7cU6PUdmyHi" title="Annual base salary"&gt;150,000&lt;/span&gt; and is eligible to receive options to purchase &lt;span id="xdx_906_esrt--StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_iI_c20260318_zgbGH4QqInh6" title="Shares purchased"&gt;2,000,000&lt;/span&gt; shares of the Company&#x2019;s
common stock, subject to vesting and the terms of the Company&#x2019;s equity incentive plan. The agreement contains customary terms regarding
duties, confidentiality, intellectual property, and termination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 18, 2026, VisionWave Israel also entered
into a Consulting Agreement with CO-Finance Financial and Accounting Consulting Ltd., a company controlled by Oren Attiya, pursuant to
which Mr. Attiya will provide financial and accounting services to VisionWave Israel. Under the Consulting Agreement, the consultant
will receive monthly compensation of NIS 12,000 plus VAT. The agreement is structured as an independent contractor arrangement and includes
customary terms and conditions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2026, the transaction was not closed
and the options were not granted under the employment agreement.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Advance
to supplier and customer deposit&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2025, the Company entered into a product purchase agreement and paid $98,250 advance payment to the vendor. The product was delivered
and tested by the vendor on March 13, 2025 was shipped to the client. The client, pursuant to the December 2024 product purchase agreement
made a 50% deposit totaling $108,006 in 2025. The client received the product and live fire tests were performed on September 15, 2025.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2026, the client and the Company mutually agreed to terminate the contract. The Company will repay the
deposit to the client and the company is expected to receive a refund from the vendor. At March 31, 2026, the termination was not formalized
and final negotiations were pending. At March 31, 2026 and September 30, 2025, the advance to the vendor is recorded as advances to suppliers
on the accompanying unaudited condensed consolidated balance sheets. At March 31, 2026 and September 30, 2025, the deposit of $108,006
is recorded as customer deposit on the accompanying unaudited condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Ian Share Purchase Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 12, 2026, VisionWave Israel Ltd. (&#x201c;VW
Israel&#x201d;), a wholly owned subsidiary of the Company, entered into a definitive Share Purchase and Shareholders Agreement (the &#x201c;Agreement&#x201d;)
with Mr. Ian Paklida (the &#x201c;Seller&#x201d;), pursuant to which VW Israel agreed to acquire 60% of the issued and outstanding equity
interests of VIP Lux Travel Ltd. and PKLST Tourism and Leisure Ltd., both Israeli corporations (collectively, the &#x201c;Target Companies&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Agreement is definitive; however, the transaction has not yet closed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under the terms of the Agreement, the consideration
for the acquisition of the Target Companies will be the issuance of shares of common stock of the Company, subject to the satisfaction
of various conditions precedent and regulatory approvals.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Agreement contemplates an aggregate transaction
value of up to approximately 15 million NIS, payable in the Company shares valued at approximately USD $3 million. The number of shares
to be issued will be &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260511__20260512_z8w1djB3tVab" title="Number of shares to be issued"&gt;513,752&lt;/span&gt; shares of common stock of the Company representing $6.02 cost per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Agreement includes customary representations,
warranties, covenants, indemnification provisions, confidentiality obligations, lock-up restrictions, and closing conditions. Closing
remains subject to, among other things:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#xb7; completion of legal, financial, and operational due diligence;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#xb7; receipt of all required corporate and regulatory approvals;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#xb7; applicable tax rulings and/or approvals in Israel;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#xb7; execution and delivery of final ancillary closing documents;
and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#xb7;satisfaction or waiver of other customary closing conditions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Until the closing occurs, there can be no assurance
that the acquisition will be consummated on the terms currently contemplated, or at all.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company intends to evaluate strategic opportunities
relating to the Target Companies&#x2019; operations and potential integration into VisionWave&#x2019;s broader international business activities&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002337"
      unitRef="USD">50000000</us-gaap:AdvancesOnInventoryPurchases>
    <VWAV:StructuringFeeAmount
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002339"
      unitRef="USD">30000</VWAV:StructuringFeeAmount>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31_custom_InvestorsMember"
      decimals="INF"
      id="Fact002340"
      unitRef="Shares">200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2026-03-31_custom_InvestorsMember"
      decimals="0"
      id="Fact002342"
      unitRef="USD">500000</us-gaap:CommitmentsAndContingencies>
    <us-gaap:PayableCommonStockRedeemed
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002343"
      unitRef="USD">250000</us-gaap:PayableCommonStockRedeemed>
    <us-gaap:DeferredCosts
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002344"
      unitRef="USD">1350000</us-gaap:DeferredCosts>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2025-10-012026-03-31_custom_InvestorsMember"
      decimals="0"
      id="Fact002345"
      unitRef="USD">470000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-10-012026-03-31_custom_InvestorsMember"
      decimals="INF"
      id="Fact002346"
      unitRef="Shares">200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <VWAV:ConsultingFees
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002348"
      unitRef="USD">350000</VWAV:ConsultingFees>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="From2024-10-012025-09-30"
      decimals="0"
      id="Fact002349"
      unitRef="USD">140000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <VWAV:AdditionalPrincipalAmount
      contextRef="AsOf2025-09-11"
      decimals="0"
      id="Fact002353"
      unitRef="USD">2000000</VWAV:AdditionalPrincipalAmount>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact002355"
      unitRef="Shares">233678</us-gaap:ConversionOfStockSharesIssued1>
    <VWAV:TotalProceeds
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact002357"
      unitRef="USD">1760672</VWAV:TotalProceeds>
    <VWAV:TotalProceeds
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002359"
      unitRef="USD">780462</VWAV:TotalProceeds>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-05-22"
      decimals="INF"
      id="Fact002360"
      unitRef="Shares">280534</us-gaap:SharesIssued>
    <us-gaap:AccruedSalesCommissionCurrentAndNoncurrent
      contextRef="AsOf2025-05-22"
      decimals="0"
      id="Fact002361"
      unitRef="USD">50000</us-gaap:AccruedSalesCommissionCurrentAndNoncurrent>
    <us-gaap:PrepaidTaxes
      contextRef="AsOf2025-09-24"
      decimals="0"
      id="Fact002364"
      unitRef="USD">50000</us-gaap:PrepaidTaxes>
    <VWAV:AdditionalPrepaidAdvanceFee
      contextRef="AsOf2025-09-24"
      decimals="0"
      id="Fact002366"
      unitRef="USD">50000</VWAV:AdditionalPrepaidAdvanceFee>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-03-31_custom_CryptoAssetsMember"
      decimals="INF"
      id="Fact002367"
      unitRef="Shares">250000</us-gaap:SharesIssued>
    <us-gaap:ProceedsFromRepaymentsOfDebt
      contextRef="From2026-04-162026-04-17"
      decimals="0"
      id="Fact002372"
      unitRef="USD">210000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002374"
      unitRef="USD">600000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:OtherNoncashIncomeTaxExpense
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002376"
      unitRef="USD">250000</us-gaap:OtherNoncashIncomeTaxExpense>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002378"
      unitRef="USD">350000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002380"
      unitRef="Shares">35000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002382"
      unitRef="USDPShares">10.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <VWAV:PaidAgreementToCompany
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002384"
      unitRef="USD">250000</VWAV:PaidAgreementToCompany>
    <us-gaap:RepurchaseAgreementsInterestExpenseAmount
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002386"
      unitRef="USD">350000</us-gaap:RepurchaseAgreementsInterestExpenseAmount>
    <VWAV:MonthlyFee
      contextRef="AsOf2026-03-11"
      decimals="0"
      id="Fact002394"
      unitRef="USD">50000</VWAV:MonthlyFee>
    <VWAV:FirstInstallment
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002396"
      unitRef="USD">68000</VWAV:FirstInstallment>
    <us-gaap:ContractualObligation
      contextRef="AsOf2026-02-17"
      decimals="-3"
      id="Fact002398"
      unitRef="USD">10000000</us-gaap:ContractualObligation>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002400"
      unitRef="USD">350000</us-gaap:DeferredRevenue>
    <VWAV:OrdinarySharesAuthorized
      contextRef="AsOf2026-02-20"
      decimals="INF"
      id="Fact002404"
      unitRef="Shares">30000</VWAV:OrdinarySharesAuthorized>
    <VWAV:OrdinarySharesValue
      contextRef="AsOf2026-02-20"
      decimals="0"
      id="Fact002406"
      unitRef="USD">2500000</VWAV:OrdinarySharesValue>
    <VWAV:AggregatePrincipalAmount
      contextRef="AsOf2026-02-20"
      decimals="0"
      id="Fact002408"
      unitRef="USD">5000000</VWAV:AggregatePrincipalAmount>
    <VWAV:AnnualBaseSalary
      contextRef="AsOf2026-03-18"
      decimals="0"
      id="Fact002412"
      unitRef="USD">150000</VWAV:AnnualBaseSalary>
    <srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="AsOf2026-03-18"
      decimals="INF"
      id="Fact002414"
      unitRef="Shares">2000000</srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-05-112026-05-12"
      decimals="INF"
      id="Fact002419"
      unitRef="Shares">513752</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002421">&lt;p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zMTRR6aNq1vl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 19 &#x2014;&lt;span id="xdx_823_z2f1uiZHvEud"&gt; Stockholder&#x2019;s Equity (Deficit)&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&#x2014; The Company
is authorized to issue &lt;span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20260331_zF8FT4u3c3uk" title="Preferred stock, shares authorized"&gt;&lt;span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20250930_zde9z7M9zsKl" title="Preferred stock, shares authorized"&gt;10,000,000&lt;/span&gt;&lt;/span&gt; shares of preferred stock, par value $&lt;span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260331_zmPlvfPLpDR2" title="Preferred stock, par value"&gt;&lt;span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250930_zkA2bLHvbgx1" title="Preferred stock, par value"&gt;0.01&lt;/span&gt;&lt;/span&gt; per share, with such designations, voting and other rights
and preferences as may be determined from time to time by the Company&#x2019;s board of directors. As of March 31, 2026 and September
30, 2025, there were &lt;span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_do_c20260331_zLlxJvQodZXc" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20260331_zZasleFLQsNl" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_do_c20250930_zseMEvB1JWja" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20250930_zFcwP0ypZPUj" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares of preferred stock issued or outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&#x2014; The Company
is authorized to issue &lt;span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20260331_zWgY0CkGFvo2" title="Common stock, shares authorized"&gt;&lt;span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20250930_zZNsW4r0oz5e" title="Common stock, shares authorized"&gt;150,000,000&lt;/span&gt;&lt;/span&gt; shares of common stock with par value of $&lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260331_zkBwiXBwRsRj" title="Common stock, par value"&gt;&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250930_zkIeKfw5WRg" title="Common stock, par value"&gt;0.01&lt;/span&gt;&lt;/span&gt; each. As of March 31, 2026 and September 30, 2025,
there were &lt;span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20260331_zoptDBQxcwr5" title="Common stock, shares issued"&gt;&lt;span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20260331_zT1s2s4eddI3" title="Common stock, shares outstanding"&gt;20,347,137&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20250930_zjfNncxVS9a2" title="Common stock, shares issued"&gt;&lt;span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20250930_zCeV0BSfVIK2" title="Common stock, shares outstanding"&gt;14,521,094&lt;/span&gt;&lt;/span&gt; shares of Common Stock issued and outstanding, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As part of the Bannix IPO, Bannix issued &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20260331_zkdGXDVEn6Mh"&gt;6,900,000&lt;/span&gt;
warrants to third-party investors where each whole warrant entitles the holder to purchase one share of the Company&#x2019;s Class A common
stock at an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zOB3uNr1Kjze"&gt;11.50&lt;/span&gt; per share (the &#x201c;Public Warrants&#x201d;). Simultaneously with the closing of the IPO, Bannix
completed the private sale of &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zTBW2FLpzas2"&gt;406,000&lt;/span&gt; Private Placement warrants where each warrant allows the holder to purchase one share of the Company&#x2019;s
Class A common stock at $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zDR02oouZpu4"&gt;11.50&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Bannix accounted for the &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zkygIfWa37Da"&gt;6,900,000&lt;/span&gt; warrants issued
in connection with the IPO and private placement in accordance with the guidance contained in ASC Topic 815 &#x201c;Derivatives and Hedging&#x201d;
whereby under that provision, the Private Warrants did not meet the criteria for equity treatment and were recorded as a liability. Accordingly,
Bannix classified the Private Warrants as a liability at fair value and adjusts them to fair value at each reporting period. The Public
Warrants met the classification for equity treatment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The warrants became exercisable on the later of
12 months from the closing of this offering or upon completion of its initial Business Combination and will expire five years after the
completion of Reverse Acquisition, at 5:00 p.m., Eastern Time, or earlier upon redemption or liquidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Once the warrants become exercisable, the Company may redeem the warrants:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;in whole and not in part;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;at a price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331_z4emoBu81zk7"&gt;0.01&lt;/span&gt; per warrant;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;upon not less than 30 days&#x2019; prior written notice of redemption,
                                            to each warrant holder; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;if, and only if, the reported last
                                            sale price of the Public Shares equals or exceeds $&lt;span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20260331_zeHrR8rk8OR5"&gt;18.00&lt;/span&gt; per share (as adjusted for share
                                            subdivisions, share consolidations, share capitalizations, rights issuances, reorganizations,
                                            recapitalizations and the like) for any 20 trading days within a 30-trading day period ending
                                            on the third trading day prior to the date the Company sends the notice of redemption to
                                            the warrant holders.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;if, and only if, there is a current
                                            registration statement in effect with respect to the issuance of the shares underlying such
                                            warrants at the time of redemption and for the entire 30-day trading period referred to above
                                            and continuing each day until the date of redemption.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At the time of the Reverse Acquisition, The Private
Placement Warrants became identical to the Public Warrants underlying the Units sold in the Bannix IPO. The Private Placement Warrants
were classified as Equity upon close of the Reverse Acquisition. During the three and six months ended March 31, 2026, &lt;span id="xdx_904_ecustom--ExerciseOfWarrantsShare_c20260101__20260331_zwrB8j4CrJ3c" title="Exercise of warrants, share"&gt;46,747&lt;/span&gt; and &lt;span id="xdx_90E_ecustom--ExerciseOfWarrantsShare_c20251001__20260331_z5l7WSVirNr8" title="Exercise of warrants, share"&gt;542,256&lt;/span&gt;
warrants were exercised for $&lt;span id="xdx_900_ecustom--ExerciseOfWarrant_c20260101__20260331_zEiGUODlpn94" title="Exercise of warrant"&gt;537,591&lt;/span&gt; and $&lt;span id="xdx_900_ecustom--ExerciseOfWarrant_c20251001__20260331_zgTC3PcdOgn7" title="Exercise of warrant"&gt;6,235,945&lt;/span&gt;, respectively. At March 31, 2026 and September 30, 2025, there were &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331_zfG4LTi1Wxuh"&gt;8,396,069&lt;/span&gt; and
&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930_zP9eOqRoWIwk"&gt;7,304,992&lt;/span&gt; warrants outstanding inclusive of 300,000 pre-funded warrants (See Note 9).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Conversion of public and private rights&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 14, 2025, at the close of the Reverse
Acquisition, &lt;span id="xdx_90E_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20250714__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PublicRightsMember_zwgT06CgKfbi"&gt;6,900,000&lt;/span&gt; public rights and &lt;span id="xdx_90D_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20250714__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PrivateRightsMember_zg7LyAEb1ltf"&gt;406,000&lt;/span&gt; private rights under Bannix were converted for Common shares on a ten-to-one basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following is an analysis of the warrants grant activity:&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfSharesBasedCompensationStockOptionsActivityTableTextBlock_zPOhEL4zxUN3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholder's Deficit (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_z0vRjgKJJQT4" style="display: none"&gt;Schedule of analysis of the warrants grant activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Schedule of stock option grant activity&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 43%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding
    at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20251001__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zi1O4PXv2lKg" style="width: 15%; text-align: right" title="Number of shares  stock option outstanding"&gt;7,304,992&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20241001__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_z7muR0BK8k95" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Beginning balance"&gt;11.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20251001__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zhVWQcGRI6q4" title="Weighted Average Remaining Life Granted"&gt;4.79&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251001__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_z22aZqf4rRbb" style="text-align: right" title="Number of shares outstanding granted"&gt;300,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20241001__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zlPKUSFBrXyh" style="text-align: right" title="Weighted Average Exercise Price granted"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x97;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20251001__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zZVeYaQ88Xb8" style="text-align: right" title="Number of shares outstanding expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2488"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20241001__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_z2gSXgKrwY0g" style="text-align: right" title="Weighted Average Exercise Price Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2490"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x97;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20251001__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zwxIKUeORnW9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares outstanding exercised"&gt;(495,509&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_iN_di_c20241001__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zPq8MwqqLMp1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price granted"&gt;(11.50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm2_dtY_c20251001__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zLyWs3wVlHT9" title="Weighted Average Remaining Life Forfeited"&gt;4.79&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at December
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_z8hEOWwCYt51" style="text-align: right" title="Number of shares  stock option outstanding"&gt;7,109,483&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zYKUyHhrkBda" style="text-align: right" title="Weighted Average Exercise Price Beginning balance"&gt;11.02&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm_dtY_c20251001__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zUhWswabPJJ9" title="Weighted Average Remaining Life Granted"&gt;4.56&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zrrkbepBYk7f" style="text-align: right" title="Number of shares outstanding granted"&gt;1,333,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zVvZDO0uo7s2" style="text-align: right" title="Weighted Average Exercise Price granted"&gt;9.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zPsd4PQe3m7f" title="Weighted Average Remaining Life Granted"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zf9RLsv37kx5" style="text-align: right" title="Number of shares outstanding expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2510"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zeBwdgMF6DVi" style="text-align: right" title="Weighted Average Exercise Price Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2512"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x97;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zCLNBH9M7Npl" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares outstanding exercised"&gt;(46,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_iN_di_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_z0QVSiF1EBKk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price granted"&gt;(11.50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zQLC6F3GlCmg" title="Weighted Average Remaining Life Forfeited"&gt;4.56&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at March
    31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zZzDkgi2ze94" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares  stock option outstanding"&gt;8,396,069&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zCwXb5w9BwV6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price ending balance"&gt;10.69&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zXaXlzmX1Z14" title="Weighted Average Remaining Life Outstanding"&gt;4.41&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;At March 31, 2026 and September 30, 2025, the intrinsic value of the
warrants was $&lt;span id="xdx_90C_ecustom--IntrinsicValue_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zzkIjh3Tfoug" title="Intrinsic value"&gt;1,419,000&lt;/span&gt; and $&lt;span id="xdx_900_ecustom--IntrinsicValue_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zMae8gAKl8Ig" title="Intrinsic value"&gt;0&lt;/span&gt;, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The assumptions used in Monte Carlo Simulation model related to the
February 26, 2026 &lt;span id="xdx_903_ecustom--WarrantsIssuance_iI_c20260226_zeDtuHvnvDF8" title="Warrants issuance"&gt;1,333,333&lt;/span&gt; warrants issuance are set forth in the table immediately below:&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zazYDWWrEgwa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholder's Deficit (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B3_zT5ILmcCwiK5" style="display: none"&gt;Schedule of stock option assumptions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 12pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;February
    26, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--StockPrice_c20260201__20260226_zgHH3Osrt2Cb" title="Stock Price"&gt;7.96&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--StockholdersEquityOtherShares_c20260201__20260226_zaaeNl2elb71" title="Exercise price"&gt;9.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20260201__20260226_zrVOBaMhxIMg" title="Volatility"&gt;73.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk
    free rate of return&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20260201__20260226_zJaqEEf3pkO3" title="Risk-free interest rate"&gt;3.54&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Term
    to maturity (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260201__20260226__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zh5GAHgK0TRf" title="Term to maturity (years)"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Term
    to financing (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20260201__20260226_zSRiLTEcniw8" title="Term to financing (years) (years)"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AD_zaViIEyzdT8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Stock based compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Omnibus Equity Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 5, 2025, the Board of Directors (the
&#x201c;Board&#x201d;) of Bannix adopted Bannix&#x2019;s 2025 Omnibus Equity Incentive Plan (the &#x201c;Plan&#x201d;), which authorizes the
issuance of up to &lt;span id="xdx_904_eus-gaap--SharesIssued_iI_c20250804__us-gaap--SubsidiarySaleOfStockAxis__custom--BoardOfDirectorsMember_zsOXGTfPFMq3"&gt;7,000,000&lt;/span&gt; shares of Bannix&#x2019;s common stock, par value $&lt;span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250804__us-gaap--SubsidiarySaleOfStockAxis__custom--BoardOfDirectorsMember_z7TiRzbDysog"&gt;0.01&lt;/span&gt; per share (the &#x201c;Common Stock&#x201d;). The Plan
is subject to approval by Bannix&#x2019;s shareholders within twelve (12) months of the Board&#x2019;s adoption date. If shareholder approval
is obtained, the Plan will become effective as of August 5, 2025. The Plan provides for the grant of various equity-based awards, including
non-qualified stock options, incentive stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights,
performance stock awards, performance unit awards, unrestricted stock awards, distribution equivalent rights, or any combination thereof.
The Plan is intended to assist Bannix in attracting, retaining, and incentivizing key management employees, directors, and consultants,
and to align their interests with those of Bannix&#x2019;s shareholders.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 6, 2025 and September 2, 2025, the Company
entered into several employment agreements, pursuant to which the Company granted &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20251001__20260331_zSArepSbosL9"&gt;6,350,000&lt;/span&gt; options to employees with vesting periods
of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20251001__20260331_zNz3b4WKe2g9"&gt;4&lt;/span&gt; years and exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250806__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--StockOptionMember_zRTPWLT9Y4Mg"&gt;7.2&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--StockOptionMember_zBcaPmHPQO7g"&gt;9.09&lt;/span&gt;, respectively. On January 2, 2026 and March 12, 2026, the Company granted &lt;span id="xdx_904_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20250806__20250902_z1y2wvaNu3Va" title="Granted share option"&gt;500,000&lt;/span&gt; options
each to two employees with vesting period of 3 years and &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20260102__20260312_z3hsavSG7QJ8"&gt;4&lt;/span&gt; years and exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260104__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--StockOptionMember_zd6olLwXmYme"&gt;9.26&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260312__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--StockOptionMember_zaezA8h4aXy8"&gt;7.47&lt;/span&gt;, respectively. For the three and
six months ended March 31, 2026 and 2025, total stock-based compensation related to the employments agreements was $&lt;span id="xdx_90F_eus-gaap--GeneralAndAdministrativeExpense_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--StockOptionMember_zKim5pp4zHZ4"&gt;1,119,097&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--GeneralAndAdministrativeExpense_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--StockOptionMember_zfg9fssSKyR6"&gt;0&lt;/span&gt;,
respectively, and $&lt;span id="xdx_900_eus-gaap--GeneralAndAdministrativeExpense_c20251001__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--StockOptionMember_zxeTQnvFEVk7"&gt;3,128,944&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--GeneralAndAdministrativeExpense_c20241001__20250331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--StockOptionMember_zims70JAYgR4"&gt;0&lt;/span&gt;, respectively, and included in general and administrative expense on the accompanying unaudited condensed
consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended March 31, 2026,
&lt;span id="xdx_900_ecustom--UnvestedOptionSharesForfeited_c20260101__20260331_zLPbEZJs1Fv5" title="Unvested option shares forfeited"&gt;3,600,000&lt;/span&gt; unvested options were forfeited which resulted in stock based compensation reversal of $&lt;span id="xdx_90F_ecustom--StockBasedCompensationReversal_c20260101__20260331_zoQeVsX55Yq3" title="Stock based compensation reversal"&gt;1,733,920&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 16, 2025, the Company entered into a consultant
non statutory stock option agreement with a vendor, pursuant to which the vendor was granted &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250702__20250716_z9o9cdpujVp7"&gt;500,000&lt;/span&gt; stock options that vested immediately
at an exercise price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250716__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--StockOptionMember_zSfA4BDsnH1b"&gt;3.27&lt;/span&gt; and total compensation expense of $&lt;span id="xdx_90A_ecustom--CompensationExpense_c20241001__20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--StockOptionMember_zHHze6fJJ8c2" title="compensation expense"&gt;1,452,240 &lt;/span&gt;was recognized during the year ended September 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The assumptions used in the Black-Scholes model are set forth in the
table immediately below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfBlackScholesModelTableTextBlock_zGrFf5MXQ41l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholder's Deficit (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_zGxrFK7JMLV4" style="display: none"&gt;Schedule of Black-Scholes model&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;January 2, 2026 - March 12, 2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;August 6, 2025 - September 2, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Exercise price&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;$	&lt;span id="xdx_904_eus-gaap--StockholdersEquityOtherShares_c20260102__20260312__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zGgP8c3kV5l4" title="Exercise price"&gt;9.26&lt;/span&gt; - &lt;span id="xdx_907_eus-gaap--StockholdersEquityOtherShares_c20260102__20260312__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_zAWfVzNDlGs" title="Exercise price"&gt;7.47&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;$	&lt;span id="xdx_909_eus-gaap--StockholdersEquityOtherShares_c20250805__20250902__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zw5HmulfGEUa" title="Exercise price"&gt;3.27&lt;/span&gt; - &lt;span id="xdx_90E_eus-gaap--StockholdersEquityOtherShares_c20250805__20250902__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_z98y7R3B1BFj" title="Exercise price"&gt;9.09&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk-free interest rate&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20260102__20260312__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zATqtzxOmpJh" title="Risk-free interest rate"&gt;3.74&lt;/span&gt; - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20260102__20260312__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_zFTHO06sboN5" title="Risk-free interest rate"&gt;3.84&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250805__20250902__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zXOcxM6JcIw7" title="Risk-free interest rate"&gt;3.58&lt;/span&gt; -&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250805__20250902__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_zc3f0QkdV8Yk" title="Risk-free interest rate"&gt;3.91&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20260102__20260312__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zE2cqB2oiTO8" title="Volatility"&gt;73.0&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20260102__20260312__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_zOh2WUJcbNu7" title="Volatility"&gt;86.3&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20250805__20250902__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zb5p185jOe7d" title="Volatility"&gt;101.4&lt;/span&gt; - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20250805__20250902__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_zaykx6ru3sEd" title="Volatility"&gt;114.4&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected life (years)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260102__20260312__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zGUqq2x9NsH8" title="Expected life (years)"&gt;4&lt;/span&gt; -&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260102__20260312__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_zHPBnZi3fJhj" title="Expected life (years)"&gt; 4.5&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250805__20250902__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_z34QLS67vnrf" title="Expected life (years)"&gt;3.19&lt;/span&gt; - &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250805__20250902__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_z2DqrYjMmhWl" title="Expected life (years)"&gt;5.00&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Dividend yield&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20260102__20260312__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember_z0X9tOTCRQC4" title="Expected life (years)"&gt;0&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250805__20250902__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember_z7Awx31fWgW8" title="Expected life (years)"&gt;0&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following is an analysis of the stock option grant activity:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfSharesBasedCompensationStocksOptionsActivityTableTextBlock_z5svxBzCsytl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholder's Deficit (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8BD_zXmZOcX6oVZ7" style="display: none"&gt;Schedule of stock option
    grant activity&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Outstanding at September 30, 2025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20251001__20251231_z8KHeHkDf24k" style="text-align: right" title="Number of shares  stock option outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2611"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20241001__20250930_zdvqy8WhdZ5a" style="text-align: right" title="Weighted Average Exercise Price Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2613"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 33%; text-align: left; text-indent: -10pt"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251001__20251231_znliyEz8Oiwl" style="width: 15%; text-align: right" title="Number of shares outstanding granted"&gt;6,850,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20241001__20250930_z30yxeDTiEwa" style="width: 15%; text-align: right" title="Weighted Average Exercise Price granted"&gt;7.42&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20231001__20240930_znODjEe0CmS1" title="Weighted Average Remaining Life Granted"&gt;5.23&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expired&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20251001__20251231_zUmj5kMcw0ne" style="text-align: right" title="Number of shares outstanding expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2621"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20241001__20250930_zpmLhE6r27Lk" style="text-align: right" title="Weighted Average Exercise Price Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2623"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20251001__20251231_zxXUPdUpdn51" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares outstanding exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2625"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20241001__20250930_zZTTiD3YfTij" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2627"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Outstanding at December 31, 2025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260331_zJWSyyA2gQOg" style="text-align: right" title="Number of shares  stock option outstanding"&gt;6,850,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260331_zXZMwIvmtcT9" style="text-align: right" title="Weighted Average Exercise Price Beginning balance"&gt;7.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20251001__20251231_z8jVvLS0MaTi" title="Weighted Average Remaining Life Granted"&gt;5.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Granted&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260331_zIkyE9s2JH9i" style="text-align: right" title="Number of shares outstanding granted"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260331_zYGzVS5cqkjl" style="text-align: right" title="Weighted Average Exercise Price granted"&gt;8.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331_znSXWnnCHWEh" title="Weighted Average Remaining Life Granted"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expired&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20260101__20260331_zATEE49pt212" style="text-align: right" title="Number of shares outstanding expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2641"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260101__20260331_zDkOcksdzJ1i" style="text-align: right" title="Weighted Average Exercise Price Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2643"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20260101__20260331_zwIHxuhCoXE5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares outstanding exercised"&gt;(3,600,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_iN_di_c20260101__20260331_zSB8zMoJyNt1" style="text-align: right" title="Weighted Average Exercise Price granted"&gt;(8.04&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331_zKUyWfPyWbM5" title="Weighted Average Remaining Life Forfeited"&gt;4.38&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Outstanding at March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260331_zCuXbW1AMfZ5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares  stock option outstanding"&gt;4,250,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260331_zrSXqH8C7uK" style="text-align: right" title="Weighted Average Exercise Price ending balance"&gt;7.75&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331_ztMMY2Af9c8l" title="Weighted Average Remaining Life Outstanding"&gt;5.85&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zvbVSnJdyWD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2026 and September 30, 2025, the
intrinsic value of outstanding options is $&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValues_iI_c20260331_zyLiaVeu4Tub" title="Intrinsic value of outstanding options"&gt;735,000&lt;/span&gt;&#160;and $&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValues_iI_c20250930_z1WBOA1fAlIl" title="Intrinsic value of outstanding options"&gt;14,429,000&lt;/span&gt;, respectively. At March 31, 2026 and September 30, 2025, &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20260331_zJMO74nc7amf" title="Vested and exercisable"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20250930_zhZPR1oF5mb" title="Vested and exercisable"&gt;500,000&lt;/span&gt;&lt;/span&gt;
options were vested and exercisable, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company will recognize the remaining total stock-based compensation
of $16,219,448 in future periods as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfRecognizeTheRemainingTotalStockBasedCompensationTableTextBlock_z6n8g7UZcA8h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholder's Deficit (Details 4)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BE_zAyO5WUPyOM6" style="display: none"&gt;Schedule of recognize the remaining total stock-based
compensation&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_493_20260331_z5TC5vswRqrd" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: left"&gt;Year&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--CapitalLeasesFutureMinimumPaymentNextRollingTwelveMonths_iI_z3KYnlKhTWN9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 52%; text-align: left; text-indent: -10pt"&gt;2026&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 35%; text-align: right"&gt;2,450,154&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--CapitalLeasesFutureMinimumPaymentDueInRollingYearTwo_iI_zx1UJhAjzNb2" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2027&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;4,900,308&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--CapitalLeasesFutureMinimumPaymentDueInRollingYearThree_iI_zgY4WEg2j8w4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2028&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;4,900,308&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--CapitalLeasesFutureMinimumPaymentDueInRollingYearFour_iI_zOIjMz52lSge" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2029&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,703,652&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--CapitalLeasesFutureMinimumPaymentDueInRollingYearFive_iI_z6Lnvo8K3xEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;2030&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;265,026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--CapitalLeasesFutureMinimumPaymentDue_iI_zlx2VeU5XUL4" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;16,219,448&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AD_zghVa1DUCSIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Restricted stock units (&#x201c;RSUs&#x201d;)&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 1, 2025, the Company entered into agreements
with three independent directors, pursuant to which each independent directors will be granted $&lt;span id="xdx_90F_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20250730__20250801_za2kNNy5vPwa"&gt;60,000&lt;/span&gt; of restricted stock units annually.
On January 30, 2026, the Company issued an additional 14,961 RSUs to independent directors. The restricted stock units will vest after
1 year of service. For the three and six months ended March 31, 2026 and 2025, the Company recorded stock-based compensation expense
related to the RSUs of $&lt;span id="xdx_902_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20260101__20260331_zbHPkBIcWDD4"&gt;143,221&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20250101__20250331_zyfmQmk4150c"&gt;0&lt;/span&gt;, respectively, and $&lt;span id="xdx_90B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20251001__20260331_zivSdUP9x0Kd"&gt;188,221&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20241001__20250331_znGn6uvWF8qc"&gt;0&lt;/span&gt; in the six months ended March 31, 2026 and 2025, respectively.
At March 31, 2026 and September 30, 2025, unearned compensation is $&lt;span id="xdx_904_eus-gaap--DeferredCompensationEquity_iI_c20260331_zlU7JAg61tuc"&gt;146,840&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--DeferredCompensationEquity_iI_c20250930_zS8HqCtrRjl8"&gt;150,000&lt;/span&gt;, respectively and will be recognized in the
future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes RSU issuance and related stock-based
expense,&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BC_zPuV7702woYl" style="display: none"&gt;Schedule of RSU issuance and related stock-based expense&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: left"&gt;Quarter ended&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;RSU issued&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Value of RSUs issued&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Stock based compensation&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 33%; text-align: left; text-indent: -10pt"&gt;September 30, 2025&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_c20251001__20260331__us-gaap--TaxPeriodAxis__custom--Septmber302025Member_zXh5fo51jZ12" style="width: 15%; text-align: right" title="RSU issued"&gt;15,735&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--RestrictedStockExpense_c20251001__20260331__us-gaap--TaxPeriodAxis__custom--September302025Member_zF9fNkfiWPyk" style="width: 15%; text-align: right" title="Value of RSUs issued"&gt;180,000&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_985_ecustom--EmployeeBenefitsAndShareBasedCompensations_c20251001__20260331__us-gaap--TaxPeriodAxis__custom--September302025Member_zghk17ru8VK3" style="width: 15%; text-align: right" title="Stock based compensation"&gt;30,000&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;December 31, 2025&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_c20251001__20260331__us-gaap--TaxPeriodAxis__custom--December312025Member_z4eIUbtVFW1d" style="text-align: right" title="RSU issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2695"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--RestrictedStockExpense_c20251001__20260331__us-gaap--TaxPeriodAxis__custom--December312025Member_zcxiaqPp9k51" style="text-align: right" title="Value of RSUs issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2697"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_ecustom--EmployeeBenefitsAndShareBasedCompensations_c20251001__20260331__us-gaap--TaxPeriodAxis__custom--December312025Member_zkR15fXM5OEd" style="text-align: right" title="Stock based compensation"&gt;45,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;March 31, 2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_c20251001__20260331__us-gaap--TaxPeriodAxis__custom--March312026Member_z84LbN3IJdw9" style="border-bottom: Black 1pt solid; text-align: right" title="RSU issued"&gt;14,961&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--RestrictedStockExpense_c20251001__20260331__us-gaap--TaxPeriodAxis__custom--March312026Member_zyU5wo9vDF5c" style="border-bottom: Black 1pt solid; text-align: right" title="Value of RSUs issued"&gt;295,000&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_982_ecustom--EmployeeBenefitsAndShareBasedCompensations_c20251001__20260331__us-gaap--TaxPeriodAxis__custom--March312026Member_zvOclonoxYlh" style="border-bottom: Black 1pt solid; text-align: right" title="Stock based compensation"&gt;143,221&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_c20251001__20260331_zUeqTwIflkf7" style="border-bottom: Black 2.5pt double; text-align: right" title="Value of RSUs issued"&gt;30,696&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--RestrictedStockExpense_c20251001__20260331_zg5N5gKFBhF2" style="border-bottom: Black 2.5pt double; text-align: right" title="Value of RSUs issued"&gt;475,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_ecustom--EmployeeBenefitsAndShareBasedCompensations_c20251001__20260331_zfcViQrKHNf4" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation"&gt;218,221&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A2_zraKvGlxm6yk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Issuance of shares to former directors&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_90B_ecustom--IssuanceOfSharesToFormerDirectorsDescription_c20250208__20250809_zfqPQ5L5Y9A4" title="Issuance Of Shares To Former Directors Description"&gt;On August 9, 2025, the Company entered into compensation
agreements with three former directors, pursuant to which each director will receive $120,000 payable in cash or shares. Two directors
elected to receive a total of $125,000 in shares and on September 10, 2025, total shares of 10,927 were issued and stock-based compensation
of $125,000 related the compensation agreements with two former directors was included in general and administrative expense on the consolidated
statements of operations during the year ended September 30, 2025. There was no issuance of shares for the three and six months ended
March 31, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Other share issuances&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As outlined in Note 14, the Company issued &lt;span id="xdx_909_ecustom--CommonStockShareIssued_iI_c20250725_zF6I5oxJ8SA1" title="Common stock share issued"&gt;200,000&lt;/span&gt;
shares of Common stock at a fair value of $&lt;span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20251001__20260331_zqIL0JKGVV6h" title="Common Stock Fair Value Issued"&gt;470,000&lt;/span&gt; pursuant to the SEPA during the year ended September 30, 2025. There were no issuance
of shares under this agreement for the three and six months ended March 31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At the close of the Reverse Acquisition, Bannix
owed a vendor &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250702__20250725_zHdigeaZFES6"&gt;22,500&lt;/span&gt; shares pursuant to an agreement for the provision of services. On July 25, 2025, the Company issued the Common Shares
to the vendor to satisfy the outstanding obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As stated in Note 8, the Company issued &lt;span id="xdx_908_ecustom--IssuanceOfSharesInAssetAcquisitionsShare_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZtjwpg494Xi" title="Issuance of shares in asset acquisition, shares"&gt;1,500,000&lt;/span&gt; Common Shares pursuant
to the asset acquisition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 28, 2026, the Company issued &lt;span id="xdx_906_ecustom--IssuanceOfSharesInAssetAcquisitionsShare_c20260127__20260128__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSsKwK7X4yOk" title="Issuance of shares in asset acquisition, shares"&gt;8,532&lt;/span&gt;
shares to the vendor in satisfaction of the terms under the $75,000 RSUs issuable under the consulting arrangement (See Note 19).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Stock-based compensation liability&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2025, the Company entered into an
advisory services agreement with an independent member of the board of directors. As compensation for the services of the board member,
a compensation of $&lt;span id="xdx_901_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20251128__20251130_zF87FgsLtS12"&gt;30,000&lt;/span&gt; monthly payable in cash and $5,000 monthly payable in shares. At March 31, 2026 and September 30, 2025, the
$&lt;span id="xdx_90E_ecustom--SharesIssuedToDirectors_iI_c20260331_z2d8nVdeyabk" title="Shares issued to directors"&gt;25,000&lt;/span&gt; and $&lt;span id="xdx_90F_ecustom--SharesIssuedToDirectors_iI_c20250930_zM18lj5blnK8" title="Shares issued to directors"&gt;0&lt;/span&gt; payable in shares was not issued to the director and is included in stock-based compensation liability on the accompanying
unaudited condensed consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 9, 2025, the Company entered into a
consulting arrangement with a vendor, pursuant to which $&lt;span id="xdx_901_ecustom--EmployeeBenefitsAndShareBasedCompensations_c20251007__20251009_zBHVjDevrxyl" title="RSUs stock based compensation"&gt;75,000&lt;/span&gt; of RSUs will be issued within 5 days of the execution date and the contract
then 6 months later. The Company issued 8,352 shares to the vendor during the three months ended March 31, 2025. There were no shares
payable and unissued at March 31, 2026 and September 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As stated in Note 16, pursuant to the PVML Agreement,
the payment contains an equity component valued at $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_c20251001__20260331_ziKFYVdwQzv9" title="Equity component value"&gt;350,000&lt;/span&gt;, to be settled through the issuance of &lt;span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260331_zaHY0hDMiPh8" title="Issuance of shares"&gt;35,000&lt;/span&gt; shares of the Company&#x2019;s
common stock valued at $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20260331_zLWswkdI3qn6" title="Share price"&gt;10.00&lt;/span&gt; per share. At March 31, 2026, did not issue these shares and the $&lt;span id="xdx_907_ecustom--StockbasedCompensationLiability_pp0d_c20251001__20260331_zkMlrVYAucM1" title="Stock-based compensation liability"&gt;350,000&lt;/span&gt; payable in shares is included
in stock-based compensation liability on the accompanying unaudited condensed consolidated balance sheets. There were no shares payable
and unissued at September 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002423"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact002425"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002427"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact002429"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002431"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002433"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact002435"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact002437"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002439"
      unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact002441"
      unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002443"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact002445"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002447"
      unitRef="Shares">20347137</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002449"
      unitRef="Shares">20347137</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact002451"
      unitRef="Shares">14521094</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact002453"
      unitRef="Shares">14521094</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002456"
      unitRef="Shares">6900000</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact002457"
      unitRef="USDPShares">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2026-03-31_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact002458"
      unitRef="Shares">406000</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact002459"
      unitRef="USDPShares">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2026-03-31_us-gaap_IPOMember"
      decimals="INF"
      id="Fact002460"
      unitRef="Shares">6900000</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002461"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002462"
      unitRef="USDPShares">18.00</us-gaap:SaleOfStockPricePerShare>
    <VWAV:ExerciseOfWarrantsShare
      contextRef="From2026-01-012026-03-31"
      decimals="INF"
      id="Fact002464"
      unitRef="Shares">46747</VWAV:ExerciseOfWarrantsShare>
    <VWAV:ExerciseOfWarrantsShare
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact002466"
      unitRef="Shares">542256</VWAV:ExerciseOfWarrantsShare>
    <VWAV:ExerciseOfWarrant
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact002468"
      unitRef="USD">537591</VWAV:ExerciseOfWarrant>
    <VWAV:ExerciseOfWarrant
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002470"
      unitRef="USD">6235945</VWAV:ExerciseOfWarrant>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002471"
      unitRef="Shares">8396069</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact002472"
      unitRef="Shares">7304992</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2025-07-14_custom_PublicRightsMember"
      decimals="INF"
      id="Fact002473"
      unitRef="Shares">6900000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2025-07-14_custom_PrivateRightsMember"
      decimals="INF"
      id="Fact002474"
      unitRef="Shares">406000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <VWAV:ScheduleOfSharesBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002476">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfSharesBasedCompensationStockOptionsActivityTableTextBlock_zPOhEL4zxUN3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholder's Deficit (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_z0vRjgKJJQT4" style="display: none"&gt;Schedule of analysis of the warrants grant activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Schedule of stock option grant activity&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 43%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding
    at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20251001__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zi1O4PXv2lKg" style="width: 15%; text-align: right" title="Number of shares  stock option outstanding"&gt;7,304,992&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20241001__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_z7muR0BK8k95" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Beginning balance"&gt;11.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20251001__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zhVWQcGRI6q4" title="Weighted Average Remaining Life Granted"&gt;4.79&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251001__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_z22aZqf4rRbb" style="text-align: right" title="Number of shares outstanding granted"&gt;300,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20241001__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zlPKUSFBrXyh" style="text-align: right" title="Weighted Average Exercise Price granted"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x97;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20251001__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zZVeYaQ88Xb8" style="text-align: right" title="Number of shares outstanding expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2488"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20241001__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_z2gSXgKrwY0g" style="text-align: right" title="Weighted Average Exercise Price Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2490"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x97;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20251001__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zwxIKUeORnW9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares outstanding exercised"&gt;(495,509&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_iN_di_c20241001__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zPq8MwqqLMp1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price granted"&gt;(11.50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm2_dtY_c20251001__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zLyWs3wVlHT9" title="Weighted Average Remaining Life Forfeited"&gt;4.79&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at December
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_z8hEOWwCYt51" style="text-align: right" title="Number of shares  stock option outstanding"&gt;7,109,483&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zYKUyHhrkBda" style="text-align: right" title="Weighted Average Exercise Price Beginning balance"&gt;11.02&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm_dtY_c20251001__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zUhWswabPJJ9" title="Weighted Average Remaining Life Granted"&gt;4.56&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zrrkbepBYk7f" style="text-align: right" title="Number of shares outstanding granted"&gt;1,333,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zVvZDO0uo7s2" style="text-align: right" title="Weighted Average Exercise Price granted"&gt;9.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zPsd4PQe3m7f" title="Weighted Average Remaining Life Granted"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zf9RLsv37kx5" style="text-align: right" title="Number of shares outstanding expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2510"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zeBwdgMF6DVi" style="text-align: right" title="Weighted Average Exercise Price Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2512"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x97;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zCLNBH9M7Npl" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares outstanding exercised"&gt;(46,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_iN_di_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_z0QVSiF1EBKk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price granted"&gt;(11.50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zQLC6F3GlCmg" title="Weighted Average Remaining Life Forfeited"&gt;4.56&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at March
    31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zZzDkgi2ze94" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares  stock option outstanding"&gt;8,396,069&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zCwXb5w9BwV6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price ending balance"&gt;10.69&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zXaXlzmX1Z14" title="Weighted Average Remaining Life Outstanding"&gt;4.41&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;At March 31, 2026 and September 30, 2025, the intrinsic value of the
warrants was $&lt;span id="xdx_90C_ecustom--IntrinsicValue_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zzkIjh3Tfoug" title="Intrinsic value"&gt;1,419,000&lt;/span&gt; and $&lt;span id="xdx_900_ecustom--IntrinsicValue_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WarrantsMember_zMae8gAKl8Ig" title="Intrinsic value"&gt;0&lt;/span&gt;, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The assumptions used in Monte Carlo Simulation model related to the
February 26, 2026 &lt;span id="xdx_903_ecustom--WarrantsIssuance_iI_c20260226_zeDtuHvnvDF8" title="Warrants issuance"&gt;1,333,333&lt;/span&gt; warrants issuance are set forth in the table immediately below:&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zazYDWWrEgwa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholder's Deficit (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B3_zT5ILmcCwiK5" style="display: none"&gt;Schedule of stock option assumptions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 12pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;February
    26, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--StockPrice_c20260201__20260226_zgHH3Osrt2Cb" title="Stock Price"&gt;7.96&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--StockholdersEquityOtherShares_c20260201__20260226_zaaeNl2elb71" title="Exercise price"&gt;9.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20260201__20260226_zrVOBaMhxIMg" title="Volatility"&gt;73.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk
    free rate of return&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20260201__20260226_zJaqEEf3pkO3" title="Risk-free interest rate"&gt;3.54&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Term
    to maturity (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260201__20260226__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zh5GAHgK0TRf" title="Term to maturity (years)"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Term
    to financing (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20260201__20260226_zSRiLTEcniw8" title="Term to financing (years) (years)"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</VWAV:ScheduleOfSharesBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-09-30_custom_WarrantsMember"
      decimals="0"
      id="Fact002478"
      unitRef="USD">7304992</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_custom_WarrantsMember"
      decimals="INF"
      id="Fact002480"
      unitRef="USDPShares">11.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-10-012025-12-31_custom_WarrantsMember"
      id="Fact002482">P4Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-10-012025-12-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact002484"
      unitRef="Shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-10-012025-09-30_custom_WarrantsMember"
      decimals="INF"
      id="Fact002486"
      unitRef="USDPShares">0.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-10-012025-12-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact002492"
      unitRef="Shares">495509</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-10-012025-09-30_custom_WarrantsMember"
      decimals="INF"
      id="Fact002494"
      unitRef="USDPShares">11.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <VWAV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm2
      contextRef="From2025-10-012025-12-31_custom_WarrantsMember"
      id="Fact002496">P4Y9M14D</VWAV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-12-31_custom_WarrantsMember"
      decimals="0"
      id="Fact002498"
      unitRef="USD">7109483</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact002500"
      unitRef="USDPShares">11.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <VWAV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm
      contextRef="From2025-10-012025-12-31_custom_WarrantsMember"
      id="Fact002502">P4Y6M21D</VWAV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2026-01-012026-03-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact002504"
      unitRef="Shares">1333333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2026-01-012026-03-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact002506"
      unitRef="USDPShares">9.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2026-01-012026-03-31_custom_WarrantsMember"
      id="Fact002508">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2026-01-012026-03-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact002514"
      unitRef="Shares">46747</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2026-01-012026-03-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact002516"
      unitRef="USDPShares">11.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <VWAV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm2
      contextRef="From2026-01-012026-03-31_custom_WarrantsMember"
      id="Fact002518">P4Y6M21D</VWAV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2026-03-31_custom_WarrantsMember"
      decimals="0"
      id="Fact002520"
      unitRef="USD">8396069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2026-03-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact002522"
      unitRef="USDPShares">10.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2026-01-012026-03-31_custom_WarrantsMember"
      id="Fact002524">P4Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <VWAV:IntrinsicValue
      contextRef="AsOf2026-03-31_custom_WarrantsMember"
      decimals="0"
      id="Fact002526"
      unitRef="USD">1419000</VWAV:IntrinsicValue>
    <VWAV:IntrinsicValue
      contextRef="AsOf2025-09-30_custom_WarrantsMember"
      decimals="0"
      id="Fact002528"
      unitRef="USD">0</VWAV:IntrinsicValue>
    <VWAV:WarrantsIssuance
      contextRef="AsOf2026-02-26"
      decimals="0"
      id="Fact002530"
      unitRef="USD">1333333</VWAV:WarrantsIssuance>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002532">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zazYDWWrEgwa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholder's Deficit (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B3_zT5ILmcCwiK5" style="display: none"&gt;Schedule of stock option assumptions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 12pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;February
    26, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--StockPrice_c20260201__20260226_zgHH3Osrt2Cb" title="Stock Price"&gt;7.96&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--StockholdersEquityOtherShares_c20260201__20260226_zaaeNl2elb71" title="Exercise price"&gt;9.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20260201__20260226_zrVOBaMhxIMg" title="Volatility"&gt;73.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk
    free rate of return&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20260201__20260226_zJaqEEf3pkO3" title="Risk-free interest rate"&gt;3.54&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Term
    to maturity (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260201__20260226__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zh5GAHgK0TRf" title="Term to maturity (years)"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Term
    to financing (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20260201__20260226_zSRiLTEcniw8" title="Term to financing (years) (years)"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <VWAV:StockPrice
      contextRef="From2026-02-012026-02-26"
      decimals="INF"
      id="Fact002534"
      unitRef="USDPShares">7.96</VWAV:StockPrice>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="From2026-02-012026-02-26"
      decimals="INF"
      id="Fact002536"
      unitRef="Shares">9.00</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2026-02-012026-02-26"
      decimals="INF"
      id="Fact002538"
      unitRef="Ratio">0.730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2026-02-012026-02-26"
      decimals="INF"
      id="Fact002540"
      unitRef="Ratio">0.0354</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2026-02-012026-02-26_custom_BlackScholesModelMember_srt_MinimumMember"
      id="Fact002542">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <VWAV:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm contextRef="From2026-02-012026-02-26" id="Fact002544">P2Y6M</VWAV:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-08-04_custom_BoardOfDirectorsMember"
      decimals="INF"
      id="Fact002545"
      unitRef="Shares">7000000</us-gaap:SharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-08-04_custom_BoardOfDirectorsMember"
      decimals="INF"
      id="Fact002546"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact002549"
      unitRef="Shares">6350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2025-10-01to2026-03-31" id="Fact002550">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-08-06_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact002551"
      unitRef="USDPShares">7.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact002552"
      unitRef="USDPShares">9.09</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-08-062025-09-02"
      decimals="0"
      id="Fact002554"
      unitRef="USD">500000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2026-01-022026-03-12" id="Fact002555">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-01-04_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact002556"
      unitRef="USDPShares">9.26</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-12_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact002557"
      unitRef="USDPShares">7.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-03-31_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact002558"
      unitRef="USD">1119097</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-03-31_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact002559"
      unitRef="USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-10-012026-03-31_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact002560"
      unitRef="USD">3128944</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact002561"
      unitRef="USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <VWAV:UnvestedOptionSharesForfeited
      contextRef="From2026-01-012026-03-31"
      decimals="INF"
      id="Fact002563"
      unitRef="Shares">3600000</VWAV:UnvestedOptionSharesForfeited>
    <VWAV:StockBasedCompensationReversal
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact002565"
      unitRef="USD">1733920</VWAV:StockBasedCompensationReversal>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-07-022025-07-16"
      decimals="INF"
      id="Fact002566"
      unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-07-16_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact002567"
      unitRef="USDPShares">3.27</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <VWAV:CompensationExpense
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact002569"
      unitRef="USD">1452240</VWAV:CompensationExpense>
    <VWAV:ScheduleOfBlackScholesModelTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002571">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfBlackScholesModelTableTextBlock_zGrFf5MXQ41l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholder's Deficit (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_zGxrFK7JMLV4" style="display: none"&gt;Schedule of Black-Scholes model&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;January 2, 2026 - March 12, 2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;August 6, 2025 - September 2, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Exercise price&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;$	&lt;span id="xdx_904_eus-gaap--StockholdersEquityOtherShares_c20260102__20260312__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zGgP8c3kV5l4" title="Exercise price"&gt;9.26&lt;/span&gt; - &lt;span id="xdx_907_eus-gaap--StockholdersEquityOtherShares_c20260102__20260312__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_zAWfVzNDlGs" title="Exercise price"&gt;7.47&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;$	&lt;span id="xdx_909_eus-gaap--StockholdersEquityOtherShares_c20250805__20250902__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zw5HmulfGEUa" title="Exercise price"&gt;3.27&lt;/span&gt; - &lt;span id="xdx_90E_eus-gaap--StockholdersEquityOtherShares_c20250805__20250902__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_z98y7R3B1BFj" title="Exercise price"&gt;9.09&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk-free interest rate&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20260102__20260312__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zATqtzxOmpJh" title="Risk-free interest rate"&gt;3.74&lt;/span&gt; - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20260102__20260312__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_zFTHO06sboN5" title="Risk-free interest rate"&gt;3.84&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250805__20250902__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zXOcxM6JcIw7" title="Risk-free interest rate"&gt;3.58&lt;/span&gt; -&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250805__20250902__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_zc3f0QkdV8Yk" title="Risk-free interest rate"&gt;3.91&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20260102__20260312__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zE2cqB2oiTO8" title="Volatility"&gt;73.0&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20260102__20260312__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_zOh2WUJcbNu7" title="Volatility"&gt;86.3&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20250805__20250902__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zb5p185jOe7d" title="Volatility"&gt;101.4&lt;/span&gt; - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20250805__20250902__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_zaykx6ru3sEd" title="Volatility"&gt;114.4&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected life (years)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260102__20260312__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_zGUqq2x9NsH8" title="Expected life (years)"&gt;4&lt;/span&gt; -&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260102__20260312__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_zHPBnZi3fJhj" title="Expected life (years)"&gt; 4.5&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250805__20250902__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MinimumMember_z34QLS67vnrf" title="Expected life (years)"&gt;3.19&lt;/span&gt; - &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250805__20250902__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember__srt--RangeAxis__srt--MaximumMember_z2DqrYjMmhWl" title="Expected life (years)"&gt;5.00&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Dividend yield&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20260102__20260312__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember_z0X9tOTCRQC4" title="Expected life (years)"&gt;0&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250805__20250902__us-gaap--DebtInstrumentAxis__custom--BlackScholesModelMember_z7Awx31fWgW8" title="Expected life (years)"&gt;0&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following is an analysis of the stock option grant activity:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfSharesBasedCompensationStocksOptionsActivityTableTextBlock_z5svxBzCsytl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholder's Deficit (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8BD_zXmZOcX6oVZ7" style="display: none"&gt;Schedule of stock option
    grant activity&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Outstanding at September 30, 2025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20251001__20251231_z8KHeHkDf24k" style="text-align: right" title="Number of shares  stock option outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2611"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20241001__20250930_zdvqy8WhdZ5a" style="text-align: right" title="Weighted Average Exercise Price Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2613"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 33%; text-align: left; text-indent: -10pt"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251001__20251231_znliyEz8Oiwl" style="width: 15%; text-align: right" title="Number of shares outstanding granted"&gt;6,850,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20241001__20250930_z30yxeDTiEwa" style="width: 15%; text-align: right" title="Weighted Average Exercise Price granted"&gt;7.42&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20231001__20240930_znODjEe0CmS1" title="Weighted Average Remaining Life Granted"&gt;5.23&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expired&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20251001__20251231_zUmj5kMcw0ne" style="text-align: right" title="Number of shares outstanding expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2621"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20241001__20250930_zpmLhE6r27Lk" style="text-align: right" title="Weighted Average Exercise Price Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2623"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20251001__20251231_zxXUPdUpdn51" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares outstanding exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2625"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20241001__20250930_zZTTiD3YfTij" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2627"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Outstanding at December 31, 2025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260331_zJWSyyA2gQOg" style="text-align: right" title="Number of shares  stock option outstanding"&gt;6,850,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260331_zXZMwIvmtcT9" style="text-align: right" title="Weighted Average Exercise Price Beginning balance"&gt;7.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20251001__20251231_z8jVvLS0MaTi" title="Weighted Average Remaining Life Granted"&gt;5.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Granted&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260331_zIkyE9s2JH9i" style="text-align: right" title="Number of shares outstanding granted"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260331_zYGzVS5cqkjl" style="text-align: right" title="Weighted Average Exercise Price granted"&gt;8.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331_znSXWnnCHWEh" title="Weighted Average Remaining Life Granted"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expired&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20260101__20260331_zATEE49pt212" style="text-align: right" title="Number of shares outstanding expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2641"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260101__20260331_zDkOcksdzJ1i" style="text-align: right" title="Weighted Average Exercise Price Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2643"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20260101__20260331_zwIHxuhCoXE5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares outstanding exercised"&gt;(3,600,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_iN_di_c20260101__20260331_zSB8zMoJyNt1" style="text-align: right" title="Weighted Average Exercise Price granted"&gt;(8.04&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331_zKUyWfPyWbM5" title="Weighted Average Remaining Life Forfeited"&gt;4.38&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Outstanding at March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260331_zCuXbW1AMfZ5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares  stock option outstanding"&gt;4,250,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260331_zrSXqH8C7uK" style="text-align: right" title="Weighted Average Exercise Price ending balance"&gt;7.75&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331_ztMMY2Af9c8l" title="Weighted Average Remaining Life Outstanding"&gt;5.85&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</VWAV:ScheduleOfBlackScholesModelTableTextBlock>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="From2026-01-022026-03-12_custom_BlackScholesModelMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002573"
      unitRef="Shares">9.26</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="From2026-01-022026-03-12_custom_BlackScholesModelMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002575"
      unitRef="Shares">7.47</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="From2025-08-052025-09-02_custom_BlackScholesModelMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002577"
      unitRef="Shares">3.27</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="From2025-08-052025-09-02_custom_BlackScholesModelMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002579"
      unitRef="Shares">9.09</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2026-01-022026-03-12_custom_BlackScholesModelMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002581"
      unitRef="Ratio">0.0374</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2026-01-022026-03-12_custom_BlackScholesModelMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002583"
      unitRef="Ratio">0.0384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-08-052025-09-02_custom_BlackScholesModelMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002585"
      unitRef="Ratio">0.0358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-08-052025-09-02_custom_BlackScholesModelMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002587"
      unitRef="Ratio">0.0391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2026-01-022026-03-12_custom_BlackScholesModelMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002589"
      unitRef="Ratio">0.730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2026-01-022026-03-12_custom_BlackScholesModelMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002591"
      unitRef="Ratio">0.863</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-08-052025-09-02_custom_BlackScholesModelMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002593"
      unitRef="Ratio">1.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-08-052025-09-02_custom_BlackScholesModelMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002595"
      unitRef="Ratio">1.144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2026-01-022026-03-12_custom_BlackScholesModelMember_srt_MinimumMember"
      id="Fact002597">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2026-01-022026-03-12_custom_BlackScholesModelMember_srt_MaximumMember"
      id="Fact002599">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-08-052025-09-02_custom_BlackScholesModelMember_srt_MinimumMember"
      id="Fact002601">P3Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-08-052025-09-02_custom_BlackScholesModelMember_srt_MaximumMember"
      id="Fact002603">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2026-01-022026-03-12_custom_BlackScholesModelMember"
      decimals="INF"
      id="Fact002605"
      unitRef="Ratio">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2025-08-052025-09-02_custom_BlackScholesModelMember"
      decimals="INF"
      id="Fact002607"
      unitRef="Ratio">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <VWAV:ScheduleOfSharesBasedCompensationStocksOptionsActivityTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002609">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfSharesBasedCompensationStocksOptionsActivityTableTextBlock_z5svxBzCsytl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholder's Deficit (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8BD_zXmZOcX6oVZ7" style="display: none"&gt;Schedule of stock option
    grant activity&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Outstanding at September 30, 2025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20251001__20251231_z8KHeHkDf24k" style="text-align: right" title="Number of shares  stock option outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2611"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20241001__20250930_zdvqy8WhdZ5a" style="text-align: right" title="Weighted Average Exercise Price Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2613"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 33%; text-align: left; text-indent: -10pt"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251001__20251231_znliyEz8Oiwl" style="width: 15%; text-align: right" title="Number of shares outstanding granted"&gt;6,850,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20241001__20250930_z30yxeDTiEwa" style="width: 15%; text-align: right" title="Weighted Average Exercise Price granted"&gt;7.42&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20231001__20240930_znODjEe0CmS1" title="Weighted Average Remaining Life Granted"&gt;5.23&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expired&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20251001__20251231_zUmj5kMcw0ne" style="text-align: right" title="Number of shares outstanding expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2621"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20241001__20250930_zpmLhE6r27Lk" style="text-align: right" title="Weighted Average Exercise Price Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2623"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20251001__20251231_zxXUPdUpdn51" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares outstanding exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2625"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20241001__20250930_zZTTiD3YfTij" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2627"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Outstanding at December 31, 2025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260331_zJWSyyA2gQOg" style="text-align: right" title="Number of shares  stock option outstanding"&gt;6,850,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260331_zXZMwIvmtcT9" style="text-align: right" title="Weighted Average Exercise Price Beginning balance"&gt;7.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20251001__20251231_z8jVvLS0MaTi" title="Weighted Average Remaining Life Granted"&gt;5.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Granted&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260331_zIkyE9s2JH9i" style="text-align: right" title="Number of shares outstanding granted"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260331_zYGzVS5cqkjl" style="text-align: right" title="Weighted Average Exercise Price granted"&gt;8.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331_znSXWnnCHWEh" title="Weighted Average Remaining Life Granted"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expired&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20260101__20260331_zATEE49pt212" style="text-align: right" title="Number of shares outstanding expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2641"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260101__20260331_zDkOcksdzJ1i" style="text-align: right" title="Weighted Average Exercise Price Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2643"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20260101__20260331_zwIHxuhCoXE5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares outstanding exercised"&gt;(3,600,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_iN_di_c20260101__20260331_zSB8zMoJyNt1" style="text-align: right" title="Weighted Average Exercise Price granted"&gt;(8.04&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331_zKUyWfPyWbM5" title="Weighted Average Remaining Life Forfeited"&gt;4.38&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Outstanding at March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260331_zCuXbW1AMfZ5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares  stock option outstanding"&gt;4,250,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260331_zrSXqH8C7uK" style="text-align: right" title="Weighted Average Exercise Price ending balance"&gt;7.75&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331_ztMMY2Af9c8l" title="Weighted Average Remaining Life Outstanding"&gt;5.85&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</VWAV:ScheduleOfSharesBasedCompensationStocksOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-10-012025-12-31"
      decimals="INF"
      id="Fact002615"
      unitRef="Shares">6850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-10-012025-09-30"
      decimals="INF"
      id="Fact002617"
      unitRef="USDPShares">7.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-10-012024-09-30" id="Fact002619">P5Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact002629"
      unitRef="USD">6850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact002631"
      unitRef="USDPShares">7.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2025-10-012025-12-31" id="Fact002633">P5Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2026-01-012026-03-31"
      decimals="INF"
      id="Fact002635"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2026-01-012026-03-31"
      decimals="INF"
      id="Fact002637"
      unitRef="USDPShares">8.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2026-01-012026-03-31" id="Fact002639">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2026-01-012026-03-31"
      decimals="INF"
      id="Fact002645"
      unitRef="Shares">3600000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2026-01-012026-03-31"
      decimals="INF"
      id="Fact002647"
      unitRef="USDPShares">8.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <VWAV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm2 contextRef="From2026-01-012026-03-31" id="Fact002649">P4Y4M17D</VWAV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002651"
      unitRef="USD">4250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002653"
      unitRef="USDPShares">7.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2026-01-012026-03-31" id="Fact002655">P5Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <VWAV:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValues
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002660"
      unitRef="USD">735000</VWAV:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValues>
    <VWAV:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValues
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact002662"
      unitRef="USD">14429000</VWAV:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002664"
      unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact002666"
      unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <VWAV:ScheduleOfRecognizeTheRemainingTotalStockBasedCompensationTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002668">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfRecognizeTheRemainingTotalStockBasedCompensationTableTextBlock_z6n8g7UZcA8h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholder's Deficit (Details 4)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BE_zAyO5WUPyOM6" style="display: none"&gt;Schedule of recognize the remaining total stock-based
compensation&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_493_20260331_z5TC5vswRqrd" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: left"&gt;Year&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--CapitalLeasesFutureMinimumPaymentNextRollingTwelveMonths_iI_z3KYnlKhTWN9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 52%; text-align: left; text-indent: -10pt"&gt;2026&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 35%; text-align: right"&gt;2,450,154&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--CapitalLeasesFutureMinimumPaymentDueInRollingYearTwo_iI_zx1UJhAjzNb2" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2027&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;4,900,308&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--CapitalLeasesFutureMinimumPaymentDueInRollingYearThree_iI_zgY4WEg2j8w4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2028&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;4,900,308&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--CapitalLeasesFutureMinimumPaymentDueInRollingYearFour_iI_zOIjMz52lSge" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2029&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,703,652&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--CapitalLeasesFutureMinimumPaymentDueInRollingYearFive_iI_z6Lnvo8K3xEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;2030&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;265,026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--CapitalLeasesFutureMinimumPaymentDue_iI_zlx2VeU5XUL4" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;16,219,448&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</VWAV:ScheduleOfRecognizeTheRemainingTotalStockBasedCompensationTableTextBlock>
    <VWAV:CapitalLeasesFutureMinimumPaymentNextRollingTwelveMonths
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002670"
      unitRef="USD">2450154</VWAV:CapitalLeasesFutureMinimumPaymentNextRollingTwelveMonths>
    <VWAV:CapitalLeasesFutureMinimumPaymentDueInRollingYearTwo
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002672"
      unitRef="USD">4900308</VWAV:CapitalLeasesFutureMinimumPaymentDueInRollingYearTwo>
    <VWAV:CapitalLeasesFutureMinimumPaymentDueInRollingYearThree
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002674"
      unitRef="USD">4900308</VWAV:CapitalLeasesFutureMinimumPaymentDueInRollingYearThree>
    <VWAV:CapitalLeasesFutureMinimumPaymentDueInRollingYearFour
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002676"
      unitRef="USD">3703652</VWAV:CapitalLeasesFutureMinimumPaymentDueInRollingYearFour>
    <VWAV:CapitalLeasesFutureMinimumPaymentDueInRollingYearFive
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002678"
      unitRef="USD">265026</VWAV:CapitalLeasesFutureMinimumPaymentDueInRollingYearFive>
    <VWAV:CapitalLeasesFutureMinimumPaymentDue
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002680"
      unitRef="USD">16219448</VWAV:CapitalLeasesFutureMinimumPaymentDue>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-07-302025-08-01"
      decimals="0"
      id="Fact002681"
      unitRef="USD">60000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact002682"
      unitRef="USD">143221</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact002683"
      unitRef="USD">0</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002684"
      unitRef="USD">188221</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact002685"
      unitRef="USD">0</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:DeferredCompensationEquity
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002686"
      unitRef="USD">146840</us-gaap:DeferredCompensationEquity>
    <us-gaap:DeferredCompensationEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact002687"
      unitRef="USD">150000</us-gaap:DeferredCompensationEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="From2025-10-012026-03-31_custom_Septmber302025Member"
      decimals="INF"
      id="Fact002689"
      unitRef="Shares">15735</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:RestrictedStockExpense
      contextRef="From2025-10-012026-03-31_custom_September302025Member"
      decimals="0"
      id="Fact002691"
      unitRef="USD">180000</us-gaap:RestrictedStockExpense>
    <VWAV:EmployeeBenefitsAndShareBasedCompensations
      contextRef="From2025-10-012026-03-31_custom_September302025Member"
      decimals="0"
      id="Fact002693"
      unitRef="USD">30000</VWAV:EmployeeBenefitsAndShareBasedCompensations>
    <VWAV:EmployeeBenefitsAndShareBasedCompensations
      contextRef="From2025-10-012026-03-31_custom_December312025Member"
      decimals="0"
      id="Fact002699"
      unitRef="USD">45000</VWAV:EmployeeBenefitsAndShareBasedCompensations>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="From2025-10-012026-03-31_custom_March312026Member"
      decimals="INF"
      id="Fact002701"
      unitRef="Shares">14961</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:RestrictedStockExpense
      contextRef="From2025-10-012026-03-31_custom_March312026Member"
      decimals="0"
      id="Fact002703"
      unitRef="USD">295000</us-gaap:RestrictedStockExpense>
    <VWAV:EmployeeBenefitsAndShareBasedCompensations
      contextRef="From2025-10-012026-03-31_custom_March312026Member"
      decimals="0"
      id="Fact002705"
      unitRef="USD">143221</VWAV:EmployeeBenefitsAndShareBasedCompensations>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact002707"
      unitRef="Shares">30696</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:RestrictedStockExpense
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002709"
      unitRef="USD">475000</us-gaap:RestrictedStockExpense>
    <VWAV:EmployeeBenefitsAndShareBasedCompensations
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002711"
      unitRef="USD">218221</VWAV:EmployeeBenefitsAndShareBasedCompensations>
    <VWAV:IssuanceOfSharesToFormerDirectorsDescription contextRef="From2025-02-082025-08-09" id="Fact002713">On August 9, 2025, the Company entered into compensation
agreements with three former directors, pursuant to which each director will receive $120,000 payable in cash or shares. Two directors
elected to receive a total of $125,000 in shares and on September 10, 2025, total shares of 10,927 were issued and stock-based compensation
of $125,000 related the compensation agreements with two former directors was included in general and administrative expense on the consolidated
statements of operations during the year ended September 30, 2025. There was no issuance of shares for the three and six months ended
March 31, 2026.</VWAV:IssuanceOfSharesToFormerDirectorsDescription>
    <VWAV:CommonStockShareIssued
      contextRef="AsOf2025-07-25"
      decimals="INF"
      id="Fact002717"
      unitRef="Shares">200000</VWAV:CommonStockShareIssued>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002719"
      unitRef="USD">470000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-07-022025-07-25"
      decimals="INF"
      id="Fact002720"
      unitRef="Shares">22500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <VWAV:IssuanceOfSharesInAssetAcquisitionsShare
      contextRef="From2025-10-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002722"
      unitRef="Shares">1500000</VWAV:IssuanceOfSharesInAssetAcquisitionsShare>
    <VWAV:IssuanceOfSharesInAssetAcquisitionsShare
      contextRef="From2026-01-272026-01-28_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002724"
      unitRef="Shares">8532</VWAV:IssuanceOfSharesInAssetAcquisitionsShare>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-11-282025-11-30"
      decimals="0"
      id="Fact002725"
      unitRef="USD">30000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <VWAV:SharesIssuedToDirectors
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact002727"
      unitRef="USD">25000</VWAV:SharesIssuedToDirectors>
    <VWAV:SharesIssuedToDirectors
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact002729"
      unitRef="USD">0</VWAV:SharesIssuedToDirectors>
    <VWAV:EmployeeBenefitsAndShareBasedCompensations
      contextRef="From2025-10-072025-10-09"
      decimals="0"
      id="Fact002731"
      unitRef="USD">75000</VWAV:EmployeeBenefitsAndShareBasedCompensations>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002733"
      unitRef="USD">350000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002735"
      unitRef="Shares">35000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact002737"
      unitRef="USDPShares">10.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <VWAV:StockbasedCompensationLiability
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002739"
      unitRef="USD">350000</VWAV:StockbasedCompensationLiability>
    <VWAV:GainOnSaleOfMarketableSecuritiesTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002741">&lt;p id="xdx_805_ecustom--GainOnSaleOfMarketableSecuritiesTextBlock_zQuCIHCuGjoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 20 &#x2014; &lt;span id="xdx_82C_zYEnKeA7ST4a"&gt;Gain on Sale of Marketable Securities&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 4, 2024, VW Tech invested in 10 million
shares Avant Technologies, Inc. (&#x201c;AVAI&#x201d;). On February 28, 2025 and March 5, 2025, VW Tech sold &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250304__20250305_z3nlHr6ysFB2"&gt;264,112&lt;/span&gt; of AVAI shares for
net proceeds of $&lt;span id="xdx_90B_eus-gaap--GainLossOnSaleOfInvestments_c20240603__20240604_z8LRnZcv9S8"&gt;114,111&lt;/span&gt; for a total gain of $104,656 on sale of marketable securities. On April 28, 2025, the Company sold its remaining
holding of &lt;span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250401__20250428_zHNdbQaSGVV4"&gt;9,735,888&lt;/span&gt; shares of AVAI, which were recorded at par value of $&lt;span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_c20250428_zoybUtLody59"&gt;0.001&lt;/span&gt; per share to a third party in exchange for 280,534 shares
of Tofla Megaline Inc. (&#x201c;TFML&#x201d;). The Company determined that the quoted price of the TFLM shares was not a reliable indicator
of fair value at the measurement date as the historical price data indicates that TFLM shares consistently reflected zero daily trading
volume over an extended period. Therefore, the Company measured the TFLM shares received at par value of $0.001 per share, which was
deemed the most reliable and supportable estimate of fair value at the transaction date under ASC 820.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As a result of this non-cash exchange, the Company
recognized a loss on sale of the &lt;span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251001__20260331_zmO7XUG7Jx8k"&gt;9,735,888&lt;/span&gt; shares of AVAI of approximately $&lt;span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20251001__20260331_zMtaEiwyP2Vf"&gt;9,455&lt;/span&gt; during the year ended September 30, 2025. The total
gain on sale of AVAI shares of $&lt;span id="xdx_90F_ecustom--GainOnSaleOfMarketableSecurities_c20251001__20260331_zpTyghSNoVui" title="Gain on sale of marketable securities"&gt;104,656&lt;/span&gt; is recorded in the recorded as gain on sale of marketable securities on the unaudited condensed
consolidated statements of operations during the year ended September 30, 2025. At March 31, 2026 and September 30, 2025, the total par
value of TFML shares of $&lt;span id="xdx_907_eus-gaap--MarketableSecurities_iI_c20250930_zkkvFNQ6QDfh"&gt;281&lt;/span&gt; is recorded as investment in marketable securities available for share on the unaudited condensed consolidated
balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







</VWAV:GainOnSaleOfMarketableSecuritiesTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-03-042025-03-05"
      decimals="INF"
      id="Fact002742"
      unitRef="Shares">264112</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2024-06-032024-06-04"
      decimals="0"
      id="Fact002743"
      unitRef="USD">114111</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-04-012025-04-28"
      decimals="INF"
      id="Fact002744"
      unitRef="Shares">9735888</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-04-28"
      decimals="INF"
      id="Fact002745"
      unitRef="USDPShares">0.001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact002746"
      unitRef="Shares">9735888</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002747"
      unitRef="USD">9455</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <VWAV:GainOnSaleOfMarketableSecurities
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002749"
      unitRef="USD">104656</VWAV:GainOnSaleOfMarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact002750"
      unitRef="USD">281</us-gaap:MarketableSecurities>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002754">&lt;p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_zabphpG2KCQe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 21 &#x2014; &lt;span id="xdx_820_zxUe8iHcYrxi"&gt;Income Tax&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company files income tax returns in the U.S.
federal jurisdiction and in various state and local jurisdictions and is subject to examination by the various taxing authorities, since
inception. At the close of the Reverse Acquisition, the Company assumed $&lt;span id="xdx_903_eus-gaap--CurrentIncomeTaxExpenseBenefit_c20251001__20260331_zu31DSIkhUji"&gt;959,639&lt;/span&gt; of income tax expenses inclusive of interest and penalties.
For the three and six months ended March 31, 2026, the Company incurred an additional $&lt;span id="xdx_901_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_c20260101__20260331_zGilYi58UJ3d"&gt;24,461&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_c20250101__20250331_zurEDovetBZb"&gt;49,228&lt;/span&gt;, respectively, in interest
and penalties for its failure to file and pay its taxes. At March 31, 2026 and September 30, 2025, the total liability of $&lt;span id="xdx_906_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_c20251001__20260331_z7QHEdsp8kYi"&gt;1,043,932&lt;/span&gt;
and $&lt;span id="xdx_90A_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_c20241001__20250331_zvpKmcUVByAd"&gt;994,704&lt;/span&gt;, respectively, is included on the unaudited condensed consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002755"
      unitRef="USD">959639</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact002756"
      unitRef="USD">24461</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact002757"
      unitRef="USD">49228</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002758"
      unitRef="USD">1043932</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact002759"
      unitRef="USD">994704</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002761">&lt;p id="xdx_805_eus-gaap--SegmentReportingDisclosureTextBlock_zrVqW0dctkg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 22 &#x2014; &lt;span id="xdx_820_ze7Mtjvw0Cli"&gt;Segment Information&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC Topic 280 establishes standards for companies
to report financial statement information about operating segments, products, services, geographic areas, and major customers. Operating
segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated
by the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), or group, in deciding how to allocate resources and assess
performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The CODM has been identified as the Chief Financial
Officer, who reviews the operating results for the Company as a whole to make decisions about allocating resources and assessing financial
performance. Accordingly, management has determined that the Company only has one operating segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The CODM assesses performance for the single segment
and decides how to allocate resources based on operating loss that also is reported on the consolidated statements of operations. The
measure of segment assets is reported on the unaudited condensed consolidated balance sheets as total assets. When evaluating the Company&#x2019;s
performance and making key decisions regarding resource allocation the CODM reviews several key metrics, which include the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zfNTYLkAb7th" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_zseALOxxDUn4" style="display: none"&gt;Schedule of Segment Information&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_498_20260101__20260331_zKdiTXmLwl9j" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_499_20250101__20250331_zithwKBLF0va" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49E_20251001__20260331_zHj0MOzqwq9g" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49C_20241001__20250331_zotIdDwjoEo3" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended March 31,&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six Months Ended March 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpense_zZaqefNlbcg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;2,922,318&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;131,463&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;7,602,857&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;275,231&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_zZDiGNXqAWL3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;271,534&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2771"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;586,609&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2773"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--BusinessDevelopment_z5LyCYRxsHR4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Sales and marketing&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;2,159,439&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;11,490&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,612,611&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;71,445&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DepreciationAndAmortization_zIZkvXkb3SIi" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,702,250&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2781"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,821,145&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2783"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OtherNonoperatingIncome_iN_di_zqboDixIyf3b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Operating loss&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(11,055,541&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(142,953&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(17,623,222&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(346,676&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The key metrics included in segment profit or
loss reviewed by the CODM are operating costs. The CODM reviews operating costs to manage and forecast cash to ensure enough capital
is available to meet operational needs and fund research and development efforts. The CODM also reviews operating costs to manage, maintain
and enforce all contractual agreements to ensure costs are aligned with all agreements and budget.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002763">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zfNTYLkAb7th" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_zseALOxxDUn4" style="display: none"&gt;Schedule of Segment Information&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_498_20260101__20260331_zKdiTXmLwl9j" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_499_20250101__20250331_zithwKBLF0va" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49E_20251001__20260331_zHj0MOzqwq9g" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49C_20241001__20250331_zotIdDwjoEo3" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended March 31,&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six Months Ended March 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpense_zZaqefNlbcg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;2,922,318&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;131,463&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;7,602,857&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;275,231&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_zZDiGNXqAWL3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;271,534&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2771"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;586,609&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2773"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--BusinessDevelopment_z5LyCYRxsHR4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Sales and marketing&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;2,159,439&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;11,490&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,612,611&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;71,445&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DepreciationAndAmortization_zIZkvXkb3SIi" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,702,250&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2781"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,821,145&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2783"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OtherNonoperatingIncome_iN_di_zqboDixIyf3b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Operating loss&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(11,055,541&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(142,953&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(17,623,222&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(346,676&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The key metrics included in segment profit or
loss reviewed by the CODM are operating costs. The CODM reviews operating costs to manage and forecast cash to ensure enough capital
is available to meet operational needs and fund research and development efforts. The CODM also reviews operating costs to manage, maintain
and enforce all contractual agreements to ensure costs are aligned with all agreements and budget.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact002765"
      unitRef="USD">2922318</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact002766"
      unitRef="USD">131463</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002767"
      unitRef="USD">7602857</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact002768"
      unitRef="USD">275231</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact002770"
      unitRef="USD">271534</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002772"
      unitRef="USD">586609</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:BusinessDevelopment
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact002775"
      unitRef="USD">2159439</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact002776"
      unitRef="USD">11490</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002777"
      unitRef="USD">3612611</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact002778"
      unitRef="USD">71445</us-gaap:BusinessDevelopment>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact002780"
      unitRef="USD">5702250</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002782"
      unitRef="USD">5821145</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact002785"
      unitRef="USD">11055541</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact002786"
      unitRef="USD">142953</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact002787"
      unitRef="USD">17623222</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2024-10-012025-03-31"
      decimals="0"
      id="Fact002788"
      unitRef="USD">346676</us-gaap:OtherNonoperatingIncome>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact002790">&lt;p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zdoZnL86ZB6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 23&#x2014;&lt;span id="xdx_82A_zhT8U1VbXVF7"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluated subsequent events and transactions
that occurred after the balance sheet date up to the date of the filing of this report. The Company did not identify any subsequent events,
other than disclosed in the Notes and discussed below, that would have required adjustment or disclosure in these unaudited condensed
consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Latin American Government Purchase Order&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 2, 2026, the Company announced the receipt
of a signed purchase order from a Latin American governmental public safety organization. The order provides for the supply of drone-based
operational systems and integrated payload technologies, including long-range observation quadrotor platforms, day/night EO/IR imaging
payloads, and network-based connectivity modules. The systems are intended to support defense, public safety, and law enforcement missions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The purchase order contemplates a multi-phase
deployment structure, with initial deliveries expected to commence in 2026. The completion of the order and subsequent deployment phases
are subject to standard commercial terms and customary conditions, including delivery milestones, quantity confirmations, performance,
and acceptance. The Company has noted that there can be no assurance that the full scope of the purchase order will be completed or that
all anticipated revenues from the order will be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Asset Purchase Agreement (xClibre Technology)&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On
                                            April 10, 2026, the Company entered into an Asset Purchase Agreement with Dream America Marketing
                                            Services, Ltda. to acquire all right, title, and interest in certain intellectual property
                                            assets related to xClibre technology. The acquired assets consist solely of intellectual
                                            property and do not constitute a &#x201c;business&#x201d; for purposes of Regulation S-X&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In consideration for the assigned intellectual
property, the Company agreed to provide aggregate consideration consisting of up to 7,000,000 shares of the Company&#x2019;s common stock
and a $6,000,000 promissory note. At the closing of the transaction, the Company issued 3,500,000 shares of common stock and executed
the $6,000,000 promissory note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The issuance of the remaining 3,500,000 contingent
shares is subject to obtaining satisfactory proof-of-concept results and Nasdaq Shareholder Approval. The Company has agreed to use commercially
reasonable efforts to obtain this proof-of-concept approval no later than nine months following the closing date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If the proof-of-concept approval is not obtained
within this nine-month period, the Company is required to promptly transfer 60% of the equity interests in xClibre Inc. (a wholly-owned
subsidiary holding the acquired intellectual property) back to the seller, free and clear of all encumbrances. In such an event, the
seller&#x2019;s security interest in the equity would be released, and the seller would retain full ownership of the initial 3,500,000
closing shares and the promissory note without any obligation to forfeit them. No alternative consideration will be provided in lieu
of the unissued contingent shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Agreement contains customary representations,
warranties, covenants and indemnification provisions for a transaction of this nature.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 10, 2026, the transactions contemplated
by the Agreement were completed. The Assigned IP consists of intellectual property rights owned by the Seller relating to the xClibre
technology, including patents, patent applications, trademarks, copyrights, trade secrets, know-how, software and other proprietary rights.
on April 10, 2026, the Company issued 3,500,000 shares of its common stock to the Seller as partial consideration for the Assigned IP.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Prospectus (S1 Registration Statement)&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 16, 2026 the Company filed a prospectus
(Form S1 registration statement) for 2,715,610 Shares of Common Stock, 2,100,000 Warrant Shares issuable upon exercise of Pre-Funded
Warrant and 1,333,333 Warrant Shares issuable upon exercise of a Warrant&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;This prospectus relates to the disposition from
time to time by the selling stockholders named in this prospectus (the &#x201c;Selling Stockholders&#x201d;) of the Company of 6,148,943
shares of our common stock, par value $0.01 per share (our &#x201c;Common Stock&#x201d;) including 1,500,000 issued or to be issued pursuant
to the Exchange Agreement and the Blade Ranger Agreement as described below, (i) 1,215,610 issued or to be issued pursuant to the Exchange
Agreement as described below, (ii) 2,100,000 shares of Common Stock issuable upon exercise of Pre-Funded Warrants issued or to be issued
pursuant to the Blade Ranger Agreement and (iii) 1,333,333 shares of Common Stock issuable pursuant to a Warrant held by YA II PN Ltd.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Appointment of Independent Director and Compensatory Arrangements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Board Appointment and changes&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 16, 2026, the Company&#x2019;s Board of
Directors appointed Shayna Quinn to serve as a member of the Board. The Board determined that Ms. Quinn qualifies as an independent director
under applicable Nasdaq and SEC rules.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with her appointment, the Company
entered into an Independent Director Engagement Agreement with Ms. Quinn. Under the terms of this agreement, she will receive the following
compensation:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#x25cf; &lt;b&gt;Cash Retainer:&lt;/b&gt; An annual cash retainer
of $36,000, payable quarterly in arrears&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#x25cf; &lt;b&gt;Equity Awards:&lt;/b&gt; An annual grant
of $60,000 in shares of restricted stock issued under the Company&#x2019;s 2024 Omnibus&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Equity Incentive Plan. These awards are to be
granted on or about August 1 of each year and will vest in full following twelve months of continuous service, subject to accelerated
vesting in the event of a change in control, death, or disability&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#x25cf; &lt;b&gt;Expenses:&lt;/b&gt; Reimbursement for expenses
in accordance with standard Company policy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 1, 2026, the Board of Directors (the &#x201c;Board&#x201d;)
of the Company approved the appointment of Atara Dzikowski as Vice President of Mergers and Acquisitions. In connection therewith, the
Company entered into an Employment Agreement dated May 1, 2026 with Ms. Dzikowski (the &#x201c;Employment Agreement&#x201d;). In addition,
the Company and Ms. Dzikowski, a current member of the Board, entered into a Proprietary &amp;amp; Confidential Information, Inventions Assignment,
Non-Solicitation and Non-Competition Agreement (the &#x201c;Restrictive Covenant Agreement&#x201d;) and the Mutual Agreement to Arbitrate
(the &#x201c;Arbitration Agreement&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Material terms of the Employment Agreement include
an initial term of three years commencing on April 1, 2026, with automatic one-year renewals absent thirty days&#x2019; prior written
notice of non-renewal by either party and an annual base salary of $240,000. On the effective date, subject to prior approval by the
Board or the Compensation Committee and the terms of the Company&#x2019;s 2025 Omnibus Equity Incentive Plan (or any successor plan),
an award of 500,000 shares of common stock or restricted stock units, of which 150,000 shares vest immediately upon the grant date. The
remaining 350,000 shares shall vest upon the earlier of: (i) time-based vesting of 100,000 shares on each of the first three (3) anniversaries
of the effective date and the final 50,000 shares on the three and one-half (3.5) year anniversary of the effective Date, or (ii) performance-based
vesting tied to consolidated revenue milestones of the Company and its subsidiaries (as determined in accordance with U.S. generally
accepted accounting principles (&#x201c;GAAP&#x201d;) and reported in the Company&#x2019;s periodic reports filed with the Securities and
Exchange Commission): 100,000 shares upon achievement of $5,000,000 in cumulative Revenue; an additional 100,000 shares upon achievement
of $10,000,000 cumulative Revenue; an additional 100,000 shares upon achievement of $15,000,000 cumulative Revenue; and the final 50,000
shares upon achievement of $17,500,000 cumulative Revenue. &#x201c;Revenue&#x201d; means the Company&#x2019;s consolidated total revenue.
Achievement of milestones shall be certified by the Board of Directors or Compensation Committee in its reasonable discretion.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Further, Ms. Dzikowski will be eligible to participate
in the Company&#x2019;s standard employee benefit plans made available to similarly situated executives, including medical, dental and
vision insurance, short- and long-term disability benefits, life insurance and retirement plan participation, subject to the terms of
such plans as they may be amended from time to time. Upon termination for death, disability, for cause, resignation without good reason,
or expiration of the term, Ms. Dzikowski will be entitled to only accrued but unpaid base salary and, to the extent required by law,
accrued unused paid time off. Upon termination without cause or for good reason, the accrued benefits plus a severance payment equal
to the then-current base salary, payable within six months of termination, conditioned upon execution of a general release of claims
in a form provided by the Company and continued compliance with post-termination obligations. Customary provisions requiring full-time
devotion of efforts, exclusive employment, and compliance with Company rules and policies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Jez Williman executive terms change&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 8, 2026, the Company entered into Amendment
No. 1 (the &#x201c;Amendment&#x201d;) to the Employment Agreement dated September 2, 2025 (the &#x201c;Original Agreement&#x201d;) with Jez
Williman (&#x201c;Executive&#x201d;), who serves as the Company&#x2019;s Managing Director, UK and European Operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the Amendment: (i) Executive&#x2019;s
title was updated to Managing Director, UK and European Operations, effective as of the date of the Amendment; (ii) Executive&#x2019;s
annual base salary was increased to $200,000, effective as of May 1, 2026 and shall be increased to an annual rate of the lesser of $300,000
or fair market rate once the Company has achieved $10,000,000 in revenue during any ninety (90) day period; and (iii) in addition to
the 250,000 options previously granted under the Original Agreement, the Company agreed to grant Executive additional performance-based
stock options under the Company&#x2019;s 2025 Omnibus Equity Incentive Plan (subject to the terms of the Plan, an option agreement, and
Executive&#x2019;s continued service), consisting of (a) 50,000 options upon issuance of the valid payable commercial invoice(s) for the
second UGV sold, and (b) 100,000 options upon issuance of valid payable commercial invoices cumulatively totaling $1 million. Such additional
options will be granted at an exercise price equal to the fair market value of the Company&#x2019;s common stock on the applicable grant
date (determined in accordance with the Plan) and will vest upon achievement of the respective milestone or as otherwise determined by
the Board of Directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Changes to Board Committee Memberships&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 22, 2026, the Board accepted the resignation
of Atara Dzikowski from the Audit Committee, the Compensation Committee, and the Nominating and Governance Committee, effective upon
the commencement of her employment as Vice President of Mergers and Acquisitions. Ms. Dzikowski will continue to serve as a non-independent
member of the Board of Directors. Concurrently, the Board appointed Daniel Ollech as a member of the Audit Committee, Mansour Khatib
as a member of the Compensation Committee, and Judit Nagypal as a member and Chair of the Nominating and Governance Committee, with such
appointments effective immediately upon Ms. Dzikowski&#x2019;s resignation from the respective committees. The Board confirmed that the
committees, as reconstituted, continue to satisfy all applicable Nasdaq independence and composition requirements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;There are no family relationships among the individuals
referenced above that require disclosure under Item 404(a) of Regulation S-K. There were no disagreements between the Company and Ms.
Dzikowski regarding her transition or resignation from the committee positions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Patent Filling&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 23, 2026, the Company issued a Corporate
Update press release which included announcing the filing of a non-provisional U.S. patent application titled &#x201c;AI-Assisted Multi-Modal
RF Fire Control System for All-Domain Target Engagement&#x201d; (Serial No. 19/652,090, filed April 20, 2026), claiming priority to provisional
application Serial No. 63/892,721 (prior provisional was filed October 3, 2025).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Potential Listing In Germany&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During May 2026, the Company commenced the process
of seeking registration of its common stock for trading on the Frankfurt Stock Exchange in Germany and, in connection therewith, obtained
a Legal Entity Identifier (&#x201c;LEI&#x201d;) from WM Datenservice for international securities settlement and regulatory purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the contemplated Frankfurt
listing and expansion of investor awareness activities in Europe, particularly within Germany, Switzerland, and Austria, the Company
entered into (i) an Investor Awareness Advisory Agreement and (ii) an Investor Awareness Services Agreement with CapitaLink Ltd, an Israeli-based
investor awareness and communications advisory firm.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under the advisory agreement, the Company agreed
to issue 55,000 restricted shares of common stock pursuant to the Company&#x2019;s 2024 Omnibus Equity Incentive Plan in consideration
for advisory and investor awareness services related to the European market and Frankfurt listing process. The shares are subject to
a 180-day lock-up and Rule 144 resale restrictions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under the services agreement, CapitaLink agreed
to assist the Company with investor awareness outreach, European media distribution, informational campaign management, and administrative
support relating to the Frankfurt Stock Exchange listing process, including support associated with exchange-related requirements and
fees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s Board of Directors approved
the engagements and determined that the agreements were intended solely for investor awareness, educational outreach, and public communications
purposes and did not constitute broker-dealer, placement agent, or investment advisory activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Ian Share Purchase Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 12, 2026, VisionWave Israel Ltd. (&#x201c;VW
Israel&#x201d;), a wholly owned subsidiary of the Company, entered into a definitive Share Purchase and Shareholders Agreement (the &#x201c;Agreement&#x201d;)
with Mr. Ian Paklida (the &#x201c;Seller&#x201d;), pursuant to which VW Israel agreed to acquire 60% of the issued and outstanding equity
interests of VIP Lux Travel Ltd. and PKLST Tourism and Leisure Ltd., both Israeli corporations (collectively, the &#x201c;Target Companies&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Agreement is definitive; however, the transaction has not yet closed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under the terms of the Agreement, the consideration
for the acquisition of the Target Companies will be the issuance of shares of common stock of the Company, subject to the satisfaction
of various conditions precedent and regulatory approvals.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Agreement contemplates an aggregate transaction
value of up to approximately 15 million NIS, payable in the Company shares valued at approximately USD $3 million. The number of shares
to be issued will be 513,752 shares of common stock of the Company representing $6.02 cost per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Agreement includes customary representations,
warranties, covenants, indemnification provisions, confidentiality obligations, lock-up restrictions, and closing conditions. Closing
remains subject to, among other things:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#xb7; completion of legal, financial, and operational due diligence;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#xb7; receipt of all required corporate and regulatory approvals;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#xb7; applicable tax rulings and/or approvals in Israel;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#xb7; execution and delivery of final ancillary closing documents;
and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#xb7;satisfaction or waiver of other customary closing conditions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Until the closing occurs, there can be no assurance
that the acquisition will be consummated on the terms currently contemplated, or at all.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company intends to evaluate
strategic opportunities relating to the Target Companies&#x2019; operations and potential integration into VisionWave&#x2019;s broader
international business activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;Other share issuances&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;Subsequent to March 31, 2026
and to the date of this report on Form 10-Q, total&#160;of 1,010,000 shares were issued to YA II PN pursuant to the SEPA.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;On May 18, 2026, the Company
issued 475,590 shares to T3 defense Inc. pursuant to a share exchange and swap agreement dated May 17, 2026.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
</xbrl>
